



Final Programme

36th Congress of the European
Society of Clinical Microbiology
and Infectious Diseases

Munich, Germany

17–21 April 2026

20
26

Table of Contents

Introduction

- 3 Welcome
- 4 Acknowledgements
- 7 Important Addresses
- 8 ESCMID Grants
- 11 ESCMID Global virtual platform and App
- 12 Congress Venue Overview

Scientific Programme

- 14 Introduction to the Scientific Programme
- 17 ESCMID Study Groups and other open meetings
- 18 Scientific Programme Overview
Friday, 17 April 2026
- 20 Scientific Programme Overview
Saturday, 18 April 2026
- 24 Scientific Programme Overview
Sunday, 19 April 2026
- 28 Scientific Programme Overview
Monday, 20 April 2026
- 32 Scientific Programme Overview
Tuesday, 21 April 2026
- 36 List of Invited Speakers
- 40 List of Chairpersons
- 46 Scientific Programme
Friday, 17 April 2026
- 52 Scientific Programme
Saturday, 18 April 2026
- 86 Scientific Programme
Sunday, 19 April 2026
- 120 Scientific Programme
Monday, 20 April 2026
- 152 Scientific Programme
Tuesday, 21 April 2026

Welcome Address


ESCMID Global is the premier annual congress where the greatest minds from the fields of infectious diseases and clinical microbiology congregate. Join us in discovering the latest breakthroughs in ongoing clinical trials, the developments in diagnostics and therapeutic interventions for better patient outcomes from infections. Let's unite at ESCMID Global 2026 in Munich and work towards a healthier tomorrow, together.



Robert Leo Skov
ESCMID President



Join us in Munich for the latest research innovations at the flagship congress for the field of infection. ESCMID Global covers everything from workshops on best practices in infection prevention and control to expert discussions on integrating artificial intelligence advancements into clinics. Draw inspiration from your mentors, colleagues and the greater research community at ESCMID Global 2026!



Annelies Zinkernagel
Immediate Past President
& Treasurer



ESCMID Global, the world's leading congress in the field of infection, convenes for its 36th edition this year in Munich. We are proud to present a rich five-day programme at the intersection of science, research, and education. Building on the success of Education Friday and Pipeline Monday, this year introduces new features such as interactive workshops and a dedicated Paediatric ID track, alongside a record number of featured abstracts. An enhanced delegate experience is in store, powered by expanded AI capabilities and integrated on-site and online offerings designed to facilitate learning, scientific exchange, and networking. Together, we will drive progress in the fight against infectious diseases. We look forward to welcoming you this spring in Munich!



Jacob Moran-Gilad
ESCMID Global
Programme Director



Acknowledgements

Programme Committee



Luisa Barzon
Padua, Italy



Stephanie Dancer
Glasgow, United Kingdom



Li Yang Hsu
Singapore, Singapore



Justyna Kowalska
Warsaw, Poland



Angelika Berger
Vienna, Austria



Giulia De Angelis
Rome, Italy



Elias Iosifidis
Thessaloniki, Greece



Florian Krammer
New York, United States



Silvio Brugger
Zurich, Switzerland



Mauricio Farfan
Santiago, Chile



Anu Kantele
Helsinki, Finland



Tyra Grove Krause
Copenhagen, Denmark



Fusun Can
Istanbul, Turkey



Fidelma Fitzpatrick
Dublin, Ireland



Antonios Katsounas
Bochum, Germany



Christian Lentz
Tromso, Norway



Christopher Chiu
London, United Kingdom



Jon Friedland
London, United Kingdom



Yoav Keynan
Winnipeg, Canada



Preeti Malani
Ann Arbor, United States



Anuradha Chowdhary
Delhi, India



Maddalena Giannella
Bologna, Italy



Jan A.J.W. Kluytmans
Utrecht, Netherlands



Sandrine Marchand
Poitiers, France



Elisa Cordero
Seville, Spain



Benjamin Howden
Parkville, Australia



Nina Khanna
Basel, Switzerland



Jacob Moran-Gilad
Be'er Sheva & Jerusalem,
Israel



Joel Mossong
Luxembourg, Luxembourg



Joseph Papapaskevas
Athens, Greece



Carlos Seas
Lima, Peru



Annelies Zinkernagel
Zurich, Switzerland



Joshua Nosanchuk
New York, United States



Neven Papic
Zagreb, Croatia



Bhanu Sinha
Groningen, Netherlands



Christina Obiero
Kilifi, Kenya



Pilar Retamar
Seville, Spain



Robert Leo Skov
Copenhagen, Denmark




Kwame Ohene Buabeng
Accra, Ghana



John WA Rossen
Groningen, Netherlands



Ermira Tartari
Malta, Malta



Rita Oladele
Lagos, Nigeria



Priscilla Rupali
Valore, India



Julie Toubiana
Paris, France



Gulsen Ozkaya
Lund, Sweden



Simona Ruta
Bucharest, Romania



Heiman Wertheim
Nijmegen, Netherlands



Jose Pano-Pardo
Zaragoza, Spain



Stefan Schwartz
Berlin, Germany



Helena Zemlickova
Prague, Czech Republic

Acknowledgements

Contributing Organisations

Asia Fungal Working Group (AFWG)
Australasian Society for Infectious Diseases (ASID)
Austrian Society for Medical Mycology (ÖGMM)
Belgian Society of Human and Animal Mycology
Biomed Alliance
Brazilian Society of Infectious Diseases (SBI)
British Infection Association (BIA)
British Society for Antimicrobial Chemotherapy (BSAC)
CAESAR Network
Clinical Microbiologists of Finland
Colombian Association of Infectious Diseases
Consortium for Clinical Metagenomics in Infectious Diseases (CCMID)
Dat'AIDS Working Group
Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.
Dominican Society of Infectious Diseases
Dutch Committee on Antimicrobial Policy
Dutch Society for Medical Microbiology (NVMM)
Ecuadorian Society for Medical Microbiology and Pediatric Infectious Diseases
EPIET alumni network (EAN)
EU Lab Semantic WG HL7
Euroguidelines in Central and Eastern Europe Network Group
European AIDS Clinical Society (EACS)
European Centre for Disease Prevention and Control (ECDC)
European Clinical Research Alliance on Infectious Diseases (ECRAID)
European Confederation of Medical Mycology (ECMM)
European Extracorporeal Life Support Organization
European Respiratory Society (ERS)
European Scientific Working group on Influenza (ESWI)
European Society for Clinical Virology (ESCV)
European Society of Intensive Care Medicine
European Society of Paediatric Infectious Diseases (ESPID)
Federation of European Societies for tropical medicine and international health (FESTMIH)
French Pediatric Infectious Diseases Group (GPIP)
German Society for Pediatric Infectious Diseases (DGPI)
German-Speaking Mycological Society
Hellenic Society of Medical Mycology
Hungarian Society of Infectious Diseases and Clinical Microbiology
Infectious Diseases Society of America (IDSA)
International Centre for Antimicrobial Resistance Solutions (ICARS)
International Immunocompromised Host Society (ICHS)
International Pediatric Association (IPA)
International Sepsis Forum (ISF)
International Society for Infectious Diseases (ISID)
International Society for Influenza and other Respiratory Viruses (ISIRV)
International Society of Antimicrobial Chemotherapy (ISAC)
International Society of Human and Animal Mycology (ISHAM)
International Society of Pediatric Respiratory Diseases (INSPIRED)
Israel Society for Medical Mycology (ISMM)
Latin American Society for Travel Medicine
Mèdecins Sans Frontières (MSF)
Nordic Society of Clinical Microbiology and Infectious Diseases (NSCMID)
Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH)

Pan-American Association Infectious Diseases (API)
Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG)
Portuguese Society of Infectious Diseases and Clinical Microbiology
Romanian Society for Medical Mycology and Mycotoxicology (SRMMM)
Slovenian Society for Infectious Diseases
Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie (SIMPIOS)
Société de Pathologie Infectieuse de Langue Française
Society for the Study of liver Diseases in Africa (SOLDA)
Society of Infectious Diseases Pharmacists (SIDP)
Spanish Study Group for Medical Mycology of SEIMC (GEMICOMED)
Study Group of Viral Hepatitis of the Spanish Society of Infectious Diseases and Clinical Microbiology
Swiss Society for Infectious Diseases (SSID)
Swiss Society for Microbiology (SSM)
Taiwan Society of Microbiology
Turkish Association for the Study of the Liver (TKAD)
Turkish Society of Paediatric Infectious Diseases
UEMS Section of Medical Microbiology
UK National Health Service Genomic Network of Excellence
Viral Hepatitis Society of Türkiye (VHSD)
World Health Organization

ESCMID entities

CMI Board of Editors
CMI Communications Board of Editors
ESCMID AMR Action Subcommittee
ESCMID Education Subcommittee
ESCMID Emerging Infections Subcommittee
ESCMID Ethics Advisory Committee
ESCMID Guidelines Subcommittee
ESCMID Parity Commission
ESCMID Professional Affairs Subcommittee
ESCMID Scientific Affairs Subcommittee
EUCAST Steering Committee
EUCIC Steering Committee
Trainee Association of ESCMID (TAE) Steering Committee

Study Groups

ESCMID Food- and Water-borne Infections Study Group (EFWISG)
www.escmid.org/efwisg
ESCMID Fungal Infection Study Group (EFISG)
www.escmid.org/efisg
ESCMID PK/PD of Anti-Infectives Study Group (EPASG)
www.escmid.org/epasg
ESCMID Study Group for Anaerobic Infections (ESGAI)
www.escmid.org/esgai
ESCMID Study Group for Artificial Intelligence and Digitalisation (ESGAID)
www.escmid.org/esgaid
ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)
www.escmid.org/esgars
ESCMID Study Group for Antimicrobial stewardship (ESGAP)
www.escmid.org/esgap
ESCMID Study Group for Biofilms (ESGB)
www.escmid.org/esgb
ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)
www.escmid.org/esgbies

Important Addresses

ESCMID Study Group for Clinical Parasitology (ESGCP)

www.escmid.org/esgcp

ESCMID Study Group for Clostridioides difficile (ESGCD)

www.escmid.org/esgcd

ESCMID Study Group for Critically Ill Patients (ESGCIP)

www.escmid.org/esgcip

ESCMID Study Group for Epidemiological Markers (ESGEM)

www.escmid.org/esgem

ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR)

www.escmid.org/esgfor

ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD)

www.escmid.org/esgmd

ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

www.escmid.org/esghami

ESCMID Study Group for Implant-associated Infections (ESGIAI)

www.escmid.org/esgiai

ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

www.escmid.org/esgich

ESCMID Study Group for Infections in the Elderly (ESGIE)

www.escmid.org/esgie

ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

www.escmid.org/esgitm

ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

www.escmid.org/esgib

ESCMID Study Group for Legionella Infections (ESGLI)

www.escmid.org/esgli

ESCMID Study Group for Lyme Borreliosis (ESGBOR)

www.escmid.org/esgbor

ESCMID Study Group for Mobile Elements and Plasmids (ESGMAP)

www.escmid.org/esgmap

ESCMID Study Group for Mycobacterial Infections (ESGMYC)

www.escmid.org/esgmyc

ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)

www.escmid.org/esgmac

ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

www.escmid.org/esgnta

ESCMID Study Group for Nosocomial Infections (ESGNI)

www.escmid.org/esgni

ESCMID Study Group for Public Health Microbiology (ESGPHM)

www.escmid.org/esgphm

ESCMID Study Group for Respiratory Viruses (ESGREV)

www.escmid.org/esgrev

ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

www.escmid.org/esgs

ESCMID Study Group for Urinary Tract Infections (ESGUTI)

www.escmid.org/esguti

ESCMID Study Group for Veterinary Microbiology (ESGVM)

www.escmid.org/esgvm

ESCMID Study Group for Viral Hepatitis (ESGVH)

www.escmid.org/esgvh

ESCMID Vaccine Study Group (EVASG)

www.escmid.org/evasg

ESCMID Sexually Transmitted Infections Study Group (ESTISG)

www.escmid.org/estisg

ESCMID President

Prof. Robert Leo Skov

Infectious Disease Preparedness

Statens Serum Institut

Copenhagen, Denmark

Programme Director

Prof. Jacob Moran-Gilad

Ben-Gurion University

Dept. of Health Systems Management

Beer Sheva, Israel

Associate Programme Director

Dr. Giulia de Angelis

Catholic University of the Sacred Heart

Institute of Microbiology

Rome, Italy

Scientific Secretariat

ESCMID Executive Office

Aeschenvorstadt 55

4051 Basel

Switzerland

Phone: +41 61 508 01 72

E-Mail: info@escmid.org

Web: www.escmid.org

Registration

36th ESCMID Global

E-Mail: escmidregistration@escmid.org

ESCMID Grants

Outreach Grant

ESCMID fosters participation of delegates from low- and lower middle-income countries, to participate at ESCMID Global. We are pleased to announce that this year ESCMID awarded 60 outreach grants for ESCMID Global.

Aboofazeli, Amir, Tehran, Iran, Islamic Republic of
Adhikari, Aayush, Chame, Nepal
Adoma, Prince Owusu, Winneba, Ghana
Ahsan, Aitezaz, Islamabad, Pakistan
Alshayyah, Madiha, Gaza, Palestine, State of
Amin, Shubha, Dhaka, Bangladesh
Asati, Himanshu, Jodhpur, India
Azerefegne, Eskedar, Addis Ababa, Ethiopia
Baba, Hala, Monastir, Tunisia
Ben Ali, Nadhir, Monastir, Tunisia
Benmohammed, Asma, Algiers, Algeria
Boamah, Vivian Etsiapa, Kumasi, Ghana
Chadwala, Hope Michael, Lilongwe, Malawi
Collado, Nathaniel, Baguio, Philippines
Cruz, Shehezady, Beira, Mozambique
Dabeet, Christina, Amman, Jordan
Duong, Thi Hong Diep, Ho Chi Minh City, Vietnam
Egualé, Tadesse, Addis Ababa, Ethiopia
Elkoumi, Ahmed, Zagazig, Egypt
Ernandes, Helmi, Tunis, Tunisia
Fiona, Magololo Mutesi, Kampala, Uganda
Gbadebo, Ayisat, Sagamu, Nigeria
Genese, Ma. Klaudyn Cletz, Baguio City, Philippines
Gouton, Adechinan Ovide Canisius, Cotonou, Benin
Hasan, Mohammad Jahid, Dhaka, Bangladesh
Ilyas, Rabia, Karachi, Pakistan
Jaiswal, Bisekha, Lalitpur, Nepal
Joshi, Shambhu Dutta, Kailali, Nepal
Kathewera, Bernard, Blantyre, Malawi
Khosravi Nia, Mohammad Mahdi, Tehran, Iran, Islamic Republic of

Kuyateh, Alieu, Banjul, Gambia
Kyeraa, Evelyn, Sunyani, Ghana
Malanchuk, Svitlana, Kharkiv, Ukraine
Maqsood, Noor Ul Aine, Karachi, Pakistan
Melendrez, Lordieliza, Quezon City, Philippines
Molla, Md Ebrahim, Bagerhat, Bangladesh
Muhumuza, Umar, Kampala, Uganda
Myronov, Petro, Sumy, Ukraine
Naim, Carine, Beirut, Lebanon
Namoune, Wail, Constantine, Algeria
Ntagereka Bisimwa, Patrick, Bukavu, Congo, the Democratic Republic of the
Obadare, Temitope, Ile-Ife, Nigeria
Ochola, Lucy, Mombasa, Kenya
Okumu, Noah, Nairobi, Kenya
Orabueze, Ibuchukwu, Enugu, Nigeria
Rafinezhad, Nasim, Kermanshah, Iran, Islamic Republic of
Ranjan, Swekcha, New Delhi, India
Shehat, Michael, Alexandria, Egypt
Sidhik, Sahina, Phnom Penh, Cambodia
Sobhy, Reham, Cairo, Egypt
Sobkova, Zhanna, Kyiv, Ukraine
Somda, Namwin Siourimè, Bobo-Dioulasso, Burkina Faso
Tessema, Michael Solomon, Addis Ababa, Ethiopia
Tiwari, Vishwa Deepak, Varanasi, India
Tonye, Theodore Alexe, Yaounde, Cameroon
Touangnou Chamda, Sabine Aimée, Yaounde, Cameroon
Vijeyakumaran, Rydhniewa, Kandy, Sri Lanka
Vu, Minh Duy, Hanoi, Vietnam
Wijewardena, Thisura, Colombo, Sri Lanka
Zemba, Charlotte, Lusaka, Zambia

Travel Grants

ESCMID sponsors travel grants to support ESCMID Global attendance by young scientists or early career professionals with outstanding accepted abstracts.

Aggarwal, Dinesh, United Kingdom
Aizouk, Raneem, United Kingdom
Andrianaki, Angeliki, Switzerland
Arandjelovic, Martina, Portugal
Baird, Rory, Ireland
Bari, Anurag Kumar, Netherlands
Baron, Sophie, France
Barrett, Kemar, United States
Bennett, Vicky, United Kingdom
Bergas Farrés, Alba, Spain
Bisono Garcia, Bismarck Steven, United States
Boettcher, Stormmy, United States
Borgonovo, Fabio, Italy
Boutillier, Audrey, France
Brahier, Thomas, Switzerland
Calvigioni, Marco, Italy
Campos Ruiz, Miriam, Spain
Cano Castaño, Beatriz, Spain
Carrizo, Paula, Spain
Cesanelli, Federico, Italy
Chandel, Abhishek, India
Chandna, Arjun, United Kingdom
Chhugani, Karishma, United States
Ciaccio, Laura, United Kingdom
Cogliati Dezza, Francesco, Spain
Dabos, Laura, France
Dennebouy, Zélie, Switzerland
Deventer, Ashley, United Kingdom
Di Gallo, Anna, Italy
Dubey, Vineet, United Kingdom
Elbediwi, Mohammed, Germany
Eriksen, Emilie, Denmark
Escolà-Vergé, Laura, Spain
Escudero Arnés, Gonzalo, Spain
Fasan, Daniele, Italy
Ferini, Sara, Italy
Francesco, Spada, Italy
Gallardo-Pizarro, Antonio, Spain
García-Larrauri, Julia, Spain
Girolamini, Luna, Italy
González Pinto, Lucía, Spain
Groenveld, Marleen Anne-Floor, Netherlands
Guevara Nuñez, Daiana, Spain
Guinsburg Hamburger, Flávio, Brazil
Gutiérrez-Pareja, Mark, Spain
Hafian Al-Homsi, Rama, Spain
Han, Renru, China
Hoog, Keegan John, United Kingdom
Hookham, Lauren, United Kingdom
Hrouda, Nicole, United Kingdom
Ismail, Abdallah, South Africa
Itani, Dana, Egypt
Jalal, Deena, Egypt
Jimenez, Adriana, United States
Jokanovic, Natali, Australia
Kagra, Poornima, India
Kelleghan, Robert, Australia
Krisna, Made, United Kingdom
Kumari, Ansu, India
Laumay, Floriane, France
Leopold, Stije J, Thailand
Lisa Samkeliso, Blundell, United Kingdom
Little, Jessica S., United States
Loader, Maria-Cristina I, United Kingdom
Makamu, Tlangelani, South Africa
Martínez Alemany, Iris, Spain
Massou, Faridath, Benin
Mathé, Philipp, Germany
Matos, Cátia, Portugal
Mauget, Matteo, France
Mcbride, Angela, United Kingdom
Montero-Vale, Mercedes, Spain
Morgan, Charlotte, United Kingdom
Morris, Tiy, France
Nakhle, Rita, Canada
Nambiraman, Malligarjunan, India
Nepal, Roshan, Australia
Ngamprasertchai, Thundon, Thailand
Nguyen, Thomas, United States
Olweny, Geoffrey, Austria
Osmaston, Alice, United Kingdom
Ouafi, Mahdi, France
Pansari, Nishtha, India
Paranos, Paschalis, United States
Pérez Rodríguez, Gloria, Spain
Picton, Charlotte, Australia
Pinto, Pedro, Ireland
Polani Chandrasekar, Rubeshkumar, United Kingdom
Pujol Perez, Misael, United States
Rabault, Charlotte, France
Reynolds, Gemma, Australia
Rizvi, Zaigham Abbas, India
Rodríguez-Pallares, Salud, Spain
Ruiz Arabí, Elisa, Spain
Ryan, Barry, Switzerland
Rydlova, Anna, United Kingdom
Sadeesh Kumar, Lamali, Australia
Sadhu, Srikanth, India
Saman, Razan, United Kingdom
Sartini, Ilaria, Italy
Schiuma, Marco, Italy
Selvakumar, Selwyn, India
Shah, Sangam, Nepal
Shamanna, Varun, India
Sharma, Rhythm, India
Shun, Hon Kiu Estie, Hong-Kong SAR, China
Skolimowska, Keira, United Kingdom
Sonpar, Ashlesha, Switzerland
Sorrentino, Rita, Italy
Spies, Ruan, Vietnam
Squitieri, Damiano, Italy
Staal, Steven Lukas, Netherlands
Stoffers, Carmen, Netherlands
Tanaka, Emi, Japan
Thomson, Kathryn, United Kingdom
Toribio, Luz M., United Kingdom
Torrecilla-Sádaba, Estibaliz, Spain
Tran, Buu Minh, Sweden
Truong, Cong Hieu, Vietnam
Turgman, Oren, Netherlands
Ünal, Gultekin, Türkiye
Valêncio Siqueira, André, United States
Van Helden, Sean R., United States
van Lieshout, Jelmer, Netherlands
Vuong, Nguyen Lam, Vietnam
Walzer, Dietrich, Germany
Wang, Zihao, Singapore
Wdowiak, Mateusz, Poland
Yang, Ping, China
Yin, Nicolas, Belgium
Zaborskyte, Greta, United Kingdom
Zumbo, Giulia, Spain

ESCMID Grants

LMIC Grant

The purpose of the LMIC grant is to offset travel and accommodation costs to attend ESCMID Global on site. 50 LMIC grants are offered to ESCMID LMIC members, and does not require an abstract submission at ESCMID Global to qualify.

Akram, Muhammad Areeb, Lahore, Pakistan
Amir, Sadia, Karachi/sindh, Pakistan
Amiri, Mehrnaz, Tehran, Iran, Islamic Republic of
Andrew, Nifarta Peingurta, Abuja, Federal Capital Territory, Nigeria
Araoud, Ahmed, Monastit, Tunisia
Awale, Daisy, Saptakhel-, Nepal
Burma, Yaroslava, Kharkiv, Ukraine
Dao, Thang, Ha Noi, Viet Nam
Diarra, Fatimata Bintou Josiane, Ouagadougou, Burkina Faso
Emad, Rana, Giza, Egypt
Foya, Gospel, Bulawayo, Zimbabwe
Garba, Bashiru, Mogadishu, Somalia
Ho, Seanghuoy, Phnom penh, Cambodia
Jallow, Mamadou JS, Banjul, Gambia
Jaya, Jervickh Jae, Tacloban city, Philippines
Jere, Samuel, Lusaka, Zambia
Kabbara, Wissam, Byblos, Lebanon
Kambewa, Leonard, Blantyre, Malawi
Kasa, Zerihun Shimelis, Addis Ababa, Ethiopia
Kashfi, Seyed Adnan, Tehran, Iran, Islamic Republic of
Kuate Ngouanom, Marius Paulin, Buea, Cameroon
Manu, Gloria Pokuaa, Accra, Ghana
Mbwana, Naima, Tanga, Tanzania, United Republic of
Nambatya, Winnie, Kampala, Uganda
Namoune, Rachida, Chlef, Algeria
Nastenko, Volodymyr, Kyiv, Ukraine
Ng'ang'a, Tabitha, Nairobi, Kenya
N'Goran, Sodji Emilie Karen, Abidjan, Cote d'Ivoire
Nguyen Thi, Hoa, Ha Noi, Viet Nam
Nwofe, Justin Onyebuchi, Abuja, Nigeria
Nzogela, Francis, Arusha, Tanzania, United Republic of
Oben epse Besong, Pamela, Buea, Cameroon
Ochi, Ghada, Tunis, Tunisia
Odebode, Adeyinka, Ishaka, Uganda
Ohouko, Okri Frejus Hans, Abomey-Calavi, Benin
Omeirat, Nadine, Tripoli, Lebanon
Otieno, David, Kisumu, Kenya
Palugod, Monica, Tacloban City, Philippines
Paranagama, Anuradha Jayanath, Piliyandala, Sri Lanka
Ramadan, Hazem, Mansoura, Egypt
Ranjan, Manish, Jammu, India
Sahury López, Sara Daniela, Tegucigalpa, Honduras
Shaly, Nusrat Jahan, Dhaka, Bangladesh
Sharma, Uday, Dharan, Nepal
Shongwe, Makhosazana, Mbabane, Eswatini
Singh, Sarita, Varanasi, India
Smara, Billel, Algiers, Algeria
Sokoni, Chalwe, Lusaka, Zambia
Srun, Huykoeng, Phnom Penh, Cambodia
Wudneh, Feven, Dilla, Ethiopia

ESCMID Global virtual platform and App

ESCMID Global virtual platform and App

The ESCMID Global virtual platform and app are online interactive programmes designed for congress attendees. Both provide enhanced functionality such as sending direct messages to other attendees, watching replays of sessions that you missed, and viewing poster presentations. ESCMID Global will also be offering personalisation features, such as individualised session recommendations to help every attendee navigate through the content more efficiently.

Tracks and personalization


ESCMID has new personalised features this year to help you navigate through the content of the entire ESCMID Global programme. ESCMID has introduced a recommendation feature that offers recommended sessions based on the information indicated in your ESCMID profile. Please make sure to update your account, so these recommendations can be optimised to your present interests. ESCMID Global has also implemented tracks, research themes such as AMR, IPC, etc so that you can find the sessions best for your needs!


Please note, these recommendations are not sponsored or advertisements, they are solely based on your profile data.

Unlock your experience – download the congress app for effortless navigation!



Congress Venue Overview





Introduction to the Scientific Programme

The ESCMID Global Programme is organised into five main pillars: three academic and two industrial. The academic pillars of Education, Science and Research form the core of the programme dedicated to advancing knowledge, innovation, and expertise in the fields of clinical microbiology and infectious diseases. The Pipeline and Industry pillars instead focus on the application of the latest scientific developments by enterprises within the field of infection. Here you can explore the academic pillars, and which sessions fall under each as well as special interest sessions. For all the details about the Pipeline and Industry sessions (not accredited by EACCME) please refer to the Expo Guide.

ESCMID Global has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 33 European CME credits (ECMEC®s). For more information, please check our website: www.escmid.org/congress-events/escmid-global/programme/certificates-and-accreditation

Scientific

Keynote Lectures

60': 45' talk + 15' Q&A

1 speaker

2 chairpersons

Targeting a broad audience of specialists and non-specialists, these sessions feature key opinion leaders who present a state-of-the-art review of a specific cutting-edge topic, including summarising their own scientific achievements in the field.

Keynote Scientific Interviews (60')

45-50' interview + Q&A

1 speaker

1 chairperson

Interviews feature two experts taking the role of interviewer (chairperson-moderator) and interviewee (keynote speaker) and discussing current experience and future challenges in CM and ID. Interviewer and interviewee may be known to have a different opinion on a specific topic or to have taken different approaches to tackle a similar situation.

Fireplace Sessions

60' interactive conversation with audience

1 speaker (keynote speaker)

1-2 chairpersons

Open sessions, taking place right after the Keynote Lecture/Interview and aiming at generating informal discussions with ESCMID trainees and early career members.

Symposia

1-hour Symposium:

2 talks of 25' + 5' Q&A each

2 speakers

2 chairpersons

2-hour Symposium:

4 talks of 25' + 5' Q&A each

4 speakers

2 chairpersons

Symposia convene renowned speakers from around the world and cover the range of topics being covered at ESCMID Global. They are tailored to give an overview of recent developments and research results, review the literature, or present as pro/con debates.

"Year in ..." and "Top papers in ..." Sessions

"Year in ..." and "Top papers in ..." sessions are 1-hour symposia where speakers present a common review on the topic based on the published literature since the last ESCMID Global. In each session, two speakers present a maximum of 10 papers, followed by a final discussion, focused on future research, ongoing controversies and take-home messages.

This year, the sessions include:

- Year in infectious diseases
- Year in clinical microbiology
- Year in infection control
- Year in public health
- Top papers in infections in immunosuppressed patients
- Top papers in imported tropical diseases and diagnosis of parasitic Infections

Open Forum

60': variable format

3-5 speakers

1 chairperson

During lunch break in designated open spaces (Arenas), speakers discuss with the audience a particular issue, typically with controversy and policy-related aspects.

Young Investigator Award for Research in CM and ID

The ESCMID Young Investigator and Emerging Young Investigator Award winners will receive their awards and present their research during the session "Young Investigator Awards for Research in CM and ID".

ESCMID Award of Excellence in CM and ID

The ESCMID Excellence Awardee will receive the award and give a keynote lecture.

Education

Meet-the-Expert

60': 2 presentations of 12' max from each speaker followed by discussions with the audience

2 speakers

Informally known as "How Best to..." sessions, these educational sessions commonly target smaller audiences. The topics addressed should have practical relevance and include exchange of personal views, discussion of cases and experiences on a matter with the audience.

Educational Sessions

120': 4 talks of 20' each + 40' panel discussion

4 speakers

2 chairpersons In special circumstances, 3h sessions are allocated

These sessions are review talks and/or case studies that lend themselves to discussions and educate on CM/ID. The goal of this format is education while focusing on core topics in CM/ID and as such formats can involve case discussions and be interactive.

Clinical Case Sessions

60': 5 talks of 11' minutes each including discussion + 5' commentary by chairperson

5 speakers

1 chairperson

Case Sessions feature case reports or small case series selected from submitted abstracts, which are discussed to highlight clinical lessons or share clinical experience within a common topic.

Clinical Grand Rounds

It is co-organised with the Infectious Disease Society of America (IDSA). In this 2-hour Session, cases are presented by trainee ID physicians from ESCMID and seven IDSA and discussed with the senior Professors.

Research

Oral Sessions

1-hour Oral Session:

5 talks of 12' each including discussion

2 chairpersons

2-hour Oral Session:

10 talks of 12' each including discussion

2 chairpersons

Oral sessions feature a range of selected abstracts covering a specific topic, bringing the most recent scientific findings forward.

ePoster Flash Sessions

60': 9 presentations of 6' each + discussion

9 abstract presenters

1 chairperson

Speakers are selected by their submitted abstracts and will present the highlights of their research work using their ePosters.

Journal sessions

These sessions are co-organised with different journals. They select 3 to 5 publications timed to be published around the congress dates and linked together by a common theme.

60': variable format

3-5 presentations selected by the journal editors, based on latest papers published

2 chairpersons

This year sessions are co-organised with CMI & CMI Comms, JAMA and The Lancet journals.

Poster Sessions

Accepted abstracts that have not been assigned to oral sessions are then presented in the poster sessions that take place every day over lunch. The sessions are organised by subcategory and posters are available also electronically on the content platform.

Colour Key & Tracks

COLOUR KEY:

- Scientific
- Educational
- Research
- Pipeline
- Industry
- Specials

ABBREVIATIONS: KN Keynotes SY Symposia FO Open Forums EW Educational sessions ME Meet the expert CS Case sessions OS Oral sessions EF Flash e-Poster sessions

IS Integrated Symposia PC Pipeline Corners PM Pipeline Monday sessions SP Special sessions LB Late-Breakers Oral sessions JS Journal sessions

TRACKS:

- CLN Clinical
- DX Diagnostics
- TRN Translational
- IPC Infection control
- ANT Antimicrobials
- VAX Vaccinology & Immunology
- AMR Antimicrobial resistance
- PHEI Public health & Emerging infections
- PRO Professional & Career
- PED Paediatrics

GO North

The text 'GO North' is written in a large, white, sans-serif font. Four reindeer are positioned across the letters, appearing to pull a sleigh. The reindeer are brown with white necks and antlers, and are wearing red harnesses. They are positioned behind the 'O', the first 'N', the 'o', and the 'h'.

**The next ESCMID Global
will be held in
Stockholm, Sweden,
April 09 – 13, 2027.**



ESCMID Global

ESCMID Study Groups and other open meetings

Everyone with a valid ESCMID Global 2026 registration who is interested in the topic is welcome to join onsite or virtually via the link provided.

Title	Start time	End time	ICM Room	Zoom Link
Saturday, 18 April 2026				
Forensic and Post-mortem Microbiology (ESGFOR)	09:30	10:30	Room 2 (Ground Floor)	🔗
Non-Traditional Antibacterial Therapy (ESGNTA)	09:30	10:30	Room 3 (Ground Floor)	🔗
Epidemiological Markers (ESGEM)	11:00	12:00	Room 2 (Ground Floor)	🔗
Clostridioides difficile (ESGCD)	11:00	12:00	Room 3 (Ground Floor)	🔗
Infections in the Elderly (ESGIE)	12:30	13:30	Room 3 (Ground Floor)	🔗
Implant-Associated Infections (ESGIAI)	12:30	13:30	Room 2 (Ground Floor)	🔗
Sexually Transmitted Infections (ESTISG)	13:30	14:30	Room 12 (First Floor)	🔗
Staphylococci and Staphylococcal Diseases (ESGS)	14:45	15:45	Room 2 (Ground Floor)	🔗
Respiratory Viruses (ESGREV)	16:15	17:15	Room 2 (Ground Floor)	🔗
Infections in Travellers and Migrants (ESGITM)	16:15	17:15	Room 3 (Ground Floor)	🔗
Sunday, 19 April 2026				
Bloodstream Infections, Endocarditis, and Sepsis (ESGBIES)	08:30	09:30	Room 3 (Ground Floor)	🔗
Mycobacterial Infections (ESGMYC)	08:30	09:30	Room 4 (Ground Floor)	🔗
ECRAID Young Investigator Workshop	09:30	10:30	Room 2 (Ground Floor)	🔗
Nosocomial Infections (ESGNI)	09:30	10:30	Room 12 (First Floor)	🔗
Anaerobic Infections (ESGAI)	11:00	12:00	Room 2 (Ground Floor)	🔗
Antimicrobial Resistance Surveillance (ESGARS)	11:00	12:00	Room 4 (Ground Floor)	🔗
Infections in Critically Ill Patients (ESGCIP)	12:30	13:30	Room 2 (Ground Floor)	🔗
Infectious Diseases of the Brain (ESGIB)	12:30	13:30	Room 4 (Ground Floor)	🔗
Legionella Infections (ESGLI)	13:30	14:30	Room 12 (First Floor)	🔗
Veterinary Microbiology (ESGVM)	14:45	15:45	Room 2 (Ground Floor)	🔗
PK/PD of Anti-Infectives (EPASG)	14:45	15:45	Room 4 (Ground Floor)	🔗
Mobile Elements and Plasmids (ESGMAP)	16:15	17:15	Room 2 (Ground Floor)	🔗
AI and Digitalisation (ESGAID)	16:15	17:15	Room 4 (Ground Floor)	🔗
Host and Microbiota Interactions (ESGHAMI)	17:30	18:30	Room 3 (Ground Floor)	🔗
Clinical Parasitology (ESGCP)	17:30	18:30	Room 12 (First Floor)	🔗
Monday, 20 April 2026				
Tick-Borne Diseases (ESGBOR)	08:30	09:30	Room 2 (Ground Floor)	🔗
Urinary Tract Infections (ESGUTI)	08:30	09:30	Room 4 (Ground Floor)	🔗
Food- and Water-borne Infections (EFWISG)	09:30	10:30	Room 3 (Ground Floor)	🔗
General Meeting of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)	10:00	11:30	Room 12 (First Floor)	🔗
Biofilms (ESGB)	11:00	12:00	Room 2 (Ground Floor)	🔗
Antimicrobial Stewardship (ESGAP)	11:00	12:00	Room 4 (Ground Floor)	🔗
Viral Hepatitis (ESGVH)	12:30	13:30	Room 2 (Ground Floor)	🔗
Genomic and Molecular Diagnostics (ESGMD)	12:30	13:30	Room 4 (Ground Floor)	🔗
Mycoplasma and Chlamydia Infections (ESGMAC)	13:30	14:30	Room 3 (Ground Floor)	🔗
General Meeting of the European Committee on Infection Control (EUCIC)	14:00	16:00	Room 12 (First Floor)	🔗
Infections in Compromised Hosts (ESGICH)	14:45	15:45	Room 4 (Ground Floor)	🔗
Public Health Microbiology (ESGPHM)	14:45	15:45	Room 2 (Ground Floor)	🔗
Fungal Infection (EFISG)	16:15	17:15	Room 4 (Ground Floor)	🔗
Vaccine (EVASG)	16:15	17:15	Room 2 (Ground Floor)	🔗

Scientific Programme Overview

Friday, 17 April 2026

Hall ICM 13a	Hall ICM 13b	Hall ICM 5	Hall B0-1	Hall B0-2
08:30 – 10:30	08:30 – 10:30	08:30 – 10:30	08:30 – 10:30	08:30 – 10:30
EW001	EW002	EW003	EW004	EW005
Strategies to tackle biofilm-associated infections	Overcoming ongoing challenges in CM/ID publishing	A gentle introduction to bioinformatics for microbial genomics	The antibiogram: from theory to clinical practice	Prevention and treatment for specific intra-abdominal infections
TRN	PRO	IPC PHEI TRN	AMR CLN DX	CLN IPC
11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00
ME007	ME008	ME009	ME010	ME012
Nosocomial infections in ECMO: clinical challenges and case-based discussion	Designing and conducting clinical trials in paediatric infectious diseases: barriers and challenges	Travel, migration and immunosuppression: a two-way challenge	Useful endpoints for antimicrobial therapy and stewardship: what if not only mortality mattered?	How best to detect ESBL and carbapenemase producers
CLN IPC	PED PRO	CLN DX	CLN PRO	AMR DX IPC

13:30 – 14:30	13:30 – 14:30	13:30 – 15:30	13:30 – 15:30	13:30 – 14:30
ME011	ME014	EW016	EW017	ME015
Different sets of diagnostic tools for endocarditis: how to resolve discrepancies and make them work?	How to approach pneumonia in patients with neutropoena	Clinical challenges in tropical medicine: lessons for global health	Advancing paediatric infectious disease management: from stewardship to precision therapeutics	Genomics in clinical microbiology and virology across settings: hype, hope, or a game-changer?
ANT CLN	CLN DX	CLN DX	CLN DX PED	DX IPC
14:45 – 15:45	14:45 – 15:45			14:45 – 15:45
ME019	ME020			ME021
Ethical discourse on isolation precautions: to isolate or not to isolate that is the question!	Hepatitis in the immunocompromised host: is it infection?			Optimising treatment of severe infections due to DTR organisms
CLN IPC PRO	CLN DX			AMR CLN
16:15 – 18:15	16:15 – 17:15	16:15 – 18:15	16:15 – 18:15	16:15 – 17:15
EW025	ME022	EW026	EW027	ME023
Enhancing infection prevention and control through implementation science: the REVERSE experience	Multi-omics dissection of bacterial pathogenesis and host-microbiome interactions	Vaccines for children: innovations, impact, and future directions	Overcoming resistant <i>Candida</i> infections	PK/PD-based dose optimisation in challenging patient groups
IPC PRO	TRN	PED VAX	AMR DX	ANT CLN
	17:30 – 18:30			17:30 – 18:30
	ME028			ME029
	De-escalation or escalation: using rapid diagnostics in patients with sepsis			Overcoming challenges to implementing system-wide antimicrobial stewardship
	CLN DX			ANT CLN

COLOUR KEY: Scientific Educational Research Pipeline Industry Specials

ABBREVIATIONS: KN Keynotes SY Symposia FO Open Forums EW Educational sessions ME Meet the expert CS Case sessions OS Oral sessions EF Flash e-Poster sessions IS Integrated Symposia PC Pipeline Corners PM Pipeline Monday sessions SP Special sessions LB Late-Breakers Oral sessions JS Journal sessions

TRACKS: CLN Clinical DX Diagnostics TRN Translational IPC Infection control ANT Antimicrobials VAX Vaccinology & Immunology
 AMR Antimicrobial resistance PED Paediatrics PHEI Public health & Emerging infections PRO Professional & Career

Hall A1-1	Hall A1-4	Hall A1-5
08:30 – 16:00	08:30 – 10:30	
IW01	EW006	
The AI health continuum: accelerating innovation in prevention and treatment strategies and driving adherence in practice	Outbreak investigation: through the eyes of a field epidemiologist and public health microbiologist AMR IPC PHEI	
	11:00 – 12:00	
	ME013	
	Legionnaires' disease: insights from recent large outbreaks IPC PHEI	
		12:15 – 13:30
		IW03
		Aligning research and policy to unlock antibiotic innovation
	13:30 – 15:30	
	EW018	
	Method morsels: breaking trial methodology down into digestible components PRO	
	16:15 – 17:15	
	ME024	
	Quality controlled AST: use your cell phone and your data AMR DX	
	17:30 – 18:30	
	ME030	
	How to prepare for pathogen X emergence: a practical approach DX PHEI	

All times are specified in CEST (UTC +2). If attending online, please convert to your local timezone.

Scientific Programme Overview

Saturday, 18 April 2026

Hall ICM 14	Hall ICM 1	Hall ICM 13a	Hall ICM 13b	Hall ICM 5	Hall B0-1
	08:30 - 11:30	08:30 - 10:30	08:30 - 10:30	08:30 - 10:30	08:30 - 10:30
09:30 - 10:30	EW038	EW039	SY031	SY032	SY033
SY041 Year in infection control IPC	EUCAST user workshop	Milk matters: risks and safe practices in a changing global landscape PHEI TRN	Biofilms, the hidden threat in healthcare environment: unveiling detection, control and prevention strategies IPC	Beyond recovery: post-acute syndromes after respiratory viral infections CLN DX VAX	AI-enhanced sepsis care: from early detection to long-term follow-up CLN
11:00 - 12:00		11:00 - 12:00	11:00 - 12:00	11:00 - 12:00	11:00 - 12:00
KN042		SY043	OS009	ME048	SY044
Containment of MRSA in hospitals: past, present, future AMR IPC		Top papers in imported tropical diseases and diagnosis of parasitic infections CLN DX	Tomorrow's antibiotics today: from first-in-human to phase III ANT	Viral threats and antibiotic resistance in wastewater in the postpandemic era IPC PHEI	The hospital bathroom as a hotspot for AMR AMR IPC

13:30 - 14:30	13:30 - 14:30	13:30 - 14:30	13:30 - 14:30	13:30 - 14:30	13:30 - 14:30
KN051	YIA	OS019	ME053	ME054	OS020
Rheumatic heart disease: a global problem PED PHEI	Young Investigator Award lecture	AMR in paediatric populations: from dynamic acquisition to predictive models AMR PED PHEI	<i>Candida auris</i> surveillance: when, how and why AMR IPC PHEI	LVAD infections: practical approaches to a complex challenge CLN IPC	From risk to resilience: advances in catheter-related infections across care settings CLN IPC
14:45 - 15:45	14:45 - 15:45	14:45 - 15:45	14:45 - 15:45	14:45 - 15:45	14:45 - 15:45
KN057	SY058	OS026	OS027	OS028	SY059
From molecules to ministries: a life in the fight against malaria CLN TRN	Chemsex, HIV and STIs: so little time, so much to do CLN DX PHEI	Redefining care in bacterial meningitis: new approaches and emerging clinical evidence CLN	Unusual causes of broken heart: cardiac infections CLN	From overuse to optimisation: smarter diagnostics in practice CLN DX	Climate change, biodiversity loss, and the future of infectious diseases PHEI
	16:15 - 18:15	16:15 - 18:15	16:15 - 18:15	16:15 - 18:15	16:15 - 18:15
	SY063	SY064	EW070	SY065	EW071
	Cracking the phage code: from clinical insights to precision design ANT CLN	Global perspectives on tuberculosis CLN PED TRN	Building a safer journey from candidate to organ transplant recipient CLN IPC VAX	Harnessing antibody response against viral and bacterial infections TRN VAX	Adaptive platform trials in infectious diseases CLN PRO

COLOUR KEY: Scientific Educational Research Pipeline Industry Specials

ABBREVIATIONS: KN Keynotes SY Symposia FO Open Forums EW Educational sessions ME Meet the expert CS Case sessions OS Oral sessions EF Flash e-Poster sessions IS Integrated Symposia PC Pipeline Corners PM Pipeline Monday sessions SP Special sessions LB Late-Breakers Oral sessions JS Journal sessions

TRACKS: CLN Clinical DX Diagnostics TRN Translational IPC Infection control ANT Antimicrobials VAX Vaccinology & Immunology
 AMR Antimicrobial resistance PED Paediatrics PHEI Public health & Emerging infections PRO Professional & Career

Hall B0-2	Hall A1-1	Hall A1-2	Hall A1-3	Hall A1-4	Hall A1-5
08:30 - 10:30	08:30 - 10:30	08:30 - 10:30	08:30 - 10:30	08:30 - 10:30	08:30 - 10:30
SY034	SY035	OS001	OS002	OS003	SY036
Rapid pathogen sequencing for patient management: advancing diagnostic implementation CLN DX	Microbial interactions and bacterial adaptation in the microbiome AMR TRN	Novel insights and tools to tackle hospital outbreaks AMR DX IPC	Three viruses, one winter: what we miss, what we treat, what comes next ANT CLN TRN	Driving global AMR action through data, economics, and policy AMR PHEI	Recent advances in malaria molecular surveillance: experiences from malaria endemic countries DX PHEI
11:00 - 12:00	11:00 - 12:00	11:00 - 12:00	11:00 - 12:00	11:00 - 12:00	11:00 - 12:00
SY045	OS010	OS011	OS012	OS013	OS014
Updates on severe pneumonia CLN	Exploiting biology for therapy: novel approaches against antimicrobial-resistant pathogens ANT TRN	Mechanisms of hypervirulence and resistance in <i>Klebsiella pneumoniae</i> TRN VAX	Sexually transmitted infections: typing to therapy CLN	Life-threatening fungal infections CLN DX	Turning AMS evidence to action ANT CLN
	12:15 - 13:15	12:15 - 13:15	12:15 - 13:15	12:15 - 13:15	12:15 - 13:15
	IS01	IS02	IS03	IS04	IS05
	RSVpreF maternal immunisation: a key strategy against a major public health challenge	Strengthening defences in older adults: FLUNITYHD analysis results and emerging role of new vaccination strategies in prevention of influenza and SARS-CoV-2	Why lifelong protection matters: evidence-based diphtheria, tetanus, pertussis and poliomyelitis vaccination strategies	From immunogenicity to public health impact: the first real-world evidence of PCV20 performance against clinical outcomes in adults	Toward zero: can we end the HIV epidemic?
13:30 - 14:30	13:30 - 15:25	13:30 - 15:00	13:30 - 15:00		13:30 - 15:15
ME055	IS06	IS07	IS08		IS09
Changing landscape of fungal infections in the solid organ transplant recipient CLN DX	Optimising management of MDR Gram-negative bacterial infections, including MBL producers	Adult immunisation: our power to reduce ID burden as health-care heroes	Battlefields to bedsides: the rise of resistance in times of war		The preparedness paradox: long-awaited antifungals, but are we ready?
14:45 - 15:45				14:45 - 15:45	
OS029				LB002	
Respiratory viral infection prevention across age groups VAX				Late-breaking public health challenges PHEI	
16:15 - 18:15	16:15 - 17:45	16:15 - 17:45	16:15 - 17:45		16:15 - 17:45
SY066	IS10	IS11	IS12		IS13
Barriers, drivers and maintenance: molecular mechanisms behind AMR gene mobility AMR PHEI TRN	The AMR puzzle: solving MDR Enterobacteriales with the new BL/BLI combinations	From sample to patient: diagnostics and infection control in the AMR era	Changing microbiology: bridging challenges with innovations		Exploring the role(s) of cefiderocol in optimising patient outcomes in CRGNI

All times are specified in CEST (UTC +2). If attending online, please convert to your local timezone.

Scientific Programme Overview

Saturday, 18 April 2026

Hall A2-1	Hall A2-2	Hall A3-1	Hall A3-2	Arena 1	Arena 2
08:30 – 10:30		08:30 - 10:30	08:30 - 10:30	08:30 - 09:30	08:30 - 09:30
EW040	09:30 - 10:30	LB001	SY037	EF004	EF005
Next-generation therapies against infectious diseases	OS007 Bad to the bone	Late-breaking vaccine trials	Unmet SDGs: Europe's struggle with HIV, TB, hepatitis and STIs	Beyond guidelines: how behaviour and social context shape antimicrobial prescribing	Old viruses, new weapons: emerging antiviral therapies from bench to bedside
ANT TRN	CLN DX	ANT CLN	PHEI VAX	ANT	ANT TRN
11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00
SY046	OS015	SY047	OS016	FO049	EF017
Engaging citizens in infectious disease surveillance, prevention, and research	Burden, immunity and management of viral infections in immunocompromised hosts	Diagnostic stewardship: asking the right questions to measure clinical impact – pro/con debate	Resistance trends in <i>Candida</i> species	Sharing made simple: how standardised data exchange improves infectious diseases research and care	Update in mosquito-borne infections and vector control
PHEI	CLN TRN VAX	CLN DX	AMR	PRO	PHEI VAX

13:30 – 14:30	13:30 – 14:30	13:30 – 14:30	13:30 – 14:30	13:30 – 14:30	13:30 – 14:30
JS001	SY052	OS021	OS022	EF023	FO056
Late-breaking research from JAMA: novel insights on treating and preventing infections around the world	Mycobacterial infections in childhood	Clinical impact of drug resistance in Gram-negative infections	Game on: leveling up education through simulation and serious play	Gut microbiota-based interventions against gastrointestinal pathogens and antibiotic resistance	Moving ahead with the AMR agenda in a changing environment
CLN IPC	CLN PED	AMR CLN	PRO	CLN IPC TRN	AMR
14:45 – 15:45	14:45 – 15:45	14:45 – 15:45	14:45 – 15:45	14:45 – 15:45	14:45 – 15:45
OS030	SY060	SY061	SY062	EF031	EF032
Unmasking infectious diseases through genomic approaches	Precision diagnostics for neonatal sepsis: from biomarkers to the bedside	Bridging the gap: aligning EUCAST standards with antimicrobial stewardship practice	Closing the antiviral gap: broadening treatment options for emerging and neglected viruses	Infection risk, response, and recovery in the immunocompromised host	Beyond the culture plate: a multi-modal overview of recent advances in gastrointestinal testing
DX	DX	AMR CLN	ANT CLN	CLN TRN	CLN DX
16:15 – 18:15	16:15 – 18:15	16:15 – 18:15	16:15 – 17:15	17:15 – 18:15	17:15 – 18:15
EW072	SY067	SY068	SY069	EF036	EF037
The microbiome and response to cancer treatment	Can you see me? HIV among underserved populations	Novel approaches to preventing neonatal infections beyond antibiotics	Outsmarting ticks: decoding tick-host-pathogen interactions and advancing vaccines against tick-borne diseases	Skin and soft tissue infections haunting us	Hospital surfaces: a touching subject
CLN TRN	CLN PHEI	IPC PED	TRN VAX	CLN TRN	AMR IPC

COLOUR KEY: Scientific Educational Research Pipeline Industry Specials

ABBREVIATIONS: KN Keynotes SY Symposia FO Open Forums EW Educational sessions ME Meet the expert CS Case sessions OS Oral sessions EF Flash e-Poster sessions IS Integrated Symposia PC Pipeline Corners PM Pipeline Monday sessions SP Special sessions LB Late-Breakers Oral sessions JS Journal sessions

TRACKS: CLN Clinical DX Diagnostics TRN Translational IPC Infection control ANT Antimicrobials VAX Vaccinology & Immunology
 AMR Antimicrobial resistance PED Paediatrics PHEI Public health & Emerging infections PRO Professional & Career

Arena 3	Arena 4
	08:30 - 09:30
09:30 - 10:30	EF006
EF008 Genomic and epidemiological patterns of antimicrobial resistance	Trending topics in TB and other mycobacterial infections
AMR CLN DX PHEI	
11:00 - 12:00	11:00 - 12:00
FO050	EF018
Sharpening communication and leadership skills in CM/ID	Socioeconomic and structural drivers of AMR
PRO AMR PHEI	

13:30 - 14:30	13:30 - 14:30
EF024	EF025
Molecular insights and surveillance of parasitic diseases	Molecular diagnostic innovations across specimens

CLN DX TRN AMR DX PHEI

14:45 - 15:45	14:45 - 15:45
EF033	EF034
Preclinical data and fundamental science on fungi and antifungals	Innovations in antimicrobial stewardship across diverse settings

AMR TRN AMR ANT IPC

17:15 - 18:15	16:15 - 17:15
EF038	EF035
Advances in clinical and pre-clinical PK/PD	From surveillance to diagnosis: catching hepatitis viruses before they catch us

ANT CLN TRN DX PHEI

All times are specified in CEST (UTC +2). If attending online, please convert to your local timezone.

Scientific Programme Overview

Sunday, 19 April 2026

Hall ICM 14	Hall ICM 1	Hall ICM 13a	Hall ICM 13b	Hall ICM 5	Hall B0-1
	08:30 – 10:30	08:30 – 10:30	08:30 – 10:30	08:30 – 10:30	08:30 – 10:30
09:30 - 10:30	EW078	SY073	SY074	SY075	SY076
KN081 Integrating technology and capacity building to strengthen disease surveillance and prevention in low-resource settings DX PHEI VAX	Duration of IV antibiotics in older adults for various infections CLN	Infections with no borders: challenges in South and Central-Eastern Europe in the context of travel, migration and war AMR PHEI VAX	The rise of tick-borne diseases: why are things changing? PHEI	Protecting the most vulnerable: infection prevention in neonatal and paediatric critical care AMR IPC PED	What drugs are missing? Exploring adjuvant therapies in immunosuppressed patients CLN TRN VAX
11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00
KN082	SY083	SY084	SY085	ME088	ME089
Rickettsioses: wide-spread and neglected CLN DX	Can large language models (LLMs) transform clinical diagnostics from start to finish? DX TRN	Moving towards patient-centered evidence in infectious diseases PRO	Early-life respiratory infections and their association with chronic lung disease CLN PED	To model or not to model? A debate on the role of modelling and simulation in clinical PK trials ANT TRN	Global health on the move: advances and strategies in travel medicine CLN DX

13:30 – 15:30	13:30 – 14:30	13:30 – 14:30	13:30 – 15:30	13:30 – 14:30	13:30 – 15:30
SEL	ME093	ME094	EW095	JS002	SY091
Selective Pressure	Novel therapeutics for <i>C. difficile</i> infection ANT CLN IPC	Recent evidence on the role of steroids in paediatric bacterial infections: focus on meningitis and pneumonia CLN PED	Updates on emerging and re-emerging vector-borne viral infections DX PHEI	Late-breaking research from CMI & CMI Comms: on invasive infections and antimicrobial resistance AMR CLN	Screening for multidrug-resistant pathogens in various populations: are we doing good? AMR IPC

	14:45 – 15:45	14:45 – 15:45		14:45 – 15:45	
	ME098	OS061		OS062	
	What's new in Antimicrobial Susceptibility Testing (AST) AMR DX	AI applications in CM/ID: speaking the new language (model) PRO		Puzzling parasites CLN PHEI	

16:15 – 17:15	16:15 – 17:15	16:15 – 17:15			16:15 – 17:15
KN100	LB005	ME104			SY102
From post-mortem discoveries to precision care: the evolution of opportunistic fungal infection management in haematological malignancies CLN	New drugs and anti-infective solutions ANT	Crimean-Congo haemorrhagic fever: best practices and advances in therapeutics and vaccines CLN PHEI			The future of clinical phage susceptibility testing AMR ANT TRN

17:30 – 18:30	17:30 – 18:30	17:30 – 18:30	17:30 – 18:30	17:30 – 18:30	17:30 – 18:30
SY106	SY107	OS074	OS075	SY108	SY109
Year in clinical microbiology DX	Machine learning to fight against MDR <i>Acinetobacter baumannii</i> CLN DX	Innovations in vector-borne and zoonotic viral infections CLN PHEI TRN	Primary care and long-term care facilities: what's going on in stewardship? ANT CLN	Immunological determinants of host-pathogen interactions in inflammation and immune compromise TRN VAX	New evidence challenging the UTI paradigm CLN DX

COLOUR KEY: Scientific Educational Research Pipeline Industry Specials

ABBREVIATIONS: KN Keynotes SY Symposia FO Open Forums EW Educational sessions ME Meet the expert CS Case sessions OS Oral sessions EF Flash e-Poster sessions IS Integrated Symposia PC Pipeline Corners PM Pipeline Monday sessions SP Special sessions LB Late-Breakers Oral sessions JS Journal sessions

TRACKS: CLN Clinical DX Diagnostics TRN Translational IPC Infection control ANT Antimicrobials VAX Vaccinology & Immunology
 AMR Antimicrobial resistance PED Paediatrics PHEI Public health & Emerging infections PRO Professional & Career

Hall B0-2	Hall A1-1	Hall A1-2	Hall A1-3	Hall A1-4	Hall A1-5
08:30 – 10:30	08:30 – 10:00	08:30 – 10:00	08:30 – 10:00	08:30 – 10:00	08:30 – 10:00
EW079	IS14	IS15	IS16	IS17	IS18
Europe's overlooked threat: the rise of zoonotic hepatitis E CLN DX PHEI	The power of COVID-19 prevention: latest insights and implications for clinical practice	The lingering shadow of <i>C. difficile</i> infection: is recovery ever complete?	Closing the adult immunisation gap: advancing pneumococcal protection through broader disease coverage and life course vaccination	Innovations in microbiology: advanced diagnostics for timely, accessible intervention	From emerging threats to diagnostic breakthroughs: a strategic look ahead in AMR
11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00
LB003	OS044	SY086	OS045	OS046	OS047
Late-breaking antiviral drug trials ANT CLN	Mechanisms of pathogenesis across different pathogens	Therapeutic management of carbapenem-resistant Gram-negative infections: where are we globally? TRN AMR ANT CLN	Invasive fungal infections: therapeutic strategies and emerging options CLN VAX	Translational science in mycobacterial infections CLN TRN	Diagnosing respiratory infections: from PCR to metagenomics CLN DX
	12:15 – 13:15	12:15 – 13:15	12:15 – 13:15	12:15 – 13:15	12:15 – 13:15
	IS19	IS20	IS21	IS22	IS23
	RSV vaccination in action: real-world successes and public health strategies to help address the RSV disease burden in adults	Not just another respiratory disease: how can we stop the reverberations of COVID-19?	Breaking through the RSV frontier: exploring data for evidence-based direct immunisation solutions for infants	The rising tide of TBE and Lyme disease in Europe	Silent progression, serious consequences. Rethinking post-transplant CMV management with latest real-world evidence
13:30 – 14:30	13:30 – 15:30	13:30 – 15:00		13:30 – 15:30	
OS054	IS24	IS25		IS26	
Harnessing artificial intelligence against AMR AMR DX TRN	Current perspectives on management of cytomegalovirus and Gram-negative infections: recent evidence and clinical implications	Winning moves: real-world experience to inform invasive mould disease (IMD) management		Integrated molecular diagnostics for clinical and public health impact	
14:45 – 15:45					
ME099					
Pathogens and people: modelling epidemics for preparedness PHEI					
16:15 – 17:15	16:15 – 17:45	16:15 – 17:45	16:15 – 17:45	16:15 – 17:45	16:15 – 17:45
LB004	IS27	IS28	IS29	IS30	IS31
Recent and ongoing high impact out-breaks IPC PHEI	STRIDES in AMR: diagnostics driving impact	Saving the vulnerable: innovative strategies against AMR in high-risk hosts	Innovating diagnostic technologies in respiratory infection	Replacing broad with smart: temocillin strikes again	Shaping the future of West Nile research in Europe
17:30 – 18:30					
SY110					
Dosing by breakpoints vs guidelines: are S/I/R results based on the focus of infection best practice or source of confusion? CLN DX					

All times are specified in CEST (UTC +2). If attending online, please convert to your local timezone.

Scientific Programme Overview

Sunday, 19 April 2026

Hall A2-1	Hall A2-2	Hall A3-1	Hall A3-2	Arena 1	Arena 2
08:30 – 10:30	08:30 – 10:30	08:30 – 10:30	08:30 – 10:30		08:30 – 09:30
SY077	EW080	OS039	OS040	09:30 - 10:30	EF041
Antimicrobial resistance on the menu: global risks across the food chain	Modelling approaches to estimate and predict the burden of AMR	Sepsis at the frontline: diagnosis, therapy, and outcome in critical care	Expanding the antimicrobial arsenal: from dual-action compounds to predictive AI	EF043 Tracking respiratory virus outbreaks in a changing world: from hospitals to wastewater	Short- and long-term consequences of viral infections
AMR PHEI	AMR PHEI	CLN DX TRN	ANT TRN	IPC PHEI	CLN
11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00
OS048	OS049	OS050	SY087	FO090	EF051
Field investigations of community-acquired infections	From silent malaria infections to severe disease in a globalised world	Personalised approaches to infectious diseases in high-risk haematologic and transplant patients	The role of the microbiota in vaccine response	IPC nurses corner: building bridges across Europe	Antibiotic use, misuse and stewardship across settings
PHEI	ANT CLN PHEI	AMR CLN PED	PED VAX	IPC	AMR ANT

13:30 – 14:30	13:30 – 14:30	13:30 – 14:30	13:30 – 14:30	13:30 – 14:30	13:30 – 14:30
OS055	OS056	SY092	OS057	EF058	EF059
Susceptibility testing of phages	Not the consult I expected this morning...	Fungi in the flow: wastewater as a hidden threat	Mind your Ps: PK/PD	Predicting complications and outcome of sepsis	Decoding herpesviruses: from bench to bedside
AMR	CLN PHEI	PHEI	ANT CLN	CLN TRN	CLN TRN VAX
14:45 – 15:45	14:45 – 15:45	14:45 – 15:45	14:45 – 15:45	14:45 – 15:45	14:45 – 15:45
OS063	OS064	OS065	SY097	EF066	EF067
Malicious <i>Mycobacteria</i>	Rattle my bones - bone and joint infections	Engineering the gut microbiome: new therapeutics and clinical practice	Capacity strengthening in antimicrobial stewardship and infection, prevention and control in LMICs	The escalating problem of antifungal resistance	Infection control and antimicrobial stewardship in neonatal and pediatric critical care
CLN PHEI	CLN TRN	IPC TRN	IPC PHEI	DX	ANT IPC PED
16:15 – 17:15		16:15 – 18:15	16:15 – 17:15	16:15 – 17:15	16:15 – 17:15
SY103		SY101	OS070	EF071	FO105
Implementation of WHO Fungal Priority Pathogens List: landscape and challenges		Pertussis resurgence: understanding epidemiological trends, immune and vaccine challenges, and policy responses	Turning mechanisms into clinical strategies in chronic viral hepatitis	Risky business: preventing respiratory virus infection in high-risk groups	Science in action: implementation science for effective CM/ID practice in diverse settings
DX PHEI		PED VAX	CLN TRN	VAX	CLN PRO
17:30 – 18:30	17:30 – 18:30		17:30 – 18:30	17:30 – 18:30	17:30 – 18:30
SY111	ME112		OS076	EF077	EF078
How to tackle congenital viral infections	Immunisation strategies for vaccine-preventable arboviral diseases: recent advances and future directions		A zoonotic carnival: masquerade syndromes and unusual presentations	Diagnosing mycobacterial infections across the globe	Prevention and management of implant-associated infections: biofilm control and beyond
PED VAX	VAX		CLN	CLN DX PHEI	CLN IPC TRN

COLOUR KEY: Scientific Educational Research Pipeline Industry Specials

ABBREVIATIONS: KN Keynotes SY Symposia FO Open Forums EW Educational sessions ME Meet the expert CS Case sessions OS Oral sessions EF Flash e-Poster sessions IS Integrated Symposia PC Pipeline Corners PM Pipeline Monday sessions SP Special sessions LB Late-Breakers Oral sessions JS Journal sessions

TRACKS: CLN Clinical DX Diagnostics TRN Translational IPC Infection control ANT Antimicrobials VAX Vaccinology & Immunology
 AMR Antimicrobial resistance PED Paediatrics PHEI Public health & Emerging infections PRO Professional & Career

Arena 3	Arena 4
08:30 – 09:30	
EF042	
How viral and host genomics shape infection and immune response	
DX PED TRN	
11:00 – 12:00	11:00 – 12:00
EF052	EF053
From epidemiology to clinical impact of infections in solid organ transplant recipients	Carbapenem resistance: surveillance, mechanisms, and clinical implications
AMR CLN	AMR TRN

13:30 – 14:30	13:30 – 14:30
FO096	EF060
Communicating science today: new media, new platforms	Zoonotic infections: expect the unexpected
PRO	CLN PHEI
14:45 – 15:45	14:45 – 15:45
EF068	EF069
Saving lives, preserving antibiotics: stewardship in the ICU	AI-powered pathogen detection and AMR prediction

16:15 – 17:15	16:15 – 17:15
EF072	EF073
Advances in sepsis diagnostics: improving speed and accuracy	Surveillance of antimicrobial use around the world
ANT CLN	ANT DX
17:30 – 18:30	17:30 – 18:30
EF079	EF080
Molecular epidemiology and genomic evolution of high-priority MDROs	Beyond the cocktail: advances in phage therapy
AMR	ANT TRN

All times are specified in CEST (UTC +2). If attending online, please convert to your local timezone.

Scientific Programme Overview

Monday, 20 April 2026

Hall ICM 14	Hall ICM 1	Hall ICM 13a	Hall ICM 13b	Hall ICM 5	Hall B0-1
	08:30 – 10:30	08:30 – 10:30	08:30 – 10:30	08:30 – 10:30	08:30 – 10:30
09:30 – 10:30	SY113	EW118	EW119	SY114	SY115
SY121 Year in public health	Sepsis 2026: practice-changing insights you can't ignore	Integrating IPC into hospital design: a collaborative approach to safer hospitals	Your attention, please! Parasitic infections in immunocompromised patients	Barriers to infectious disease control and treatment in resource-limited settings	Interconnected microbiomes and resistomes across One Health
	PHEI CLN PHEI	IPC	CLN DX	IPC PHEI	AMR TRN
11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00
KN122	ME126	OS085	OS086	SY123	ME127
On virus origin, evolution, and the next pandemic threat	Applications of machine learning for predicting virulence and resistance by MALDI-TOF MS: opportunities and challenges	Artificial intelligence: emerging applications for medical mycology	Vaccines: landmark trials and preventive immunisation	Going super small: nano-technology in infectious diseases	Microbiome-based diagnostic tools, are we ready for prime-time?
PHEI TRN	AMR DX	CLN	VAX	ANT TRN	DX TRN

	13:30 – 15:30	13:30 – 14:30	13:30 – 14:30	13:30 – 14:30	13:30 – 14:30
	LB007	OS094	OS095	ME133	SY130
	The trial run	Challenging and complicated viral infections	Precision pedagogy: AI-driven and data-driven education	Membrane vesicles: pathogenic factor and emerging targets for antimicrobial therapies	Special issues of IFI in paediatrics
	AMR CLN	CLN PHEI	PRO	ANT TRN	CLN PED
14:45 – 15:45		14:45 – 18:30	14:45 – 15:45	14:45 – 15:45	14:45 – 15:45
SY134		MOVIE	SY135	OS100	OS101
Year in infectious diseases		Behind the scenes: "Don't look up"	Resistance redefined: how to analyse biofilms and anaerobes	Microbiome-host interplay in intestinal disease and under selection pressure	Phage therapy for complex infections
CLN		PHEI PRO	AMR DX	TRN	AMR ANT CLN
16:15 – 17:15	16:15 – 17:15		16:15 – 17:15	16:15 – 17:15	16:15 – 17:15
KN136	ME140		OS109	ME141	SY138
Viral infection in the immunocompromised: from discovery to emerging therapies	Artificial intelligence in antimicrobial stewardship and infection control: from prediction to precision		Melioidosis finds new destinations	Children are not small adults: interactive paediatric cases	Bacteriophages in implant-related infections: translating a century-old concept into a modern solution for AMR
CLN DX	AMR IPC		CLN PHEI	CLN DX PED	AMR ANT CLN
	17:30 – 18:30		17:30 – 18:30	17:30 – 18:30	17:30 – 18:30
	OS115		SY142	ME145	SY143
	Functional and translational advances in microbiome analysis		Redefining One Health	Implementing WHO hepatitis guidelines in LMICs: challenges and perspectives	The future of pathogen surveillance: molecular data without borders
	CLN DX TRN		PHEI	CLN DX VAX	DX PHEI

COLOUR KEY: Scientific Educational Research Pipeline Industry Specials

ABBREVIATIONS: KN Keynotes SY Symposia FO Open Forums EW Educational sessions ME Meet the expert CS Case sessions OS Oral sessions EF Flash e-Poster sessions IS Integrated Symposia PC Pipeline Corners PM Pipeline Monday sessions SP Special sessions LB Late-Breakers Oral sessions JS Journal sessions

TRACKS: CLN Clinical DX Diagnostics TRN Translational IPC Infection control ANT Antimicrobials VAX Vaccinology & Immunology
 AMR Antimicrobial resistance PED Paediatrics PHEI Public health & Emerging infections PRO Professional & Career

Hall B0-2	Hall A1-1	Hall A1-2	Hall A1-3	Hall A1-4	Hall A1-5
08:30 – 10:30	08:30 – 10:00	08:30 – 10:00	08:30 – 10:00	08:30 – 10:00	08:30 – 10:00
OS081	IS32	IS33	IS34	IS35	IS36
Hot topics in tuberculosis CLN PED TRN	Understanding the lasting impact of COVID-19: expert insights on secondary outcomes and the role of vaccination	Precision vs power: smarter panels and the path to metagenomics	Evolving challenges in the treatment of invasive candidiasis: bridging gaps and improving outcomes	No time to kill for bacteria – appropriate antibiotic combinations including IV fosfomycin in patients with difficult-to-treat infections	Rapid, simplified and accessible NGS: transforming clinical microbiology and public health with advanced genomic solutions
11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00
ME128	LB006	OS087	OS088	OS089	OS090
The returned traveler with eosinophilia: clinical, diagnostic and therapeutic approaches CLN DX	Late-breaking disease surveillance approaches PHEI	Hospital- and ventilator-associated pneumonia: new insights on prevention, diagnosis and treatment CLN IPC	Focus on infective endocarditis: from pathogens to prognosis CLN DX TRN	Mechanistic insights into antimicrobial activity and resistance of Gramnegative bacteria AMR ANT	Overcoming diagnostic challenges in low resource settings DX PHEI
	12:15 – 13:15	12:15 – 13:15	12:15 – 13:15		
	IS37	IS38	IS39		
	Syndromic testing impact & the evidence behind it	Dual threats: RSV and HMPV in adult respiratory tract disease	Challenges in vaccine coverage: understanding the drivers and charting a path to recovery		
13:30 – 14:30	13:30 – 15:30	13:30 – 15:00	13:30 – 15:30		13:30 – 15:30
SY131	IS40	IS41	IS42		IS43
Top papers in infections in immunosuppressed patients CLN TRN	The last and next 10 years in <i>Clostridioides difficile</i> infection	RSV and hMPV: symmetry in burden, unity in prevention	Turning insight into impact: optimising bloodstream infection diagnostics with performance metrics		Point-of-care molecular testing: a practical approach to Europe's AMR challenge
14:45 – 15:45					
OS102					
16:15 – 18:15		16:15 – 17:45			
SY137		IS44			
Stronger together: rational design and use of antibiotic combination therapies AMR ANT		Implementing routine nanopore sequencing to modernise and enhance clinical microbiology and public health			
				17:30 - 18:30	
				LB008	
				Late-breaking trials in surgical infection prevention CLN IPC	

All times are specified in CEST (UTC +2). If attending online, please convert to your local timezone.

Scientific Programme Overview

Monday, 20 April 2026

Hall A2-1	Hall A2-2	Hall A3-1	Hall A3-2	Arena 1	Arena 2
08:30 – 10:30	08:30 – 10:30	08:30 – 10:30	08:30 – 10:30		08:30 – 09:30
PM001	EW120	SY116	SY117	09:30 – 10:30	EF082
AI in infectious diseases: the future is now	Future of fungi: biomarkers, big data and mycobiome	Mobile elements and plasmids in Gram-positive pathogens: new frontiers in structure, function and clinical impact	How to maintain the microbial safety of transfusion and transplantation?	EF083 Expanding the role of genomics and proteomics against AMR	Chasing resistance to anti(retro)virals
DX PHEI	TRN	AMR DX	DX PHEI	AMR DX TRN	AMR
11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00
PM002	SY124	SY125	OS091	FO129	EF092
Accelerating access: rethinking HTA to unlock AMR solutions	Innovations in the management of tuberculosis and non-tuberculous mycobacteria	Surgical site infections after solid organ transplantation: an underestimated driver of transplant outcome	Intracellular persistence of Gram-negative pathogens: immune evasion and implications for treatment	Panic vs calm: the pivotal roles of trainees in infectious disease responses	Antimicrobial stewardship in low resource countries: challenges and solutions
AMR PHEI	ANT CLN DX	CLN IPC	TRN	PRO	ANT CLN PHEI

13:30 – 14:30	13:30 – 14:30	13:30 – 14:30	13:30 – 14:30	13:30 – 14:30	13:30 – 14:30
PM004	OS096	JS003	SY132	EF097	EF098
Science under pressure: is it business as usual?	Protozoa and microsporidia: rare and emerging	Late-breaking research from The Lancet: new interventions for more established pathogens	Innovative methodologies for advancing PK/PD studies	Fosfomycin for difficult-to-treat resistant pathogens: is it really a useful weapon?	First, do no harm: allergy, kidney safety and length of stay in antimicrobial stewardship
PHEI PRO	CLN DX PHEI	CLN	ANT TRN	AMR ANT CLN	ANT CLN
14:45 – 15:45	14:45 – 15:45	14:45 – 15:45	14:45 – 15:45	14:45 – 15:45	14:45 – 15:45
PM005	OS103	OS104	OS105	EF106	EF107
From AI for evidence synthesis to decision making	What did you get in the hospital?	Emerging and repurposed therapeutic options in resistant Gram-negatives	Decoding inflammation and innovating diagnostics of parasitic diseases	Latest trends in vaccinology: from current strategies to next-generation vaccines	Infection control and prevention around the world: risks, behaviours, and solutions
PHEI PRO	CLN IPC	AMR ANT CLN	DX TRN	PHEI VAX	AMR IPC
16:15 – 18:15	16:15 – 17:15	16:15 – 17:15	16:15 – 17:15	16:15 – 17:15	16:15 – 17:15
PM006	OS110	SY139	OS111	EF112	EF113
The value of diagnostics and enhancing utilisation	New and novel approaches to complex infections	Setbacks to strength: re-imagining global health partnerships at times of geopolitical uncertainty	Novel aspects of susceptibility testing methods	Respiratory bacterial infections: challenges and advances	Parasitic diseases in a changing world: climate, mobility, and clinical impact
DX PHEI	ANT CLN TRN	PHEI	AMR ANT DX	ANT CLN	CLN PHEI
	17:30 – 18:30	17:30 – 18:30	17:30 – 18:30	17:30 – 18:30	17:30 – 18:30
	OS116	SY144	OS117	EF118	EF119
	Challenging the <i>status quo</i> in herpesvirus therapy	Update on STIs: epidemiology, drug resistance and role of DoxyPEP	PK/PD-based antimicrobial dosing optimisation in children	Beyond culture: spectroscopy for pathogen identification and typing	When fungi break the rules: rare pathogens in unusual sites
	AMR CLN TRN	AMR CLN	ANT CLN TRN	DX PHEI	CLN DX

COLOUR KEY: Scientific Educational Research Pipeline Industry Specials

ABBREVIATIONS: KN Keynotes SY Symposia FO Open Forums EW Educational sessions ME Meet the expert CS Case sessions OS Oral sessions EF Flash e-Poster sessions IS Integrated Symposia PC Pipeline Corners PM Pipeline Monday sessions SP Special sessions LB Late-Breakers Oral sessions JS Journal sessions

TRACKS: CLN Clinical DX Diagnostics TRN Translational IPC Infection control ANT Antimicrobials VAX Vaccinology & Immunology
 AMR Antimicrobial resistance PED Paediatrics PHEI Public health & Emerging infections PRO Professional & Career

Arena 3	Arena 4
	08:30 – 09:30
09:30 – 10:30	PC001
EF084	Vaccines
From virus to host and back again: exploring retroviruses	
11:00 – 12:00	11:00 – 12:00
EF093	PM003
MDR pathogens around the globe: mechanisms, risk, and treatment optimisation	Top papers in industrial diagnostics and drug development – a walkthrough and exploration of cross talk

13:30 – 14:30	13:30 – 14:30
EF099	PC003
Ask AI how to manage antibiotics!	Therapeutics
14:45 – 15:45	14:45 – 15:45
EF108	PC002
Little patients, big challenges: tackling bacterial infections in children	Diagnostics

16:15 – 17:15	16:15 – 17:15
EF114	PC004
Controlling <i>Clostridioides difficile</i> infections and hospital related challenges	Bioinformatics
17:30 – 18:30	17:30 – 18:30
EF120	PM007
Advances in AMR diagnostics	From global research priorities to national and local impact: implementing AMR priority research agendas

All times are specified in CEST (UTC +2). If attending online, please convert to your local timezone.

Scientific Programme Overview

Tuesday, 21 April 2026

Hall ICM 14	Hall ICM 1	Hall ICM 13a	Hall ICM 13b	Hall ICM 5	Hall B0-1
08:30 – 10:30	08:30 – 10:30	08:30 – 10:30		08:30 – 10:30	08:30 – 10:30
CGR	SY147	EW151	09:30 – 10:30	SY146	OS121
Clinical Grand Rounds	The what and how of using AI in antimicrobial stewardship	Bird flu is no longer just for birds: from strategic planning to public health readiness	OS124 Facing severe bacterial infections in neonates and children	Fungal OMICS: from bench to bedside	Genomic epidemiology and emerging bacterial resistance
	CLN ANT CLN	DX PHEI	ANT CLN	CLN DX TRN	AMR
11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00
KN154	SY155	OS129	OS130	SY156	SY157
Genetics underlying susceptibility and immunity to infection	Year in paediatric ID	Making phages GMP-ready: the manufacturing challenge	Navigating clinical realities in travelers and migrant populations	Decoding resistance: the new ESCMID guidelines to halt transmission of multidrug-resistant Gram-negatives	Personalised antimicrobial stewardship for resistant pathogens: beyond clinical trials
TRN VAX	CLN PED VAX	ANT TRN	CLN PHEI	AMR IPC	AMR ANT

	13:30 – 15:30	13:30 – 15:30	13:30 – 15:30	13:30 – 15:30	13:30 – 14:30
	SY163	EW167	EW168	OS139	SY165
	Global landscape of AMR surveillance in Gram-negative bacteria	Inside the black box: leading and developing clinical guidelines	A diagnostic odyssey: how to enhance diagnostic stewardship	Clinical metagenomics: from sample processing to actionable results	Beneath the caspule of <i>Klebsiella pneumoniae</i> : hypervirulence, fitness and adaptive evolution
	AMR	PRO	CLN DX	CLN DX TRN	AMR TRN

COLOUR KEY: Scientific Educational Research Pipeline Industry Specials

ABBREVIATIONS: KN Keynotes SY Symposia FO Open Forums EW Educational sessions ME Meet the expert CS Case sessions OS Oral sessions EF Flash e-Poster sessions IS Integrated Symposia PC Pipeline Corners PM Pipeline Monday sessions SP Special sessions LB Late-Breakers Oral sessions JS Journal sessions

TRACKS: CLN Clinical DX Diagnostics TRN Translational IPC Infection control ANT Antimicrobials VAX Vaccinology & Immunology
 AMR Antimicrobial resistance PED Paediatrics PHEI Public health & Emerging infections PRO Professional & Career

Hall A1-1	Hall A1-2	Hall A1-3	Hall A1-4	Hall A1-5
08:30 – 10:30	08:30 – 09:30	08:30 – 09:30	09:30 – 10:30	
SY148 Advancing diagnostic strategies for detecting bacteremia across the globe CLN DX	OS122 Moving from culture to molecular diagnostics in implant-associated infections CLN DX	LB009 Late-breaking clinical trials in sepsis management CLN	OS125 Regulatory, metabolic, and evolutionary mechanisms shaping <i>Staphylococcus aureus</i> pathogenesis TRN	
11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00
OS131 Bacterial adaptation: from colonization to pathogenesis TRN	ME161 Clinical challenges and management strategies for slowly progressing cutaneous infections CLN	OS132 Modernising surgical site infection surveillance: AI, automation and patient-centred monitoring IPC	SY158 Detecting parasites using metagenomics and proteomics DX TRN	OS133 Community-acquired pneumonia: know your enemies, treat them well ANT CLN PHEI

13:30 – 14:30	13:30 – 15:30	14:30 – 15:30	13:30 – 14:30	14:30 – 15:30
OS140 Transforming diagnostic microbiology with AI CLN DX	SY164 From childhood to adulthood: overcoming barriers in vaccine prevention PED VAX	ME174 How to use serological tests for Lyme borreliosis CLN DX	SY166 One Health beyond AMR: the challenge of <i>Clostridioides difficile</i> infection control outside the hospital IPC PHEI	SY173 Future-proofing IPC: smarter strategies for tomorrow's challenges IPC

All times are specified in CEST (UTC +2). If attending online, please convert to your local timezone.

Scientific Programme Overview

Tuesday, 21 April 2026

Hall A2-1	Hall A2-2	Hall A3-1	Hall A3-2	Arena 1	Arena 2
08:30 – 10:30	08:30 – 10:30	08:30 – 10:30			08:30 – 09:30
SY149	SY150	EW152	09:30 – 10:30	09:30 – 10:30	EF123
The role of the microbiome in shaping clinical outcomes in immunocompromised patients	The real-world impact of IVDR on patient care: threat or opportunity?	Vaccination during pregnancy: for the mother, and for the child	SY153 Pro/con debate: is One Health essential or a distraction in AMR related policies?	EF126 Clinical and diagnostic insights into invasive fungal diseases	Novel aspects on epidemiology and therapeutics of urinary tract infections
CLN TRN	DX	PED VAX	AMR PHEI	CLN DX TRN	CLN
11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00	11:00 – 12:00
SY159	OS134	SY160	OS135	FO162	EF136
To AI or not to AI: latest trends in digital innovation for respiratory virus detection and management	Changing landscape of opportunistic infections in the immunocompromised host	Emerging resistance to new antibiotics: are we already losing the newest tools?	Harnessing wastewater for surveillance of AMR	Integrating Sustainable Development Goals (SDGs) 3 and 5 in policy and practice	Novel aspects in antimicrobial susceptibility testing and resistance detection
DX PHEI	CLN DX	AMR ANT	AMR PHEI	PRO	AMR DX

13:30 – 15:30	13:30 – 15:30	13:30 – 15:30	13:30 – 15:30	14:30 – 15:30	13:30 – 14:30
EW169	EW170	EW171	EW172	EF143	EF141
UTIs off the beaten path: complex patients, complex choices	Take the right path: tips on HIV resistance management in the era of new antiretrovirals	Managing bloodstream infections and endocarditis in the context of drug injection or homelessness	Transplant infectious diseases: real-world challenges through the eyes of the next generation	Shaping policy for antimicrobial use and AMR	New threats to occupational health
CLN	CLN DX	ANT CLN	CLN DX	AMR ANT PHEI	IPC

COLOUR KEY: Scientific Educational Research Pipeline Industry Specials

ABBREVIATIONS: KN Keynotes SY Symposia FO Open Forums EW Educational sessions ME Meet the expert CS Case sessions OS Oral sessions EF Flash e-Poster sessions IS Integrated Symposia PC Pipeline Corners PM Pipeline Monday sessions SP Special sessions LB Late-Breakers Oral sessions JS Journal sessions

TRACKS: CLN Clinical DX Diagnostics TRN Translational IPC Infection control ANT Antimicrobials VAX Vaccinology & Immunology
 AMR Antimicrobial resistance PED Paediatrics PHEI Public health & Emerging infections PRO Professional & Career

Arena 3	Arena 4
<p>09:30 – 10:30</p> <p>EF127</p> <p>Genomic surveillance for infection prevention and outbreak investigation</p> <p>AMR DX IPC</p>	<p>09:30 – 10:30</p> <p>EF128</p> <p>CNS infections at a crossroad: rising lineages, host susceptibility and novel mechanisms</p> <p>CLN PED TRN</p>
<p>11:00 – 12:00</p> <p>EF137</p> <p>Bacterial vaccine pipeline: focus on <i>Staphylococcus</i> and <i>Klebsiella</i></p> <p>VAX</p>	<p>11:00 – 12:00</p> <p>EF138</p> <p>Pneumococcal vaccines: impact and serotype dynamics</p> <p>VAX</p>

<p>13:30 – 14:30</p> <p>EF142</p> <p>Next-generation diagnostics for reproductive health</p> <p>DX</p>	<p>14:30 – 15:30</p> <p>EF144</p> <p>Clinical and epidemiological perspectives on neglected parasitic and fungal diseases</p> <p>CLN PHEI</p>
--	---

All times are specified in CEST (UTC +2). If attending online, please convert to your local timezone.

Invited Speakers

A		Ceyssens, Pieter-Jan, Brussels, Belgium	SY102
Abbara, Aula, London, United Kingdom	SY073	Chabert, Paul M. I., Dumbéa, New Caledonia	CGR
Abela, Irene A, Zürich, Switzerland	SY065	Chaya, Shaakira, Cape town, South Africa	SY085
Acsa, Igizeneza, Kigali, Rwanda	SY097	Chayakulkeeree, Methee, Bangkok, Thailand	EW027
Ahmad, Raheelah, London, United Kingdom	FO105	Chowdhary, Anuradha, Delhi, India	EW027
Al-Aly, Ziyad, Saint Louis, United States	SY032	Chu, Victoria, San Francisco, United States	SY144
Alamri, Maha, Riyadh, Saudi Arabia	EW070	Cirillo, Daniela Maria, Milan, Italy	SY124
Albers, Bianca, Zurich, Switzerland	SY156	Classen, Annika Yanina, Cologne, Germany	SY102
Alcazar Fuoli, Laura, Madrid, Spain	EW120	Closser, Svea, Baltimore, United States	SY114
Alexiev, Ivailo, Sofia, Bulgaria	EW170	Coenye, Tom, Ghent, Belgium	EW001
Amirthalingam, Gayatri, London, United Kingdom	SY101	Colizza, Vittoria, Paris, France	ME099
André, Emmanuel, Leuven, Belgium	SY046	Collinge, John, London, United Kingdom	SY117
Andrea, De Vito, Sassari, Italy	SY083	Colombo, Arnaldo Lopes, São Paulo, Brazil	EW027
Androga, Grace, Blantyre, Malawi	YIA	Comas, Iñaki, Valencia, Spain	SY157
Angebault, Cecile, Creteil, France	EW120	Comoli, Patrizia, Pavia, Italy	SY076
Arkadii, Vodianyik, Kyiv, Ukraine	SY073	Corander, Jukka, Oslo, Norway	SY116
Arnoldini, Markus, Zurich, Switzerland	SY035	Cortes, Claudia, Santiago, Chile	SY067
Asin, Judith, Nairobi, Kenya	FO162	Cosgrove, Sara, Baltimore, United States	ME029
Aslam, Saima, San Diego, United States	ME054	Cowling, Benjamin, Pokfulam, Hong Kong	EW151
Asnicar, Francesco, Trento, Italy	SY158	Craddock, Hillary, Dublin, Ireland	SY044
Assadian, Ojan, Wiener Neustadt, Austria	SY075	Cummins, Enda, Dublin, Ireland	EW039
Aulin, Linda, Leiden, Netherlands	SY137	D	
Azeredo, Joana, Braga, Portugal	EW001	Daneman, Nick, Ontario, Canada	EW005, EW071
Aznar, Maria Luisa, Barcelona, Spain	ME161	Danino, Dana, Beer Sheva, Israel	SY155
B		Davis, Josh, Newcastle, Australia	EW071
Bachman, Michael, Ann Arbor, United States	SY165	Day, Nicholas, Bangkok, Thailand	KN082
Baddley, John, Baltimore, United States	ME055	De Albuquerque Bandeira, Antonio Carlos, Lauro De Freitas, Brazil	ME112
Balaban, Yasemin, Ankara, Türkiye	EW079	De Angelis, Giulia, Rome, Italy	ME053
Bartoletti, Michele, Milan, Italy	SY086	De Boer, Mark G. J., Leiden, Netherlands	EW167
Bartovska, Zofia, Prague, Czechia	SY144	De La Fuente, Javier, Barcelona, Spain	SY066
Basseres, Eugenie, Houston, United States	ME093	De Nisco, Nicole, Richardson, United States	SY109
Batista, Marjorie, São Paulo, Brazil	EW172	De Rooij, Myrna Maria Theresia, Utrecht, Netherlands	SY115
Beh, Jia Qi, Melbourne, Australia	SY116	Deibel, Ansgar, Zurich, Switzerland	EW119
Bejaoui, Semeh, Bologna, Italy	SY166	Delliere, Sarah, Paris, France	YIA
Béranger, Agathe, Paris, France	EW017	Derde, Lennie, Utrecht, Netherlands	EW071
Bertagnolio, Silvia, Geneva, Switzerland	SY103	Derosa, Lisa, Villejuif, France	EW072
Besli, Yesim, Istanbul, Türkiye	SY091	Dessau, Ram B., Slagelse, Denmark	ME174
Bielicki, Julia Anna, London, United Kingdom	SY075	Diavatopoulos, Dimitri, Nijmegen, Netherlands	SY101
Bines, Julie, Parkville, Australia	SY087	Diaz, Lorena, Santiago, Chile	SY034
Blum, Kathrin, Zurich, Switzerland	EW025	Djimde, Abdoulaye, Bamako, Mali	KN057
Boeckh, Michael, Seattle, United States	SY076	Doyle, Maeve, Waterford, Ireland	FO050
Bogaert, Camelia, Gent, Belgium	SY173	Dudman, Susanne Gjeruldsen, Oslo, Norway	ME020
Bogaert, Debby, Edinburgh, United Kingdom	ME127	Dulfer, Elisabeth, Nijmegen, Netherlands	EW026
Bortolaia, Valeria, Copenhagen, Denmark	SY077	Duricek, Marek, Prague, Czechia	ME093
Brandao, Joao, Lisbon, Portugal	SY092	Dyson, Zoe Anne, London, United Kingdom	EW003
Breuer, Judith, London, United Kingdom	ME015	E	
Briers, Erik, Antwerp, Belgium	FO090	Eckmann, Christian, Hannover, Germany	EW005
Brouwer, Michael, Utrecht, Netherlands	SY066	Egli, Adrian, Zurich, Switzerland	ME126
Buonfrate, Dora, Negrar, Italy	EW119	Ekkelenkamp, Miquel, Utrecht, Netherlands	SY110
Butic, Iva, Zagreb, Croatia	ME024	Elkrief, Arielle, Montréal, Canada	EW072
C		Emonts, Marieke, Newcastle Upon Tyne, United Kingdom	SY060
Calbo, Esther, Terrassa, Spain	ME010	Epelboin, Loïc, Cayenne, French Guiana	EW039
Calin, Ruxandra, Paris, France	EW169	Erber, Johanna, Munich, Germany	CGR
Canton, Rafael, Madrid, Spain	ME098	Ergönül, Önder, Istanbul, Türkiye	ME104
Carattoli, Alessandra, Rome, Italy	SY066	EMAIL, Hanif, London, United Kingdom	SY064
Carey, Megan, Amsterdam, Netherlands	SY077	Esposito, Susanna, Parma, Italy	ME094
Carrara, Elena, Verona, Italy	SY160	Essack, Sabiha, Durban, South Africa	SY153
Cartau, Tom, Caen, France	CGR	Ethelberg, Steen, Copenhagen, Denmark	ME048
Carter, Vanessa, Altrincham, United Kingdom	SY084	F	
Carugati, Manuela, Durham, United States	SY125	Falcone, Marco, Pisa, Italy	SY091
Cauchie, Henry-Michel, Belvaux, Luxembourg	ME048	Farkas, Ferenc Balázs, Budapest, Hungary	FO129
Cavaleri, Marco, Amsterdam, Belgium	EW151	Fernandez, Marisa Liliana, Buenos Aires, Argentina	EW119
Cevik, Muge, Edinburgh, United Kingdom	FO050		

Ferreras-Antolin, Laura, London, United Kingdom	SY130	Hrabak, Jaroslav, Plzen, Czechia	ME126
Ferry, Tristan, Lyon, France	SY138	Hsu, Li Yang, Singapore, Singapore	FO056
Finn, Adam, Bristol, United Kingdom	SY164	Huang, Susan, Irvine, United States	KN042
Fisman, David, Toronto, Canada	SY121	Hübner, Johannes, Munich, Germany	EW017
Foldvari, Gabor, Budapest, Hungary	SY074	Huttner, Benedikt, Geneva, Switzerland	SY061
Fornace, Kimberly, Singapore, Singapore	SY059	I	
Friberg, Lena, Uppsala, Sweden	ME088	Iacob, Diana Gabriela, Bucharest, Romania	EW025
Fritz, Blaine, Copenhagen, Denmark	SY031	Ianiro, Gianluca, Rome, Italy	ME127
Fuhrmann, Gregor, Erlangen, Germany	ME133	Ip, Margaret, Hong Kong, Hong Kong	SY134
Fusco, Daniela, Hamburg, Germany	FO162	Isler, Burcu, Gold Coast, Australia	EW171
Futila Kyong-Shin, Ronald, Chapel Hill, United States	SY036	J	
G		Jackson, Holly, Singapore, Singapore	EW071
Gabaldón, Toni, Barcelona, Spain	SY146	Jarvinen, Asko, Helsinki, Finland	EW171
Gacser, Attila, Szeged, Hungary	SY146	Jeannot, Katy, Besançon, France	EW004
Gales, Ana, São Paulo, Brazil	ME028	Jeker, Lukas, Basel, Switzerland	EW040
Gan, Yunn-Hwen, Singapore, Singapore	SY165	Johansen, Helle Krogh, Copenhagen, Denmark	SY035
Gastaldi, Silvana, Mazzano, Italy	FO090	Jones, Chrissie, Southampton, United Kingdom	SY111
Gatermann, Sören, Bochum, Germany	EW038	Joseph, Amelia, Nottingham, United Kingdom	EW002
Geretti, Anna Maria, London, United Kingdom	EW170	K	
Geva-Zatorsky, Naama, , Israel	SY035	Kahl, Olaf, Berlin, Germany	SY074
Giacobbe, Daniele Roberto, Genoa, Italy	EW120	Kalanxhi, Ert, Washington, United States	EW080
Giannella, Maddalena, Bologna, Italy	EW070	Kaparakis-Liaskos, Maria, Melbourne, Australia	ME133
Gibb, Diana, London, United Kingdom	SY052	Karafillakis, Emilie, London, United Kingdom	EW152
Giovanetti, Marta, Rome, Italy	EW095	Karakike, Eleni, Athens, Greece	SY113
Giske, Christian, Stockholm, Sweden	SY083	Karatuna, Onur, Växjö, Sweden	ME024
Gkrania-Klotsas, Effrossyni, Cambridge, United Kingdom	SY131	Karkey, Abhilasha, Kathmandu, Nepal	ME015
Gohil, Shruti, Irvine, United States	SY033	Katragkou, Aspasia, Morristown, United States	EW017
Gola, Marco, Milan, Italy	EW118	Katsemi, Evdokia, Frankfurt, Germany	EW118
Gonzalez-Zorn, Bruno, Madrid, Spain	SY115	Katsounas, Antonios, Bochum, Germany	ME010
Gorfinkel, Rotem, Kibbutz beeri, Israel	CGR	Keynan, Yoav, Winnipeg, Canada	SY067
Govender, Nelesh, Johannesburg, South Africa	SY103	Kipnis, Eric, Lille, France	SY033
Goyal, Girija, Boston, United States	SY132	Kitsou, Chrysoula, College Park, United States	SY069
Grillo, Sara, Barcelona, Spain	EW171	Klein, Florian, Cologne, Germany	SY065
Grobusch, Martin Peter, Amsterdam, Netherlands	ME009	Kline, Kimberly, Geneva, Switzerland	EW001
Grohmann, Elisabeth, Berlin, Germany	SY116	Ko, Kwan Ki Karrie, Singapore, Singapore	SY148
Gudiol, Carlota, Barcelona, Spain	SY076	Koch, Birgit, Rotterdam, Netherlands	ME023
Guéillot, Romain, Melbourne, Australia	ME022	Koenig, Rainer, Jena, Germany	SY062
Gurgel-Gonçalves, Rodrigo, Brasília, Brazil	SY074	Kong, Jude, Toronto, Canada	SY159
H		König, Christina, Hamburg, Germany	ME023
Haerynck, Filomeen, Ghent, Belgium	KN154	Kontoyiannis, Dimitrios P., Houston, United States	KN100
Hanage, William, Boston, United States	ME099	Kowalska, Justyna, Warsaw, Poland	SY067
Hanevik, Kurt, Bergen, Norway	SY121	Kramer, Boris, Poznan, Poland	SY068
Hannan, Margaret, Dublin, Ireland	ME054	Krishnan, Ankur, Heidelberg, Germany	FO049
Hardy, Liselotte, Antwerp, Belgium	SY148	Kruzik, Hynek, Prague, Czechia	FO049
Harvala, Heli, Turku, Finland	SY117	Kurt, Özgür, Istanbul, Türkiye	EW016
Hasse, Barbara, Zurich, Switzerland	EW078	L	
Hayman, David, Palmerston north, New Zealand	ME030	Ladhani, Shamez, London, United Kingdom	EW152
Hazenberg, Mette, Amsterdam, Netherlands	SY149	Lagrou, Katrien, Leuven, Belgium	EW168
Heger, Florian, Vienna, Austria	ME013	Lakatos, Botond, Budapest, Hungary	SY073
Heining, Ulrich, Basel, Switzerland	EW026	Lange, Christoph, Borstel, Germany	EW168
Henao, Andrés, Aurora, United States	EW120	Langford, Bradley, Etobicoke, Canada	SY147
Henostroza, German, Lima, Peru	ME089	Larsen, Tine Graakjær, Værløse, Denmark	SY046
Hernández-Meneses, Marta, Barcelona, Spain	ME007, ME011	Lass-Flörl, Cornelia, Innsbruck, Austria	EW027
Higgins, Paul G., Cologne, Germany	SY163	Leefflang, Mariska, Amsterdam, Netherlands	ME174
Hirsch, Hans H., Tromsø, Norway	KN136	Lefrancq, Noémie, Basel, Switzerland	SY101
Hofer, Ursula, London, United Kingdom	EW002	Legua, Pedro, Lima, Peru	SY043
Hoffmann, Alexandra, Berlin, Germany	FO049	Leitner, Lorenz, Zurich, Switzerland	EW169
Hohl, Tobias, New York, United States	SY146	Len, Oscar, Barcelona, Spain	EW070
Holmes, Edward, Sydney, Australia	KN122	Lesi, Olufunmilayo, Geneva, Switzerland	ME145
Holzknacht, Barbara Juliane, Copenhagen, Denmark	EW038	Leslie, Toby Joseph, London, United Kingdom	EW080
Hovius, Joppe Willem Robert, Amsterdam, Netherlands	SY069	Lestrade, Bram, Roermond, Netherlands	FO049
Howden, Benjamin Peter, Melbourne, Australia	SY143	Levrier, Antoine, Montpellier, France	SY063
Howe, Robin, Cardiff, United Kingdom	EW004	Lindemann, Paul Christoffer, Bergen, Norway	EW004

Invited Speakers

Ling, Lowell, Hong Kong, Hong Kong	ME021
Lopes, Bruno, Middlesbrough, United Kingdom	SY077
Lorenatto, Fabiana, London, United Kingdom	FO105
Low, Nicola, Bern, Switzerland	SY037
Lutsar, Irja, Tartu, Estonia	ME008
Lye, David Chien, Singapore, Singapore	ME030
Lynch, Tarah, Calgary, Canada	EW003

M

Mabayoje, Diana Ayoola, London, United Kingdom	ME128
Maertens, Johan, Leuven, Belgium	ME014
Maillard, Alexis, Paris, France	SY147
Maillard, Jean-Yves, Cardiff, United Kingdom	SY031
Mairpady Shambat, Srikanth, Zurich, Germany	SY108
Malani, Preeti, Ann Arbor, United States	EW002
Malavige, Gathsaurie Neelika, Nugegoda, Sri Lanka	EW095
Malhotra-Kumar, Surbhi, Antwerp, Belgium	EW017, SY106
Manageiro, Vera, Lisbon, Portugal	EW006
Mangioni, Davide, Milan, Italy	EW025
Manuel, Oriol, Lausanne, Switzerland	SY131
Manzoni, Paolo, Turin, Italy	SY130
Marais, Gert, Cape Town, South Africa	SY107
Margalit, Ili, Ramat Gan, Israel	EW078
Marimuthu, Kalisvar, Singapore, Singapore	SY044
Markel, Gal, Petach Tikva, Israel	EW072
Markey, Kate, Seattle, United States	SY149
Marlene, Amara, Paris, France	SY061
Martin, Nicole, Ithaca, United States	EW039
Mathers, Amy, Charlottesville, United States	SY115
Matuschek, Erika, Växjö, Sweden	ME098
McCreary, Erin, Pittsburgh, United States	FO096
Mcdonald, Emily, Montreal, Canada	EW018
McNally, Alan, Birmingham, United Kingdom	SY066
Meintjes, Graeme Ayton, Observatory, South Africa	SY076
Meisner, Julianne, Seattle, United States	SY142
Meletiadis, Joseph, Athens, Greece	ME053
Melidou, Angeliki, Stockholm, Sweden	EW151
Merbl, Yifat, Rehovot, Israel	EW040
Mexia, Ricardo, Lisbon, Portugal	EW006
Meylan, Sylvain, Lausanne, Switzerland	SY033
Ming, Damien, London, United Kingdom	ME140
Minichmayr, Iris K., Vienna, Austria	YIA
Miragaia, Maria, Oeiras, Portugal	SY116
Mirazimi, Ali, Stockholm, Sweden	ME104
Mittal, Ankit, Hyderabad, India	EW172
Mo, Yin, Singapore, Singapore	EW018
Molina Gil-Bermejo, José, Seville, Spain	FO105
Mölling, Paula, Örebro, Sweden	SY034
Montes, Martin, Lima, Peru	ME128
Moran-Gilad, Jacob, Beer Sheva, Israel	SY115
Morel, Chantal, Bonn, Germany	FO056
Moriarty, Thomas Fintan, Davos, Switzerland	SY138
Moshabela, Mosa, Cape town, South Africa	SY139
Mueller, Nicolas, Zurich, Switzerland	SY125
Muhumuza, Umar, Kampala, Uganda	SY113
Mularoni, Alessandra, Palermo, Italy	ME055
Mulder, Willem, Eindhoven, Netherlands	SY123
Murk, Jean-Luc, Blaricum, Netherlands	EW168
Mutters, Nico Tom, Bonn, Germany	SY041, SY173
Mwenda, Mulenga Chilumba, Lusaka, Zambia	SY036
Myaing, Tin Tin, Bangkok, Thailand	SY163

N

Nachtigall, Irit, Berlin, Germany	FO162
Naghavi, Mohsen, Seattle, United States	EW080

Naucler, Pontus, Stockholm, Sweden	SY147
Naveca, Felipe, Manaus, Brazil	EW095
Navon-Venezia, Shiri, Ariel, Israel	ME012
Ndao, Momar, Montreal, Canada	SY158
Neofytos, Dionysios, Geneva, Switzerland	EW169
Neumayr, Andreas, Basel, Switzerland	ME089
Neuzillet, Cindy, Saint Cloud, France	EW072
Ng, Oon Tek, Singapore, Singapore	SY034
Nguyen, Duc Ninh, Frederiksberg, Denmark	SY068
Nguyen, Thanh Thuy Nhien, Ho Chi Minh City, Vietnam	SY036
Nir-Paz, Ran, Jerusalem, Israel	SY063
Njouom, Richard, Yaounde, Cameroon	EW079
Novak Babič, Monika, Ljubljana, Slovenia	SY092
Nsubuga, Mike, Bristol, United Kingdom	SY147
Nunes, Marta, Lyon, France	EW152

O

Ochoa, Theresa J., Lima, Peru	SY068
Oh, Julia, Durham, United States	SY035
Oleastro, Mónica, Lisbon, Portugal	SY166
Ollila, Hanna, Helsinki, Finland	SY032
Ong, Sean Wei Xiang, Toronto, Singapore	EW018
Otelea, Dan, Bucharest, Romania	EW170
Özkaya Şahin, Gülşen, Lund, Sweden	SY150

P

Palma, Paolo, Antwerp, Italy	EW026
Pammi, Mohan, Bellaire, United States	SY060
Pan, Angelo, Cremona, Italy	ME019
Pan, Daniel, Leicester, United Kingdom	YIA
Paño-Pardo, José Ramón, Zaragoza, Spain	EW167, ME140
Papa-Konidari, Anna, Thessaloniki, Greece	EW095
Paraskevis, Dimitrios, Athens, Greece	EW170
Pascucci, Ilaria, Pesaro, Italy	SY074
Patel, Rohan, London, United Kingdom	CGR
Patel, Sanjay, Southampton, United Kingdom	ME141
Paton, Nicholas, Singapore, Singapore	SY064
Paul, Mical, Haifa, Israel	EW167
Peled, Jonathan, New York, United States	SY149
Peleg, Anton, Melbourne, Australia	SY107
Pérez-Rodríguez, María Teresa, Vigo, Spain	EW025
Perrin, Christophe, Paris, France	SY037
Pharris, Anastasia, Stockholm, Sweden	SY037
Phillips, Richard Odame, Kumasi, Ghana	ME161
Phiri, Sam, Lilongwe, Malawi	SY114
Pires, João, Oslo, Norway	EW006
Pistol, Adriana, Bucharest, Romania	SY164
Povoa, Pedro, Lisbon, Portugal	SY045

R

Rahbek, Carsten, Copenhagen, Denmark	SY059
Ramage, Gordon, Glasgow, United Kingdom	SY031
Rao, Gauri, Rancho Palos Verdes, United States	SY132
Ravindra, Akshatha, Karnataka, India	FO050
Read, Robert C., Southampton, United Kingdom	EW002
Reinwald, Mark, Brandenburg, Germany	ME014
Rello, Jordi, Barcelona, Spain	SY045
Rescigno, Maria, Pieve Emanuele, Italy	SY149
Righi, Elda, London, United Kingdom	SY091
Rivero-Juarez, Antonio, Córdoba, Spain	EW079
Robles Aguilar, Gisela, Oxford, United Kingdom	EW080
Rodrigues, Carla, Paris, France	SY101
Rodríguez-Baño, Jesús, Seville, Spain	EW038
Rodríguez-Morales, Alfonso J., Pereira, Colombia	ME112
Rodríguez-Sanchez, Belen, Madrid, Spain	SY106
Roilides, Emmanuel, Thessaloniki, Greece	ME008

Roloff, Tim-Christoph, Zurich, Switzerland	SY143	Tattevin, Pierre, Rennes, France	EW171
Ronalte Alves, Lysangela, Curitiba, Brazil	SY146	Thampy, Anupa, Vellore, Tamil Nadu, India	SY086
Rose, Winsley, Vellore, India	SY114	Timsit, Jean-Francois, Paris, France	ME021
Rosenthal, Anat, Beer Sheva, Israel	SY114	Tiseo, Giusy, Pisa, Italy	EW078
Rothe, Camilla, Munich, Germany	EW016	Tosas Auguet, Olga, Geneva, Switzerland	FO056
Rueda, Zulma Vanessa, Winnipeg, Canada	SY058	Tostmann, Alma, Nijmegen, Netherlands	EW006
Rump, Babette, Middelburg, Netherlands	ME019	Toubiana, Julie, Paris, France	ME141
Rupali, Priscilla, Vellore, India	EW070	Trautner, Barbara, St. Louis, United States	EW169
Russell, Clark, Edinburgh, United Kingdom	YIA	Tsiodras, Sotirios, Athens, Greece	SY032
Ruta, Simona, Bucharest, Romania	SY073	Tsioutis, Constantinos, Nicosia, Cyprus	FO090
Rybniker, Jan, Köln, Germany	EW040	Turner, Paul, Siem Reap, Cambodia	ME029
S		U	
Saha, Senjuti, Dhaka, Bangladesh	KN081	Ushiro-Lumb, Ines, Marlow, United Kingdom	SY117
Said, Zeinab, Cairo, Egypt	ME145	V	
Saint, Lauren, Chapel Hill, United States	CGR, SST01	Valiente, Esmeralda, Berlin, Germany	SY150
Samuelsen, Orjan, Tromso, Norway	ME012	van De Laar, Thijs, Amsterdam, Netherlands	SY117
Sanchez, Pablo, Columbus, United States	SY075	Van Der Vaart, Thomas Wouter, Asmterdam, Netherlands	ME011
Sánchez Céspedes, Javier, Seville, Spain	SY062	Van Ingen, Jakkko, Nijmegen, Netherlands	SY052
Sandulescu, Oana, Bucharest, Romania	ME020	Van Kerkhove, Maria, Geneva, Switzerland	SY139
Sanguinetti, Maurizio, Rome, Italy	SY150	Van Mourik, Maaik, Utrecht, Netherlands	SY041
Sartelli, Massimo, Macerata, Italy	EW005	Van Puyvelde, Sandra, Wilrijk, Belgium	SY077
Satlin, Michael, New York, United States	SY091	Van Santvoort, Hjalmar, Utrecht, Netherlands	EW005
Savic, Rada, San Francisco, United States	SY064	van Sorge, Nina, Amsterdam, Netherlands	SY065
Scaturro, Maria, Rome, Italy	ME013	Vanbiervliet, Yuri, Leuven, Belgium	EW172
Schembri, Aaron, Attard, Malta	SY067	Varon, Emmanuelle, Créteil, France	SY164
Schouten, Jeroen, Nijmegen, Netherlands	SY097	Veeraraghavan, Balaji, Vellore, India	SY163
Scotta, Marcelo, Porto alegre, Brazil	SY064	Velasco, María, Madrid, Spain	ME009
Seale, Holly, Sydney, Australia	SY159	Viale, Pierluigi, Bologna, Italy	ME028
Seas, Carlos, Lima, Peru	EW016	Villa, Jules, Paris, France	FO129
Seemann, Torsten, Melbourne, Australia	EW003	von Both, Ulrich, Munich, Germany	SY155
Seles Dorneles, Elaine Maria, Lavras, Brazil	EW039	Vos, Margreet C., Rotterdam, Netherlands	EW118
Semret, Makeda, Montreal, Canada	SY148	W	
Showalter, Samuel, Aurora, United States	CGR, SST01	Wagenlehner, Florian, Giessen, Germany	SY109
Siegel, Jeffrey, Toronto, Canada	EW118	Walsh, Timothy R., Oxford, United Kingdom	SY160
Simonis, Alexander, Cologne, Germany	SY065	Walti, Carla, Basel, Switzerland	EW172
Skevaki, Chrysanthi, Marburg, Germany	SY032	Wang, Hao, Gothenburg, Sweden	EW079
Skoura, Lemonia, Thessaloniki, Greece	SY163	Waters, Valerie, Toronto, Canada	EW001, SY135
Snell, Luke Blagdon, London, United Kingdom	SY034	Webster, Bonnie, London, United Kingdom	EW016
Snelling, Tom, Sydney, Australia	EW018	Weinbren, Michael, London, United Kingdom	SY031
Sohn, Kai, Stuttgart, Germany	SY148	Wertheim, Heiman, Nijmegen, Netherlands	SY047, SY153
Soto-Martinez, Manuel E., San Jose, Costa Rica	SY085	Weterings, Veronica, Breda, Netherlands	FO090
Sousa-Pinto, Bernardo, Porto, Portugal	SY084	Wicha, Sebastian, Hamburg, Germany	SY137
Spoulou, Vana, Athens, Greece	EW026	Widmer, Andreas F., Füllinsdorf, Switzerland	SY075
Sriruttan-Nel, Charlotte, Johannesburg, South Africa	SY043	Wiersinga, Willem Joost, Amsterdam, Netherlands	SY113
Standing, Joe, London, United Kingdom	SY137	Wolf, Dana, Jerusalem, Israel	SY111
Stefani, Stefania, Catania, Italy	EW004	Wootton, Mandy, Cardiff, United Kingdom	EW038, SY110
Stefanoff, Pawel, Stockholm, Sweden	EW152	Wouthuyzen-Bakker, Marjan, Groningen, Netherlands	EW078
Stévenin, Virginie, Toulouse, France	ME022	Wozniak, Hannah, Geneva, Switzerland	SY033
Stingu, Catalina Suzana, Leipzig, Germany	SY135	Y	
Stock, Michiel, Ghent, Belgium	SY063	Yahav, Dafna, Ramat-Gan, Israel	SY134
Stone, Neil, London, United Kingdom	FO096	Yang, Qiwen, Beijing, China	EW038
Strahilevitz, Jacob, Jerusalem, Israel	SY157	Yassour, Moran, Jerusalem, Israel	SY068
Stride, Eleanor, Oxford, United Kingdom	SY123	Yusuf, Erlangga, Rotterdam, Netherlands	SY150
Stroehlein, Andreas, Berlin, Germany	EW003	Z	
Subbarao, Kanta, Quebec City, Canada	EW151	Zeitlinger, Markus, Vienna, Austria	ME088
Svensson, Elin, Uppsala, Sweden	SY124, SY137	Zekan, Sime, Zagreb, Croatia	SY058
Syrogianopoulos, George A., Larissa, Greece	ME094	Zenner, Dominik, London, United Kingdom	SY037
Szuldrzynski, Konstanty, Mazowieckie, Poland	ME007	Zervos, Marcus, Detroit, United States	EW167
T		Zidovec Lepej, Snjezana, Zagreb, Croatia	EW168
Tacconelli, Evelina, Verona, Italy	SY047, SY156	Zimmermann, Petra, Lucerne, Switzerland	SY087
Tadesse, Fitsum, Addis Ababa, Ethiopia	SY036	Zinkernagel, Annelies, Zurich, Switzerland	SY113
Tamma, Pranita, Philadelphia, United States	SY063	Zinsstag, Jakob, Basel, Switzerland	SY142
Tapadar née Chakravarty, Jaya, Varanasi, India	EW119	Zuhlke, Liesl, Cape Town, South Africa	KN051

Chairpersons

A		
Aamot, Hege Vangstein, Lørenskog, Norway	IS44, OS122, OS139, SY107	
Abbara, Aula, London, United Kingdom	OS048	
Abela, Irene A, Zürich, Switzerland	OS012	
Acsa, Igizeneza, Kigali, Rwanda	EF092	
Aguilar-Zapata, Daniel, Mexico City, Mexico	OS013	
Akova, Murat, Ankara, Türkiye	KN100, SY134	
Alanio, Alexandre, Paris, France	EW027, IS25	
Alastruey, Ana, Madrid, Spain	EF066	
Albers, Bianca, Zurich, Switzerland	SY075	
Alvarez Martinez, Miriam José, Barcelona, Spain	EF032, EW119, SY043	
Amirthalingam, Gayatri, London, United Kingdom	IS03	
André, Emmanuel, Leuven, Belgium	OS063	
Angebault, Cecile, Créteil, France	EF126	
Annabel, Niessen, Utrecht, Netherlands	OS094, OS133, SEL	
Antonelli, Alberto, Florence, Italy	EF136	
Arendrup, Maiken Cavling, Copenhagen, Denmark	OS016	
Arnoldini, Markus, Zurich, Switzerland	OS044, OS065	
Asgeirsson, Hilmi, Stockholm, Sweden	EW016, OS062	
Ashiru-Oredope, Diane, London, United Kingdom	MOVIE, OS003, OS027	
Aslam, Saima, San Diego, United States	SY102	
Aulin, Linda, Leiden, Netherlands	OS057	
Azap, Özlem Kurt, Ankara, Türkiye	EF072, EF137	
Azeredo, Joana, Braga, Portugal	SY031	
B		
Bachman, Michael, Ann Arbor, United States	OS131	
Bachmann, Till T., Edinburgh, United Kingdom	PC003, PM004, PM006	
Baddley, John, Baltimore, United States	EF126	
Barac, Aleksandra, Belgrade, Serbia	EF144, OS096	
Bartoletti, Michele, Milan, Italy	SY033	
Barzon, Luisa, Padua, Italy	WT001	
Bassetti, Matteo, Genoa, Italy	OS133	
Bélard, Sabine, Tübingen, Germany	FO162	
Ben-Ami, Ronen, Tel Aviv, Israel	EF066, OS085	
Benech, Nicolas, Lyon, France	EW072, IS15, SY149	
Berger, Angelika, Vienna, Austria	OS124, SY068, SY075	
Berry, David, Vienna, Austria	OS115	
Besli, Yesim, Istanbul, Türkiye	SY077	
Bhimraj, Adarsh, Houston, United States	SY047	
Bibbins-Domingo, Kirsten, Chicago, United States	EW002, JS001, OS140	
Biehl, Lena, Cologne, Germany	OS115	
Bielec, Filip, Łódź, Poland	EF008, EF127	
Bielicki, Julia Anna, London, United Kingdom	SY155	
Bines, Julie, Parkville, Australia	SY062	
Birgand, Gabriel, Nantes, France	EF078, OS132	
Boeckh, Michael, Seattle, United States	EF031, IS23	
Bogaert, Debby, Edinburgh, United Kingdom	SY115	
Bonten, Marc J.M., Utrecht, Netherlands	EW071, FO049	
Bortolaia, Valeria, Copenhagen, Denmark	OS121	
Both, Anna, Hamburg, Germany	EW080, IS37	
Bottieau, Emmanuel, Antwerp, Belgium	EF024, OS049, OS096	
Brekke, Hanne, Oslo, Norway	EW119, SY158	
Breuer, Judith, London, United Kingdom	EF082	
Brown, Lottie, London, United Kingdom	SY146	
Brugger, Silvio Daniel, Zurich, Switzerland	SY065, SY108	
Buabeng, Kwame Ohene, Ho, Ghana	EF034, EF051, EF092, OS001, OS089, OS090, OS104	
Budimir, Ana, Zagreb, Croatia	SY156	
Bulescu, Casandra, Bucharest, Romania	FO129, OS074, OS109	
Buonfrate, Dora, Negrar, Italy	SY158	
Butic, Iva, Zagreb, Croatia	IS04, SY110	
C		
Calandra, Thierry, Epalinges, Lausanne, Switzerland	SY113	
Calbo, Esther, Terrassa, Spain	EF004, SY061	
Calin, Ruxandra, Paris, France	OS070	
Cambau, Emmanuelle, Paris, France	OS081	
Can, Fusun, Istanbul, Türkiye	IS29, OS001, OS054, OS101, WT002	
Canton, Rafael, Madrid, Spain	EF053	
Carattoli, Alessandra, Rome, Italy	OS011	
Carev, Merica, Split, Croatia	EF093, SY077	
Carevic, Biljana, Oslo, Norway	EF037, EF078, EF079, EF099, EF141, OS014	
Carey, Megan, Amsterdam, Netherlands	LB006	
Carra, Giorgia, Lausanne, Switzerland	PM001	
Carrara, Elena, Verona, Italy	SY153	
Carugati, Manuela, Durham, United States	EF060	
Cauchie, Henry-Michel, Belvaux, Luxembourg	OS135	
Cavaco, Lina, Copenhagen, Denmark	EW072	
Chayakulkeeree, Methee, Bangkok, Thailand	EW120	
Chemaly, Roy, Houston, United States	EW172	
Chiu, Christopher, London, United Kingdom	IS19, OS002, OS029	
Chong, Deborah, London, United Kingdom	OS046	
Chowdhary, Anuradha, Delhi, India	KN100, SSP	
Classen, Annika Yanina, Cologne, Germany	OS055	
Clemente, Wanessa, Belo Horizonte, Brazil	EW070, SY125	
Coenye, Tom, Ghent, Belgium	SY135	
Colizza, Vittoria, Paris, France	OS002	
Colombo, Arnaldo Lopes, São Paulo, Brazil	EW001	
Colzani, Edoardo, Solna, Sweden	EW151	
Comoli, Patrizia, Pavia, Italy	EW040	
Cooper, Ben, Oxford, United Kingdom	SPF001	
Corcione, Silvia, Turin, Italy	OS100, SY149	
Cordoba, Gloria, Copenhagen, Denmark	OS028, SY097	
Cornely, Oliver A., Cologne, Germany	EW120, OS045	
Cortes, Claudia, Santiago, Chile	EW170, IS05	
Cosgrove, Sara, Baltimore, United States	OS014, SSP	
Couet, William, Poitiers, France	OS117	
Couto, Natacha, Cardiff, United Kingdom	EW003, OS030	
Cowling, Benjamin, Pokfulam, Hong Kong	SY159	
Cutler, Sally Jane, London, United Kingdom	EW039, SY074	
D		
Dagan, Ron, Beer-Sheva, Israel	EF138	
Danino, Dana, Beer Sheva, Israel	OS124	
Das, Shampa, Liverpool, United Kingdom	LB005, OS040	
Davies, Kerrie, Leeds, United Kingdom	EF114	
De Angelis, Giulia, Rome, Italy	EW004, KN122	
De Boer, Mark G. J., Leiden, Netherlands	SY147	
De Nisco, Nicole, Richardson, United States	EF142	
Defres, Sylviane, Liverpool, United Kingdom	EF059, OS116	
Delliere, Sarah, Paris, France	OS095	
Diaz, Lorena, Santiago, Chile	OS021	
Dinh, Aurélien, Garches, France	OS133	
Djimde, Abdoulaye, Bamako, Mali	SY036	
Dreesen, Erwin, Leuven, Belgium	EF038	
Drexler, Jan Felix, Berlin, Germany	SY062	
Drulis-Kawa, Zuzanna, Wroclaw, Poland	EF080, OS101, OS129, SY035	
Duarte, Raquel, Porto, Portugal	OS063, SY032	
Dudman, Susanne Gjeruldsen, Oslo, Norway	SY111	
E		
Egli, Adrian, Zurich, Switzerland	SY143	

Epaulard, Olivier, Grenoble, France	EW152
Epelboin, Loïc, Cayenne, French Guiana	OS049, OS076
Esmail, Hanif, London, United Kingdom	EF006
Esposito, Susanna, Parma, Italy	IS21, SY085
Essack, Sabiha, Durban, South Africa	EW118
Esser, Stefan, , Germany	EF142
Ethelberg, Steen, Copenhagen, Denmark	OS048, OS135
Eyre, David, Oxford, United Kingdom	PM005
F	
Falcone, Marco, Pisa, Italy	SY073
Farfan, Mauricio, Santiago, Chile	EF032, SY035
Farkas, Ferenc Balázs, Budapest, Hungary	SY043
Ferreras-Antolin, Laura, London, United Kingdom	SY064
Ferry, Tristan, Lyon, France	SY063
Finn, Adam, Bristol, United Kingdom	IS01
Fisman, David, Toronto, Canada	LB002
Fitzpatrick, Fidelma, Dublin, Ireland	KN051, OS065, SY044
Fragkou, Paraskevi C., Markopoulo Mesogeion, Greece	IS38, SY032
Freitas, Ana Raquel, Porto, Portugal	EW039, MOVIE
Friedland, Jon S., London, United Kingdom	EF077, KN081, YIA
Friedrichs, Anette, Kiel, Germany	OS022
Fuchs, Andre, Augsburg, Germany	OS096
Fuhrmann, Gregor, Erlangen, Germany	OS091, SY123
G	
Gabaldón, Toni, Barcelona, Spain	OS085
Gales, Ana, São Paulo, Brazil	OS055, SY160
Gan, Yunn-Hwen, Singapore, Singapore	OS011
Gangneux, Jean-Pierre, Rennes, France	OS016
Garcia Vidal, Carolina, Barcelona, Spain	EF099
Gatermann, Sören, Bochum, Germany	EF136, OS111, SY110
Gavazzi, Gaetan, Grenoble, France	OS075
Geerlings, Suzanne, Amsterdam, Netherlands	EF123, EW169
Geretti, Anna Maria, London, United Kingdom	EF084
Giacobbe, Daniele Roberto, Genoa, Italy	OS009
Giannella, Maddalena, Bologna, Italy	KN136, OS019, OS021
Giannitsioti, Efthymia, Athens, Greece	EW078, SY135
Gilchrist, Mark, London, United Kingdom	SY147
Giske, Christian, Stockholm, Sweden	IS30
Gkrania-Klotsas, Effrossyni, Cambridge, United Kingdom	SY076
Glauser, Michel P., Lausanne, Switzerland	OS013
Gmizic, Ivana, Belgrade, Serbia	SY058
Goering, Richard V., Omaha, United States	EF127
Gohil, Shruti, Irvine, United States	OS020
Goletti, Delia, Rome, Italy	OS046
Govender, Nelesh, Johannesburg, South Africa	EW027
Greub, Gilbert, Lausanne, Switzerland	IS26, OS047, OS139
Grobusch, Martin Peter, Amsterdam, Netherlands	SY036
Grohmann, Elisabeth, Berlin, Germany	OS131
Groll, Andreas H., Münster, Germany	OS050, SY130
Grupel, Daniel, Jerusalem, Israel	LB004, OS022
Gudiol, Carlota, Barcelona, Spain	EF031, SY131
Guglielmetti, Lorenzo, Negrar Di Valpolicella, Italy	OS081, SY064, SY157
Gupta, Nitin, Manipal, India	OS090, SY114
Gupta, Yogesh Kumar, Jaipur, India	EF059, OS070, OS074, OS109
Gurgel-Gonçalves, Rodrigo, Brasília, Brazil	OS062
H	
Haas, Hervé, Nice, France	OS124, SY155, SY164
Hakanen, Antti, Turku, Finland	SY150
Hall, Victoria, Melbourne, Australia	EF042, EF043, EW070
Hanage, William, Boston, United States	MOVIE
Hannan, Margaret, Dublin, Ireland	OS027
Harboe, Zitta Barrella, Hillerød, Denmark	EF138, LB001, SY087
Harvala, Heli, Turku, Finland	EF005
Harxhi, Arjan, Tirana, Albania	EF035, OS102, SY144
Hassan, Syeda Saleha, London, United Kingdom	JS003
Hassoun-Kheir, Nasreen, Pitach Tikva, Israel	EF107, EF120
Hayman, David, Palmerston North, New Zealand	OS056
Hegstad, Kristin, Tromso, Norway	SY116
Heininger, Ulrich, Basel, Switzerland	EW152
Henningsson, Anna J., Jönköping, Sweden	IS22, SY069
Hensgens, Marjolein, Utrecht, Netherlands	OS055
Higgins, Paul G., Cologne, Germany	IS11
Holzknicht, Barbara Juliane, Copenhagen, Denmark	LB004
Horgan, Mary, Dublin, Ireland	FO050, OS095, SSP
Howden, Benjamin Peter, Melbourne, Australia	OS011, OS140, SSP
Hrabak, Jaroslav, Plzen, Czechia	EF079, OS104
Hsu, Li Yang, Singapore, Singapore	KN082
Hübner, Johannes, Munich, Germany	OS019, OS124
Hulscher, Marlies, Nijmegen, Netherlands	FO105
Hussein, Khetam, Nahariya, Israel	OS030
Huttner, Angela, Geneva, Switzerland	EW169, FO096, LB007
Huttner, Benedikt, Geneva, Switzerland	FO056, PM007
I	
Iaria, Chiara, Palermo, Italy	EF097
Iosifidis, Ilias P., Thessaloniki, Greece	EW026, SY060, WT008
Ip, Margaret, Hong Kong, Hong Kong	EF112, EF114, IS16
J	
Jarvinen, Asko, Helsinki, Finland	EF058
Jeannot, Katy, Besançon, France	OS010
Jokelainen, Pikka, Copenhagen, Denmark	OS105, SY142
Joseph, Amelia, Nottingham, United Kingdom	EW018
K	
Kahlmeter, Gunnar, Tävelsås, Sweden	EF008
Kaiser, Laurent, Geneva, Switzerland	LB003
Kalil, Andre, Omaha, United States	EF097, JS002, OS020, OS065
Kantele, Anu, Helsinki, Finland	KN057
Kaparakis-Liaskos, Maria, Melbourne, Australia	OS044
Karatuna, Onur, Växjö, Sweden	IS18
Karkey, Abhilasha, Kathmandu, Nepal	SY107
Katragkou, Aspasia, Morristown, United States	SY130
Katsounas, Antonios, Bochum, Germany	IS08, OS087, SY045, WT006
Kelly, Christine, Dublin, United Kingdom	SY065
Keynan, Yoav, Winnipeg, Canada	CGR, SY134
Khanna, Nina, Basel, Switzerland	CGR, SY076
Kilgarriff, Sinead, Dublin, Ireland	EF143
Kline, Kimberly, Geneva, Switzerland	SSP, SY123
Kluytmans, Jan A.J.W., Utrecht, Netherlands	KN154, OS131, YIA
Koch, Birgit, Rotterdam, Netherlands	SSP, SY132
König, Christina, Hamburg, Germany	IS13, OS057, OS103
Kontoyiannis, Dimitrios P., Houston, United States	CGR, IS09
Koopmans, Marion, Rotterdam, Netherlands	SY059
Kostyanev, Tomislav, Esbjerg, Denmark	EF068, EF120, SY157
Koulenti, Despoina, London, United Kingdom	EF058, OS039
Kowalska, Justyna, Warsaw, Poland	IS20, OS102
Kramer, Boris, Poznan, Poland	SY111
Krammer, Florian, New York, United States	OS003
Krause, Tyra Grove, Copenhagen, Denmark	OS029, SY046, SY059
Krutova, Marcela, Prague, Czechia	EF023, SY166
Kuijper, Ed J., Leiden, Netherlands	OS100, SY087
Kurt, Özgür, Istanbul, Türkiye	EF024, SSP
L	
Ladhani, Shamez, London, United Kingdom	IS39
Lagrou, Katrien, Leuven, Belgium	SY103

Chairpersons

Lakatos, Botond, Budapest, Hungary	EW170	Moser, Claus, Copenhagen, Denmark	SY031
Lambrechts, Merel, Leiden, Netherlands	SY109	Mossong, Joel, Luxembourg, Luxembourg	OS086, SY046, WT003
Lamy, Brigitte, Bobigny, France	EW171, SY106	Mpundu, Mirfin, Lusaka, Zambia	EF018
Lange, Christoph, Borstel, Germany	EF006	Mueller, Nicolas, Zurich, Switzerland	EW040
Langford, Bradley, Etobicoke, Canada	OS075	Mularoni, Alessandra, Palermo, Italy	IS40
Lass-Flörl, Cornelia, Innsbruck, Austria	OS045	Muller, Anouk Edwina, The Hague, Netherlands	SY137
Laurent, Frédéric, Lyon, France	OS125, SY102	Munoz Garcia-Paredes, Patricia, Madrid, Spain	EF052
Leefflang, Mariska, Amsterdam, Netherlands	OS140	Murri, Rita, Rome, Italy	EF051, WT007
Leibovici, Leonard, Yahud, Israel	EW002	Myaing, Tin Tin, Bangkok, Thailand	OS062
Lejko Zupanc, Tatjana, Ljubljana, Slovenia	EW025, OS088	N	
Len, Oscar, Barcelona, Spain	SY117	Nagavci, Blin, Gjakova, Kosovo	EW167
Lentz, Christian Stephan, Tromsø, Norway	OS091, SY165, WT009	Narayanan, Navaneeth, New Brunswick, United States	EW018
Lescure, Xavier, Paris, France	EW095, KN082, OS030	Navon-Venezia, Shiri, Ariel, Israel	SY165
Lestrade, Bram, Roermond, Netherlands	SY083	Neidhöfer, Claudio, Basel, Switzerland	SY034
Lindemann, Paul Christoffer, Bergen, Norway	SY061	Neofytos, Dionysios, Geneva, Switzerland	OS116, OS134
Lindsay, Diane, Glasgow, United Kingdom	EF083	Nesher, Lior, Beersheba, Israel	OS134
Loader, Maria Cristina, London, United Kingdom	EW016	Neumayr, Andreas, Basel, Switzerland	OS130
Lofmark Behrendtz, Sonja, Solna, Sweden	SY142	Ng, Rita, Hong Kong, Hong Kong	SY091
Lopes, Maria João, Amadora, Portugal	EF107, OS075, OS109	Nguyen, Tuyen, Laval, Canada	OS026
Lopez Cerero, Lorena, Seville, Spain	EF083, OS054	Nir-Paz, Ran, Jerusalem, Israel	OS129
Low, Nicola, Bern, Switzerland	OS012	Nohynek, Hanna M., Helsinki, Finland	EW026, IS14
Lutsar, Irja, Tartu, Estonia	EF067, IS07	Nolte, Oliver, Zürich, Switzerland	PM001
Lye, David Chien, Singapore, Singapore	EF106	Norrby-Teglund, Anna, Stockholm, Sweden	OS044, SY108
M		Nosanchuk, Josh, Bronx, United States	EF119, SEL, SY146
MacGowan, Alasdair Peter, Bristol, United Kingdom	EW038, IS35, LB005	Novais, Angela, Porto, Portugal	EF093, EF118, EW006
MacKenzie, Colin R., Neuss, Germany	SY084	Nsubuga, Mike, Bristol, United Kingdom	OS132
Maertens, Johan, Leuven, Belgium	EF119	Nyčová, Aneta, Praha, Czechia	EW171
Mahmood, Syed Faisal, Karachi, Pakistan	SY097	Nyemazi, Jean Pierre, Genf, Switzerland	SPF003
Mailles, Alexandra, Saint-Maurice, France	OS094, SY121	O	
Malani, Preeti, Ann Arbor, United States	JS001, SY045	Obiero, Christina, Kilifi, Kenya	EF108, SY148, WT010
Malavige, Gathsaurie Neelika, Nugegoda, Sri Lanka	EF017	Ochoa, Theresa J., Lima, Peru	OS019
Manuel, Oriol, Lausanne, Switzerland	EF052	O'Donnell, Sinead, Dublin, Ireland	EF037
Marais, Gert, Cape Town, South Africa	IS27	Oh, Julia, Durham, United States	OS100
Marchand, Sandrine, Poitiers, France	IS10, SY137	Oladele, Rita, Lagos, Nigeria	SY103, SY121
Mares, Mihai, Iași, Romania	SY092	Oleary, Flaminia, Berlin, Germany	OS014, OS056
Margalit, Ili, Ramat Gan, Israel	LB008	Ong, Catherine, Singapore, Singapore	OS046, SY124
Marimuthu, Kalisvar, Singapore, Singapore	EF073	Ong, David, Rotterdam, Netherlands	EF072, SY150
Marlene, Amara, Paris, France	EW038	Opota, Onya, Lausanne, Switzerland	SY124
Martin, Luise, Berlin, Germany	EF108, EW017	Osaigbovo, Iriagbonse, Nigeria	OS045
Märtson, Anne-Grete, Leiden, Netherlands	JS002	Özkaya Şahin, Gülşen, Lund, Sweden	EW079, KN154
Mathers, Amy, Charlottesville, United States	OS135, IS42	P	
Maver Vodincar, Polona, Ljubljana, Slovenia	EW168, OS028	Pai Mangalore, Rekha, Melbourne, Australia	OS001, OS090, OS110
McCreary, Erin, Pittsburgh, United States	OS009	Palos, Carlos, Lisbon, Portugal	EF036
Mcdonald, Emily, Montreal, Canada	SSP	Paño-Pardo, José Ramón, Zaragoza, Spain	SEL
McGann, Patrick, Silver Spring, United States	SY163	Papa-Konidari, Anna, Thessaloniki, Greece	IS31, SY117
Meletiadis, Joseph, Athens, Greece	OS057	Papapaskevas, Joseph, Athens, Greece	OS027, OS076
Melnyk, Tetiana, Paris, France	SY139	Papic, Neven, Zagreb, Croatia	EF035, EW168, OS002
Melo, Luís, Coimbra, Portugal	EW001	Parczewski, Milosz, Szczecin, Poland	EF084
Mestrovic, Tomislav, Varaždin, Croatia	EW080, SY037	Patel, Robin, Rochester, United States	SY113
Mexia, Ricardo, Lisbon, Portugal	LB002, SSP	Paterson, David L., Singapore, Singapore	CGR, LB007
Mikulska, Malgorzata, Genoa, Italy	OS134	Peiffer-Smadja, Nathan, Paris, France	EF034, EW172
Ming, Damien, London, United Kingdom	SY033	Peleg, Anton, Melbourne, Australia	EF118
Minichmayr, Iris K., Vienna, Austria	EF038, OS040, OS117	Pellejero, Galadriel, Zaragoza, Spain	EF051
Mo, Yin, Singapore, Singapore	SY086	Perencevich, Eli, Iowa City, United States	LB008
Molina, Jean-Michel, Paris, France	SY144	Pires, João, Oslo, Norway	OS121
Molina Gil-Bermejo, José, Seville, Spain	OS009	Pirnay, Jean-Paul, Brussels, Belgium	OS129, SY063
Mölling, Paula, Örebro, Sweden	SY143	Postma, Maarten, Groningen, Netherlands	PM002
Montes, Martin, Lima, Peru	OS105	Pournaras, Spyros, Athens, Greece	IS28, OS101, SY091
Moran-Gilad, Jacob, Beer Sheva, Israel	KN122, SEL	Presterl, Elisabeth, Vienna, Austria	OS087, SY173
Mora-Rillo, Marta, Madrid, Spain	LB003	R	
Morel, Chantal, Bonn, Germany	OS003	Rabbi, Lorenzo, Berlin, Germany	SY058
Moriarty, Thomas Fintan, Davos, Switzerland	OS122	Raffetin, Alice, Villeneuve-Saint-Georges, France	SY074
		Rahmel, Tim, Bochum, Germany	OS039

Ramasamy, Maheshi, Oxford, United Kingdom	LB001
Ramirez, Mario, Lisbon, Portugal	EF025, SY083
Rath, Barbara, New Orleans, United States	EW151
Rawat, Sumit Kumar, Sagar, India	EF113, EW079
Read, Robert C., Southampton, United Kingdom	OS010
Rego, Ryan, Ceske Budejovice, Czechia	OS056, SY069
Rello, Jordi, Barcelona, Spain	EW078
Retamar Gentil, Pilar, Seville, Spain	EF098, OS020, OS087
Richardson, Riina, Manchester, United Kingdom	OS061
Righi, Elda, London, United Kingdom	SY125
Rodrigues, Carla, Paris, France	LB006
Rodríguez-Baño, Jesús, Seville, Spain	SEL
Rodríguez-Morales, Alfonso J., Pereira, Colombia	EW095
Rodríguez-Sánchez, Belen, Madrid, Spain	EF025, EF069, IS36
Roer, Louise, Copenhagen, Denmark	SY066
Rohde, Holger, Hamburg, Germany	EW004, MOVIE, PC002, PM005, SPF002, SY106
Roloff, Tim-Christoph, Zurich, Switzerland	PC004
Ronalte Alves, Lysangela, Curitiba, Brazil	EF033
Rosales-Klintz, Senia, Solna, Sweden	SY037
Rosińska, Magdalena, Warsaw, Poland	EF043, SY067
Rossen, John W. A., Groningen, Netherlands	EW003, IS17, SY115
Rossolini, Gian Maria, Florence, Italy	OS089
Rothe, Camilla, Munich, Germany	EF113
Rump, Babette, Middelburg, Netherlands	EF143
Rupali, Priscilla, Vellore, India	CGR, SY114
Ruta, Simona, Bucharest, Romania	OS029, WT005
Rybniker, Jan, Köln, Germany	OS010
S	
Salmanton-García, Jon, Cologne, Germany	IS34, OS015
Sanchez, Pablo, Columbus, United States	SY068
Sandulescu, Oana, Bucharest, Romania	EF042, EF053, OS070, OS086
Sanguinetti, Maurizio, Rome, Italy	OS115, IS33
Schembri, Aaron, Attard, Malta	OS012
Schölvinck, Elisabeth, Groningen, Netherlands	SY052
Schouten, Jeroen, Nijmegen, Netherlands	OS087
Schuepbach, Reto, Zurich, Switzerland	OS039
Schwartz, Stefan, Berlin, Germany	OS050, SY131
Scudeller, Luigia, Pavia, Italy	EW167, MOVIE, SY084
Seale, Holly, Sydney, Australia	IS02
Seas, Carlos, Lima, Peru	EF017, KN057, WT004
Seemann, Torsten, Melbourne, Australia	SY034
Segal, Esther, Tel Aviv, Israel	OS016, SY092
Sekkides, Onisillos, London, United Kingdom	JS003
Seles Dorneles, Elaine Maria, Lavras, Minas Gerais, Brazil	OS130
Sendi, Parham, Bern, Switzerland	OS064, OS088
Severin, Juliette, Rotterdam, Netherlands	OS090, SY044
Sharland, Mike, London, United Kingdom	EF067, SPF001
Shingadia, Delane, London, United Kingdom	SY052
Simkins, Jacques, Miami, United States	OS110
Sinha, Bhanu, Groningen, Netherlands	EF068, SY047
Skevaki, Chrysanthi, Marburg, Germany	IS41, SY085
Skov, Robert Leo, Copenhagen, Denmark	KN042, OS121, PM004, SPF002
Slavin, Monica, Melbourne, Australia	CGR, KN136, OS015
Soki, Jozsef, Szeged, Hungary	SY066
Sonnevend, Agnes Maria, Pécs, Hungary	IS43, OS028, SY148
Sousa-Pinto, Bernardo, Porto, Portugal	OS061
Spoulou, Vana, Athens, Greece	EF071, SSP
Sriruttan-Nel, Charlotte, Johannesburg, South Africa	EF128, OS026
Stegger, Marc, Copenhagen, Denmark	OS125, SY116

Šterbenc, Anja, Ljubljana, Slovenia	SEL
Stevanovikj, Milena, Skopje, North Macedonia	OS102, SY067
Stroehlein, Andreas, Berlin, Germany	OS105
Struelens, Marc Jean, Rochefort, Belgium	SY139
Suh, Gina, Rochester, United States	OS007, SY138
T	
Tadesse, Fitsum, Addis Ababa, Ethiopia	OS049
Tambic Andrasevic, Arjana, Zagreb, Croatia	OS111, SY109
Tambyah, Paul A., Singapore, Singapore	SY163
Tamma, Pranita, Philadelphia, United States	SY086
Tan, Tina, Chicago, United States	SY164
Tängdén, Thomas, Uppsala, Switzerland	OS089
Tapadar née Chakravarty, Jaya, Varanasi, India	EF144
Tartari, Ermira, Msida, Malta	FO090, SY041, WT011
Tassios, Panayotis T., Athens, Greece	OS089
Tcholakov, Yassen, Montréal, Canada	EW006
Telles, João Paulo, São Paulo, Brazil	EW017
Ten Oever, Jaap, Nijmegen, Netherlands	EF004
Thampy, Anupa, Vellore, Tamil Nadu, India	OS063
Timsit, Jean-Francois, Paris, France	LB009
Tiseo, Giusy, Pisa, Italy	OS104
Tomczyk, Sara, Berlin, Germany	EF018, OS103, OS133
Tong, Steven, Melbourne, Australia	LB007, LB009
Toubiana, Julie, Paris, France	SSP, SY101
Trampuz, Andrej, Brisbane, Australia	OS064, SY138
Tsiodras, Sotirios, Athens, Greece	MOVIE
Tsioutis, Constantinos, Nicosia, Cyprus	EW118
Turner, Paul, Siem Reap, Cambodia	SSP
U	
Uckay, Ilker Hasan, Zurich, Switzerland	EF036, OS064
Ushiro-Lumb, Ines, Marlow, United Kingdom	OS074, OS130
V	
Vale, Ana, Dublin, Ireland	SY166
Valiente, Esmeralda, Berlin, Germany	SY159
van Duin, David, Chapel Hill, United States	IS06, SEL
Van Ingen, Jakkko, Nijmegen, Netherlands	EF077
van Sorge, Nina, Amsterdam, Netherlands	OS091
Varon, Emmanuelle, Creteil, France	EF112, EF128
Veeraraghavan, Balaji, Vellore, India	SY160
Vehreschild, Maria, Frankfurt Am Main, Germany	EF080, OS085
Veloo, Alida C.M., Groningen, Netherlands	EW005
Vernhes, Charlotte, Brussels, Belgium	PC001, PM002
Villalobos, Armelle, Winnipeg, Canada	OS013
von Both, Ulrich, Munich, Germany	EF108
Voordouw, Bettie, Culemborg, Netherlands	EF005, EF041
Vos, Margreet C., Rotterdam, Netherlands	KN042
Voss, Andreas, Groningen, Netherlands	OS111, SY156
W	
Walsh, Timothy R., Oxford, United Kingdom	SY153
Walti, Carla, Basel, Switzerland	OS015
Wang, Hao, Gothenburg, Sweden	OS140
Warris, Adilia, Exeter, United Kingdom	EF033
Wejse, Christian, Aarhus, Denmark	OS081, SY073
Werner, Guido, Wernigerode, Germany	EF137, OS139
Wertheim, Heiman, Nijmegen, Netherlands	IS12
Wicha, Sebastian, Hamburg, Germany	SY132
Widmer, Andreas F., Füllinsdorf, Switzerland	EF069, SY173
Wiersinga, Willem Joost, Amsterdam, Netherlands	EF098
Willinger, Birgit, Vienna, Austria	EW005, SY060
Wolf, Dana, Jerusalem, Israel	IS32
Wolkewitz, Martin, Freiburg, Germany	OS132
Wonderly Trainor, Betsy, Boston, United States	PM006, SPF002
Wouthuyzen-Bakker, Marjan, Groningen, Netherlands	OS122

Chairpersons

Y

Yahav, Dafna, Ramat-Gan, Israel	EF073, EW071, IS24
Yang, Qiwen, Beijing, China	OS047
Yusuf, Erlangga, Rotterdam, Netherlands	OS007, OS047

Z

Zeitlinger, Markus, Vienna, Austria	OS040
Zeller, Georg, Leiden, Netherlands	OS115
Zemlickova, Helena, Prague, Czechia	EF079, OS021, WT012
Zervos, Marcus, Detroit, United States	EF123
Zidovec Lepej, Snjezana, Zagreb, Croatia	EF082
Zimmermann, Stefan, Heidelberg, Germany	OS094, OS116
Zingg, Walter, Zurich, Switzerland	EW025, SY041
Zinkernagel, Annelies, Zurich, Switzerland	KN051



**Scientific Programme
with Session Details**

Munich, Germany
17–21 April 2026

**20
26**

Scientific Programme

Friday, 17 April 2026

EW001 08:30 - 10:30 Hall ICM 13a
 TRN 2-hour Educational Session

Strategies to tackle biofilm-associated infections

Chairs Arnaldo Lopes Colombo (Sao Paulo, Brazil)
 Luis Melo (Coimbra, Portugal)

- W0061 08:30 Pathogenesis of biofilm-associated infections**
 Kimberly Kline (Geneva, Switzerland)
- W0062 08:50 Viral therapies to tackle biofilm-associated infections**
 Joana Azeredo (Braga, Portugal)
- W0063 09:10 Molecular basis of tolerance and resistance in biofilms**
 Tom Coenye (Ghent, Belgium)
- W0064 09:30 Assessing *in vivo* anti-biofilm activity**
 Valerie Waters (Toronto, Canada)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

EW002 08:30 - 10:30 Hall ICM 13b
 PRO 2-hour Educational Session

Overcoming ongoing challenges in CM/ID publishing

Chairs Kirsten Bibbins-Domingo (San Francisco, United States)
 Leonard Leibovici (Yahud, Israel)

- W0065 08:30 Peer-review: the future?**
 Amelia Joseph (Nottingham, United Kingdom)
- W0066 08:50 Preparing the next generation of peer reviewers**
 Preeti Malani (Ann Arbor, Michigan, United States)
- W0067 09:10 Efforts to make the literature unbiased**
 Ursula Hofer (London, United Kingdom)
- W0068 09:30 From authors to peer reviewers to editors: how should we handle the use of AI in publishing?**
 Robert C. Read (Southampton, United Kingdom)

Co-organised with: CMI Board of Editors, CMI Communications Board of Editors

EW003 08:30 - 10:30 Hall ICM 5
 IPC PHEI TRN 2-hour Educational Session

A gentle introduction to bioinformatics for microbial genomics

Chairs Natacha Couto (Cardiff, United Kingdom)
 John W. A. Rossen (Groningen, Netherlands)

- W0069 08:30 Quality control of whole genome sequencing data**
 Tarah Lynch (Calgary, Canada)
- W0070 08:50 Genome assembly, read mapping and variant calling**
 Torsten Seemann (Melbourne, Australia)
- W0071 09:10 Species determination, genotyping and AMR prediction**
 Andreas Stroehlein (Berlin, Germany)
- W0072 09:30 Understating trees: phylogenomics for infection control**
 Zoe Anne Dyson (London, United Kingdom)

EW004 08:30 - 10:30 Hall B0-1
 AMR CLN DX 2-hour Educational Session

The antibiogram: from theory to clinical practice

Chairs Giulia De Angelis (Rome, Italy)
 Holger Rohde (Hamburg, Germany)

- W0073 08:30 The antibiogram demystified: principles, methods, and clinical significance**
 Paul Christoffer Lindemann (Bergen, Norway)
- W0074 08:50 Interpreting Gram-negative antibiograms**
 Katy Jeannot (Besançon, France)
- W0075 09:10 Interpreting Gram-positive antibiograms**
 Stefania Stefani (Catania, Italy)
- W0076 09:30 From the antibiogram to antibiotic choice: clinical reasoning in action**
 Robin Howe (Cardiff, United Kingdom)

Co-organised with: ESCMID AMR Action Subcommittee

EW005 08:30 - 10:30 Hall B0-2
 CLN IPC 2-hour Educational Session

Prevention and treatment for specific intra-abdominal infections

Chairs Alida C.M. Veloo (Groningen, Netherlands)
 Birgit Willinger (Vienna, Austria)

W0077 08:30 Prevention of postoperative infection in bowel surgery: mechanical and/or oral antibiotics: what and when?
 Christian Eckmann (Hannover, Germany)

W0078 08:50 Selective decontamination: benefits and resistance development
 Nick Daneman (Ontario, Canada)

W0079 09:10 Necrotising pancreatitis and antibiotics: prophylaxis or early therapy?
 Hjalmar Van Santvoort (Utrecht, Netherlands)

W0080 09:30 Diverticulitis: exact diagnosis and indications for antibiotic therapy
 Massimo Sartelli (Macerata, Italy)

Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), ESCMID Study Group for Anaerobic Infections (ESGAI)

EW006 08:30 - 10:30 Hall A1-4
 AMR IPC PHEI 2-hour Educational Session

Outbreak investigation: through the eyes of a field epidemiologist and public health microbiologist

Chairs Angela Novais (Porto, Portugal)
 Yassen Tcholakov (Montréal, Canada)

W0081 08:30 Field epidemiology: principles and the 10 steps of outbreak investigation
 Ricardo Mexia (Lisbon, Portugal)

W0082 08:50 Public health microbiology: practical applications of epidemiological markers and key tools for outbreak response
 João Pires (Oslo, Norway)

W0083 09:10 Real case study of healthcare-associated infection outbreak
 Vera Manageiro (Lisbon, Portugal),
 Alma Tostmann (Nijmegen, Netherlands)

Co-organised with: EPIET alumni network (EAN), ESCMID Study Group for Epidemiological Markers (ESGEM)

ME007 11:00 - 12:00 Hall ICM 13a
 CLN IPC Meet-the-Expert

Nosocomial infections in ECMO: clinical challenges and case-based discussion

M0019 11:00 Konstanty Szuldrzynski (Mazowieckie, Poland)

M0020 11:12 Marta Hernández-Meneses (Barcelona, Spain)

Co-organised with: European Extracorporeal Life Support Organization

ME008 11:00 - 12:00 Hall ICM 13b
 PED PRO Meet-the-Expert

Designing and conducting clinical trials in paediatric infectious diseases: barriers and challenges

M0021 11:00 Emmanuel Roilides (Thessaloniki, Greece)

M0022 11:12 Irja Lutsar (Tartu, Estonia)

ME009 11:00 - 12:00 Hall ICM 5
 CLN DX Meet-the-Expert

Travel, migration and immunosuppression: a two-way challenge

M0023 11:00 Martin Peter Grobusch (Amsterdam, Netherlands)

M0024 11:12 María Velasco (Alcorcon. Madrid, Spain)

Co-organised with: Federation of European Societies for tropical medicine and international health (FESTMIH)

ME010 11:00 - 12:00 Hall B0-1
 CLN PRO Meet-the-Expert

Useful endpoints for antimicrobial therapy and stewardship: what if NOT only mortality mattered?

M0025 11:00 Esther Calbo (Terrassa, Spain)

M0026 11:12 Antonios Katsounas (Bochum, Germany)

ME012 11:00 - 12:00 Hall B0-2
 AMR DX IPC Meet-the-Expert

How best to detect ESBL and carbapenemase producers

M0029 11:00 Orjan Samuelsen (Tromso, Norway)

M0030 11:12 Shiri Navon-Venezia (Ariel, Israel)

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), EUCAST Steering Committee

Scientific Programme

Friday, 17 April 2026

ME013 11:00 - 12:00 Hall A1-4
 IPC PHEI Meet-the-Expert

Legionnaires disease: insights from recent large outbreaks

M0001 11:00 *Maria Scaturro (Rome, Italy)*
 M0002 23:12 *Florian Heger (Vienna, Austria)*

Co-organised with: ESCMID Study Group for Legionella Infections (ESGLI)

EW016 13:30 - 15:30 Hall ICM 5
 CLN DX 2-hour Educational Session

Clinical challenges in tropical medicine: lessons for global health

Chairs *Hilmir Asgeirsson (Stockholm, Sweden)*
Maria Cristina Loader (London, United Kingdom)

W0007 13:30 **Clinical impact of hybrid *Leishmania* strains**
Özgür Kurt (Istanbul, Türkiye)
 W0008 13:50 **Hybrid *Schistosoma*: what's the real picture?**
Bonnie Webster (London, United Kingdom)
 W0009 14:10 **Therapeutic challenges for nematode and trematode infections**
Carlos Seas (Lima, Peru)
 W0010 14:30 **Imported tropical diseases: what clinicians need to know**
Camilla Rothe (Munich, Germany)

Co-organised with: Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V, ESCMID Study Group for Clinical Parasitology (ESGCP)

EW017 13:30 - 15:30 Hall B0-1
 CLN DX PED 2-hour Educational Session

Advancing paediatric infectious disease management: from stewardship to precision therapeutics

Chairs *Luise Martin (Berlin, Germany)*
João Paulo Telles (Sao Paulo, Brazil)

W0011 13:30 **Paediatric antimicrobial stewardship: evidence-based interventions and practical barriers**
Johannes Hübner (Munich, Germany)
 W0012 13:50 **Optimising treatment in infants with access to newer antimicrobials**
Aspasia Katragkou (Morristown, United States)
 W0013 14:10 **Modelling and simulation for optimising initial paediatric and neonatal dosing**
Agathe Béranger (Paris, France)

W0014 14:30 **Rapid identification and resistance profiling in neonates**
Surbhi Malhotra-Kumar (Antwerp, Belgium)

Co-organised with: German Society for Pediatric Infectious Diseases (DGPI), ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

EW018 13:30 - 15:30 Hall A1-4
 PRO 2-hour Educational Session

Method morsels: breaking trial methodology down into digestible components

Chairs *Amelia Joseph (Nottingham, United Kingdom)*
Navaneeth Narayanan (New Brunswick, United States)

W0015 13:30 **How much is enough? Old and new methods for calculating sample size**
Yin Mo (Singapore, Singapore)
 W0016 13:50 **Bayesian versus frequentist statistics: differences and advantages**
Tom Snelling (Sydney, Australia)
 W0017 14:10 **Immortal time bias: avoiding, recognising, and addressing it**
Emily Mcdonald (Montreal, Canada)
 W0018 14:30 **Open the DOOR and win? How to understand and interpret novel outcome measures**
Sean Wei Xiang Ong (Toronto, Singapore)

Co-organised with: CMI Communications Board of Editors

ME011 13:30 - 14:30 Hall ICM 13a
 ANT CLN Meet-the-Expert

Different sets of diagnostic tools for endocarditis: how to resolve discrepancies and make them work?

M0027 13:30 *Thomas Wouter Van Der Vaart (Amsterdam, Netherlands)*
 M0028 13:42 *Marta Hernández-Meneses (Barcelona, Spain)*

ME014 13:30 - 14:30 Hall ICM 13b
 CLN DX Meet-the-Expert

How to approach pneumonia in patients with neutropaenia

M0003 13:30 *Mark Reinwald (Brandenburg An Der Havel, Germany)*
 M0004 13:42 *Johan Maertens (Leuven, Belgium)*

ME015 13:30 - 14:30 Hall B0-2
Meet-the-Expert

Genomics in clinical microbiology and virology across settings: hype, hope, or game-change?

M0005 13:30 *Abhilasha Karkey (Kathmandu, Nepal)*

M0006 13:42 *Judith Breuer (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS), European Society of Clinical Virology

ME019 14:45 - 15:45 Hall ICM 13a
CLN IPC PRO Meet-the-Expert

Ethical discourse on isolation precautions: to isolate or not to isolate that is the question!

M0031 14:45 *Babette Rump (Bilthoven, Netherlands)*

M0032 14:57 *Angelo Pan (Cremona, Italy)*

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

ME020 14:45 - 15:45 Hall ICM 13b
CLN DX Meet-the-Expert

Hepatitis in the immunocompromised host: is it infection?

M0033 14:45 *Susanne Gjeruldsen Dudman (Oslo, Norway)*

M0034 14:57 *Oana Sandulescu (Bucharest, Romania)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Viral Hepatitis (ESGVH), Viral Hepatitis Society of Türkiye (Viral Hepatitle Savaşım Derneği [VHSD])

ME021 14:45 - 15:45 Hall B0-2
AMR CLN Meet-the-Expert

Optimising treatment of severe infections due to DTR organisms

M0035 14:45 *Jean-Francois Timsit (Paris, France)*

M0036 14:57 *Lowell Ling (Hong Kong, Hong Kong)*

Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP), European Society of Intensive Care Medicine

EW025 16:15 - 18:15 Hall ICM 13a
IPC PRO 2-hour Educational Session

Enhancing infection prevention and control through implementation science: the REVERSE experience

Chairs *Tatjana Lejko Zupanc (Videm – Dobropolje, Slovenia)*
Walter Zingg (Zurich, Switzerland)

W0043 16:15 **Embedding implementation science in infection prevention and control**
Kathrin Blum (Zurich, Switzerland)

W0044 16:35 **Culture as a determinant of IPC implementation**
Diana Gabriela Iacob (Bucharest, Romania)

W0045 16:55 **Boundary spanning as a prerequisite to IPC implementation**
María Teresa Pérez-Rodríguez (Vigo, Spain)

W0046 17:15 **When implementation leadership facilitates IPC implementation**
Davide Mangioni (Milan, Italy)

Co-organised with: ESCMID Study Group for Antimicrobial stewardship (ESGAP), Swiss Society for Infectious Diseases (SSID), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

EW026 16:15 - 18:15 Hall ICM 5
PED VAX 2-hour Educational Session

Vaccines for children: innovations, impact, and future directions

Chairs *Ilias P. Iosifidis (Thessaloniki, Greece)*
Hanna M. Nohynek (Helsinki, Finland)

W0047 16:15 **New and emerging frontiers in paediatric vaccinology**
Paolo Palma (Antwerp, Italy)

W0048 16:35 **Beyond the needle: innovative delivery systems for paediatric vaccines**
Ulrich Heininger (Basel, Switzerland)

W0049 16:55 **Direct and indirect roles for vaccines against antimicrobial resistance**
Vana Spoulou (Athens, Greece)

W0050 17:15 **Vaccines and innate immunity: harnessing trained immunity in early life**
Elisabeth Dulfer (Nijmegen, Netherlands)

Scientific Programme

Friday, 17 April 2026

EW027 16:15 - 18:15 Hall B0-1
 AMR DX 2-hour Educational Session

Overcoming resistant *Candida* infections

Chairs Alexandre Alanio (Paris, France)
 Nelesh Govender
 (Johannesburg, South Africa)

W0051 16:15 Global epidemiology of Antifungal Resistance in *Candida*: trends and hotspots
 Arnaldo Lopes Colombo
 (Sao Paulo, Brazil)

W0052 16:35 Next-generation diagnostics: rapid tests and molecular methods

W0053 16:55 *Candida auris* and *Candida parapsilosis* resistance and transmission
 Anuradha Chowdhary (Delhi, India)

W0054 17:15 Adopting guidelines and resources for *Candida* diseases in LMICs
 Methee Chayakulkeeree
 (Bangkok, Thailand)

Co-organised with: German-Speaking Mycological Society, ÖGACH, EFISG, Portuguese Society of Infectious Diseases and Clinical Microbiology, Hellenic Society of Medical Mycology, Turkish Society of Paediatric Infectious Diseases

ME022 16:15 - 17:15 Hall ICM 13b
 TRN Meet-the-Expert

Multi-omics dissection of bacterial pathogenesis and host-microbiome interactions

M0037 16:15 Virginie Stévenin (Toulouse, France)

M0038 16:27 Romain Guérillot (Melbourne, Australia)

ME023 16:15 - 17:15 Hall B0-2
 ANT CLN Meet-the-Expert

PK/PD-based dose optimisation in challenging patient groups

M0039 16:15 Birgit Koch (Rotterdam, The Netherlands)

M0040 16:27 Christina König (Hamburg, Germany)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

ME024 16:15 - 17:15 Hall A1-4
 AMR DX Meet-the-Expert

Quality controlled AST: use your cell phone and your data

M0041 16:15 Onur Karatuna (Växjö, Sweden)

M0042 16:27 Iva Butic (Zagreb, Croatia)

Co-organised with: Médecins Sans Frontières (MSF), CAESAR Network, ESCMID Education Subcommittee

ME028 17:30 - 18:30 Hall ICM 13b
 CLN DX Meet-the-Expert

De-escalation or escalation: using rapid diagnostics in patients with sepsis

M0055 17:30 Pierluigi Viale (Bologna, Italy)

M0056 17:42 Ana Gales (Sao Paulo, Brazil)

ME029 17:30 - 18:30 Hall B0-2
 ANT CLN Meet-the-Expert

Overcoming challenges to implementing system-wide antimicrobial stewardship

M0057 17:30 Sara Cosgrove
 (Baltimore, Maryland, United States)

M0058 17:42 Paul Turner (Siem Reap, Cambodia)

Co-organised with: British Society for Antimicrobial Chemotherapy (BSAC)

ME030 17:30 - 18:30 Hall A1-4
 DX PHEI Meet-the-Expert

How to prepare for pathogen X emergence: a practical approach

M0059 17:30 David Chien Lye (Singapore, Singapore)

M0060 17:42 David Hayman (Palmerston North, New Zealand)

Scientific Programme

Saturday, 18 April 2026

EF004 08:30 - 09:30 Arena 1
 ANT CLN ePoster Flash Session

Beyond guidelines: how behaviour and social context shape antimicrobial prescribing

Chair Jaap Ten Oever (Nijmegen, Netherlands)

E0031 08:30 Prescribing inequities: Evaluating under- and over-treatment across patient and neighborhood factors
 C. Evans* (Chicago, United States), S. Reddy, M. Dhanani, A. Rivera, D. Glover, G. Wilson, S. Balbale, M. Keintz, K. Suda, J. Marcelin

E0032 08:36 Understanding what matters to patients in antimicrobial stewardship in hospitals: a mixed-method study
 B. Jacob* (Dublin, Ireland), A. Kurian, E. De Barra

E0033 08:42 Impact in capacity building of an online training program and evaluation of factors related to behavioural change in infection prevention and control and antimicrobial stewardship practices
 O. Neth* (Seville, Spain), W. Goycochea-Valdivia, A. Gâchet, M. Amores, I. Kopsidas, G. Brigadoi, E. Barbieri, M. Bason, D. Kousi, M. Aboza, V. Serena, D. Daniele, T. Grammatiki-Christina, A. Arias, L. Cantarutti, C. Gianquinto, I. Gastesi, P. Rojo, C. Epalza

E0034 08:48 Reframing antimicrobial stewardship by empowering stakeholders through the One Health lens
 C. Mulrooney* (Waterford, Ireland), Z. Ramsamaroo, J. Britton, H. Awad, G. Rothwell-Kelly, M. Doyle, G. Chan

E0035 08:54 Evaluating primary care antimicrobial stewardship through simulated patient visits: a scoping review and application of patient management indicators in an intervention evaluation in two LMIC
 B. Ingelbeen* (Antwerpen, Belgium), D. Valia, V. Bertels, B. Mbangi, E. Tiendrebeogo, S. Declercq, D. Phanzu, H. Tinto

E0036 09:00 Beyond the algorithm: Human factors driving AI-adoption in antimicrobial stewardship (AMS)
 D. Yii* (Singapore, Singapore), S. Tang, L. Loo, J. Chung, W. Lee, A. Kwa, E. Lum

E0037 09:06 Knowledge and attitudes of allied healthcare professionals towards antibiotic use and antimicrobial resistance: questionnaire-development and a quantitative, cross-sectional study
 M. Gajdács* (Szeged, Hungary), Z.L. Szabó, E.R. Major, R. Finta, E. Paulik

E0038 09:12 Patients' and the public's knowledge and understanding of antimicrobial resistance and antimicrobial stewardship: a systematic review and meta-analysis
 B. Jacob* (Dublin, Ireland), A. Kurian, E. De Barra

E0039 09:18 Behavioural determinants of hospital antimicrobial prescribing in italy: a multi-centre COM-B and TDF-informed study
 M. Torre* (Rome, Italy), A. Bandera, S. Leone, A. Tedesco, A. Capone, S. Tedeschi, A. Mularoni, A. Cona, R. Murri, C. Torti, S. Cicalini

EF005 08:30 - 09:30 Arena 2
 ANT TRN ePoster Flash Session

Old viruses, new weapons: emerging antiviral therapies from bench to bedside

Chair Heli Harvala (Turku, Finland)

E0040 08:30 MDL-001, an oral direct-acting Thumb-1 polymerase inhibitor, demonstrates single-agent efficacy against HCV/HBV co-infection *in vitro*, and achieves HCV and HBV preclinical proof-of-concept
 D. Haders* (San Diego, United States), V. Woods, T. Umansky, S. Russell, A. Goodman, M. Bobardt, W. Brubaker, P. Galloway, D. Smith

E0041 08:36 Real-world effectiveness of extended use of letermovir among adult allogeneic haematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies
 R. Chemaly* (Houston, United States), A. Vyas, H. Appaneal, A. Beyer

E0042 08:42 Antiviral efficacy of a single dose of EV25, a novel antibody recruiting molecule, in a human influenza A/H3N2 challenge trial
 A. Cohen* (The Sea Ranch, United States), A. Wozniak, M. Niedrauer, S. Low, A. Blouin, C.L. Campbell, I. Shahriar, J. Nielsen, P.S. Low

E0043 08:48 Zelicapavir demonstrates high clinical and functional barrier against antiviral resistance: results from a randomised double-blind placebo-controlled paediatric RSV antiviral clinical trial
 J. Devincenzo* (Watertown, United States), M. Rhodin, T. Ngo, A. Ahmad, C. Harris, R. Levene, S. Rottinghaus

E0044 08:54 Safety, tolerability, and pharmacokinetics of secutrelvir: single and multiple oral doses, and drug-drug interaction with midazolam
 H. Koshimichi* (Osaka, Japan), T. Sonoyama, R. Yonemoto, R. Kubota

- E0045 09:00 Identification and structural characterisation of CID-375076 as a promising small molecule inhibitor of HCV NS3 protease**
D. Diksha (Rishikesh, India), S.K. Gupta, Y.P. Mathuria*
- E0046 09:06 Next-generation alkaloid entry inhibitors against emerging flaviviruses and coronaviruses: a step toward broad-spectrum antivirals**
S. Sadhu (Faridabad, India), A. Awasthi*
- E0047 09:12 DEN-HOST: a randomised, adaptive phase III trial evaluating host-directed therapeutics for moderate and severe dengue**
A. Mccbride (Oxford, United Kingdom), L. Peto, H.Q. Chanh, P.K. Lam, J. Catrall, N.L. Vuong, P.Y. Chia, A. Rojek, J. Whitehorn, L. Villar, P. Horby, T.W. Yeo, J. Watson, E. Kestelyn, S. Yacoub*
- E0048 09:18 Factors influencing ganciclovir trough concentrations during prophylaxis or therapy of CMV infections**
O. Epaulard (Grenoble, France), C. Massebeuf, L. Liaigre, C. Chapuis, R. Le Cras, R. Germi, E. Gautier-Veyret*
-
- EF006 08:30 - 09:30 Arena 4**
CLN DX PHEI ePoster Flash Session
- Trending topics in TB and other mycobacterial infections**
- Chair Hanif Esmail (London, United Kingdom)*
- E0049 08:30 CRISPR and phage footprints reveal an aquatic ancestry for the tuberculosis pathogen**
A. Ghodousi (Milan, Italy), M. Omrani, C. Gaudin, M. Marceau, P. Supply, D.M. Cirillo*
- E0050 08:36 Developing a 2-gene host-response lateral flow test for TB**
R. Reid (London, United Kingdom), C. Patwardhan, R. Armiger, J. Sturgeon, J. Herberg*
- E0051 08:42 Asymptomatic is not less infectious: school-based study using Targeted Maximum Likelihood Estimation method highlights critical role of asymptomatic TB in transmission**
Q. Ruan (Shanghai, China), S. Ge, Y. Ren*
- E0052 08:48 Seeing what symptoms can't: community-based PDX screening as a game-changer for asymptomatic TB diagnosis in Nigeria**
S. Batur (Abuja, Nigeria), A. Okoh, M. Sheshi*
- E0053 08:54 Asymptomatic mediastinal tuberculosis (TB) emerging in non-TB clinical pathways: findings from a multi-centre UK EBUS cohort**
F. Fama (London, United Kingdom), A. Read, J. Murray, D. Creer, M. Belton, M. Brown, A. Garcia Mingo, J. Goldring, P. Gothard, H. Ip, H. Jarvis, S. Lee, Z. Magera, R. Moores, N. Navani, A. Patel, R. Thakrar, C. Tweed, C. Valerio, S. Bamunugama, H. Sansum, R. Bhatia, P. Papineni, A. Whittington, M. Burman, S. Moody, N. Kakkar, A. Houston, M. Ye, O. Kon, A. Alexiadis, R. Merriman, F. Perrin, H. Burgess, G. Santis, H. Kunst, J. Brown, R. Gupta, S. Joseph, A. Daunt, J. Potter, S. Capocci, M. Lipman*
- E0054 09:00 Comparative transmissibility of bacteriologically confirmed vs clinically diagnosed pulmonary TB in school settings: implications for contact screening strategies**
C. Chu (Shanghai, China), Y. Ren*
- E0055 09:06 Interim findings from community-wide screening to treat TB disease and infection in a high prevalence MDR-TB setting in Papua New Guinea**
S. Majumdar (Melbourne, Australia), T. Marukutira, N. Pank, A. Aung, G. Kama, I. Krangaie, M. Boga, S. Islam, S. Maguri, J. Greig, A. Maha, G. Chan, G.K.L. Huang, W. Pomat, M. Kal, S. Graham*
- E0056 09:12 Pre-existing isoniazid resistance and acquired rifampicin-resistant tuberculosis**
R. Spies (Ho Chi Minh City, Vietnam), N.H. Hanh, P.T. Phu, N.L. Quang, D.D.A. Thu, T.T.B. Tram, V.T.N. Ha, G. Thwaites, M. Choisy, N.T.T. Thuong, J. Watson, T. Walker*
- E0057 09:18 Longitudinal imaging reveals severe lung pathology in preclinical M. avium BALB/c mouse model using hypervirulent clinical isolates**
T. Van Win (Leuven, Belgium), W. Brangers, G.J. Wijnant, A. Reséndiz Sharpe, G. Vande Velde, E. André*

Scientific Programme

Saturday, 18 April 2026

EW038 08:30 - 11:30 Hall ICM 1
 AMR DX 3-hour Educational Session

EUCAST User Workshop

- Chairs* Alasdair Peter Macgowan (Bristol, United Kingdom)
 Amara Marlene (Paris, France)
- W0195 08:30 EUCAST Update**
 Sören Gatermann (Bochum, Germany)
- W0196 09:00 Challenges of testing beta-lactam/beta-lactamase inhibitors**
 Mandy Wootton (Cardiff, United Kingdom)
- W0197 09:30 When do you need an MIC**
 Barbara Juliane Holzknacht (Copenhagen, Denmark)
- W0198 10:00 Challenges of setting up a NAC in a large country**
 Qiwen Yang (Beijing, China)
- W0199 10:30 The role of clinical data in setting breakpoints**
 Jesús Rodríguez-Baño (Seville, Spain)

Co-organised with: EUCAST Steering Committee

EW039 08:30 - 10:30 Hall ICM 13a
 PHEI TRN 2-hour Educational Session

Milk matters: risks and safe practices in a changing global landscape

- Chairs* Sally Jane Cutler (London, United Kingdom)
 Ana Raquel Freitas (Porto, Portugal)
- W0200 08:30 Raw milk misconceptions: health benefits vs. risks**
 Enda Cummins (Dublin, Ireland)
- W0201 08:50 Brucellosis and bovine tuberculosis in LMICs**
 Elaine Maria Seles Dorneles (Lavras, Minas Gerais, Brazil)
- W0202 09:10 Coxiella burnetii in milk and cheese**
 Loïc Epelboin (Cayenne, French Guiana)
- W0203 09:30 Unexpected surprises in milk: avian influenza to Listeria monocytogenes**
 Nicole Martin (Ithaca, New York, United States)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM)

EW040 08:30 - 10:30 Hall A2-1
 ANT TRN 2-hour Educational Session

Next-generation therapies against infectious diseases

- Chairs* Nicolas Mueller (Zurich, Switzerland)
 Ursula Theuretzbacher (Vienna, Austria)
- W0204 08:30 Cellular therapies targeting infectious diseases**
 Lukas Jeker (Basel, Switzerland)
- W0205 08:50 Discovery of new antibody-based anti-infectives**
 Jan Rybniker (Köln, Germany)
- W0206 09:10 Proteasome-derived defence peptides**
 Yifat Merbl (Rehovot, Israel)
- W0207 09:30 Modulation of gut-brain and gut-liver axis**
 Co-organised with: Swiss Society for Infectious Diseases (SSID), ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group of Forensic and Post-Mortem Microbiology (ESGFOR)

LB001 08:30 - 10:30 Hall A3-1
 ANT CLN 2-hour Oral Session

Late-breaking vaccine trials

- Chairs* Zitta Barrella Harboe (Hillerød, Denmark)
 Maheshi Ramasamy (Oxford, United Kingdom)
- L0001 08:30 Impact of colonisation acquisition and PCV15 on symptoms following serotype 3 experimental human pneumococcal challenge (EHPC): results from a phase IV double-blind randomised clinical trial**
 J.L. Martinelli* (Oxford, United Kingdom), Y. Ni, K. Tanha, R. Huq, B. Rocha De Macedo, C. Solórzano, A. Hyder-Wright, R. Mahmud, H. Gill, R. White, A. Singha, F. Elterish, T. Condreanu, B. Urban, E. Mitsi, X. Liu, A.M. Collins, D.M. Ferreira, S.B. Drysdale
- L0002 08:42 Updated safety and immunogenicity results from a UK-based phase I clinical trial of the Nipah virus candidate vaccine ChAdOx1 NipahB**
 D. Jenkin* (Oxford, United Kingdom), R. Kenneil, N. Marchevsky, I. Haeusler, L. Saldana Ortega, R. White, Y. Zhang, E. Morey, T. Madupuri, N. Panchal, E. Sheehan, J. Wright, E. Vannaxay, H. Zhang, S. Kelly, L. Hahn, D. Pulido-Gomez, G. Morshead, A. Boyd, A. Pollard, T. Lambe, S. Gilbert, B. Angus

L0003 08:54 High-dose influenza vaccine effectiveness in immunosuppressed older adults: an individual-level pooled analysis (FLUNITY-HD)
A.M. Reimer Jensen (Copenhagen, Denmark), N.D. Johansen, J. Pardo-Seco, C. Rodriguez-Tenreiro-Sánchez, M.M. Loiacono, R.C. Harris, K. Sharff, J.A. Hill, Y. Huang, R. Van Aalst, A. Chit, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B.L. Claggett, K.H. Janstrup, C. Duran-Parrondo, M. Piñeiro-Sotelo, M. Cribeiro-González, M. Conde-Pájaro, S. Mirás-Carballal, J.M. González-Pérez, S.D. Solomon, P. Sivapalan, C.J.M. Martel, J.U.S. Jensen, F. Martín-Torres, T. Biering-Sørensen*

L0004 09:06 Safety, tolerability and immunogenicity of SPVX02, a fridge-free thermostable tetanus-diphtheria vaccine compared to Tetadif and diTeBooster: a multi-centre, phase I, blinded, randomised clinical trial
S.N. Faust (Southampton, United Kingdom), T.A.N. Reed, P. Clarke, M. Razzaque, J. De La Torre Arrieta, A. Garcia De Castro, R. Alexiev, C. Panainte, N. Khan, L. Grey, M. Matheson, H. Cuthbertson, O. Tuncer, S. Chatfield, B. Roser, A. Boyd, J.S. Nguyen-Van Tam, K. O'hanlon, A.P. Dale*

L0005 09:18 Safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine: first results of the *TherVacB* phase Ia trial
M. Schunk (Munich, Germany), S.D. Jeske, N. Körber, S. Hardtke, H.M. Weichel, T. Bauer, F. Thiele, M. Wiegand, M. Hoelscher, U. Protzer, M.M. Addo*

L0006 09:30 Safety and immunogenicity of heterologous RSV revaccination with mRNA-1345 after primary vaccination with protein-based vaccine
M. Desai (Cambridge, United States), J. Cardona, S. Khetan, S. Mehta, A. Kapoor, A. Okparavero, Z. Lin, F. Priddy*

L0007 09:42 A double-blind randomised controlled trial on baloxavir marboxil and flufenamic acid combination for severe hospitalised influenza infection
I.F. Hung (Hong Kong, Hong Kong), E. Chu, J. Choi, T. Anthony*

L0008 09:54 First-in-human study of EVT894, a monoclonal antibody against chikungunya virus
H. Watson (Lyon, France), K. Miller, A. Safder, S. Raja, L. Jordan, M. Mack, X. Boulenc, M. Mandron, M. Gordon, M. Jahromi, S. Woodson*

L0010 10:06 Longitudinal B cell immunity after adjuvanted respiratory syncytial virus (RSV) vaccination in high-risk transplant recipients
M. Kern-Smith (Toronto, Canada), P.M. Lavoie, A. Humar, D. Kumar, J. Mattsson, V.G. Hall, V.H. Ferreira*

L0009 10:18 Sequential administration of an mRNA-based seasonal influenza vaccine in older adults
E. Malkin (Cambridge, United States), A. Kohli, R. Chen, E. Du, A. Pucci, R. Das, E. Wilson*

OS001 08:30 - 10:30 Hall A1-2
 AMR DX IPC 2-hour Oral Session

Novel insights and tools to tackle hospital outbreaks

Chairs
Fusun Can (Istanbul, Türkiye)
Rekha Pai Mangalore (Melbourne, Australia)

O0001 08:30 A Pathogen-Agnostic Machine Learning Framework for Precision Outbreak Detection in Hospital and Community Settings
K. Ko (Singapore, Singapore), C. Suphavitai, P. Boonsimma, H. Yingtaweessittikul, K.M. Lim, U. Shanmugam, W.E. Ong, J.H. Yeo, T.H.N. Wong*

O0002 08:42 Towards data-driven refinement of an automated hospital outbreak detection system: validation of expert classification through genotypic evidence in neonatology wards
F.D. Ruether (Berlin, Germany), B. Piening, F. Maechler, A. Weber, C. Geffers, S.J.S. Aghdassi*

O0003 08:54 Designing and evaluating an infection prevention and control (IPC) dashboard to track and interrupt spread of healthcare-associated infections
A. Luk (Oxford, United Kingdom), D. Adlard, H. Thai, G. Durant, S.A. Walker, D. Eyre*

O0004 09:06 Ceftazidime/avibactam-resistant *Klebsiella pneumoniae* driven by multiple β -lactamase mutation: a hospital outbreak report
W. Yang (Shanghai, China), C. Tang, Q. Shi, H. Ou, D. Yin, R. Han, J. Chen, Y. Guo, F. Hu*

O0005 09:18 Comparative evaluation of the IR Biotyper and whole genome sequencing for detecting bacterial outbreak
C. Sakr (Creteil, France), C. Subramanian, F. Cizeau, D. Ducellier, M. Danjean, J.W. Decusser*

Scientific Programme

Saturday, 18 April 2026

00006	09:30	<p>Nosocomial outbreak by NDM- and OXA-48-producing hypermucoviscous high-risk ST383 <i>Klebsiella pneumoniae</i> clone</p> <p><i>J.M. Sánchez-Calvo* (Jerez De La Frontera, Spain), S. López-Cárdenas, J.A. Córdoba Doña, M. Murillo-Pineda, R. Lobato-Cano, I.M. Santiago Soler, I. Pozo Jiménez, M. Coppi, I. Baccani, A. Antonelli, G.M. Rossolini, N. Zuabi, J. Rodríguez-Baño, P. Retamar</i></p>	OS002	08:30 - 10:30	Hall A1-3	
			ANT	CLN	PHEI	2-hour Oral Session
			<p>Three viruses, one winter: what we miss, what we treat, what comes next</p>			
			Chairs	<p><i>Christopher Chiu (London, United Kingdom)</i> <i>Neven Papic (Zagreb, Croatia)</i></p>		
00007	09:42	<p>Chasing accuracy: does 1% really change the story in an ExPEC outbreak?</p> <p><i>T. Severs* (Zwolle, The Netherlands), A.J. Gebbink, A.K.P.K. Bari, H. Gremmels, S. Debast, J.H.E. De Lange, B. Sinha, J.W.A. Rossen, B.B. Xavier</i></p>	00011	08:30	<p>Pathogen-specific viral infections among adults hospitalised with severe acute respiratory infection: European multi-centre surveillance study, 2024–2025 (id.DRIVE)</p> <p><i>K. Newell* (Rotterdam, Netherlands), N. Vroom, C. Marques, E. Maslova, F. Khan, K.Y. Ngew, H.R. Volkman, C. Wang, J.V. Hernandez-Villena, N. Aliabadi, E. Begier, J. Nguyen, H. Dunford, S. Basu, A. Antón, I. Casas, B. Grüner, G. Icardi, F.M. Torres, A. Mira-Iglesias, C.M. Oñoro López, A. Orrico-Sánchez, O. Parés-Badell, W. Gleiber, A. Torres, K. Bollaerts</i></p>	
00008	09:54	<p>Whole genome sequencing (WGS) and improved diagnostics uncover a multispecies plasmid-borne GES-5/OXA-917 carbapenemase outbreak driven by the <i>Citrobacter freundii</i> complex</p> <p><i>A. Rath* (Regensburg, Germany), N. Förster, N. Pfennigwerth, C. Keller, B. Neumann, A. Caplunik-Pratsch, B. Lenker, A. Eichner, J. Fritsch, W. Schneider-Brachert, B. Kieninger</i></p>	00012	08:42	<p>Predictors of severe outcomes in hospitalised patients with viral respiratory tract infections: a prospective cohort study</p> <p><i>O. Usta* (Istanbul, Türkiye), Ö. Aktaş, B. Çakan, A. Ardalı, Y. Beşli, Ö. Ergönül, Ş. Keske</i></p>	
00009	10:06	<p>Development of outbreak-specific TaqMan PCR assays for tracking vancomycin-resistant <i>Enterococcus faecium</i> in Dutch hospitals</p> <p><i>A.J. Sabat* (Groningen, Netherlands), J. Flipse, C.J.H. Von Wintersdorff, A. Pettersson, V. Akkerboom, W.C. Van Der Zwet, P.H.M. Savelkoul, A. Voss, E. Bathoorn</i></p>	00013	08:54	<p>Zelicapavir decreases symptom duration, hospitalisation and viral load in a global, randomised, double-blinded, placebo-controlled phase II trial of high-risk adults with RSV</p> <p><i>S. Rottinghaus* (Watertown, Massachusetts, United States), C. Harris, J. Devincenzo, S. Chen, T. Ngo, A. Ahmad, M. Turnak</i></p>	
00010	10:18	<p>Beyond species: integrated bacterial and OXA-48 plasmid clustering with EPISEQ® reveals a polyclonal, multi-species hospital outbreak</p> <p><i>L. Aguilera Muros* (Granada, Spain), M.A. Roldán Ruiz, A. Badillo Carrasco, C. Roldán Fontana, F. García García, N. Chueca Porcuna</i></p>	00014	09:06	<p>Postmortem study: analysis of mortality associated with respiratory viruses in four seasons of influenza</p> <p><i>L. Argente* (Pamplona, Spain), M. Olazabal, A. Navascues, I. Martinez-Baz, C. Trabajo, J. Castilla, M.E. Portillo</i></p>	
			00015	09:18	<p>Antiviral efficacy of baloxavir marboxil, favipiravir, and oseltamivir in adults with acute non-severe influenza virus infection: an open-label, phase II, randomised, controlled, adaptive platform trial</p> <p><i>S.J. Leopold* (Bangkok, Thailand), P. Jittamala, K. Kotchum, P. Wongnak, T. Asawasriworanan, T. Seers, S. Boyd, E. Beer, S. Singh, E. Batty, K. Chotivanich, S. Pukrittayakamee, A.M. Dondorp, N.P. Day, A. Karkey, M.M. Teixeira, E.A. Ashley, M. Imwong, W. Phumratanaprapin, J.A. Watson, W.H. Schilling, N.J. White</i></p>	

O0016 09:30 A sequence-based update on mutations in influenza polymerase acidic protein in Europe conferring resistance to baloxavir from 2009 to 2025: the old, the new, and the emerging mutations

A. Martín-Toribio (Valladolid, Spain), M. Toquero-Asensio, S. Garcia-Díaz, J. Sanchez-Martinez, C. Rodriguez-Crespo, I. Inchausti-Moya, S. Rojo-Rello, M. Dominguez-Gil, E. Nistal-Villán, M. Hernandez-Perez, J.M. Eiros, I. Sanz-Muñoz*

O0017 09:42 Effectiveness of nirmatrelvir/ritonavir in preventing severe COVID-19 outcomes: national multi-year real-world data from Greece

E.G. Kostaki (Athens, Greece), M. Gkova, K. Mathioudakis, D. Menegas, V. Grammelis, V. Kossyvakis, I. Antoniou, P. Nikolopoulou, L. Puzniak, T. Bergroth, D. Paraskevis*

O0018 09:54 Phase II study of secutrelvir, a second-generation 3C-like protease inhibitor as oral treatment for COVID-19

S. Kezbor (Florham Park, United States), E. Mitchell, Y. Iwasaki, G. Ichihashi, T. Baba, S. Lacey, H. Nobori, A.C. Hurt, A. Fukushi, Y. Takeda*

O0019 10:06 Macrophage and platelet activation drive inflammation in people living with Long COVID, irrespective of symptom cluster

E. Wall (London, United Kingdom), D. Greenwood, G. Ahimbisibwe, C. Dubois, I. Aniq, O. Haguge, A. Parabita, G. Prescott, M. Skehl, M. Scully, T. Hillman, A. Banerjee, E. Carr*

O0020 10:18 MDL-001, an oral direct-acting Thumb-1 polymerase inhibitor, demonstrates broad-spectrum activity against influenza viruses, respiratory syncytial virus, and SARS-CoV-2 with oral proof-of-concept in mice

D. Haders (La Jolla, United States), V. Woods, T. Umansky, S. Russell, A. Goodman, M. Bobardt, B. McGovern, M. Rodriguez, A. Garcia-Sastre, K. White, W. Brubaker, P. Galloway, D. Smith*

OS003 08:30 - 10:30 Hall A1-4
2-hour Oral Session

Driving global AMR action through data, economics, and policy

Chairs
*Diane Ashiru-Oredope (London, United Kingdom)
Chantal Morel (Bonn, Germany)*

O0021 08:30 Past, present and future of bacterial antimicrobial resistance (AMR) in the WHO Eastern Mediterranean Region: Comprehensive AMR burden modelling from 1990 to 2021 with forecasts to 2050
T. Mestrovic (Varaždin, Croatia), M. Naghavi, G. Robles Aguilar, N.D. Weaver, L.R. Swetschinski, D.T. Araki, E.E. Wool, A. Gray, A. Gershberg Hayoon, C. Han, K.S. Ikuta, E. Rosenblad, R.L. Hsu, B.S. Cooper, C. Dolecek, B. Sartorius, S. Hay, C.J.L. Murray*

O0022 08:42 Novel metrics for antimicrobial resistance surveillance: velocity, acceleration, and indicator antibiotic analysis using 191,810 global records
P. Kilgore (Detroit, United States)*

O0023 08:54 Mapping and synthesising global antibiotic use datasets to improve evidence for surveillance, modelling, and policy
K. Zay Ya (London, United Kingdom), D. R M Smith, A. Cook, K. B Pouwels, M. Sharland*

O0024 09:06 The cost-effectiveness of a personalised *in vitro* antibiotic combination testing (iACT) service for treatment of carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) infections
Y. Cai (Singapore, Singapore), T.P. Lim, W. Lee, J.Q. Teo, A.L. Kwa, N. Graves*

O0025 09:18 Costs of hospital admissions linked with Gram-negative bloodstream infections among adults in England: an analysis using health resource groups
K. Hayes (London, United Kingdom), L. Miller, E. Van Leeuwen, J. Robotham, L. Uwais, E. Agnew, S. Evans*

O0026 09:30 Beyond the tip of the iceberg: quantifying the effect of MDRO-carriage on postacute inpatient rehabilitation
H. Kaba (Goettingen, Germany), P. Wenzlaff-Lodge, S. Scheithauer*

O0027 09:42 Mind the governance gap: A One Health systematic review of national AMR performance indicators
E. O'neill (London, United Kingdom), U. Shafaque, V. Karadimitris, B. Hill, S. Ranganathan, E. Mossialos, M. Anderson*

Scientific Programme

Saturday, 18 April 2026

O0028 09:54 **Benchmarking AWaRe: estimating expected need of AWaRe antibiotic use in 186 countries based on infection and resistance burden**
A. Cook (London, United Kingdom), K. Pouwels, M. Sharland, B. Cooper*

O0029 10:06 **Interactive Causal Inference Framework for Assessing Policy and Consumption Effects on Antimicrobial Resistance**
A. Gupta (Natick, United States), C. Vania*

O0030 10:18 **UKHSA's contribution to the UK Antimicrobial Resistance National Action Plan 2024–2029 (year one)**
C. Brown (London, United Kingdom), R. Hope, V. Finistrella, J. Conneely, G. Eldridge, J. Charlesworth, S. De Cordova, E. Ombakho, F. Ambreen, J. Gritton*

SY031 08:30 - 10:30 **Hall ICM 13b**
IPC 2-hour Symposium

Biofilms, the hidden threat in healthcare environment: unveiling detection, control and prevention strategies

Chairs *Joana Azeredo (Braga, Portugal), Claus Moser (Copenhagen, Denmark)*

S0167 08:30 **Tackling dry surface biofilms**
Jean-Yves Maillard (Cardiff, United Kingdom)

S0168 09:00 **That slimy stuff in water pipes!**
Michael Weinbren (London, United Kingdom)

S0169 09:30 **Skin and soft tissue microbiomes and biofilms**
Blaine Fritz (Denmark)

S0170 10:00 **Biofilm coats catheters**
Gordon Ramage (Glasgow, United Kingdom)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESGNI)

SY032 08:30 - 10:30 **Hall ICM 5**
CLN DX VAX 2-hour Symposium

Beyond recovery: post-acute syndromes after respiratory viral infections

Chairs *Raquel Duarte (Porto, Portugal), Paraskevi C. Fragkou (Markopoulo Mesogeion, Greece)*

S0171 08:30 **Post-COVID-19 syndrome: respiratory and multisystem sequelae**
Ziyad Al-Aly (Saint Louis, United States)

S0172 09:00 **Post-influenza syndromes: a hidden burden in clinical practice**
Sotirios Tsiodras (Athens, Greece)

S0173 09:30 **RSV and other endemic respiratory viruses: what comes after acute infection?**
Chrysanthi Skevaki (Marburg, Germany)

S0174 10:00 **Genetic basis of post-acute viral syndromes**
Hanna Ollila (Helsinki, Finland)

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), European Respiratory Society (ERS)

SY033 08:30 - 10:30 **Hall B0-1**
CLN 2-hour Symposium

AI-enhanced sepsis care: from early detection to long-term follow-up

Chairs *Michele Bartoletti (Milan, Italy), Damien Ming (London, United Kingdom)*

S0175 08:30 **Early recognition and decision-making in sepsis: the role of AI-enhanced clinical pathways**
Sylvain Meylan (Lausanne, Switzerland)

S0176 09:00 **Initial and adaptive antimicrobial therapy in sepsis: personalisation and stewardship in the age of AI**
Shruti Gohil (Irvine, United States)

S0177 09:30 **From stabilisation to supportive care: integrating the ICU-level multimodal strategy**
Eric Kipnis (Lille, France)

S0178 10:00 **Beyond survival: post-sepsis care, risk stratification, and AI-driven follow-up models**
Hannah Wozniak (Geneva, Switzerland)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

SY034 08:30 - 10:30 **Hall B0-2**
CLN DX 2-hour Symposium

Rapid pathogen sequencing for patient management: advancing diagnostic implementation

Chairs *Claudio Neidhöfer (Basel, Switzerland), Torsten Seemann (Melbourne, Australia)*

S0179 08:30 **State-of-the-art methodologies for clinical pathogen sequencing: bridging technology and application**
Oon Tek Ng (Singapore, Singapore)

S0180 09:00 **Ensuring reliability: validation, regulation, and quality control in pathogen sequencing**
Paula Mölling (Örebro, Sweden)

S0181 09:30 **From data to decision: clinical interpretation and integration of pathogen sequencing in patient pathways**
Luke Blagdon Snell (London, United Kingdom)

S0182 10:00 Genotypic predictions of antimicrobial resistance: unlocking the power of sequencing for treatment decisions
Lorena Diaz (Santiago, Chile)

Co-organised with: UK National Health Service Genomic Network of Excellence; Consortium for Clinical Metagenomics in Infectious Diseases (CCMID), ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee

SY035 08:30 - 10:30 Hall A1-1
2-hour Symposium
AMR TRN

Microbial interactions and bacterial adaptation in the microbiome

Chairs *Zuzanna Drulis-Kawa (Wroclaw, Poland)*
Mauricio Farfan (Santiago, Chile)

S0183 08:30 The interplay of genetic drift and bacterial adaptation in skin microbiomes
Julia Oh (Durham, United States)

S0184 09:00 Pathways of adaptive evolution in chronic lung infections
Helle Krogh Johansen (Copenhagen, Denmark)

S0185 09:30 Bacteriophages and their interaction with the gut microbiome

S0186 10:00 Quantifying microbiome-host interactions in the human gut
Markus Arnoldini (Zürich, Switzerland)

SY036 08:30 - 10:30 Hall A1-5
2-hour Symposium
DX PHEI

Recent advances in malaria molecular surveillance: experiences from malaria endemic countries

Chairs *Abdoulaye Djimde (Bamako, Mali)*
Martin Peter Grobusch (Amsterdam, Netherlands)

S0187 08:30 Malaria molecular surveillance in the Horn of Africa using the MAD4HatTeR amplicon sequencing panel
Fitsum Tadesse (Addis Ababa, Ethiopia)

S0188 09:00 A field-based nanopore amplicon sequencing (NOMADS) assay for malaria parasites and vectors
Mulenga Chilumba Mwenda (Lusaka, Zambia)

S0189 09:30 Molecular surveillance in Africa using the Pf-SMARRT assay
Ronald Futila Kyong-Shin (Chapel Hill, United States)

S0190 10:00 Genetic surveillance of *P. vivax* in the Greater Mekong Subregion using the Pv Microhaplotype AmpSeq assay
Thanh Thuy Nhien Nguyen (Ho Chi Minh City, Vietnam)

SY037 08:30 - 10:30 Hall A3-2
2-hour Symposium
PHEI VAX

Unmet SDGs: Europe's struggle with HIV, TB, hepatitis and STIs

Chairs *Tomislav Mestrovic (Varaždin, Croatia)*
Senia Rosales-Klintz (Solna, Sweden)

S0191 08:30 Current epidemiological concerns and key gaps in progress towards the SDGs: where should Europe focus efforts to achieve maximum impact?
Anastasia Pharris (Stockholm, Sweden)

S0192 09:00 Prevention of STIs across Europe: what is working and how to stem the tide?
Nicola Low (Bern, Switzerland)

S0193 09:30 Equity in treatment: why is Europe lagging behind in terms of optimal TB care and access to all necessary medical products?
Christophe Perrin (Paris, France)

S0194 10:00 Migration and the importance of an international approach to tackling the SDGs for TB, HIV and hepatitis
Dominik Zenner (London, United Kingdom)

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

EF008 09:30 - 10:30 Arena 3
ePoster Flash Session
AMR

Genomic and epidemiological patterns of antimicrobial resistance

Chair *Filip Bielec (Łódź, Poland)*

E0063 09:30 Epidemiologic shift in MRSA bacteraemia in Chile: clinical impact of emerging community strains
L. Rojas (Puerto Montt, Chile), A. Peters, B. Conrads, J. Martinez, A. Aguayo, J.M. Munita, L. Diaz, L. Rivas, P. Garcia, M.L. Rioseco, J. Moreno*

E0064 09:36 High-risk clones and resistance gene convergence among community uropathogens in India: genomic evidence from a nationwide study
S. Pundir (New Delhi, India)*

E0065 09:42 The Coverage Paradox in Global AMR Surveillance: Low-Coverage Countries Report 3.4-Fold Higher Resistance Rates
P. Kilgore (Detroit, United States)*

Scientific Programme

Saturday, 18 April 2026

E0066 09:48 **Is the high prevalence of antibiotic resistance in LMICs the result of local or global emergence?**
S. Benvari (St Andrews, United Kingdom), M. Holden, K. Keenan, A. Sandeman*

E0067 09:54 **The effects of broad-spectrum antibiotics vs placebo on antimicrobial resistance of faecal *Escherichia coli***
A. Pajander (Turku, Finland), P. Salminen, A. Hakanen, T. Kallonen, S. Vanhatalo, S. Hurme, M. Gunell, R. Penttinen, E. Munukka, J. Haijanen, S. Sippola*

E0068 10:00 **Sentinel surveillance of macrolide resistance in *Salmonella*: genomic prevalence and phenotypic expression**
A. Robinson (London, United Kingdom), S. Nair, C. Maguire, A. Levy, D. Powell, A. Ismailahmed, M.A. Chattaway*

E0069 10:06 **Epidemiological evolution of shigellosis after COVID-19: data from a tertiary hospital in Spain**
L. Argente (Pamplona, Spain), G. Martinez, I. Beguiristain, C. Martin, M. Elia, M-E Portillo*

E0070 10:12 **Genomic epidemiology and plasmid architecture of NDM carbapenemase-producing Enterobacteriales in Germany (2015–2021)**
M. Elbediwi (Oldenburg, Germany), J. Sattler, A.F. Wendel, B. Bader, J. Müller, S. Peter, A. Hamprecht*

E0071 10:18 **Continental structural break patterns in *Escherichia coli* antimicrobial resistance across Europe (2000–2024): a multi-country breakpoint analysis using ECDC surveillance data**
A. Sergouniotti (Amfissa, Greece), P. Dimitrelou, E. Alonaris, D. Rigas*

OS007 09:30 - 10:30 **Hall A2-2**
 1-hour Case Session
 CLN PHEI

Bad to the bone

Chairs *Gina Suh (Scottsdale, United States), Erlangga Yusuf (Rotterdam, Netherlands)*

O0058 09:30 **Disseminated MDR tuberculosis manifesting as Pott's disease with tuberculous septic ankle arthritis: an uncommon sequential dual-site involvement**
J. Muqtadir (Rochester, United States), I. Batool*

O0059 09:41 ***Bacteroids fragilis* an unusual cause of bone and joint infection in children, a case report**
H. Al Dhanhani (Abu Dhabi, United Arab Emirates), N. Elsayed, E. Shebany*

O0060 09:52 **A rare aetiology of periprosthetic joint infection in a patient from a rural area**
C. Gay González (Logroño, Spain), I. Arregui García, J.A. Madrigal Cruz, J.R. Blanco Ramos*

O0061 10:03 **Extensive tibial and calcaneal osteomyelitis with bilateral knee septic arthritis caused by *Burkholderia thailandensis***
K.V. Abalajon (Pasig City, Philippines), K. E. Henson*

O0062 10:14 **Conventional and unconventional use of the BIOFIRE® Joint Infection Panel in paediatric patients with severe infections: the experience of the paediatric hospital of Padua, Italy**
D. Doni (Padua, Italy), B. Veronica, M. Sciro, C. Mariachiara, M. De Pieri, G. Brigadoi, D. Donà*

SY041 09:30 - 10:30 **Hall ICM 14**
 1-hour Symposium
 IPC

Year in infection control

Chairs *Stephanie Dancer (Glasgow, Lanarkshire, United Kingdom), Walter Zingg (Zurich, Switzerland)*

S0208 09:30 - *Nico Tom Mutters (Bonn, Germany)*

S0209 10:00 - *Maaïke Van Mourik (Utrecht, Netherlands)*

EF017 11:00 - 12:00 **Arena 2**
 ePoster Flash Session
 PHEI VAX

Update in mosquito-borne infections and vector control

Chair *Gathsaurie Neelika Malavige (Nugegoda, Sri Lanka)*

E0112 11:00 **A one health regional framework for predictive dengue surveillance and early warning in Southeast Asia**
S. Sidhik (Phnom Penh, Cambodia), S. Boyer*

E0114 11:12 **Humoral and cellular immune responses to an intradermal live attenuated tetravalent dengue vaccine: a pilot study among healthy adults**
T. Khaimook (Hat Yai, Thailand), S. Chusri, N. Pinpathomrat, P. Siripaitoon, N. Kositpantawong, S. Kanchanasuwan, S. Chittrakarn, S. Uppanisakorn*

E0115	11:18	Immune response to TAK-003: updated results from the DENG-VAC Study <i>A. D'abramo* (Rome, Italy), L. Ponzetta, F. Colavita, S. Vita, E. Cimini, P. De Marco, L. Rosa, M. Tiberi, F. Maggi, D. Goletti, E. Nicastri</i>	E0122	11:06	Socioeconomic Inequality and Corruption as Determinants of Antibiotic Access and AMR Burden <i>S. Saeedi Moghaddam* (Kiel, Germany), M. Stolpe</i>
E0116	11:24	Wolbachia-mediated incompatible-insect technique robust to future climate change scenarios <i>L. Geng* (Singapore, Singapore), P. Ross, A. Hoffmann, J.T. Lim</i>	E0123	11:12	Everyday realities of antibacterial drug resistance in Uganda: an ethnographic study of social and economic impacts <i>S. Nayiga* (London, United Kingdom), A. Namajja, C. Chandler</i>
E0117	11:30	Projected chikungunya transmission in Australia is virus genotype dependent <i>F. Frentiu* (Herston, Australia)</i>	E0124	11:18	"Bacteria and the Resistance": A Microbial Comic Book <i>G. Greub* (Lausanne, Switzerland), C. Aubry</i>
E0118	11:36	Modelling the efficacy of vaccine and vector control tools of chikungunya in Asia Pacific <i>E. Choo* (Singapore, Singapore), J.T. Lim</i>	E0125	11:24	Critical Levels of Multidrug Resistance in Pathogens Circulating in the Niger River: Implications for Public Health Surveillance <i>C. Touré* (Bamako, Mali), T. Cheick</i>
E0119	11:42	Rollout of Seasonal R21 Malaria Vaccination and Chemoprevention for children in Kule Refugee Camp in Gambela, Ethiopia during the 2024 malaria season <i>Y. Atnafu* (Yeka Sub City, Ethiopia), Y. Girma, K. Siferaw, K. Lavilla, A. Tawassar, D. Koang, D. Tugizimana, A. Dirks, M. Ayalew, J. Loonen, C. Ariti, G. Mapiye, W. Mulanda, A.D.L. Pereira, A. Bestman, K. Velivela, B. Rao, B. Stringer, R. Wilson, A. Abbara, P. Keating</i>	E0126	11:30	A case study on effective student engagement in antimicrobial resistance: the Makerere University AMR club model <i>V. Nabisere* (Kampala, Uganda), C. Akello</i>
E0120	11:48	Blood-stage controlled human malaria infection in Tanzanian adults to assess the protective effect of the malaria vaccine candidates R78C and/or RH5.1 in Matrix-M[®] adjuvant <i>J. Van Heerden* (Oxford, United Kingdom), A.E. Kahatano, S. Silk, C. Rigby, S. Pollock, N. Lilolime, L. Batao, J. Salkeld, N. Kamau, R. Roberts, H. Msami, N. Urasa, E. Kenya, M. Mohamed, I. Mtaka, C. Carnrot, C. Nielsen, M. Mpina, S. Draper, A. Minassian, A. Olotu</i>	E0127	11:36	Sex, gender, and antimicrobial resistance: evidence and gaps across across infection, selection and transmission <i>G. Knight* (London, United Kingdom), O. Edun, A. Kjaersgaard, K. Horton, K. Keenan, J. Robotham, C. Wenham, C. Chandler</i>
			E0128	11:42	Caste-based disparities and AMR risks <i>S. Goel* (Bengaluru, India), R. Bhagawati, A. Banerji, D. Batheja</i>
			E0129	11:48	Integrating antibiotic stewardship within a One Health framework: a pilot study on knowledge, attitude and practice questionnaire in companion animal veterinary medicine of Northern Italy <i>F. Compostella* (Verona, Italy), M. Domaschio, D. Fasan, F. Sbardellati, E. Tacconelli, E. Carrara</i>

FO049 11:00 - 12:00 Arena 1
PRO Open Forum

Sharing made simple: how standardised data exchange improves infectious diseases research and care

Chair *Marc J.M. Bonten (Utrecht, Netherlands)*

F0111 11:00 **Sharing clinical laboratory and infectious disease data in the European Health Data Space for primary and secondary use**
Hynek Kruzik (Prague, Czechia)

F0112 11:10 **Using standards to bridge the divide between clinical trials and cohort studies: the ECRAID Base experience**
Ankur Krishnan (Heidelberg, Germany)

EF018 11:00 - 12:00 Arena 4
PHEI ePoster Flash Session

Socioeconomic and structural drivers of AMR

Chair *Sara Tomczyk (Berlin, Germany)*

E0121 11:00 **National priority assessment of multidrug-resistant microorganisms based on the multicriteria decision analysis**
Y.K. Yoon (Seoul, Korea, Republic of), S.Y. Yu, E.Y. Bae, H. Seok, Y.J. Choe, S.J. Choi, H.S. Oh, J.W. Suh, J.Y. Kim*

Scientific Programme

Saturday, 18 April 2026

- F0113 11:20 Standardised sharing of national AMR surveillance data: showcase Netherlands**
Bram Lestrade (Roermond, Netherlands)
- F0114 11:30 Standardised exchange of microbiological data for patient care, research and surveillance**
Alexandra Hoffmann (Berlin, Germany)

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), European Clinical Research Alliance on Infectious Diseases (ECRAID), EU Lab Semantic WG HL7

FO050 11:00 - 12:00 Arena 3
Open Forum

Sharpening communication and leadership skills in CM/ID

- Chair Mary Horgan (Dublin, Ireland)*
- F0115 11:00 Communication skills for culturally competent infectious disease care**
Muge Cevik (Edinburgh, United Kingdom)
- F0116 11:10 Becoming doctor-influencers for better redefining CM/ID professionalism**
Akshatha Ravindra (Karnataka, India)
- F0117 11:20 Dealing with the Imposter syndrome**
Maeve Doyle (Waterford, Ireland)

Co-organised with: ESCMID Parity Commission, ESCMID Professional Affairs Subcommittee, ESCMID Education Subcommittee, TAE Steering Committee

KN042 11:00 - 12:00 Hall ICM 14
Keynote Lecture

AMR IPC

Containment of MRSA in hospitals: past, present, future

*Chairs Robert Leo Skov (Copenhagen, Denmark)
Margreet C. Vos (Rotterdam, Netherlands)*

KO098 11:00 Susan Huang (Irvine, United States)



Susan Huang, MD MPH is Chancellor's Professor in Infectious Diseases at the University of California Irvine (UCI) School of Medicine, and Medical Director of Epidemiology and Infection Prevention at UCI Health. For over 20 years, Huang has been studying healthcare-associated infections (HAIs) with a focus on multi-drug-resistant organisms. Her research seeks to identify risk factors for acquisition and disease, and preventative strategies for containment. Huang has led several large randomised clinical trials involving decolonisation to prevent methicillin-resistant *Staphylococcus aureus* (MRSA) disease and other HAIs across hospitals and nursing homes. Huang has over 200 publications and has received two Top 10 US Clinical Research Achievement Awards from the Clinical Research Forum.

Fireplace Session 18 April, 12:15 - 13:15

ME048 11:00 - 12:00 Hall ICM 5
Meet-the-Expert

IPC PHEI

Viral threats and antibiotic resistance in wastewater in the postpandemic era

- M0109 11:00 Steen Ethelberg (Copenhagen, Denmark)**
- M0110 11:12 Henry-Michel Cauchie (Belvau, Luxembourg)**

OS009 11:00 - 12:00 Hall ICM 13b
ANT 1-hour Oral Session

Tomorrow's antibiotics today: from first-in-human to phase III

Chairs Daniele Roberto Giacobbe (Genoa, Italy)
Erin McCreary (Pittsburgh, United States)

O0107 11:00 Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam vs best available therapy in adults with cUTI/AP, HABP/VABP, cIAI due to carbapenem resistant Enterobacterales: integral-2, single-blind, randomised phase III trial

R. Takaya (Tokyo, Japan), K. Yanagihara, K. Tateda, H. Huang, H. Mukae, H. Ohge, Y. Doi, S. Takahashi, M. Yasuda, K. Matsumoto, M. Sumiya, K. Suwada, S. Kamiyabu, Y. Sasagawa, T. Minamida, S. Kato, K. Kondo, T. Naruse, H. Mikamo*

O0108 11:12 Subgroup analysis of tebipenem pivoxil efficacy in patients with complicated urinary tract infection or acute pyelonephritis: results from the phase III PIVOT-PO study

S. Ascioğlu (London, United Kingdom), D. Hong, T. Otiker, Y. Sánchez-Pearson, A.J. Sheets, M. Sprys, N.E. Scangarella-Oman, N. Bhatt, I.A. Critchley, L.B. Gasink, K.A. Hamed, D. Sotolongo, K. Wrzosek, A. Peppercorn*

O0109 11:24 Characterisation of *Pseudomonas aeruginosa* isolates from bronchiectasis patients in a phase II trial of a bispecific monoclonal antibody: GREAT-2

R.C. Hull (Dundee, United Kingdom), M.B. Long, A. Gilmour, I. Petrou, R. Galloway, K. Viligorska, H. Richardson, J.M. New, C. Hennayake, E. Johnson, E. Mcintosh, Z. Eke, H. Lind, M. Band, H. Bandara, G. Martin, S. Aliberti, M. Vendrell, E. Polverino, G. Suarez-Cuartin, M.R. Loebinger, M. Tunney, K. Cartwright, R. Hughes, A. Digiandomenico, M.G. Belvisi, W. Brailsford, C. Haworth, O. Sibila, J. Stobo, J.D. Chalmers*

O0110 11:36 Overall response and microbiological eradication of cefepime/enmetazobactam vs piperacillin/tazobactam in patients with acute pyelonephritis: a post-hoc subgroup analysis from the ALLIUM phase III trial

J. Quevedo Marin (Cartagena, United Kingdom), S. Cure, N. Dunkel, N. Jemmely*

O0111 11:48 Evaluating the efficiency of platform trial designs relative to stand-alone trials: A simulation study for the evaluation of new antibacterials

M. Hardy (Herston, Australia), P. Harris, Y. Mo, D. Paterson*

OS010 11:00 - 12:00 Hall A1-1
ANT TRN 1-hour Oral Session

Exploiting biology for therapy: novel approaches against antimicrobial-resistant pathogens

Chairs Katy Jeannot (Besançon, France)
Robert C. Read (Southampton, United Kingdom)

O0077 11:00 Calcium phosphate nanostructures: alternative approach against antibiotic-resistant *Staphylococcus aureus* and *Pseudomonas aeruginosa*

M. Mariotti (Rome, Italy), D. Squitieri, L. Degli Esposti, C. Fusacchia, R. Torelli, M. Sanguinetti, M. Iafisco, F. Bugli*

O0078 11:12 AMR-endemic flies represent an underexplored reservoir of lytic bacteriophages

W. Martins (Oxford, United Kingdom), C. Rubio, K. Cook, T. Lannetelli, S. Premchand-Branker, E. Portal, G. Jordao, T. Beard, A. Lankapalli, K. Iregbu, S. Afegbua, A. Aliyu, Y. Mohammed, I. Nwafia, O. Oduyobo, A. Ibrahim, Z. Tanko, T. Walsh, C. Achi, K. Sands*

O0079 11:24 Neutrophil peptidyl-arginine deiminase enzymes as dual anti-bacterial and anti-biofilm agents

R. Baird (Dublin, Ireland), D. Gogoi, L. Forde, M. Niu, S.W. Ahmed, F. Fitzpatrick, E.P. Reeves*

O0080 11:36 Af-DAP10-CD3z-CAR-NK92 cells exert enhanced antifungal activity against *A. fumigatus*

M. Mauget (Rennes, France), A.L. Schmitt, H. Einsele, M. Hudecek, J. Löffler, M. Seif*

O0081 11:48 Characterisation of novel vibrio phages as biocontrol agents against *Vibrio alginolyticus* and insights into its phage-resistant mutant

R. Nepal (Battery Point, Australia), T. Charles, R. Taylor, J. Wynne*

Scientific Programme

Saturday, 18 April 2026

OS011 11:00 - 12:00 Hall A1-2
 TRN VAX 1-hour Oral Session

Mechanisms of hypervirulence and resistance in *Klebsiella pneumoniae*

- Chairs* *Alessandra Carattoli (Rome, Italy)*
Yunn-Hwen Gan (Singapore, Singapore)
- O0082 11:00** **Immunotherapeutic monoclonal antibodies against antibiotic-resistant *Klebsiella pneumoniae* derived from glycoconjugate-based immunisation**
B. Fries (Yes, United States), K. Mihooliya, C. Boniche-Alfaro, T. Imeraj*
- O0083 11:12** **The plasmid-borne lytic transglycosylase PLT-1 augments virulence in ST11 carbapenem-resistant hypervirulent *Klebsiella pneumoniae* by exacerbating immune responses and macrophage death**
P. Jia (Beijing, China), W. Yu, Q. Yang*
- O0084 11:24** **Differences in basal adaptation of core proteome expression between hypervirulent and multidrug-resistant *Klebsiella pneumoniae* lineages**
P. Miguela-Villoldo (Madrid, Spain), D. Fousteris, I. Alonso-González, L. Vaughan, A. Tajuelo, B. Cano-Castaño, S. Prieto Martín-Gil, E. Gato, A. Peláez-García, V. Martín, A. Pérez, A.J. Martín-Galiano*
- O0085 11:36** **The virulence related response of Hypervirulent *Klebsiella pneumoniae* to phagocytosis by murine macrophage**
S. Belge (Istanbul, Türkiye), C. Vatanserver, Ö. Albayrak, S. Yalçın, A. Akpınar, F. Can*
- O0086 11:48** **Genetically-defined hypervirulent carbapenem-resistant *Klebsiella pneumoniae* (Hv-CRKP) exhibited diverse biological phenotypes: evidence from different clades of ST11-KL64, the most prevalent hv-CRKP strains in China**
X. Chu (Beijing, China), Q. Zhang, W. Yu, Y. Zhu, X. Jia, Q. Yang*

OS012 11:00 - 12:00 Hall A1-3
 CLN 1-hour Oral Session

Sexually transmitted infections: typing to therapy

- Chairs* *Nicola Low (Bern, Switzerland)*
Aaron Schembri (Attard, Malta)
- O0088 11:12** **Towards global harmonisation of the mgpB typing scheme for *Mycoplasma genitalium*: updating the PubMLST platform to enable effective surveillance**
S. Manoharan-Basil (Antwerp, Belgium), I. De Baetselier, S. Pereyre, J. Guiraud, L. Piñeiro, J. Danielewski, M.J. Borrego, N. Adriaens, J.S. Jensen, N. Nordal-Budinsky, K. Imai, R. Dumke, O. Harrison*
- O0089 11:24** **Benzathine penicillin G plus doxycycline vs benzathine penicillin G alone for early syphilis in people with HIV: interim analysis**
K.Y. Lin (Taipei, Taiwan), C.P. Chen, C.S. Tsai, M.S. Tsai, P.L. Lu, K.H. Chen, P.L. Chen, Y.W. Weng, H.J. Tang, C.C. Hung*
- O0090 11:36** **Advancing STI care in low- and middle-income countries: development of a multiplex lateral flow assay for gonorrhoea and chlamydia**
B. Blumel (Geneva, Switzerland), H. Ramachandraiah, B. Gleeson, V. Chuchu, S. Mchugh, M. Lear, E. Cruz-Andres, K. Keith, J. D. Klausner*
- O0091 11:48** **Syphilis in bone and joint: what the skeletons tell us and why it matters today**
F. Massou (Cotonou, Benin), F. Spada, N. Schiano Moriello, J. Kowalska, G. Monsel, K. Roberts, M. Augello, F.B. Farkas, M. Farajova, A. Harxhi, A. Fidji Glaria Campo, I. Gentile*

OS013 11:00 - 12:00 Hall A1-4
 CLN DX 1-hour Case Session

Life-threatening fungal infections

- Chairs* *Daniel Aguilar-Zapata (Mexico City, Mexico)*
Armelle Villalobos (Winnipeg, Canada)
- O0072 11:00** **Importance of source control in prosthetic fungal endocarditis: multiple antifungal therapy failures, including breakthrough infection under long-term suppressive rezafungin therapy**
C. Colarossi (Piacenza, Italy), G. Priante, V. Lepera, L. Gerra, D. Aschieri, S. El Qarra, F. Nicolini, G. Lo Cascio, F. Trapani*

- O0073 11:11** **Recurrent Prosthetic Valve Endocarditis by *Candida* parapsilosis With De Novo Azole Resistance: A Five-Thousand-Day Clinical Evolution Confirmed by Genomic Sequencing**
*P. Merino Amador** (Madrid, Spain),
F. Gonzalez Romo, I. Vilacosta, C. Olmo, O. Zaragoza
- O0074 11:22** **Disseminated mucormycosis in an apparently immunocompetent adult: case report and systematic review**
*S. Rao Kordcal** (New Delhi, India),
A. Sengupta, R. Sarda, G. Singh, M. Soneja
- O0075 11:33** **Cerebral histoplasmosis in a patient under ibrutinib therapy: diagnostic challenges and paradoxical radiological progression after treatment initiation**
*G. Thizy** (Paris, France), *M. Schmitt, S. Hamane, A. Alanio, B. Denis*
- O0076 11:44** **Disseminated aspergillosis and cryptococcal meningitis in patients treated for immunotherapy-related myocarditis and myocarditis-myositis-myasthenia gravis (Triple M) overlap syndrome: an unmet need for antifungal prophylaxis?**
*J. Cruise** (Liverpool, United Kingdom),
L. Cossar, T. Guinan, A. Johnson, A. Howard, L. Turtle, N. Garbutt, A. Olsson-Brown

- O0094 11:24** **Active auditing in antimicrobial stewardship programs improves appropriateness of prescribing: an observational cohort study**
*C. Chen** (Melbourne, Australia), *L. Hall, K. Thursky, N. Sivapragasam, N. White, C. Ierano, R. James, L. Marquart-Wilson*
- O0095 11:36** **Multidrug-resistant Gram-negative bacteria screening to guide perioperative prophylaxis in colorectal surgery: a multi-centre quasi-experimental study**
*D. Fasan** (Verona, Italy), *M. Morra, M. Da Meda, M.D. Pezzani, M. Tebon, V. Mengardo, A. Di Gioia, M. Genna, S. Zerva, A.R. Andritsos, I.M. Fieraru, D. Costin, I. Salcedo-Leal, C. Díaz-López, A. Sonpar, J. Rodríguez-Baño, P. Retamar-Gentil, N. Zuabi-Garcia, A. Hristea, C.M. Niculae, W. Zingg, E. Tacconelli, E. Carrara*
- O0096 11:48** **An electronic medical record-based 'persuasive' antimicrobial stewardship intervention to align bloodstream infection treatment duration with evidence from the BALANCE trial**
*J. Bramwell** (Melbourne, Australia),
J. Hinh, S. Koning, K. Horne, L. Upjohn, J. Hughes, R. Junckerstorff, B. Rogers

OS014 11:00 - 12:00 Hall A1-5
 ANT CLN 1-hour Oral Session

Turning AMS evidence to action

Chairs Sara Cosgrove (Baltimore, Maryland, United States)
 Flaminia Olearo (Berlin, Germany)

- O0092 11:00** **Bridging surveillance and stewardship: Using the ECRAID Emerging Resistance Index to prioritise reserve antibiotics when guidelines offer equivalent options**
*M.D. Pezzani** (Verona, Italy), *D. Ortiz, J. Garlasco, K. Odoj, F. Arieti, M. Morra, E. Addis, M. Tebon, O. Awwad, A. Cassini, S. Harbarth, E. Presterl, G. Kahlmeter, A. Savoldi, E. Tacconelli*
- O0093 11:12** **A cluster-randomised controlled pragmatic trial to evaluate antibiotic stewardship strategies for short-course and oral-switch antibiotic therapy for Enterobacterales bloodstream infections**
*C.Y.G. Lui** (Hong Kong, Hong Kong),
C.M.T. Li, M. Mung, C. Cheung, C.T. Au-Yeung, H.Y. Ho, W.L.F. Luk, C.M. Leung, C. Lai, V. Chow

OS015 11:00 - 12:00 Hall A2-2
 CLN TRN VAX 1-hour Oral Session

Burden, immunity and management of viral infections in immunocompromised hosts

Chairs Jon Salmanton-García (Cologne, Germany)
 Carla Walti (Basel, Switzerland)

- O0097 11:00** **Durability of immunity six months after adjuvanted respiratory syncytial virus (RSV) vaccination in high-risk transplant recipients**
*V.G. Hall** (Toronto, Canada), *A. Alexander, F. Mavandadnejad, M. Kern-Smith, R. Kang, X. Dang, P. Lavoie, S. Humar, P. Winichakoon, R. Johnstone, M. Aversa, I. Novitzky-Basso, D. Kumar, J. Mattsson, V.H. Ferreira*
- O0098 11:12** **Adoptive transfer of polyomavirus-specific T cells in progressive multifocal leukoencephalopathy: a multi-centre retrospective real-world analysis**
*G. Martin-Blondel** (Toulouse, France),
A. Chevallier, B. Bonneau, I. Cortese, D. Bensoussan, L. Grote-Levi, N. Möhn, P. Cinque, J. Rubinstein, R. Wicklein, T. Pfeiffer, B. Omer, M. Steinhardt, J.J. Tudesq, N. Testard, P. Chevallier, R. Bernard-Valnet, M. Le Maréchal, G. Catalano, B. Pignolet, A. Sommet, B. Eiz-Vesper, P. Comoli, T. Skripuletz

Scientific Programme

Saturday, 18 April 2026

00099	11:24	<p>Cytomegalovirus Infections after Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma <i>J.S. Little*</i> (Boston, United States), <i>I.A. Perez Villa, E. Arbona Haddad, E.B. Kim, A.J. Yee, O. Nadeem, S. Midha, A.S. Sperling, N. Munshi, N.S. Raje, D.D. Cirstea, S.P. Hammond</i></p>
00100	11:36	<p>Therapeutic drug monitoring of letermovir in allogeneic haematopoietic stem cell transplant (allo-HSCT) recipients: a prospective, two-centre observational study <i>J. Tang*</i> (Taipei, Taiwan), <i>T.Y. Pai, Y.W. Wang, C.Y. Chen, H.A. Hou, B.S. Ko, P.Y. Chen, Y.J. Liu, H.Y. Lin, Y.H. Wu, Y.J. Chen, S.W. Lin</i></p>
00101	11:48	<p>Target trial emulation of viral infection vs no infection and risk of invasive fungal disease after haematopoietic stem cell transplantation <i>L. Bussini*</i> (Pieve Emanuele, Milan, Italy), <i>D.F. Bavaro, D. Sacchet, F. Mediolli, F. Berardi, M. Ronconi, P. Crombie, F.M.P. Tordato, B. Varisco, L. Diella, D. Mannina, J. Mariotti, C. Scuderi, M. Calabrò, R. Renzulli, V. Cento, S. Bramanti, M. Bartoletti</i></p>
<hr/>		
OS016	11:00 - 12:00	Hall A3-2
<p>AMR DX 1-hour Oral Session</p>		
<p>Resistance trends in <i>Candida</i> species</p>		
<p><i>Chairs</i> <i>Maiken Cavling Arendrup</i> (Copenhagen, Denmark) <i>Jean-Pierre Gangneux</i> (Rennes, France)</p>		
00102	11:00	<p>Activity of comparator antifungal agents against drug-resistant <i>Candida glabrata</i> <i>M. Winkler*</i> (North Liberty, United States), <i>A. Klauer, S. Edeker, H. Kimbrough, P. Rhomberg, M. Castanheira</i></p>
00103	11:12	<p>Clinical emergence and spread of <i>Candidozyma auris</i> outbreak-adapted lineages harboring mutations in RBA1 <i>L. Doorley*</i> (Memphis, United States), <i>A. La Bella, S. Jones, G. Zhao, M. Asadzadeh, Q. Choudhury, S. Ahmad, E. Mokaddas, I. Al-Obaid, W. Alfouzan, K. Al-Banwan, T. O'meara, F. Santiago-Tirado, A. Flores-Mireles, J. Rybak</i></p>
00104	11:24	<p>Genomic analysis of <i>Candida parapsilosis</i> over a decade across multiple hospitals highlights clonal persistence and increasing fluconazole resistance <i>S. Srivastava*</i> (Delhi, India), <i>N. Shukla, P. Kagra, K. Jain, A. Chowdhary</i></p>

00105	11:36	<p>Calcineurin mediates caspofungin heteroresistance, a precursor to stable resistance in <i>Nakaseomyces glabratus</i> <i>Y. Su*</i> (Beijing, China), <i>Y. Li, Y. Xu</i></p>
00106	11:48	<p>Comparison of manogepix activity against 8,722 community-acquired and nosocomial yeast isolates from the SENTRY Antimicrobial Surveillance Program (2017-2024) <i>M. Winkler*</i> (North Liberty, United States), <i>P. Rhomberg, S. Edeker, A. Klauer, M. Castanheira, M. Huband</i></p>

SY043	11:00 - 12:00	Hall ICM 13a
<p>CLN DX 1-hour Symposium</p>		

Top papers in imported tropical diseases and diagnosis of parasitic Infections

<i>Chairs</i>		<i>Miriam José Alvarez Martinez</i> (Barcelona, Spain) <i>Ferenc Balázs Farkas</i> (Budapest, Hungary)
S0099	11:00	<p>Top papers in tropical diseases <i>Pedro Legua</i> (Lima, Peru)</p>
S0100	11:30	<p>Top papers in diagnosis of imported parasitic diseases <i>Charlotte Sriruttan-Nel</i> (Johannesburg, South Africa)</p>

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

SY044	11:00 - 12:00	Hall BO-1
<p>AMR IPC 1-hour Symposium</p>		

The hospital bathroom as a hotspot for AMR

<i>Chairs</i>		<i>Stephanie Dancer</i> (Glasgow, Lanarkshire, United Kingdom) <i>Fidelma Fitzpatrick</i> (Dublin, Ireland)
S0101	11:00	<p>The sink: design and behavioural aspects to mitigate risks: towards a "sink bundle" <i>Hillary Craddock</i> (Dublin, Ireland)</p>
S0102	11:30	<p>Toilets: flushing and spread of pathogens <i>Kalisvar Marimuthu</i> (Singapore, Singapore)</p>

SY045	11:00 - 12:00	Hall BO-2
<p>CLN 1-hour Symposium</p>		

Updates on severe pneumonia

<i>Chairs</i>		<i>Antonios Katsounas</i> (Bochum, Germany) <i>Preeti Malani</i> (Ann Arbor, Michigan, United States)
S0103	11:00	<p>Severe community-acquired pneumonia <i>Pedro Pova</i> (Lisbon, Portugal)</p>

S0104 11:30 Severe hospital-acquired pneumonia
Jordi Rello (Barcelona, Spain)

Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP), ESCMID Study Group for Infections in the Elderly (ESGIE), European Extracorporeal Life Support Organization, European Society of Intensive Care Medicine

SY046 11:00 - 12:00 Hall A2-1
PHEI 1-hour Symposium

Engaging citizens in infectious disease surveillance, prevention, and research

Chairs *Tyra Grove Krause (Copenhagen, Denmark)*
Joel Mossong (Luxembourg, Luxembourg)

S0105 11:00 Digital countermeasures for epidemic control
Emmanuel André (Leuven, Belgium)

S0106 11:30 Virus monitoring at workplaces
Tine Graakjær Larsen (Værløse, Denmark)

SY047 11:00 - 12:00 Hall A3-1
CLN DX 1-hour Symposium

Diagnostic stewardship: asking the right questions to measure clinical impact - Pro/Con debate

Chairs *Adarsh Bhimraj (Houston, Texas, United States)*
Bhanu Sinha (Groningen, Netherlands)

S0107 11:00 Diagnostic stewardship is an important part of quality of care and has clinical impact
Heiman Wertheim (Nijmegen, Netherlands)

S0108 11:30 Diagnostic stewardship is an auxiliary to antimicrobial stewardship, but has no impact on quality of care
Evelina Tacconelli (Verona, Italy)

EF023 13:30 - 14:30 Arena 1
CLN IPC TRN ePoster Flash Session

Gut microbiota-based interventions against gastrointestinal pathogens and antibiotic resistance

Chair *Marcela Krutova (Prague, Czechia)*

E0150 13:30 VE303 strains disrupt *Clostridioides difficile* growth and induce transition metal starvation responses
L.P. Cornacchione (Cambridge, United States), J.N. Brehm, Z. Anderson, G.L. Medlock, J.A. Sorg*

E0151 13:36 Tolerance and efficacy of the *Faecalibacterium prausnitzii* EXL01 strain for preventing recurrence of *Clostridioides difficile* infection: results from a multi-centre phase I study
N. Benech (Lyon, France), P. Guarino-Vignon, P. Mclellan, S. Truong, A. Delmeule, C. Landman, A. Bourrier, L. Alric, J. Scanzi, N. Cassir, A. Dureault, E. Piet, S. Gallet, E. Botelho-Nevers, M. Guillet, F. Ader, H. Sokol*

E0152 13:42 Impact of a defined bacterial consortium on host immune response and gut function in patients with *Clostridioides difficile* infection (CDI)
J. Norman (Cambridge, United States), R. Menon, S. Bhattarai, A. Prince, Y. Huang, M. Giddins, V. Bucci, B. Olle, J.L. Silber, J. Faith*

E0153 13:48 A global evaluation of the use of faecal microbiota transplant
B. Merrick (Harrow, United Kingdom), B.H. Mullish, S.D. Goldenberg, S. Khanna, V. Ahuja, C.L. Hvas, G.K. Makharia, H.R.T. Williams*

E0154 13:54 Investigation of enterococcus colonisation impact on *Clostridioides difficile* disease severity
T. Eubank (Houston, United States), A. Mai, A. Horvath, K. Begum, T. Horvath, K. Garey*

E0155 14:00 Faecal microbiota transplantation in paediatric patients: the first national experience
B. Szabo (Budapest, Hungary), D. Korózs, J. Czelecz, L. Takács, Á. Visnyovszki, K. Csordás, C. Kassa, G. Kriván*

E0156 14:06 Faecal microbiota transplantation in patients with irritable bowel syndrome profoundly reshapes the gut microbiome, but does not have any detectable clinical effects
O. Cinek (Prague, Czechia), J. Vejmelka, K. Hubáčková, K. Litosova, L. Hlinakova, M. Kulich, P. Kohout, J. Hurych*

E0158 14:18 Improved clinical outcomes and shifts in intestinal microbiome and metabolites following intestinal microbiota transplantation in patients colonised with multidrug-resistant organisms
R. Ghani (London, United Kingdom), J. Bilinski, L. Martinez-Gili, P. Takis, J. Miguens Blanco, N. Geva-Zatorsky, H. Bar-Yoseph, M.R. Thursz, F. Davies, B.H. Mullish, J.R. Marchesi*

Scientific Programme

Saturday, 18 April 2026

EF024 13:30 - 14:30 Arena 3
 CLN DX ePoster Flash Session

Molecular insights and surveillance of parasitic diseases

Chair Özgür Kurt (Istanbul, Türkiye)

- E0159 13:30** Differential expression of carboxypeptidase (metallopeptidase M32) protein contributes to miltefosine drug resistance in *Leishmania donovani*
 K. Kumar* (Hyderabad, India), R. Maurya
- E0160 13:36** Integrating PCR on Giemsa-Stained Smears for accurate diagnosis of cutaneous leishmaniasis
 F. Maatallah* (Tunis, Tunisia), W. Aissi, N. Boulehmi, O. Souissi, A. Bouratbine, K. Aoun
- E0161 13:42** Protein-protein network is responsible for artemisinin induced cyto-toxic effects in liver cells
 E. Dodwani* (Guwahati, India), V. Trivedi
- E0162 13:48** Temporal and Geo-ecological Patterns of Malaria Transmission and *Plasmodium falciparum* Antimalarial Drug Resistance in Cameroon, 2019-2021 and 2025
 V.N.N. Ntui* (Banjul, Gambia), O.C. Eniyou, M.A. Demba, T.O. Apinjoh, A. Amambua-Ngwa
- E0163 13:54** Dengue mortality rates in the elderly population of Brazil and Colombia, 2019 and 2020
 A. Rodriguez-Morales* (Pereira, Colombia), J.A. Cardona-Ospina, C. E. Perez, T.D.S.S. Chaves, P. Quispe, R.N. Angerami
- E0165 14:06** Molecular characterisation of *Cryptosporidium* infections in a tertiary hospital in Barcelona during three years of post-COVID19 pandemic period
 M. Alguacil Guillén* (Barcelona, Spain), D. Carmena, M.J. Álvarez-Martínez, P. Köster, S. Sánchez-Prieto, P. Juan-Pardo, C. Aylagas, M.R. Ferré, J. Barrachina, P. Rodriguez, L. Horvath, J. Iglesias, M. Espasa, M-E Valls
- E0166 14:12** Ten-year retrospective surveillance of *Cryptosporidium* spp., *Giardia lamblia* and *Entamoeba histolytica* in the Netherlands
 E.M.J. Groenen* (Bilthoven, Netherlands), T.J. Roodsant, A. Al-Dawaf, A. Bart, G.J.H. Bastiaens, M. Berends, D.A.T. Hanssen, J.J. Van Hellemond, S.D. Kuil, S. Lekkerkerk, J.D. Machiels, B. Mulder, M.R. Ramos Diaz, E. Ruizendaal, J.M. Da Silva, S. Slavenburg, D. Souverein, E. Schaftenaar, K. Tassche-Borggreve, E. Vermeer, J.J. Verweij, A.L.M. Vlek, L.J. Wammes, R. Zonneveld, J.J. Hofstra, L. Mughini-Gras, I.H.M. Friesema

- E0167 14:18** Proteomic profiling of eluted *Schistosoma* antigens for enhanced diagnostic sensitivity
 B. Babalola* (Ondo, Nigeria), K. Sulaiman, T. Oriade, O. Oyeyemi

EF025 13:30 - 14:30 Arena 4
 DX PHEI ePoster Flash Session

Molecular diagnostic innovations across specimens

Chair Mario Ramirez (Lisbon, Portugal)

- E0168 13:30** PCNE: a tool for plasmid copy number estimation
 R. Bollini* (Pavia, Italy), V. Cento
- E0169 13:36** Cerebrospinal fluid lipidome in central nervous system infections: A study of diagnostic accuracy
 S. Staal* (Amsterdam, Netherlands), S. Olie, J.B. Van Klinken, M. Van Weeghel, F. Vaz, J. Bodilsen, H. Nielsen, D. Van De Beek, M. Brouwer
- E0170 13:42** Use of a multiplex joint infection PCR panel on non-synovial fluids: comparing PCR vs culture
 G.M. Chuang* (Singapore, Singapore), S.Y.L. Tan, Y.E. Tan, K.S. Chan, L.L-E Oon
- E0171 13:48** Clinical evaluation of the OCEAN Dx culture-free assay for early detection of bacteraemia in critically ill patients
 A. Dewitte* (Bordeaux, France), J. Thierry, S. Cronier, O. Peuchany, V. Dubois, M. Mamani
- E0172 13:54** Performance assessment of a real-time test for intrapartum detection of group B *Streptococcus* vaginal colonisation
 A. Tazi* (Paris, France), M. Selmi, S. Snoussi, C. Poyart, C. Plainvert
- E0173 14:00** Breath aerosol PCR for detection of lower respiratory tract infections: Evaluation of a non-invasive face mask collector in pneumonia patients
 M. Osthoff* (Basel, Switzerland), S. Dräger, K. Tiseo, H. Santhosh Kumar, M. Alkhazashvili, A. Hammann, P. Risch, R. Willi, T. Mkhavar, C. Fialová, C. Adlhart, D. Szabó, M. Suknidze, I. Pachkoria, T. Broger, E. Ivanova Reipold, K. Varshanidze
- E0174 14:06** Enhancing molecular and genomic approaches for *Bordetella pertussis* investigation and public health surveillance in Victoria, Australia
 L. Sadeesh Kumar* (Melbourne, Australia), M. Sait, J. Merrett, J. Lacey, S. Baines, J. Strachan, N. Sherry, B. Howden

E0175 14:12 **Viral dominance in CNS infections: Five-year epidemiological surveillance using multiplex PCR panel**
Z. Tsinaris (Thessaloniki, Greece), A. Tychala, G. Kagkalou, K. Kouirouxis, O. Vasilaki, P. Mantzana, L. Skoura, E. Protonotariou*

E0176 14:18 **Impact of rapid multiplex PCR testing on the clinical and therapeutic management of pneumonia: a prospective randomised study**
A. Galar (Madrid, Spain), E. Bouza, A. Álvarez-Uría, P. Martín-Rabadán, E. Cercenado, M. Ferris-Villanueva, L. Martín-Aguilera, J. Serrano, L. Alcalá, M.L. Sánchez-Alegre, J. De La Torre Fernández, J.J. García-López, L. Puente, P. Muñoz*

FO056 13:30 - 14:30 **Open Forum** **Arena 2**
AMR

Moving ahead with the AMR agenda in a changing environment

Chair Benedikt Huttner (Geneva, Switzerland)

FO095 13:30 **From 'making the economic case' for AMR to securing financing for core interventions**
Chantal Morel (Bonn, Germany)

FO096 13:40 **Reaching out to those who need to act: education and pre-service training of health workforce**
Li Yang Hsu (Singapore, Singapore)

FO097 13:50 **Progress in measuring prevalence and impact on human health**
Olga Tosas Auguet (Founex, Switzerland)

Co-organised with: World Health Organisation (WHO)

JS001 13:30 - 14:30 **Journal Session** **Hall A2-1**
CLN IPC

Late-breaking research from JAMA: novel insights on treating and preventing infections around the world

Chairs Kirsten Bibbins-Domingo (San Francisco, United States), Preeti Malani (Ann Arbor, Michigan, United States)

J0001 13:30 **Amoxicillin-clavulanate vs amoxicillin for acute sinusitis in adults**
Timothy Savage (Boston, United States)

J0002 13:45 **Long-term cognitive ability and academic achievement after childhood severe malaria**
Chandy John (Indianapolis, United States)

J0003 14:00 **Dalbavancin pharmacokinetics in complicated *Staphylococcus aureus* bacteraemia. A secondary analysis of the DOTS randomised clinical trial**
Thomas Holland (Durham, United States)

KN051 13:30 - 14:30 **Keynote Lecture** **Hall ICM 14**
PED PHEI

Rheumatic heart disease: a global problem

Chairs Fidelma Fitzpatrick (Dublin, Ireland), Annelies Zinkernagel (Zurich, Switzerland)

K0086 13:30 **Liesl Zuhlke (Cape Town, South Africa)**



Liesl Zuhlke is Vice President of the South African Medical Research Council and a paediatric cardiologist at Red Cross Children's Hospital and the University of Cape Town (UCT). A global leader in rheumatic and congenital heart disease, her work spans clinical care, implementation science, genetics, and health systems strengthening. She is committed to advancing equity, empowering women in medicine, and shaping a resilient, inclusive research ecosystem across Africa. She directs the Children's Heart Disease Research Unit based at the Red Cross Hospital and Faculty of Health Sciences, UCT. She has over 250 publications, has been cited over 86,000 times and was the recipient of numerous awards for research, social impact and public health.

Fireplace Session 18 April, 14:45 - 15:45

ME053 13:30 - 14:30 **Meet-the-Expert** **Hall ICM 13b**
AMR IPC PHEI

Candida auris surveillance: when, how and why

M0089 13:30 *Joseph Meletiadis (Athens, Greece)*

M0090 13:42 *Giulia De Angelis (Rome, Italy)*

Co-organised with: Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie (SIMPIOS), International Society of Human and Animal Mycology (ISHAM), EUCIC Steering Committee

Scientific Programme

Saturday, 18 April 2026

ME054 13:30 - 14:30 Hall ICM 5
 CLN IPC Meet-the-Expert

LVAD infections: practical approaches to a complex challenge

M0091 13:30 Saima Aslam (San Diego, United States)

M0092 13:42 Margaret Hannan (Dublin, Ireland)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Implant-associated Infections (ESGIAI)

ME055 13:30 - 14:30 Hall BO-2
 CLN DX Meet-the-Expert

Changing landscape of fungal infections in the solid organ transplant recipient

M0093 13:30 Alessandra Mularoni (Palermo, Italy)

M0094 13:42 John Baddley (Baltimore, United States)

OS019 13:30 - 14:30 Hall ICM 13a
 AMR PED PHEI 1-hour Oral Session

AMR in paediatric populations: from dynamic acquisition to predictive models

Chairs Johannes Hübner (Munich, Germany)
 Theresa J. Ochoa (Lima, Peru)

O0145 13:30 **Modelling the acquisition of extended-spectrum β -lactamase (ESBL)-producing *Enterobacteriaceae* in neonates in Madagascar households**
 M. Alexa* (Paris, France), B.T. Huynh, L. Opatowski, A.L. Beaumont, A. Harimanana, A. Rakotondrasoa, L. Odile Rivoarilala, A. Criscuolo, E. Fara Nandrasana Rakotomanana, P. Herindrainy, J.M. Collard, T. Crucitti

O0146 13:42 **Intestinal acquisition and clearance dynamics of extended-spectrum β -lactamase-producing *Enterobacteriales* in hospitalised Kenyan children: a longitudinal, multi-site follow-up study**
 R. Aizouk* (Oxford, United Kingdom), C. Tigo, S. Yan, M. Timbwa, M. Shalton, M. Ngari, R. Musyimi, H. Browne, J. Walson, T. Lawley, N. Stoesser, E. Van Kleef, J. Berkley

O0147 13:54 **Global surveillance gaps in maternal antimicrobial resistance: insights from isolate-level data on Gram-negative bacteria in LMICs**
 L. Hookham* (Falmer, United Kingdom), J.R. Price, M. Sekikubo, J. Alger, F.A. Dávila Ramírez, O. Dissanayake, J.A. Frem, O. Herrera, O. Makanjuola, I. Martin-Jorge, J. Leach, J.H. Cross

O0148 14:06 **Multidrug-resistant bacterial and fungal colonisation and transmission dynamics in hospitalised neonates**

R. Kelleghan* (Sydney, Australia), M. Aberoumand, J. Beardsley, L.T. Cao, C. Duc Pham, T.M. Duong Nu, P.T. Hang, M. Harrison, L. Howie, M.H. Le, K. Luu Boi, N. Ngo, T. Ngo, T.M.A. Nguyen, T.A. Nguyen, P.A. Pham Dinh, A.T. Pham, V.A. Nguyen, T.D. Thi Hoang, P. Williams

O0149 14:18 **Artificial intelligence to predict antimicrobial resistance in Gram-negative bloodstream infections among paediatric onco-haematology patients**

I. Sartini* (Bologna, Italy), E. Rocchi, C. Campoli, C. Bonazzetti, D. Leardini, F. Baccelli, L. Chiusaroli, D. Zama, M. Spadea, G. Tridello, P. Viale, S. Cesaro, M. Giannella

OS020 13:30 - 14:30 Hall BO-1
 CLN IPC 1-hour Oral Session

From risk to resilience: advances in catheter-related infections across care settings

Chairs Shruti Gohil (Irvine, United States)
 Pilar Retamar Gentil (Seville, Spain)

O0140 13:30 **Risk of catheter-related infections with peripherally vs centrally inserted central catheters in critically ill patients: a propensity score-matched emulated target trial**
 N. Boulet* (Nimes, France), A. Friggeri, A. Gavaille, M. Gautier, B. Louart, A. Machut, A. Lepape, C. Roger

O0141 13:42 **Incidence, risk factors and mortality of catheter-related bloodstream infections: retrospective single centre study in non-ICU wards**
 L. Gazzola* (Milano, Italy), V. Vitaletti, E. Pezzoli, A. Tavelli, G.C. Marchetti

O0142 13:54 **Impact of a National Quality-Improvement Programme on CLABSI Reduction in Ten Greek Hospitals: Results from the GRIPP-SNF Consortium**
 I. Kopsidas* (Athens, Greece), G.C. Tsopela, A. Moutou, P. Varda, P. Pantelidou, D. Kousi, E. Kourkouni, A. Karaiskou, E. Thireos, D. Kaitelidou, A. Koutsoukou, T. Zautis

O0143 14:06 **Epidemiology and Outcomes of Nosocomial Infections in Patients Undergoing ECMO Support: An Eight-Year Retrospective Cohort Study**
 M. Oliveira* (Sao Paulo, Brazil), R. Lobo, F. Galas, C. Sambo, L. Pastore, N. Matos, E. Costa, H. Fernandes, D. Araujo, L. Cardoso, A.R. Guedes

00144 14:18 Genomic characterisation and molecular epidemiology of *Ralstonia thomasii* catheter-related bloodstream infections: report of an outbreak after disruption of the standardised process for venous catheter care

*M. Delaye Martinez** (Mexico City, Mexico), *P. Volkow-Fernández, E. López-Jácome, J. Ortiz-Álvarez, C. Velazquez-Acosta, M.D.L. García-Hernández, M. Hernández-Durán, C.F. Hernández-Pérez, M.D.R. Vázquez-Olivares, C.U. Franco-Frias, P. Cornejo-Juárez, F.M. Medina-Aguilar, D. Vilar-Compte*

00133 14:06 Colonisation with multidrug-resistant Gram-negative bacteria in a low endemic country is associated with substantial morbidity: a population-based observational study

*V. Andrews** (Lund, Sweden), *M. Inghammar, E. Senneby, O. Ljungquist*

00134 14:18 Comparison of mortality after bloodstream infection with piperacillin/tazobactam-resistant vs -susceptible *Escherichia coli* and *Klebsiella pneumoniae*: a nationwide cohort study in Denmark, 2018-2024

*E. Tusch** (Copenhagen, Denmark), *B. Holzkecht, M. Lindegaard, R. Thoft Nielsen, U. S. Justesen, K. Kobberøe Søgaard, T.S. Kostyanov, F. Boetius Hertz, M. Pedersen, R. B. Dessau, S. Skovgaard, J. Gitz Holler, L. Lützen, S. Ellermann-Eriksen, B. Kristensen, R. Skov, L. Engbo Christensen, A. Rhod Larsen, A. Hviid, A. Hammerum, P. Bager*

OS021 13:30 - 14:30 Hall A3-1
AMR ANT CLN 1-hour Oral Session

Clinical impact of drug resistance in Gram-negative infections

Chairs *Lorena Diaz* (Santiago, Chile)
Helena Zemlickova (Prague, Czechia)

00130 13:30 Clinical Impact of Delayed Appropriate Antibiotic Therapy in Bloodstream Infections Caused by WHO Critical Priority Gram-Negative Pathogens: A Target Trial Emulation

*L. Mezzadri** (Singapore, Singapore), *W.C. Tan, X. Hao, J. Quah, A. Manesh, Y.T. Chang, A.T.K. Nguyen, Y. Ding, Y. Cao, Y. Cai, S. Kitsaran, H.H. Chua, S. Bory, S.S.L.S. Ponnampalavanar, S. Anunnatsiri, M.Z. Mazlan, A.K. Dhiloo, R. Plongla, A.L.H. Kwa, S. Faisal Mahmood, A.D. Roman, L. Thwaites, P.V. Tho, S. Wu, D. Chotiprasitsakul, K.J. Wong, H. Wijaya, C.L. Abad, M.O. Rehman Khalid, G.M. Salahuddin Mamun, G.S. Rajahram, H. Guterres, H.N. Hon, T. Van Giang, N.T. Pham, A. Karkey, S. Gunasekara, R. Hamers, R. Sinto, I.N.D. Lubis, M. Wang, M. Moni, P.Y. Liu, Y. Xiao, B. Khanal, N.L. Priya, Y. Doi, H. Hitoshi, B. Baljin, U. Gurjav, R. Asli, L. Ling, A. Dhungana, L.Y. Hsu, D. Paterson, Y. Mo*

00131 13:42 Impact of third-generation cephalosporin resistance on mortality in Enterobacterales bloodstream infections: an individual participant data meta-analysis

*M. Guedes** (Seville, Spain), *M. E.A. De Kraker, N. Hassoun-Kheir, E. Salamanca, E. Rubio, A.D.L.S. Bazan, L.B. Pulido, A. Dambrauskiene, J. Rodríguez-Baño*

00132 13:54 Antibiotic prescribing for presumed *Stenotrophomonas maltophilia* infections in the United States using Epic Cosmos

*S. Boettcher** (Detroit, United States), *R. Kenney, R. Tibbetts, A. Shallal, G. Suleyman, S. Davis, M. Veve*

OS022 13:30 - 14:30 Hall A3-2
PRO 1-hour Oral Session

Game on: leveling up education through simulation and serious play

Chairs *Anette Friedrichs* (Kiel, Germany)
Daniel Grupel (Jerusalem, Israel)

00135 13:30 Enhancing infectious diseases clinical practice through in situ simulation: a feedback-based evaluation

*R. Francis** (Nottingham, United Kingdom), *Y. Milnes, P. Bailey*

00136 13:42 Innovative Use of WHO Tabletop Simulation to Enhance Infection Prevention and Control Education in Ukraine: Experience with Medical Students, Interns, and Practicing Physicians

*D. Paliy** (Vinnytsya, Ukraine), *I. Paliy, O. Voinalovych*

00137 13:54 Design and Development of an Educational Card Game on Infectious Diseases for Anaesthesiology Residents: An Innovative Approach to Medical Education

*P. Lunenburg** (Groningen, Netherlands), *W. Bult, H. Aardema, G. Wietasch, C. Van Den Berg*

00138 14:06 Septris 2.0: A Mixed-Methods Multinational Evaluation of a Gamified Digital Tool for Sepsis Education and Quality Improvement

*S. Meylan** (Lausanne, Switzerland), *L. Shieh, S. Gupta, I. Pottmeyer, N. Mischler, E. Moulin, R. Williams*

Scientific Programme

Saturday, 18 April 2026

00139 14:18 First implementation of an educational escape room for the key symptom "diarrhea" within the course "key symptoms of internal medicine" of the medical curriculum at Christian-Albrechts-University Kiel to strengthen diagnostic and therapeutic reasoning and teamwork skills
C. Kujat (Kiel, Germany), N. Mirwald, U. Macioszek, A. Friedrichs*

SY052 13:30 - 14:30 Hall A2-2
 1-hour Symposium

Mycobacterial infections in childhood

Chairs Elisabeth Schölvinck (Groningen, Netherlands)
 Delane Shingadia (London, United Kingdom)

S0087 13:30 New treatments and management of Tuberculous meningitis in children
Diana Gibb (London, United Kingdom)

S0088 14:00 Optimising the diagnosis of NTM infections in childhood
Jakko Van Ingen (Nijmegen, Netherlands)

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

YIA 13:30 - 14:30 Hall ICM 1
 Awards

Young Investigator Award Lecture

Chairs Jon S. Friedland (London, United Kingdom)
 Jan A.J.W. Kluytmans (Utrecht, Netherlands)

A001 13:30 Re-thinking diagnostics to improve care in resource-limited settings
Grace Androga (Blantyre, Malawi)

A002 13:42 Antibiotics on Target: Predicting Efficacious Dosing in Challenging Patient Populations
Iris K. Minichmayr (Vienna, Austria)

A003 13:54 Can we develop better tests to measure individual infectiousness in respiratory virus infections?
Daniel Pan (Leicester, United Kingdom)

A004 14:06 Beyond the Mold: Shifting Diagnosis and Therapy Through Host Immunity
Sarah Delliere (Paris, France)

A005 14:18 Host-directed therapies and patient stratification for common bacterial diseases
Clark Russell (Edinburgh, United Kingdom)

EF031 14:45 - 15:45 Arena 1
 ePoster Flash Session

Infection risk, response, and recovery in the immunocompromised host

Chair Michael Boeckh (Seattle, United States)

E0202 14:45 Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy
N. Lambert (Liège, Belgium), M. El Moussaoui, A. Le Guilloux, M. Joly, M.D.C. Garcia Martearena, R. Bernard-Valnet, C. Pinnetti, K.F. Greve, X. Brousse, W.F. Westendorp, M.T. Wijburg, L. Grote-Levi, N. Moehn, V. Pourcher, S. Gressens, C.V. Cruz, V. Van Pesch, M. Vidal, C. Morvan, A. Makinson, A.M. Konitsioti, B. Hoellinger, L. Nitsch, D.E. Ney, E. Faure, K.B. Alstadhaug, M. Martinot, F. Genderini, J. Legras, M. Garzaro, S. Bianchi, S. Gazonnes, S. Borrelli, S. Patrat-Delon, D. Vydrář, P. Nicolas-Vullierme, M. Moutel, T. Cartau, F. London, A. Cabié, K. Boullier, A. Montcuquet, P. Loubet, N. Sayre, P. Maquet, G. Darcis, M. Le Marechal, D.B. Clifford, T. Skripuletz, M.C. Brouwer, J. Bodilsen, R. Du Pasquier, P. Cinque, A. Sommet, G. Martin-Blondel*

E0203 14:51 Pritelivir demonstrated superior lesion healing with extended treatment compared to investigator's choice for refractory herpes simplex virus infection in immunocompromised patients in the PRIOH-1 phase III trial
R. Chemaly (Houston, United States), J.M. Molina, K. Workowski, R. Avery, Y.J. Lee, K. Peggs, D. Neofytos, M. Yong, J. Sasadeusz, R. Maves, B. Gaborit, D. Teschner, A. Perez-Rios, A. Birkmann, C. Wat, D.C. Herath, A. Marini, B. Surujbally, M. Sumner, A. Wald, G.A. Papanicolaou*

E0204 14:57 Impaired type I interferon response early after SARS-CoV-2 infection is associated with the occurrence of persistent COVID-19 in solid organ transplanted recipients
Q. Richier (Paris, France), K. Lacombe, D. Duffy, K. Zafilaza, M. Briard, V. Bondet, M. Robert, V. Leducq, A. Fauchois, E. Ghidaoui, S. Sayon, C. Dorival, C. Lusivika-Nzinga, Y. Yordanov, G. Martin-Blondel, F. Carrat, A.G. Marcelin, C. Soulie*

E0205 15:03 Blood virome and acute graft vs host disease
K. Hosszu-Fellous (Geneva, Switzerland), S. Cordey, M. Gumowski, F. Laubscher, L. Royston, S. Masouridi-Levrat, Y. Chalandon, D. Neofytos, L. Kaiser*

- E0206 15:09** **Towards personalised empirical antibiotic therapy in febrile neutropaenia: a theoretical model based on machine learning and prior colonisation with multidrug-resistant Gram-negative bacilli**
A. Gallardo-Pizarro* (Barcelona, Spain), C. Teijón-Lumbreras, T.F. Aiello, P. Monzó-Gallo, A. Martínez-Urrea, C. Terrones-Campos, A. Castiella, G. Cuervo, L. Morata, P. Castro, C. Casals, M. Espasa, J. Esteve, J.M. Nicolas, J. Mensa, A. Soriano, C. Garcia-Vidal
- E0207 15:15** **Burden and clinical outcomes of hospital-coded respiratory virus infection in patients with haematological malignancy: a longitudinal multi-centre cohort study from 2011-2023**
V. Hall* (Melbourne, Australia), T. Spelman, A.P. Ng, M.K. Yong, M.A. Slavin, B.W. Teh
- E0208 15:21** **Steroid-linked invasive fungal infections after CAR-T: insights from a national Australian cohort**
G. Reynolds* (Heidelberg, Australia), M. Dowling, S. Belbachir, N. Perera, J. Li, J. Valencia-Klug, B.W. Teh, M.A. Anderson, A. Barraclough, C. Tam, P.J. Ho, S.J. Harrison, A.S. Henden, M. Slavin
- E0209 15:27** **Role of colonising multidrug-resistant bacteria in haematological patients: a retrospective observational study**
A. Lovecchio* (Trieste, Italy), N. Benvenuto, S. Babich, A. Misin, S. Mohamed, G. Sanson, S. Di Bella
- E0210 15:33** **Serious infection risk with advanced therapies across immune-mediated inflammatory diseases**
V. Allen* (London, United Kingdom), I. Muzafar, R. Chavali, S. Muzafar, N. Suresh, Y. Yoon, L. De Gracia, M. Gibson, M. Russell, K. Bechman, M. Adas, S. Norton, D. Phillipppo, A. Goodman, J. Galloway
- E0212 14:51** **Efficient and easy preparation of stool specimens for molecular diagnostics without nucleic acid purification**
T. Schuurman* (Dordrecht, Netherlands), M. Pellikaan, I. Huijskens
- E0213 14:57** **A multi-centre clinical trial evaluating molecular mini-panels for bacterial gastrointestinal pathogen detection**
A. Nenninger* (San Diego, United States), C. Remillard, Y. Liu, A. Menez
- E0214 15:03** **Diagnostic efficacy of two immunochromatographic tests for the rapid detection of rotavirus, adenovirus, and norovirus compare**
G. Sánchez De Luis* (Madrid, Spain), R. Blázquez Batanero, A.I. Peñalver López, H. Bermúdez Marval, V.A. Robles Curvelo, C. Rescalvo-Casas, M. Hernando-Gozalo, A. Rojas Díaz, F. Pérez-García, Á. Irigoyen-Von-Sierakowski, B. Rodríguez-Ponga, J.A. Cuadros-González, R. Pérez-Tanoira
- E0215 15:09** **Comparative evaluation of diagnostic methods for Entamoeba histolytica: A Four-Year retrospective study**
S. Cebeci* (Çankaya, Türkiye), F. Demirel, U. Berberoğlu, B. Dinç
- E0216 15:15** **Bristol-scale guided using a POCT vs non-POCT molecular syndromic testing and clinical outcomes in traveler's diarrhoea**
M. Bugés Bascompte* (Barcelona, Spain), S.M. San José Villar, N. Vila-Olmo, P. García-Mellado, M. Muixí-Duran, I. Oliveira-Souto, P. Nadal-Barón, M. Vicente-Ciurans, A. Canals, V. Rodríguez-Garrido, C. Arconada-Rojano, C. Rubio-Maturana, L. Goterris-Bonet, E. Sulleiro
- E0217 15:21** **Optimising bacterial stool diagnostics: PCR-guided culture improves sensitivity and accelerates result reporting**
G. Hagn* (Munich, Germany), T. Fleige
- E0218 15:27** **Evaluation of a syndromic real-time PCR approach for non-invasive detection of Helicobacter pylori and clarithromycin resistance in stool specimen: a performance evaluation**
L. Hyeonji* (Seoul, Korea, Republic of), H. Lee, H. Jang, S. Choi, H. Kim, E. Won
- E0219 15:33** **Clinical validation of the BB-ELISA for predicting recurrent Clostridioides difficile infection study**
E. Basseres* (Houston, United States), H. Yu, R. Lee, S. Kumari, J. Fowler, A. Saint Fleur, T. Eubank, Y. Zhang, E. Von Rosenvinge, K. Garey, Z. Yang, H. Feng
-
- EF032 14:45 - 15:45** Arena 2
CLN DX
ePoster Flash Session
- Beyond the culture plate: a multi-modal overview of recent advances in gastrointestinal testing**
- Chair* Mauricio Farfan (Santiago, Chile)
- E0211 14:45** **Evaluation of Copan FecalSwab™ Collection and Transport device for molecular applications**
F. Bonometti* (Brescia, Italy), S. Savi, C. Sabelli

Scientific Programme

Saturday, 18 April 2026

EF033 14:45 - 15:45 Arena 3
 TRN ePoster Flash Session

Preclinical data and fundamental science on fungi and antifungals

Chair *Lysangela Ronalte Alves (Curitiba, Brazil)*

- E0220 14:45** **Impact of azithromycin on neutrophil-mediated immune responses against *Aspergillus fumigatus***
R. Manchon (Paris, France), E. Dudoignon, A. Agathe, W. Sarah, Q. Jessica, D. Sarah*
- E0221 14:51** **A novel infection model to study immunobiology, antifungal pharmacotherapy, and immunomodulatory therapy of invasive pulmonary aspergillosis in mice with acute myeloid leukemia**
S. Wurster (Houston, United States), N.D. Albert, J. Pantaleon Garcia, L. Matula, S. Evans, D.P. Kontoyiannis*
- E0222 14:57** **Efficacy of BAL2062 in immunosuppressed mice infected with azole-sensitive and azole-resistant *Aspergillus fumigatus***
A. Ibrahim (Allschwil, Switzerland), T. Gebremariam, S. Alkhazraji, Y. Gu, E. Youssef, S. Nabeela, T. Elsayed, S. Dolati, K. Litherland*
- E0223 15:03** **Invasive pulmonary mucormycosis is associated with siderophore secretion, neutrophil recruitment, and lipid remodelling in the lungs**
D. Luptáková (Prague 4, Czechia), T. Hřivnová Juříková, M. Petřík, K. Dvořáková Bendová, B. Neužilová, H. Marešová, A. Palyzová, M. Lackner, P. Hubáček, V. Havlíček*
- E0224 15:09** **Once-daily SCY-247 as oral and intravenous formulations has linear pharmacokinetics and is efficacious in a murine model of invasive *Candida glabrata* infection**
N. Wiederhold (San Antonio, United States), L. Najvar, S. Wring, K. Borroto-Esoda, D. Angulo, R. Jaramillo, M. Olivo, T. Patterson*
- E0225 15:15** **Phenotypic and genotypic characterisation of multiple *Candida albicans* laboratory-induced drug resistant isolates reveals convergent and divergent responses to resistance**
R. Khalaf (Byblos, Lebanon), M. Abbas, S. El Hachem, C. Chedraoui, I. Bitar, N. Fattouh*

E0226 15:21 **Engineered CAR-T Cells Targeting Fungal Cell Wall Show Limited Antifungal Activity**
E. Dolader Ballesteros (Zaragoza, Spain), S. Redrado, D. Sánchez-Navarro, M.P. Domingo, P. Esteban, M. Arias, J. Paul-Bernal, V. Taleb, A. Ramirez, R. Hurtado, J. Pardo, E.M. Gálvez*

E0227 15:27 **Host cell receptors on human lung epithelial cells for *Lomentospora prolificans*: an emerging fungal pathogen**
V. Bruno (Baltimore, United States), P. Kavaliauskas, R. Risteen, S. Alkhazraji, T. Walsh, A. Ibrahim*

E0228 15:33 **Azole-induced in-host microevolution of *Candida parapsilosis* drives MRR1-mediated antifungal resistance**
R. Zhang (Beijing, China)*

EF034 14:45 - 15:45 Arena 4
 AMR ANT CLN ePoster Flash Session

Innovations in antimicrobial stewardship across diverse settings

Chair *Nathan Peiffer-Smadja (Paris, France)*

- E0229 14:45** **Strengthening infection control and antimicrobial stewardship through quality improvement in a refugee-serving hospital: lessons from Nakivale, Uganda**
Z. Nahumuza (Entebbe, Uganda), M. Umar*
- E0231 14:57** **"No breakpoints? no problem!" evaluating gentamicin perioperative prophylaxis for *Pseudomonas aeruginosa* asymptomatic bacteriuria before urological surgery**
N. Reidy (London, United Kingdom), S. Dewan, A. Sajyed, A. Raza, D. Smith, A. Lima Soares, G. Pollara, R. Ghani*
- E0232 15:03** **A multi-seasonal mixed-method point-prevalence study of antibiotic prescription patterns in a tertiary healthcare facility in India**
V. Modgil (New Delhi, India), R. Surial, O. Sinha, S. Kumar, S. Raina, R. Chauhan, A. Mukherjee, S. Sahay*
- E0233 15:09** **TDM (Therapeutic Drug Monitoring)-guided meropenem therapy for bone and joint infections caused by Gram-negative bacilli**
M. Sanz-De Mena (Barcelona, Spain), S. Luque, L. Sorlí, D. Pérez-Prieto, A. Alier, G. Rodriguez-Cabalé, I. Pelegrín, M. Montero, J.P. Horcajada, J. Gómez-Junyent*

E0234 15:15 Antimicrobial Stewardship (AMS) program in Lombardy Region: analysis of effectiveness and costs

*G. Renisi** (Milano, Italy), *A. Comelli, L. Scudeller, A. Mazzone, G. Macaluso, M. Zanforlini, S. Schiatti, D. Cereda, G. Del Castillo, U. Restelli, S. Silvola, N. De Fazio, P. Bonfanti, M. Bartoletti, A. Tebaldi, S. Piconi, M. Puoti, A. Castagna, P. Grossi, G.C. Marchetti, A. Regazzetti, F. Castelli, A. Zoncada, B. Castiglioni, L. Pusterla, R. Bruno, S. Rusconi, S. Antinori, A. Muscatello, A. Gori, A. Bandera, S. Chiappetta*

E0235 15:21 Disparities in Infection Prevention and Control, and Antimicrobial Stewardship Practices across Healthcare Settings with Varied Resource Levels: Findings from the BALANCE Study

*R. Farzana** (Oxford, United Kingdom), *N. Haque, S.B. Shahid, G. Ferdous, N. Haque, M. Rahman, S. Afroj, E. Carretto, D.B. Roatti, E. Kibaru, L. Kiguongo, G. Ganda, D. Adera, C. Achi, K. Iregbu, P. Nwajobi-Princewill, O-E Ben, A. Aminu, F.H. Auwal, I.N. Nwafia, O.S. Ukaegbu, R. Zahra, M. Hamza, B. Hassan, A. Naqvi, G. Guljanan, K. Shafique, M. Nawaz, M. Idrees, M. Umair, A. Zukowska, A. Zukowska, M. Zukowski, M. Borowiak, O. Ergonul, L.S. Gucer, Ö.K. Azap, N. Sari, E.T. Tigen, B-E Sengel, M. De Kraker, S. Harbarth, N. Hassoun-Kheir, K. Onjuro, E. Owinoh, T. Walsh*

E0236 15:27 Addressing prescribing behaviour to reduce broad-spectrum antibiotic use

*V. Chorro-Mari** (Ashford, United Kingdom), *A. Dalton, S. Yan, S. Glass, L. White*

E0237 15:33 From culture positives to positive culture: changing behaviour around ASB treatment

*M. Arandjelovic** (Aveiro, Portugal), *L. Maia, A. Ribeiro, T. Mariano, M. Santos, F. Freitas*

KN057

14:45 - 15:45

Hall ICM 14

CLN TRN

Keynote Lecture

From molecules to ministries: a life in the fight against malaria

Chairs

Anu Kantele (Helsinki, Finland)
Carlos Seas (Lima, Peru)

K0118 14:45

Abdoulaye Djimde (Bamako, Mali)



Abdoulaye Djimde is CAMES Professor of Parasitology and Mycology at the Malaria Research and Training Centre University of Science, Techniques and Technologies of Bamako, Mali and a Calestous Juma Research Leadership Fellow. His primary research focus is to understand how variations in the genomes of the malaria parasite, the human host, and the mosquito vector relate to disease outcomes like the spread of drug resistance. As founding President of the Pathogens genomic Diversity Network Africa, he leads efforts in bringing knowledge derived from pathogens genetics and genomics to help solve public health problems with the communities, and health policy decision makers. Currently he serves as coordinator of the West African Network for Clinical Trials of Antimalarial Drugs, and President of the African Association for research and control of AntiMicrobial Resistance.

Fireplace Session 18 April, 16:00 - 17:00

Scientific Programme

Saturday, 18 April 2026

LB002 14:45 - 15:45 Hall A1-4
 PHEI 1-hour Oral Session

Late-breaking public health challenges

- Chair* David Fisman (Toronto, Canada)
TBA
- L0011 14:45 Stress testing acute care chains for high-volume war-related trauma and MDROs**
A. Tostmann* (Nijmegen, Netherlands), B. Beishuizen, V. Stirler, E. Ruizendaal, D. De Jong, E. Tan, C. Rovers
- L0012 14:57 Imported MERS-CoV cases in France, November 2025: diagnosis, management and public health response**
A. Bal* (Lyon, France), L. Van-Den-Bogaart, A. Maisa, S. Dan, M. Bouscambert-Duchamp, S. Burrel, A. Avondo, A. Cossard, E. Fougere, Z. Boudalaa, C. Castor, E. Hope-Rapp, C. Durand, J.S. Casalegno, L. Josset, A. De-Clercq, H. Regue, D. Nguyen, C. Vignals, L. Rojas-Lopez, A. Oblette, A. Brinza, A. Massardier-Pilonchery, C. Dananche, P. Fascia, J. Godon, M. Simon, M.A. Rameix Welti, J.M. Turmel, N. Leveque, D. Perez-Bercoff, B. Lina, A. Lapendry, X. Lescure, M. Mailhe, F. Ader, B. Coignard, A. Gaymard, T. Perpoint
- L0013 15:09 Measles Hospitalizations During an Outbreak in Jerusalem, 2025**
O. Gordon* (Jerusalem, Israel), G. Oren, O. Itamar, S. Dorozhko, S. Zahran, E. Roda, N. Peled, A. Bracha Moshe, N. Juven Wetzler, D. Averbuch, S. Hashavya, U. Pollak, D. Wolf, J. Strahilevitz, Y. Oster, N. Abramson, Z. Mor, N. Bar Zeev, O. Megged, R. Brooks, A. Tenenbaum
- L0014 15:21 Epidemic of Chlamydia pneumoniae infections in France in 2024**
S. Trombert Paolantoni* (Frepillon, France), L. Baussant, K. Sood, E. Hedbaut, A. Bergeron, Y. Tandjaoui-Lambiotte, B. Visseaux
- L0015 15:33 Scrub typhus in children: an emerging under-recognised threat: seroprevalence, demographic trends, co-infections and cross-reactions in a tertiary care paediatric institute in North India**
S. Nandwani* (Noida, India), J. Sachdev, A. Puri, R. Edoliya, N. Perween, D.K. Singh, D.K. Sahu

OS026 14:45 - 15:45 Hall ICM 13a
 CLN PHEI TRN 1-hour Oral Session

Redefining care in bacterial meningitis: new approaches and emerging clinical evidence

- Chairs* Tuyen Nguyen (Laval, Canada)
Charlotte Srirottan-Nel (Johannesburg, South Africa)
- 00192 14:45 Continuous intracranial pressure monitoring in acute bacterial meningitis: a nationwide multi-centre cohort study**
J. Karlsson Valik* (Stockholm, Sweden), A. Grahm, M. Veje, P. Almqvist, C. Åkerlund, J. Widén, G. Westman
- 00193 14:57 Addition of daptomycin in the treatment of pneumococcal meningitis in adults: results of the phase II AddaMap trial**
T. Sixt* (Dijon, France), T. Sixt*, I. Fournel, A. Bourredjem, M. Blot, B. Mourvillier*, D. Grandgirard*, S. Leib*, X. Duval, L. Piroth, P. Chavanet*
- 00194 15:09 Effectiveness of ceftriaxone in the management of neurosyphilis: experience of a UK tertiary centre**
L. Carson* (Cambridge, United Kingdom), B. Warne, O. Sule, M. Routledge
- 00195 15:21 Early oral step-down therapy in pyogenic brain abscesses: a bicentric retrospective study**
J. Brouard* (Clichy, France), D. Morizet, R. Rahli, A. Lefort, P. Decq, H. Kimseng, A.L. Munier, V. De Lastours
- 00196 15:33 Continued corticosteroids for non-pneumococcal bacterial meningitis in adults: A target trial emulation**
E. Eriksen* (Aalborg, Denmark), K.F. Greve, S.Ø. Larsen, L. Larsen, M. Storgaard, H. Mens, L. Wiese, M.P.G. Jepsen, B.R. Hansen, H.R. Lüttichau, H. Nielsen, J. Bodilsen

OS027 14:45 - 15:45 Hall ICM 13b
 CLN PHEI 1-hour Case Session

Unusual causes of broken heart - cardiac infections

- Chair* Diane Ashiru-Oredope (London, United Kingdom)
TBA
- 00182 14:45 Outbreak investigation of non-tuberculous mycobacteria (NTM) sepsis following cardiac surgery in an LMIC tertiary care centre: implication of contaminated heater-cooler units**
M. Khan* (Peshawar, Pakistan)

00183 14:56 Beyond the usual suspects: three cases of infective endocarditis by rare pathogens
N. Pansari (Ahmedabad, India), S. Madan, B. Thacker, M. Chag, D. Shah, K. Gupta*

00184 15:07 Disseminated BCG infection with cardiac device involvement and immune thrombocytopenia
A. Bergas Farrés (Barcelona, Spain), R. Vila-Olives, S. Molinos, M.D. Quesada, A. Sarrías, R. Villuendas, A. Peris, A. Antuori, E. Berastegui, N. Fernández-Hidalgo, M.T. Tórtola, J.J. López-González, M.L. Pedro-Botet, R. Paredes, L. Mateu*

00185 15:18 Bartonella henselae a great mimicker: endocarditis, bone marrow infiltration and glomerulonephritis mimicking vasculitis ANCA-positive
J. Alza Arcila (Medellín, Colombia), S. Cobaleda-Cano, C. Rincón-Márquez, J.M. Bacca-Gonzalez*

00186 15:29 Intracardiac Cysticercosis: a case report and diagnostic challenge
R. Manchon (Paris, France), N. Argy, A. Sivapathasundaram, D. Lussato, J. Feignoux, D. Attias, P. Le Besnerais, J. Rousseau, S. Lariven, N. Peiffer-Smadja*

OS028 14:45 - 15:45 Hall ICM 5
 CLN DX 1-hour Oral Session

From overuse to optimisation: smarter diagnostics in practice

Chairs Gloria Cordoba (Copenhagen, Denmark) Polona Maver Vodicar (Ljubljana, Slovenia)

00197 14:45 The implementation of electronic clinical decision tools to reduce inappropriate urine and swab requests: a diagnostic stewardship intervention to reduce the environmental impact of laboratory testing
R. Shorten (Manchester, United Kingdom), S. Shafiq, L. Roberts, G. Williams*

00198 14:57 Diagnostic stewardship in critical care: should overexpressed AmpC Enterobacterales detected on rectal screening be reported? predictive value for infection and comparison with ESBL
A. Mizrahi (Paris, France), G. Péan De Ponfilly, M. Holub, T. Genty, F. Philippart, C. Couzigou, B. Pilmis, A. Le Monnier*

00199 15:09 Development of an infectious diseases diagnostic excellence program using the centres for Disease Control and Prevention (CDC) core elements
T. Jenkins (Denver, United States), M. Cooper, K. Shihadeh, L. Triplett, L. Fish, M. Wolfe, A. Penick, M. Wilson*

00200 15:21 Optimising blood cultures: a diagnostic stewardship intervention
L. Mejdoubi (Vienna, Austria)*

00201 15:33 Reducing CoNStant testing: Impact of a diagnostic stewardship intervention targeting coagulase-negative staphylococci in blood cultures on vancomycin, daptomycin and linezolid consumption
K. Tanida (Hamburg, Germany), B. Berinson, M. Florey, L. Middendorf, C. Sommer, M. Aepfelbacher, H. Rohde, M. Christner*

OS029 14:45 - 15:45 Hall B0-2
 VAX 1-hour Oral Session

Respiratory viral infection prevention across age groups

Chairs Christopher Chiu (London, United Kingdom) Simona Ruta (Bucharest, Romania)

00187 14:45 Maternal RSV vaccination and reduced risk of hospitalisation for babies in England, 2024/25
M. Wilson (London, United Kingdom), H. Whitaker, J. Walker, E. Heymer, A. Cobbold, C. Watson, N. Andrews*

00188 14:57 Impact of universal infant immunisation with nirsevimab on RSV-related hospitalisation beyond the first season: the NIRSE-GAL study
F. Martín-Torres (Santiago De Compostela, Spain), J.L. Razzini, I. Giné-Vázquez, J. Jin, N. Mallah, M.I. Santiago-Pérez, O. Pérez-Martínez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, Á. Manzanares-Casteleiro, A.I. Dacosta-Urbieta, C. Álvarez-Smith, I. Rivero-Calle, A. Salas, C. Durán-Parrondo*

Scientific Programme

Saturday, 18 April 2026

00189	15:09	<p>Real-world emergence of nirsevimab resistance in RSV-B breakthrough infections</p> <p><i>S. Fourati* (Créteil, France), A. Reslan, J. Bourret, J.S. Casalegno, Y. Rahou, L. Softic, L. Chollet, P. Tremeaux, B.M. Imbert-Marcille, S. Pillet, N. Veyrenche, A. Boudet, L. Deroche, S. Burrel, L. Mouna, T. Cocherie, A. Schnuriger, C. Pronier, L. Handala, F. Gallais, S. Larrat, A. Regueme, N.C. Dossou, A. Henry, E. Gault, C. Hartard, S. Brichler, A. Moisan, V. Avettand-Fenoel, C. Lefeuvre, I. Engelmann, S. Castelain, A. Mirand, M. Salmona, M.C. Jaffar-Bandjee, P. Cappy, C. Rodriguez, G. Dos Santos, S. Berreira Ibrahim, K. Da Silva, A. Recoing, J.M. Pawlotsky, F. Lemoine, E. Audureau, M.A. Rameix-Welti</i></p>	OS030	14:45 - 15:45	Hall A2-1
			CLN	DX	1-hour Case Session
Unmasking infectious diseases through genomic approaches					
			Chairs	<i>Natacha Couto (Cardiff, United Kingdom), Khetam Hussein (Nahariya, Israel)</i>	
	00177	14:45	<p>Shotgun metagenomics for CSF diagnostics guides targeted therapy in culture-negative bacterial meningitis caused by <i>Capnocytophaga canimorsus</i></p> <p><i>G. Lorenzin* (Trento, Italy), M. Bertoldi, F. Bonaffini, M. Carlin, C. Scarparo</i></p>		
	00178	14:56	<p>Genomic characterisation of an extensively drug-resistant <i>Shigella sonnei</i> carrying blaCTX-M-15 in a sexually transmitted infection in an MSM patient in Spain</p> <p><i>N. Valcárcel Fraile* (Santander, Spain), B.M. Armas-Luján, D. Fernández-Vecilla, M.J. Urrutikoetxea-Gutiérrez, J. Rodríguez Grande, C. Ruiz De Alegría Puig, S. Labrador Descalzo, E. Mesa Santana, S. Riesco Alonso, A. Ocampo-Sosa, M.P. Roiz Mesones</i></p>		
00190	15:21	<p>Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan</p> <p><i>L. Kostanyan* (Cambridge, United States), H. Fukase, A. Rumyantsev, O. Kogawara, K. Hashizume, S. Osibajo</i></p>			
00191	15:33	<p>High-dose vs standard-dose influenza vaccination across laboratory-confirmed influenza severity levels in older adults: the DANFLU-2 randomised trial</p> <p><i>F.S. Davidovski* (Hellerup, Denmark), N.D. Johansen, N. Shaikh, R. Harris, D. Modin, P.S. Wolff, K.G. Skaarup, C.S. Søndergaard, M. Loiacono, Y. Huang, J. Bartelt-Hofer, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B. Claggett, K. Janstrup, R. Jessen, N. Steenhard, K. Bartholdy, K. Bernholm, J. Borchsenius, L. Davodian, M. Dons, L. Duus, C. Espersen, F. Fusing, A.M. Jensen, N. Landler, A. Langhoff, M. Lassen, A.B. Nielsen, C. Ottosen, M. Sengeløv, S. Solomon, M. Landray, G. Gislason, L. Køber, P. Sivapalan, C. Martel, J.U. Jensen, T.B. Sørensen</i></p>			
	00179	15:07	<p>Dual enterococcal bacteraemia with central nervous system infection by <i>Enterococcus faecium</i> ST117: a whole genome analysis</p> <p><i>M. Roch* (Geneva, Switzerland), R. Sierra, P. Vetter, D. Neofytos, C. Van Delden, K.A. Kline, D.O. Andrey</i></p>		
	00180	15:18	<p>Unmasking the pathogen: how metagenomics enables the diagnosis of hard-to-detect infections</p> <p><i>A. Belati* (Bergamo, Italy), L.B. Giva, R. Bruschi, T. Perrone, M. Bartoli, M. Mazzoni, G. Albano, P.G.G. Panisi, M. Sampaolo, N. Clementi, V. Cento, M. Bartoletti, C. Filippi</i></p>		
	00181	15:29	<p>Chronic <i>Mycobacterium kansasii</i> pleural infection mimicking metastatic breast cancer: a seven-year diagnostic odyssey and the critical role of metagenomic sequencing</p> <p><i>Q. Miao* (Shanghai, China), T. Fang, P. Hu, Y. Zhang, B. Hu</i></p>		

SY058 14:45 - 15:45 Hall ICM 1
 CLN DX PHEI 1-hour Symposium

Chemsex, HIV and STIs: so little time, so much to do

Chairs *Ivana Gmizic (Belgrade, Serbia)*
Lorenzo Rabbi (Berlin, Germany)

S0119 14:45 **Chemsex plus STIs syndemic: how to test and how to treat**
Zulma Vanessa Rueda (Winnipeg, Canada)

S0120 15:15 **Chemsex and the costs of its ignorance: example from Central and Eastern Europe**
Sime Zekan (Zagreb, Croatia)

Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), ESCMID Study Group for Sexually Transmitted Infections (ESTISG), ESCMID Study Group for Viral Hepatitis (ESGVH), Euroguidelines in Central and Eastern Europe Network Group

SY059 14:45 - 15:45 Hall B0-1
 PHEI 1-hour Symposium

Climate change, biodiversity loss, and the future of infectious diseases

Chairs *Marion Koopmans (Rotterdam, Netherlands)*
Tyra Grove Krause (Copenhagen, Denmark)

S0121 14:45 **Impact of climate change on infections**
Kimberly Fornace (Singapore, Singapore)

S0122 15:15 **Biodiversity loss and risk of spill-over events and epidemics**
Carsten Rahbek (Copenhagen, Denmark)

SY060 14:45 - 15:45 Hall A2-2
 DX 1-hour Symposium

Precision diagnostics for neonatal sepsis: from biomarkers to the bedside

Chairs *Ilias P. Iosifidis (Thessaloniki, Greece)*
Birgit Willinger (Vienna, Austria)

S0123 14:45 **Rapid diagnostic tools for neonatal sepsis: from biomarkers to AI-powered screening**
Mohan Pammi (Bellaire, United States)

S0124 15:15 **How to differentiate viral vs. bacterial infections in neonates?**
Marieke Emonts (Newcastle Upon Tyne, United Kingdom)

SY061 14:45 - 15:45 Hall A3-1
 AMR CLN 1-hour Symposium

Bridging the gap: aligning EUCAST standards with antimicrobial stewardship practice

Chairs *Esther Calbo (Terrassa, Spain)*
Paul Christoffer Lindemann (Bergen, Norway)

S0125 14:45 **From report to treatment: challenges in applying AST results in clinical practice**
Benedikt Huttner (Geneva, Switzerland)

S0126 15:15 **Enhancing clinical relevance: EUCAST's vision for improving AST interpretability**
Amara Marlene (Paris, France)

SY062 14:45 - 15:45 Hall A3-2
 ANT CLN 1-hour Symposium

Closing the antiviral gap: broadening treatment options for emerging and neglected viruses

Chairs *Julie Bines (Parkville, Australia)*
Jan Felix Drexler (Berlin, Germany)

S0127 14:45 **New host-directed approaches against emerging viral infections**
Rainer Koenig (Jena, Germany)

S0128 15:15 **Outlook of new antiviral molecules in the pipeline**
Javier Sánchez Céspedes (Sevilla, Spain)

EF035 16:15 - 17:15 Arena 4
 CLN DX PHEI ePoster Flash Session

From surveillance to diagnosis: catching hepatitis viruses before they catch us

Chair *Arjan Harxhi (Tirana, Albania)*

E0238 16:15 **A One Health, pan-European network strengthening surveillance, clinical management and control of zoonotic hepeviruses**
I. Hasanoglu (Ankara, Türkiye), A. Elena Anita, F. Abravanel, G. Reuter, S. Dudman, N. Kamar, L. Jemeršič, I. Di Bartolo, N. Cook, S. Ruta, I. Nauwelaers, L. Milojević, E. Todorovska, S. Mojsova, A. Zerja, A. Avellon, R. Hakze, B. Velebit, R. John, J. Mesquita, A. Rivero-Juarez*

E0239 16:21 **Tracing Rat-to-Human Transmission of Hepatitis E Virus within a One Health Framework**
H.K.E. Shun (Hong Kong, Hong Kong), S.F.S. Ho, X. Ma, S. Sridhar*

Scientific Programme

Saturday, 18 April 2026

- E0240 16:27** **Epidemiology of hepatitis E infection in England between 2014/15 and 2024/25**
A.A. Dattoo* (London, United Kingdom), A. Yunusa, D. Chudasama, S. Ijaz, B. Haywood, R. Pudney
- E0241 16:33** **Prospective characterisation of hepatitis delta in Spain: insights from the nationwide DDR cohort**
A. Alberola* (Granada, Spain), A. Vázquez Blanquiño, A. De Salazar, R. Carracedo, A. Fuentes, L. Chaves Blanco, L. Gozalo Álvarez, W. Sanchez-Yebra, C. Freyre, B. Becerril, I. Viciano, I. López Rodríguez, T. Trujillo Soto, A.M. Domínguez Castaño, M.D.P. Luzón-García, E. Ramírez Arellano, C. Liébana, F. Franco Álvarez De Luna, M.C. Lozano, B. Palop, A. Sampedro, A.B. Pérez, S. Algarate, S. Rojo Alba, P. Fraile, D. Ocete, M.J. Alcaraz, J.C. Rodríguez, F.J. Hernández-Felices, O. Martínez, V. Domínguez, N. Orta, D. Gómez, C. Cortell Cortell, J. Camacho Marín, S. Sabater, L.Á. Iglesias Sánchez, Y. Martín, A. Vallejo, L. Molina, M. Aroca, T. Tosco, M. Lara, M.J. Pena, D. Pablo Marcos, A. González Praetorius, J.J. Blas, A. Beteta, C. Gómez, M.J. Rodríguez, M. González, M. Abreu, J. García Díez, I. Beltrán, M. Sandoval Torrientes, R. Sáez, T. Martín, P. Tajada Alegre, B. Lorenzo, M.T. García Valero, I. Jiménez Sansegundo, S. García-De Cruz, S. Garcinuño, M.Á. Sáiz, A.M. Blázquez, I. Fernández, H.M. Lorenzo Juanes, M.R. Vidal-Acuña, L.M. Moldes, N. Calvo, M. Trigo, M.J. Gude, P. Ordóñez, S. Cortizo, M. Blasco, M. Sigcha, I. Falces, L. Martínez, A. Arribi, R. Alonso, A. Iborra, M.J. Del Amor Espín, E. Cascales, C. Pérez, P. Fernández, M.D. Navarro, M.L. Núñez, M. Cámara, L.J. Gil-Gallardo, A. Miqueleiz, G. Reina, L. Elorduy, M. Macho, C. Gómez, P. Liendo, M. Aranzamendi Zaldumbide, A. Aguilera, F. García
- E0242 16:39** **The future of HDV testing: Saliva-based PCR for scalable and field-friendly detection**
S.K. Rawat* (Sagar, India), N. Mishra, R.K. Nema, I. Hasanoğlu
- E0243 16:45** **Impact of nucleic acid extraction methods on the quantitative detection of hepatitis delta virus RNA by real-time PCR: a comparative evaluation of manual and automated systems**
H. Alonso* (San Mateo De Gállego, Spain), M. López, N. Gil
- E0244 16:51** **Are We Screening or Wasting? The Hidden Burden of Repeat Anti-HCV Testing in the Hepatitis Elimination Era**
A. Sertçelik* (Ankara, Türkiye), R. Güner, İ. Hasanoğlu, E. Güney, A. Kaya, F. Eser, B. Dinç, B. Kayaaslan

- E0245 16:57** **Impact of screening and direct-acting antiviral treatment of hepatitis C among people who inject drugs in Singapore: a mathematical modelling study**
J.J. Ong* (Singapore, Singapore), W.Y. Lim, S. -, B. Choh, C. Gao, C.S. Wong, J. Tay, A. Han
- E0246 17:03** **Comparison of lyophilised vs native samples for hepatitis B surface antibody testing across four fully automated immunoassays**
M. Obermeier* (Berlin, Germany), J. Wenzlaff, J. Geisler, R. Ehret, I. Schellenberg, P. Kaiser, V. Lindig, U. Dühring, S. Samuleit, M. Kammel

EW070 16:15 - 18:15 Hall ICM 13b
CLN IPC VAX 2-hour Educational Session

Building a safer journey from candidate to organ transplant recipient

- Chairs** Wanessa Clemente (Belo Horizonte, Brazil)
Victoria Hall (Melbourne, Australia)
- W0155 16:15** **Ready for the fight: candidate evaluation and vaccination**
Maha Alamri (Riyadh, Saudi Arabia)
- W0156 16:35** **It starts with the donor: minimising the risk of donor-derived infections**
Oscar Len (Barcelona, Spain)
- W0157 16:55** **At the table: surgical and perioperative challenges for infection control**
Maddalena Giannella (Bologna, Italy)
- W0158 17:15** **Traveling the world and safe living post-transplant**
Priscilla Rupali (Vellore, India)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

EW071 16:15 - 18:15 Hall B0-1
CLN PRO 2-hour Educational Session

Adaptive platform trials in infectious diseases

- Chairs** Marc J.M. Bonten (Utrecht, Netherlands)
Dafna Yahav (Ramat-Gan, Israel)
- W0159 16:15** **One and the same, or two and different? History and definitions of adaptive and platform trials**
Holly Jackson (Singapore, Singapore)
- W0160 16:35** **BALANCE PLUS: a platform trial answering challenging questions on Gram-negative infections**
Nick Daneman (Ontario, Canada)
- W0161 16:55** **Keeping it going: lessons learned from REMAP-CAP**
Lennie Derde (Utrecht, Netherlands)

W0162 17:15 **Getting it off the ground: successes and failures from the SNAP platform**
Josh Davis (Newcastle, Australia)

Co-organised with: CMI Communications Board of Editors

EW072 16:15 - 18:15 **2-hour Educational Session** **Hall A2-1**
CLN TRN

The microbiome and response to cancer treatment

Chairs *Nicolas Benech (Lyon, France)*
Lina Cavaco (Copenhagen, Denmark)

W0163 16:15 **How the microbiome can impact response to cancer treatment**
Gal Markel (Petach Tikva, Israel)

W0164 16:35 **How antibiotic treatment can impact response to immunotherapy**
Lisa Derosa (Villejuif, France)

W0165 16:55 **How to preserve the microbiome during infection management in cancer patients?**
Arielle Elkrief (Montréal, Canada)

W0166 17:15 **How the gut microbiome influences chemotherapy tolerance and efficacy**
Cindy Neuzillet (Saint Cloud, France)

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

SY063 16:15 - 18:15 **2-hour Symposium** **Hall ICM 1**
ANT CLN

Cracking the phage code: from clinical insights to precision design

Chairs *Tristan Ferry (Lyon, France)*
Jean-Paul Pirnay (Brussels, Belgium)

S0129 16:15 **Designing Clinical Trials around Phage Therapy**
Pranita Tamma (Philadelphia, United States)

S0130 16:45 **Randomised controlled trials of phage therapy in diabetic foot ulcers**
Ran Nir-Paz (Jerusalem, Israel)

S0131 17:15 **AI for host-phage interaction prediction**
Michiel Stock (Ghent, Belgium)

S0132 17:45 **Towards cell-free production and selection of therapeutic phages**
Antoine Levrier (Montpellier, France)

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

SY064 16:15 - 18:15 **2-hour Symposium** **Hall ICM 13a**
CLN PED TRN

Global perspectives on tuberculosis

Chairs *Laura Ferreras-Antolin (London, United Kingdom)*
Lorenzo Guglielmetti (Negrar Di Valpolicella, Verona, Italy)

S0133 16:15 **Computer modelling to improve TB outcomes: progress and problems**
Rada Savic (San Francisco, United States)

S0134 16:45 **Contribution of asymptomatic TB to the global TB burden**
Hanif Esmail (London, United Kingdom)

S0135 17:15 **The Brazil-wide TBPed study on active and latent tuberculosis in childhood**
Marcelo Scotta (Porto Alegre, Brazil)

S0136 17:45 **Radical shortening of the duration of TB treatment: here and now?**
Nicholas Paton (Singapore, Singapore)

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), International Society of Pediatric Respiratory Diseases (INSPIRED)

SY065 16:15 - 18:15 **2-hour Symposium** **Hall ICM 5**
TRN VAX

Harnessing antibody response against viral and bacterial infections

Chairs *Silvio Daniel Brugger (Zurich, Switzerland)*
Christine Kelly (Dublin, United Kingdom)

S0137 16:15 **Mechanisms and clinical relevance of antibody response during viral infection**
Irene A Abela (Zürich, Switzerland)

S0138 16:45 **Mechanistic insights into human antibody responses to bacterial virulence factors**
Alexander Simonis (Cologne, Germany)

S0139 17:15 **Bacterial cell wall polysaccharides as strategies against invasive bacterial infection**
Nina Van Sorge (Amsterdam, Netherlands)

S0140 17:45 **Advances in antibody-based strategies for targeting HIV infection**
Florian Klein (Cologne, Germany)

Scientific Programme

Saturday, 18 April 2026

SY066 16:15 - 18:15 Hall B0-2
 AMR PHEI TRN 2-hour Symposium

Barriers, drivers and maintenance: molecular mechanism behind AMR gene mobility

- Chairs* Louise Roer (Copenhagen, Denmark)
 Jozsef Soki (Szeged, Hungary)
- S0141 16:15 Classification and typing of plasmids carrying multi-drug resistance**
 Alessandra Carattoli (Rome, Italy)
- S0142 16:45 Plasmid-host co-evolution that stabilises antibiotic resistance**
 Javier De La Fuente (Barcelona, Spain)
- S0143 17:15 The evolution and transmission of multi-drug-resistant *Escherichia coli* and *Klebsiella pneumoniae*: complexity of clones and plasmids**
 Alan McNally (Birmingham, United Kingdom)
- S0144 17:45 Antibiotic resistance plasmids in a One Health context**
 Michael Brouwer (Utrecht, Netherlands)

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Mobile Elements and Plasmids (ESGMAP)

SY067 16:15 - 18:15 Hall A2-2
 CLN PHEI 2-hour Symposium

Can you see me? HIV among underserved populations

- Chairs* Magdalena Rosińska (Warszawa, Poland)
 Milena Stevanovikj (Skopje, North Macedonia)
- S0145 16:15 Learning from Malta's experience on HIV care for refugees and migrants**
 Aaron Schembri (Attard, Malta)
- S0146 16:45 HIV transmission and intimate partner violence in South America**
 Claudia Cortes (Santiago, Chile)
- S0147 17:15 Can people in homelessness crisis be effectively treated for HIV? a voice from Canada**
 Yoav Keynan (Winnipeg, Canada)
- S0148 17:45 STIs, HIV and hepatitis in penitentiary system: how to test and treat them all?**
 Justyna Kowalska (Warsaw, Poland)

SY068 16:15 - 18:15 Hall A3-1
 IPC PED 2-hour Symposium

Novel approaches to preventing neonatal infections beyond antibiotics

- Chairs* Angelika Berger (Vienna, Austria)
 Pablo Sanchez (Columbus, United States)
- S0149 16:15 Lactoferrin: a natural defense against neonatal sepsis and necrotising enterocolitis**
 Theresa J. Ochoa (Lima, Peru)
- S0150 16:45 Immunometabolic approaches to prevent neonatal sepsis**
 Duc Ninh Nguyen (Frederiksberg, Denmark)
- S0151 17:15 Human milk oligosaccharides and the microbiome in preterm infants: mechanisms and evidence for infection protection**
 Moran Yassour (Jerusalem, Israel)
- S0152 17:45 Human fortifier to prevent infections in preterm infants: clinical data and future perspectives**
 Boris Kramer (Poznan, Poland)

SY069 16:15 - 17:15 Hall A3-2
 TRN VAX 1-hour Symposium

Outsmarting ticks: decoding tick-host-pathogen interactions and advancing vaccines against tick-borne diseases

- Chairs* Anna J. Henningsson (Jönköping, Sweden)
 Ryan Rego (Ceske Budejovice, Czechia)
- S0153 16:15 Insights into tick immune-developmental pathways impacting vector biology and pathogen persistence**
 Chrysoula Kitsou (College Park, United States)
- S0154 16:45 Counter-attacking the tick bite: anti-tick vaccines to prevent tick-borne diseases**
 Joppe Willem Robert Hovius (Amsterdam, Netherlands)

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)

EF036 17:15 - 18:15 Arena 1
CLN TRN ePoster Flash Session

Skin and soft tissue infections haunting us

Chair Carlos Palos (Lisbon, Portugal)

E0247 17:15 Mpox-HIV syndemics in the 2024–2025 clade 1b outbreak: a framework for understanding synergistic vulnerabilities, clinical trajectories, and interventions in high-burden African settings
U. Muhumuza* (Kampala, Uganda), B.B. Nanyange, Z. Nahumuza

E0248 17:21 Hand infections: epidemiology and adverse prognostic factors in a six-year retrospective single-centre study of 496 patients
M. Pellegrino* (Modena, Italy), G. Franceschi, L. Benassi, S. Generoso, M. Sarti, A. Leti Acciaro, M.C. Gagliano, C. Mussini, A. Bedini

E0249 17:27 Urease is key factor in the pathogenicity of *Staphylococcus aureus* in atopic dermatitis
M. Araújo* (Oeiras, Portugal), N. A. Faria, M. Gonçalo, J. Nakonieczna, C. Torres, F. Campanile, K. Netto Dos Santos, R. Sobral, M. Miragaia

E0250 17:33 MSSA-ST398: a lineage highly adapted to the atopic dermatitis skin environment
D. Caieiro* (Lisbon, Portugal), N. A. Faria, M. Araújo, A. Botelho, M. Gonçalo, L. Ramos, M. Miragaia

E0251 17:39 Recurrent facial folliculitis by *Klebsiella aerogenes* ST117 in men who have sex with men: an emerging sexually transmitted SSTI?
G. Monsel* (Paris, France), C. Emeraud, B. Rached, V. Bérot, L. Porter, N. Yin, J. Krygier, F. Durupt, M. Jachiet, M. Godinot, V. Pourcher, O. Chosidow, L. Dortet, A. Bleibtreu

E0252 17:45 Diabetic wound healing enabled by a tri-functional MAX phase via Cu doping
M. Yang* (Chengdu, China), S. Zhu, B. Ying

E0253 17:51 Clinical and inflammatory predictors of treatment failure in uncomplicated skin and soft tissue infections: a multi-centre study from Türkiye
M.N. Özçelik* (Tekirdag, Türkiye), M.S. Sayar, N.N. Aydın, D. Başkol Elik, Ö. Günal, P. Yürük Atasoy, A. Tuna, C. Semet, S. Erol, A. Yetişen, Y. Gezer, M.R. Tayşi, N.B. Baysal, G. Eser Karlıdağ, M. Çelik, E. Aydın, Y. Kürekçi, Y. Akkoyunlu, Ö. Akyıldız, A.S. Özel, O. Yapıcı, D. Özer, Ş. Kaya, T. Damar Çakırca, Ş. Balın Özer, İ.N. Hakyemez

E0254 17:57 Skin and soft tissue infections in UK Armed Forces populations: the past, the present and the future
A. Mason* (Camberley, United Kingdom), L. Lamb, W. Nevin, K. Morris, S. Pallett, M. Riley, T. Davey, J. Fallowfield, S. Sriskandan, E. Jauneikaite, S. D'arc, M. Dermont, G. Holden, K. Wilkinson, D. Tupper, H. Taylor

E0255 18:03 Chronic non-puerperal mastitis: a complex condition, a new multidisciplinary approach
M. Arias* (London, United Kingdom), A. Brown, L. Ragad, A. Boyd, C. Shah, G. Weston-Petrides, J. Galloway

EF037 17:15 - 18:15 Arena 2
AMR CLN IPC ePoster Flash Session

Hospital surfaces: a touching subject

Chair Sinead O'donnell (Dublin, Ireland)

E0256 17:15 Metagenomics vs Culture: Identification of priority bacterial pathogens on hospital surfaces
R. Lins De Andrade* (São Paulo, Brazil), R.A. Tavella, M.S. Constâncio, A.P. Christoff, A.F.R.S. Sereia, B.L. Teixeira, L.F.V. Oliveira, J.F. Ribeiro, T.C.R.L. Nogueira, G.J. Oliveira, A.C. Gales

E0257 17:21 *Klebsiella pneumoniae* biofilm formation and biocide tolerance on hospital surface materials: the influence of matrix components
M. Nieto Rosado* (Oxford, United Kingdom), K.M. Thomson, L.C. Powell, B. Hassan, R. Zahra, E. Rashid, M.I. Shah, M.H. Hamid, S. Shabbir, M. Bashir, R. Temur, A. Balqees, A. Ali, T.R. Walsh, G. Zaborskytė, K. Sands

E0258 17:27 Environmental reservoir driving hospital endemicity of a multispecies *bla*NDM-1 IncC plasmid
A. Anantharajah* (Brussels, Belgium), F. Goormaghtigh, A. Vanderheeren, W. Abdel Hadi, M. Argudin, N. Olive, E. Nguvuyila Mantu, A. Demur, C. Schirvel, A. Verroken, F. Van Bambeke, H. Rodriguez-Villalobos

E0259 17:33 Patient-environment transmission dynamics of multidrug resistant *Enterobacteriaceae* in two Dutch intensive care units: a longitudinal retrospective and prospective analysis in a non-outbreak setting
C. Rossel* (Sittard-Geleen, Netherlands), E.R. Heddema, R.M. Koeck, P.H.M. Savelkoul, L.B. Van Alphen

Scientific Programme

Saturday, 18 April 2026

E0260	17:39	<p>Genomic comparison of carbapenemase-producing <i>Enterobacter</i> species isolated from patients and hospital environments, 2019-2024, reveals striking overlap between these niches</p> <p><i>E. Cronin*</i> (Galway, Ireland), <i>A. O'connor</i>, <i>M. Maguire</i>, <i>C. Clarke</i>, <i>A. Tuohy</i>, <i>M. Cormican</i>, <i>M.J. Dorman</i>, <i>L.P. Burke</i></p>	E0265	17:15 - 18:15	Arena 3
E0261	17:45	<p>Bacteriophage-based environmental decontamination to reduce carbapenem-resistant <i>Klebsiella pneumoniae</i>: results from the FagoLimp, a cluster-randomised controlled crossover study</p> <p><i>A. Gales*</i> (Sao Paulo, Brazil), <i>T. Fagolimp</i></p>	<p>ANT CLN TRN ePoster Flash Session</p>		
E0262	17:51	<p>Gold nanocluster-based bactericidal surface coatings: A novel approach to combat healthcare-associated bacterial infections and antimicrobial resistance</p> <p><i>K. Burdova*</i> (London, United Kingdom), <i>S. Ali</i>, <i>N. Kapil</i>, <i>M.O. Coppens</i></p>	<p>Advances in clinical and pre-clinical PK/PD</p>		
E0263	17:57	<p>Impact of probiotic-based cleaning in intensive care units on the acquisition of <i>Pseudomonas aeruginosa</i> and multidrug-resistant organisms: an interrupted time-series analysis</p> <p><i>L.A. Denkel*</i> (Berlin, Germany), <i>F. Schwab</i>, <i>S. Wolke</i>, <i>G. Zakonsky</i>, <i>B. Raguse</i>, <i>P. Gastmeier</i>, <i>C. Geffers</i></p>	Chair	<i>Iris K. Minichmayr</i> (Vienna, Austria)	
E0264	18:03	<p>Underfloor heating as a potential ally against <i>Candida auris</i> and <i>Candida albicans</i> surface contamination: impact on cleaning and disinfection effectiveness</p> <p><i>A. Clifford*</i> (Vienna, Austria), <i>B. Leeb-Zatorska</i>, <i>K. Nikolova</i>, <i>J. Zottl</i>, <i>E. Presterl</i></p>	E0265	17:15	<p>Synergistic activity of Pep16 with cefiderocol against cefiderocol-resistant <i>Escherichia coli</i></p> <p><i>I. Bourdalis*</i> (Paris, France), <i>E. O Van Den Daele</i>, <i>I. El Meouche</i>, <i>S. Magreault</i>, <i>M.C. Verdier</i>, <i>F. Guerin</i>, <i>A. Jousset</i>, <i>A. Birgy</i>, <i>B. Fantin</i>, <i>V. Cattoir</i>, <i>V. De Lastours</i></p>
			E0266	17:21	<p>Pharmacodynamic evaluation of aztreonam/avibactam and aztreonam plus ceftazidime/avibactam against clinical <i>Stenotrophomonas maltophilia</i> isolates in hollow fibre infection models</p> <p><i>A. Kunz Coyne*</i> (Lexington, United States), <i>R. Gray</i>, <i>P. Gonnabathula</i>, <i>E. May</i></p>
			E0267	17:27	<p>Microdialysis Assessment of Gentamicin for Second-Line Antimicrobial Prophylaxis in Abdominal Surgery</p> <p><i>Q. Saint-Genis*</i> (Poitiers, France), <i>N. Gregoire</i>, <i>M. Boisson</i>, <i>S. Marchand</i>, <i>A. Chauzy</i>, <i>H. Mirfendereski</i></p>
			E0268	17:33	<p>Population pharmacokinetic model of ceftolozane/tazobactam and ceftazidime/avibactam in plasma and ELF administered by continuous infusion in ICU patients with nosocomial pneumonia: are the standard doses adequate?</p> <p><i>S. Luque*</i> (Barcelona, Spain), <i>A. Benítez-Cano</i>, <i>A. Araiz</i>, <i>I. Ramos</i>, <i>R. Adalia</i>, <i>E. Navarrete</i>, <i>J.P. Horcajada</i>, <i>M. Montero</i>, <i>J. Gomez-Junyent</i>, <i>R. Barquin</i>, <i>A. Juanes</i>, <i>J. Roberts</i>, <i>L. Sorli</i></p>
			E0269	17:39	<p>Long-acting antibiotics in osteoarticular infections: clinical outcomes and the role of therapeutic drug monitoring and serum bactericidal titre</p> <p><i>F. Petrucci*</i> (Rome, Italy), <i>G. Iaiani</i>, <i>D. De Meo</i>, <i>A. Lesina</i>, <i>M. Rivano</i>, <i>Capparuccia</i>, <i>C. Luceri</i>, <i>A. Lorusso</i>, <i>B.M. Goffredo</i>, <i>S. Cairoli</i>, <i>M. Raponi</i>, <i>F. Sacco</i>, <i>C.M. Mastroianni</i>, <i>A. Oliva</i></p>
			E0270	17:45	<p>PK/PD-based optimisation of temocillin dosing for the treatment of complicated urinary tract infections in non-ICU patients according to their renal function</p> <p><i>J. Ermtraud*</i> (Hamburg, Germany), <i>G.J. Wijnant</i>, <i>F. Van Bambeke</i>, <i>S.G. Wicha</i>, <i>S. Vervaeke</i>, <i>W. Follens</i>, <i>L. Dedeene</i>, <i>L. Goeman</i>, <i>G. Devos</i>, <i>M. Boeykens</i>, <i>V. Miendjedeyi</i>, <i>A. Reschner</i>, <i>C. Necsoi</i>, <i>D. Konopnicki</i>, <i>S. Vandecasteele</i>, <i>V. Grootaert</i></p>

- E0271 17:51 Daptomycin levels in vancomycin-resistant Enterococcus bloodstream infections (DELIVRE-BSI)**
K. Cairns (Melbourne, Australia),
C.B. Landersdorfer, A.Y. Peleg, Z-X. Mun,
A.A. Udy, T.N. Peel, M.J. Dooley,
J. Coutsouvelis, S. Patil, B. Mcwhinney*
- E0272 17:57 Adapting meropenem administration to the constraints of home nursing care for OPAT: PK/PD evaluation of a new regimen for the administration of 2g 3x/day in non-critically ill patients**
F. Van Bambeke (Brussels, Belgium),
C. Briquet, P. Ngougni Pokem, J.C. Yombi,
X. Liu, G.J. Wijnant, O. Cornu, H. Yildiz,
A. Verroken, J.A. Roberts*
- E0273 18:03 Piperacillin/tazobactam and meropenem exposure-outcomes relationship in patients with Gram-negative sepsis: results from the BLING III PK/PD sub-study**
J. Roberts (Brisbane, Australia)*

Scientific Programme

Sunday, 19 April 2026

EF041 08:30 - 09:30 Arena 2
 CLN ePoster Flash Session

Short- and long-term consequences of viral infections

Chair Bettie Voordouw
 (Culemborg, Netherlands)

E0294 08:30 **Breath-based volatile organic compound signatures for long COVID identification: A machine learning approach for differential diagnosis**
P. Esteban Sánchez (Zaragoza, Spain), S. Letona, M.P. Domingo, D. Recalde, E. Morte, G. Pellejero, A. Ramirez, R. Sanz-Pamplona, J. Pardo, J.R. Paño, E. Del Corral Beamonte, E.M. Gálvez*

E0295 08:36 **Time-stratified, variant-specific risks of major adverse cardiovascular events following COVID-19 across α -omicron variants: a nationwide matched cohort study in Japan**
K. Ikeuchi (Tokyo, Japan), S. Harada, R. Sekiya, Y. Arisato, S. Matsumoto, T. Kishida, A. Kado, K. Okushin, H. Yotsuyanagi, T. Tsutsumi*

E0296 08:42 **Metformin and ursodeoxycholic acid for the treatment of post-acute sequelae of COVID-19: a randomised clinical trial**
S.Y. Lim (Seoul, Korea, Republic of), J. Lee, E. Chang, S.H. Kim, J.S. Kwon, C.Y. Jang, Y. Seo, J.J. Park, S.H. Na, H. Park, H.M. Jang, S.C. Yun*

E0297 08:48 **T Cell Exhaustion and Gut Microbiota in HIV/SARS-CoV-2 Co-infection**
Y. Yinzhong (Shanghai, China), X. Yan, X. Zhang, Y. Shen*

E0298 08:54 **Maternal and fetal outcomes of Crimean-Congo haemorrhagic fever in pregnancy: an individual patient data meta-analysis**
D. Güllü (Istanbul, Türkiye), B. Donk, A.M. Cirik, H. Alay, F. Karakeçili, K. Özden, F. Kesmez Can, O. Barkay, N. Pshenichnaya, Ö. Ergönül*

E0299 09:00 **Myocarditis in chikungunya virus infection: a systematic review and meta-analysis**
S. Shah (Kathmandu, Nepal)*

E0300 09:06 **Predictors and clinical spectrum of long-term sequelae after tick-borne encephalitis: results of a prospective multi-centre cohort study**
M. Slížek (Prague, Czechia), D. Smíšková, O. Džupová, L. Chovanec, V. Pražák, A. Chrdle, K. Pohludková, L. Petroušová, J. Sečnik*

E0301 09:12 **Epidemiological, clinical, and virological findings in 1600 patients with West Nile virus infection, Northern Italy, 2008–2025**
L. Barzon (Padua, Italy), M. Pacenti, S. Vogiatzis, C. Lucca, E. Dal Molin, A. Sinigaglia, A. Giaretta, V. Lisi, S. Simonato, S. Satto, J. Rampazzo, C. Boldrin, M. Cattai*

E0302 09:18 **Mpox-related ocular disease: a prospective cohort study in South-Kivu, Democratic Republic of Congo**
C. Van Dijck (Antwerp, Belgium), T. Kabesha, S. Mudwanga, S. Houben, Y. Mujula Kanundey, P. Munganga, S. Yeh, N. Kabedi, V. Nussenblatt, O. Tshiani Mbaya, I. Crozier, S. Sabiti Nundu, J. Kindrachuk, P. Mbala Kingebeni, L. Liesenborghs*

EF042 08:30 - 09:30 Arena 3
 CLN DX TRN ePoster Flash Session

How viral and host genomics shape infection and immune response

Chair Victoria Hall (Melbourne, Australia)

E0303 08:30 **Distinct antigenic signatures and neutralising antibody responses following MVA-BN vaccination and monkeypox virus infection**
U.M. Chan (Taipei, Taiwan), T.L. Chao, W.D. Liu, C.C. Hung, S.Y. Chang*

E0304 08:36 **NGS sequencing with application of different methods and phylogenetic analyses in MPXV positive samples in Berlin 2022 to 2025**
M. Obermeier (Berlin, Germany), Ö. Yildirim, M. Lautner, M. Prentice, R. Ehret*

E0305 08:42 **Emerging human spillovers of H5N1: viral adaptations and pandemic preparedness**
J. Acosta España (Quito, Ecuador), J.B. Altamirano-Jara, D.K. Bonilla-Aldana, A. Rodríguez-Morales*

E0306 08:48 **Plasma miRNA-619-5p as a novel biomarker for infectious mononucleosis**
S. Feng (Chengdu, China), F. Liao, J. Zhong*

E0307 08:54 **Prediction of conserved long-range RNA-RNA interactions in the hepatitis E virus genome**
B.Y. Alhatlani (Buraydah, Saudi Arabia)*

E0308 09:00 **Molecular evidence of active Dengue Virus transmission and DENV-2/DENV-3 circulation in Ondo, South-West Nigeria: Implications for Malaria-Coendemic Settings**
S. Kayode (Ondo, Nigeria), B. Onoja, F. Akinkunmi, R. Nwuba*

E0309 09:06 Acute hepatitis of unknown origin in the paediatric population: clinical, virological and genetic characterisation in a prospective case series
D. Henares (Barcelona, Spain), A. Avellon, I. Loverdos, M. Pons-Espinal, M. Muñoz-Chimeno, A. Garcia-Soler, E. Ruiz De Pedro, C. Molera, P. Brotons, M.F. De Sevilla, J. Martinez-Laso, C. Muñoz-Almagro*

E0310 09:12 From pol to whole genome: advancing HIV drug resistance testing
F. Stefanelli (Genoa, Italy), N. Randazzo, G. Guarona, B. Galano, S. Ferrari, R. Qosja, A. Di Biagio, A. Domnich, N. Nigro, B. Bruzzone*

E0311 09:18 Clinical significance of viral DNA findings by mNGS in a large cohort of patients
T. Schroeder (Nuertingen, Germany), J. Baake, M. Eliwi Alsaffan, A. Dervishi, P. Kawaletz, H. Stäudle*

EW078 08:30 - 10:30 Hall ICM 1
 2-hour Educational Session
 CLN

Duration of IV antibiotics in older adults for various infections

Chairs Efthymia Giannitsioti (Athens, Greece) Jordi Rello (Barcelona, Spain)

W0299 08:30 Duration of therapy and oral switch for Gram-positive bacteraemia
Giusy Tiseo (Pisa, Italy)

W0300 08:50 Duration of therapy and oral switch for mycobacterial and nocardial infections
li Margalit (Ramat Gan, Israel)

W0301 09:10 Duration of therapy, suppressive therapy and oral switch for endovascular infections
Barbara Hasse (Zurich, Switzerland)

W0302 09:30 Duration of therapy, suppressive therapy and oral switch for orthopaedic infections
Marjan Wouthuyzen-Bakker (Groningen, Netherlands)

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE)

EW079 08:30 - 10:30 Hall B0-2
 2-hour Educational Session
 CLN DX PHEI

Europe`s overlooked threat: the rise of zoonotic hepatitis E

Chairs Gülşen Özkaya Şahin (Lund, Sweden) Sumit Kumar Rawat (Sagar, India)

W0303 08:30 Zoonotic hepatitis E reservoirs and transmission in Europe from a One-Health perspective
Hao Wang (Gothenburg, Sweden)

W0304 08:50 When the liver is just the beginning: a zoonotic journey beyond the liver
Yasemin Balaban (Ankara, Türkiye)

W0305 09:10 Epidemiological features of hepatitis E virus infection in Sub-Saharan Africa
Richard Njouom (Yaounde, Cameroon)

W0306 09:30 The rise of rat HEV: a new zoonotic herpesvirus
Antonio Rivero-Juarez (Córdoba, Spain)

Co-organised with: ESCMID Study Group for Veterinary Microbiology (ESGVM), ESCMID Study Group for Viral Hepatitis (ESGVH), Study Group of Viral Hepatitis of the Spanish Society of Infectious Diseases and Clinical Microbiology, Turkish Association for the Study of the Liver (TKAD); Society on Liver Diseases in Africa (SOLDA)

EW080 08:30 - 10:30 Hall A2-2
 2-hour Educational Session
 AMR PHEI

Modelling approaches to estimate and predict the burden of AMR

Chairs Anna Both (Hamburg, Germany) Tomislav Mestrovic (Varaždin, Croatia)

W0307 08:30 Methodological approach and pressing data need to model the burden of AMR
Mohsen Naghavi (Seattle, United States)

W0308 08:50 A comprehensive approach to estimate the AMR burden using IHME data
Gisela Robles Aguilar (Oxford, United Kingdom)

W0309 09:10 Expanding use of AMR burden data to influence policy and practice - the experience of the Fleming Fund
Toby Joseph Leslie (London, United Kingdom)

W0310 09:30 Interventions to improve targeted access to effective antibiotics
Erta Kalanxhi (Côte d'Ivoire)

Co-organised with: ESCMID AMR Action Subcommittee

Scientific Programme

Sunday, 19 April 2026

OS039 08:30 - 10:30 Hall A3-1
 CLN DX TRN 2-hour Oral Session

Sepsis at the frontline: diagnosis, therapy, and outcome in critical care

Chairs
 Despoina Koulenti
 (London, United Kingdom)
 Tim Rahmel (Bochum, Germany)

00274 08:30 Real-world longitudinal validation of high-income-country-derived sepsis endotypes in Sub-Saharan Africa: a nested prospective multi-centre study
*O. Turgman** (Amsterdam, Netherlands),
J. Wiersinga, S. Jacob, J. Butler, P. Haguma, S. Nyesiga, J. Phulusa, L. Carey, J. Rylance, T. Van Der Poll

00275 08:42 ARMOR-BSI: a nationwide analysis of the incidence and risk factors of ICU-acquired bloodstream infections in a multidrug-resistant organisms endemic country
*C. Genovese** (Milan, Italy), *M. Offer, S. Finazzi, M. Colaneri, E. Palomba, G. Scaglione, F. Dore, G. Montrucchio, G. Monti, B. Viaggi, A. Gori*

00276 08:54 Multi-centre quality improvement intervention to optimise blood culture use among adults in medical intensive care units and wards at four university hospitals
*V. Fabre** (Baltimore, United States),
Y.J. Hsu, A. Xie, A. Salinas, E. Gettler, J.K. Johnson, R. Moehring, A. Ressler, G. Rodriguez-Nava, J. Salinas, G. Schrank, A. Wasylshyn, S. Cosgrove

00277 09:06 Diagnostic efficacy and impacts on antibiotic use of digital droplet PCR in patients with suspected sepsis: the PROGRESS randomised, open-labeled, multi-centre trial
*X. Xu** (Shanghai, China), *H. Zhang, K. Lin, J. Ai, R. Wang, W. Zhang*

00278 09:18 Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bloodstream infections: a case-control study
*R. Morena** (Catanzaro, Italy), *S. Rotundo, A. Russo, A. Quirino, F. Serapide, E. Garofalo, H.L. Morrone, G. Mazza, G. Neri, N. Marascio, A. Bruni, G. Matera*

00279 09:30 Differential expression of miRNAs involved in shock are able to characterise mortality
*I. Rebollo Mato** (Valladolid, Spain),
A. García Concejo, L. Polo Sánchez, R.D. Prieto Utrera, P.J. Martínez De Paz, M. Álvarez Bardón, J. Matesanz Isabel, H. Gonzalo Benito, R.M. Cobo Zubia, E. Gómez Sánchez, M. Martín Fernández, E. Tamayo Gómez

00280 09:42 High-dose vs standard-dose intermittent meropenem in critically ill patients: an observational cohort study
*F. Bergmann** (Vienna, Austria), *M. Prager, L. Pracher, K. Kumpff, M. Zeitlinger, A. Jorda*

00281 09:54 Impact of appropriateness and type of empirical antibiotic therapy on outcomes of intensive care unit patients with bacteraemia by carbapenem-resistant *A. baumannii*
*S. Karakonstantis** (Heraklion, Greece),
E. Kritsotakis, E. Petrakis, N.R. Tziolos, D. Kypraiou, S. Papazisi, S. Anagnostou, E. Kondili, D. Kofteridis

00282 10:06 Therapeutic approaches and predictors of mortality in colistin-resistant *Klebsiella* bloodstream infections: a real-world study
*G. Kul** (Ankara, Türkiye), *N. Korkmaz, G.Ç. Şentürk, F. Ayçan, B. Güldoğan, H.M. Yılmaz, F.Z. Şahin, H. Ertekin, A.H. Solay, S. Kuzi, D. Bulut, E. E. Tütüncü*

00283 10:18 Mortality attributable to mismatch with *in vitro* susceptibility of empirical antibiotics in patients with bacterial bloodstream infections
*G.K. Zheng** (Hong Kong, Hong Kong),
W. Zhang, J. Blais, P. Wu, B. Cowling

OS040 08:30 - 10:30 Hall A3-2
 AMR ANT TRN 2-hour Oral Session

Expanding the antimicrobial arsenal: from dual-action compounds to predictive AI

Chairs
 Shampa Das (Liverpool, United Kingdom)
 Markus Zeitlinger (Vienna, Austria)

00284 08:30 3A11, an antibacterial molecule that reveals a dual mechanism of action
*A. Jouault** (Rennes, France), *B. Durand, N. Amiot, S. Ray, V. Bordeaux, Y. Augagneur, G. Lina, V. Cattoir*

00285 08:42 *In vitro* activity of a new antibiotic derivative of the lactvicin class, FPI-2119, tested against a challenge set of multidrug-resistant Enterobacterales clinical isolates
*R. Mendes** (North Liberty, United States),
G. Morgan, R. Jankowska, Y. Edah, R. Brianna, S. Charbon, S. Salama

00286 08:54 Antimicrobial activity of short ionic peptides is defined by fibre architecture, not charge
*N. Dad** (Manchester, United Kingdom),
G. Humphreys, A. Pluen, M. Elsayy, A. Mcbain

00287 09:06 OMN6: a novel antimicrobial peptide demonstrating LPS sequestration and *in vivo* efficacy in LPS-induced sepsis model
*N. Bachnoff** (Jerusalem, Israel),
O. Heyman, O. Mayost Lev-Ari, N. Nur Maymon, S. Mandel, J. Zazoun, A. Ben Dror, T. Shachar, M. Cohen-Kutner

00288 09:18 Augmenting cytotoxicity of pathogen-specific antibodies that initiate complement activation independent of the classical pathway against *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Streptococcus pneumoniae*, and *Neisseria meningitidis*
*T. Walsh** (Richmond, United States),
Y.M. Ali, M. Yabuki, C. Arachchilage, K. Priyanka, N.J. Lynch, S. Bruchmann, A. Weimann, K. Brown, R.A. Floto, J. Parhill, D-E. Briles, L.S. Macdaniel, H. Utsugi, G. Gragerova, R. Petraitiene, V. Petraitis, A. Misquith, C. Doulami, G. Demopulos, W. Schwaeble

00289 09:30 Chalcone-based scaffolds as promising antibacterial agents against clinical *Staphylococcus aureus* strains
*A. Israyilova** (Baku, Azerbaijan),
M. Uygun, N. Atac, A. Huseynzada, K. Shahverdiyeva, F. Can, U. Hasanova

00290 09:42 Fighting Carbapenem-resistant *Klebsiella pneumoniae* (CR-Kp): mechanistic insights into a novel metal-based complex
*R. Almeida** (Oeiras, Portugal), *N.A. Faria, B. Royo, O. Lenis-Rojas, M. Miragaia*

00291 09:54 Reviving antibiotic potency: pharmacological assessment of JS238 a newly designed potentiator against *P. aeruginosa*
*P. Rasouli** (Brussels, Belgium),
J.M. Brunel, H. Rodriguez-Villalobos, J.H. Lorent, F. Van Bambeke

00292 10:06 Integrating *in vitro*, *in silico*, and machine learning approaches to identify potent phytochemicals from *Phyllanthus amarus* leaf extracts with activity against multidrug-resistant pathogens
*A. Adeniyi** (Kano, Nigeria), *O. Olumide, A. Temiloluwa, A. Peter, A. Bolanle, B. Damilola*

00293 10:18 A hypergraph neural-network framework for predicting synergistic and antagonistic antimicrobial combinations: a triplet-based approach integrating antimicrobial peptides, antibiotics, and bacterial taxonomy
*A. Khavaran** (Philadelphia, United States),
F. Midjani, M. Malekpour, A.H. Rajabi, F.Z. Keshtkar, F. Golabi, A. Abbasi, M. Farhadi, B. Khosravi, A. Amanati

SY073 08:30 - 10:30 Hall ICM 13a
 AMR PHEI VAX 2-hour Symposium

Infections with no borders: challenges in South and Central-Eastern Europe in the context of travel, migration and war

Chairs *Marco Falcone (Pisa, Italy)*
Christian Wejse (Aarhus, Denmark)

S0279 08:30 Epidemiology and burden of imported travel related infectious diseases in the CEE region
Botond Lakatos (Budapest, Hungary)

S0280 09:00 The impact of armed conflicts and migration on antimicrobial resistance
Vodianyuk Arkadii (Kyiv, Ukraine)

S0281 09:30 Leishmaniasis outbreaks in conflict zones
Aula Abbara (London, United Kingdom)

S0282 10:00 "Threat of spread": vaccine preventable diseases in the CEE region
Simona Ruta (Bucharest, Romania)

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM), Hungarian Society of Infectious Diseases and Clinical Microbiology, International Society of Antimicrobial Chemotherapy (ISAC), ESCMID Study Group for Epidemiological Markers (ESGEM)

SY074 08:30 - 10:30 Hall ICM 13b
 PHEI 2-hour Symposium

The rise of tick-borne diseases: why are things changing?

Chairs *Sally Jane Cutler (London, United Kingdom)*
Alice Raffetin (Villeneuve-Saint-Georges, France)

S0283 08:30 Urban green spaces, fragmented forests and the transmission of tick-borne pathogens
Olaf Kahl (Berlin, Germany)

S0284 09:00 Automated classification of disease vectors
Rodrigo Gurgel-Gonçalves (Brasília, Brazil)

S0285 09:30 Hitching a ride: role of migratory birds in transferring ticks to new habitats
Ilaria Pascucci (Pesaro, Italy)

S0286 10:00 'Seek and thou shall find': harnessing the power of citizen science
Gabor Foldvari (Budapest, Hungary)

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)

Scientific Programme

Sunday, 19 April 2026

SY075 08:30 - 10:30 Hall ICM 5
 AMR IPC PED 2-hour Symposium

Protecting the most vulnerable: infection prevention in neonatal and paediatric critical care

- Chairs* Bianca Albers (Zurich, Switzerland)
 Angelika Berger (Vienna, Austria)
- S0287 08:30 Biofilm related infections in children**
Ojan Assadian (Wiener Neustadt, Austria)
- S0288 09:00 Multidrug-resistant infections in the neonatal and paediatric ICU: how can we prevent outbreaks?**
Pablo Sanchez (Columbus, United States)
- S0289 09:30 Surveillance and stewardship in the NICU/PICU: what works and what doesn't?**
Julia Anna Bielicki (London, United Kingdom)
- S0290 10:00 Neonatal skin, device, and environmental hygiene: how to translate evidence into practice?**
Andreas F. Widmer (Füllinsdorf, Switzerland)

SY076 08:30 - 10:30 Hall BO-1
 CLN TRN VAX 2-hour Symposium

What drugs are missing? Exploring adjuvant therapies in immunosuppressed patients

- Chairs* Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)
 Nina Khanna (Basel, Switzerland)
- S0291 08:30 Immunotherapy meets infection: the case for host-directed treatment strategies**
Patrizia Comoli (Pavia, Italy)
- S0292 09:00 Too little or too much? Balancing immune modulation in transplant and oncology patients**
Carlota Gudiol (Barcelona, Spain)
- S0293 09:30 Adjuvant therapies in practice: lessons from mycobacteria**
Graeme Ayton Meintjes (Observatory, South Africa)
- S0294 10:00 What drugs are missing? Unmet needs and promising directions in the immunocompromised host**
Michael Boeckh (Seattle, United States)

SY077 08:30 - 10:30 Hall A2-1
 AMR PHEI 2-hour Symposium

Antimicrobial resistance on the menu: global risks across the food chain

- Chairs* Yesim Besli (Istanbul, Türkiye)
 Merica Carev (Split, Croatia)
- S0295 08:30 Global risk mapping of XDR Typhoid: from genomic insights to possible threats**
Megan Carey (Amsterdam, Netherlands)
- S0296 09:00 Global resistance trend of Campylobacter, predictive modelling and novel intervention strategies**
Bruno Lopes (Middlesbrough, United Kingdom)
- S0297 09:30 Exploring the Rise of AMR in Invasive NTS: Mechanisms, Mobility, and Global Trends**
Sandra Van Puyvelde (Wilrijk, Belgium)
- S0298 10:00 Silent Spreaders: Tracking Carbapenemase-Producing Enterobacterales in the Food Chain**
Valeria Bortolaia (Copenhagen, Denmark)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

EF043 09:30 - 10:30 Arena 1
 ePoster Flash Session

Tracking respiratory virus outbreaks in a changing world: from hospitals to wastewater

- Chair* Magdalena Rosińska (Warszawa, Poland)
- E0312 09:30 Comparing COVID-19, influenza, and RSV positivity from a longitudinal cohort with US national surveillance data**
D. Nash (New York, United States), M.S. Rane, K. Penrose, K.E. Allen, F.R. Ernst, A. Srivastava, Y. Shen, M.M. Robertson, J. Zamparo, S.G. Kulkarni, L. Puzniak*
- E0313 09:36 Pandemic-induced reorganisation of respiratory virus ecology: seven-year analysis of COVID-19, influenza, and RSV hospitalisation dynamics from RESP-NET surveillance (2018-2025)**
P. Kilgore (Detroit, United States)*
- E0314 09:42 Hospitalisation and healthcare consumption burden of respiratory syncytial virus (RSV) in older adults in France**
M. Vacheret (Paris, France), S. Fievez, E. Blanc, L. Watier, L. Baschet, C. Bignon-Favary, P. Mckelvie-Sebileau, P. Loubet*

- E0315 09:48 Incidence of human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) among adults 50 years and older in the outpatient setting in the US: interim results from the ARIA study**
*H. Groom** (Portland, United States),
M. Schmidt, J. Kuntz, N. Smith, J. Meece, R. Mularski, W. Hu, M. O'keeffe-Rosetti, N. Klein, K. Jacobson, C. Oxandale, A. Wiesner, L. Glasser, S. Venkatesan, C. Talarico
- E0316 09:54 Using latent class analysis to improve classification of nosocomial SARS-CoV-2 infections in Ontario, Canada**
*N. Wilson** (Toronto, Canada), *C. E. Lee, D. Fisman*
- E0317 10:00 Hospital Outbreaks Predict Community COVID-19 Spread: Evidence for Healthcare-Driven Transmission**
*N. Wilson** (Toronto, Canada), *C. Lee, D. Fisman*
- E0318 10:06 Self-testing for five respiratory viruses in adults ≥50 years of age in Germany for longitudinal monitoring of community-acquired acute respiratory infections**
*J.A. Nacov** (Cologne, Germany),
J. Salmanton-García, J. Jakobs, M. Anggitakirana, S. Grimm, J. Leckler, K. Köbe, L. Cremer, P. Wipfler, J. Stemler, H.J. Schmitt, U. Bethé, O. Cornely
- E0319 10:12 Comparison of emergency department indoor air and citywide wastewater for respiratory and enteric virus surveillance using hybrid-capture viral metagenomics**
*M. Karatas** (Leuven, Belgium),
S. Gorissen, C. Geenen, J. Swinnen, E. Hosten, K. Van Dyck, L. Cuypers, M. Bloemen, E. Wollants, M. Van Ranst, B. Verschueren, M. Sabbe, J. Matthjnsens, E. André
- E0320 10:18 Detection of SARS-CoV-2 variants of concern in Swiss wastewater without prior lineage classification**
*R. Kociurzynski** (Freiburg, Germany),
T. Donker

KN081 09:30 - 10:30 Hall ICM 14
DX PHEI VAX **Keynote Scientific Interview**

Integrating technology and capacity building to strengthen disease surveillance and prevention in low-resource settings

Chair **Jon S. Friedland**
 (London, United Kingdom)

K0311 09:30 Senjuti Saha (Dhaka, Bangladesh)



Senjuti Saha is the Deputy Executive Director of the Child Health Research Foundation (CHRF), Bangladesh, where she leads research on paediatric infectious diseases. She earned her PhD in Molecular Genetics from the University of Toronto, Canada, and completed postdoctoral fellowships at The Hospital for Sick Children (SickKids), Canada, and Stanford University, US. Saha joined CHRF in 2016 to establish a state-of-the-art genomics centre. Her team conducts genomic surveillance, maps antimicrobial resistance, and tracks endemic and emerging viruses. Saha has received multiple national and international honours, and serves on several World Health Organization advisory committees and editorial boards. She is a strong advocate for equitable science through the "Building Scientists for Bangladesh" initiative and believes that everyone should have equal access to both the practice and the benefits of science.

Fireplace Session 19 April, 10:45 - 11:45

EF051 11:00 - 12:00 Arena 2
ANT **ePoster Flash Session**

Antibiotic use, misuse and stewardship across settings

Chair **Rita Murri** (Rome, Italy)

E0356 11:00 Understanding factors associated with antibiotic misuse among persons living with HIV at two large HIV clinics in Uganda
*F. Magololo Mutesi** (Kampala, Uganda),
N. Mukiza, R. Nakalega, E. Twinomuhwezi, H. Mackline, A. Twimukye, F. Kakooza, A. Kambugu, D.M. Byonanebye, H. Kajumbula

E0357 11:06 The global spatiotemporal distribution of substandard and falsified antibiotic medicines
*L. Adipo** (Oxford, United Kingdom),
S. Cavany, C. Caillet, J. Mendes, S.M. Nanyonga, N. Stoesser, C. Dolecek, P. Newton, B. Cooper

Scientific Programme

Sunday, 19 April 2026

E0358	11:12	<p>EU Joint Clinical Assessments: a missed opportunity to recognise the wider benefits of novel antimicrobials?</p> <p><i>M. Hofer*</i> (London, United Kingdom), <i>A. Macfarlane, G. Bray, E. Hamson, G. Hampson</i></p>	EF052	11:00 - 12:00	Arena 3
E0359	11:18	<p>Profile of high-volume antibiotic prescribers, a population-based study from the French National Health Data System, 2023</p> <p><i>G. Beraud*</i> (Orleans, France), <i>H. Desmars, A.I. Lecuyer, F. Coustillères, E. Laurent, C. Carvalho, L. Grammatico-Guillon</i></p>	CLN	ePoster Flash Session	
E0360	11:24	<p>In search of innovative 'alter-biotic treatments': non-traditional therapies and the sociotechnical frameworks they require</p> <p><i>C. Haddad*</i> (Vienna, Austria), <i>A. Albiez, K. Bentley, E. Paterson</i></p>	<p>From epidemiology to clinical impact of infections in solid organ transplant recipients</p>		
E0361	11:30	<p>Laboratory-based Antimicrobial Stewardship: An Australian and New Zealand Perspective</p> <p><i>K. Ryan*</i> (St Leonards, Australia), <i>J. Elvy, M. Otormin, M. Jayawardena, M. Graham</i></p>	Chair	<i>Patricia Munoz</i> (Madrid, Spain)	
E0362	11:36	<p>European multidisciplinary AMR modified Delphi panel: Root causes of undervaluation of novel antibiotics and opportunities for alternative payment models</p> <p><i>E. Broughton*</i> (Berlin, Germany), <i>H. Armstrong, J. Benitez Rodriguez, C. Capdevila, S. Capri, S. Delgado-Collins, L. Diamond, M. Gheorghe, C. Hng, S. Kelly, K.E. Kypreos, M. Larguem, E. Rinaki, N.V. Sipsas, J.P. Stahl, P. Tilleul, J. Torre-Cisneros, A. Townsend, J.A. Valles Callol</i></p>	E0365	11:00	<p>Tuberculosis incidence in solid organ transplant recipients in Europe: a multi-centre TBnet cohort study</p> <p><i>T.T. Brehm*</i> (Borstel, Germany), <i>B. Lange, S.M. Arend, M. Arias-Guillén, M. Bakker, C. Berastegui, M. Babiker, R. Charif, R. Duarte, H. Flick, R.W. Hofland, J. Ismail, D. Kniepeiss, J. Krepel, N. Krishnan, D. Kuijpers, H. Kunst, F. Van Leth, V. Lezaic, I. Los-Arcos, J. Machová, H. Milburn, S.A. Morais, O.M. Kon, C. Osoro-Suarez, H. Pessegueiro Miranda, D.P. Pesut, A. Rahman, T. Reischig, A. Sánchez-Montalvá, H-E Spohn, M.T. Stegenga, A.P.J. De Vries, D. Wagner, R. Wobser, C. Lange, M. Sester</i></p>
E0363	11:42	<p>Achieving Europe's fair share: the need for European countries to complement EU-level pull incentives with national provisions for novel antimicrobials</p> <p><i>E. Damato*</i> (London, United Kingdom), <i>H. Armstrong, R. Lawlor, T. Wilsdon, D. Zhou</i></p>	E0366	11:06	<p>Comparative Risk of Tuberculosis in Solid Organ Transplant Recipients and Matched General Population Controls</p> <p><i>S. Hosseini-Moghaddam*</i> (Toronto, Canada), <i>H.M. Seyed M., D. Fridman, S.S.M. Drover, S.K. Brode, T.K. Marras, F.B. Jamieson, S. Husain, J.C. Kwong</i></p>
E0364	11:48	<p>Off-label antibiotic consumption behaviour increases the threat of antimicrobial resistance</p> <p><i>D. Batheja*</i> (Hyderabad, India), <i>S. Reddy, C. Achar</i></p>	E0367	11:12	<p>Bacterial respiratory infections in solid organ transplant recipients with a focus on atypical pathogens: data from a prospective national cohort</p> <p><i>J. Bisch-Karatas*</i> (Bern, Switzerland), <i>I. Abela, A. Boyd, P. Kohler, N. Khanna, A. Koutsokera, M. Schuurmans, O. Manuel, C. Van Delden, N.J. Mueller, C. Hirzel, L.N. Walti</i></p>
			E0368	11:18	<p>Transplantation confers improved survival in ESBL-E BSI compared with non-transplant patients: insights from two multinational matched cohorts (INCREMENT vs INCREMENT-SOT)</p> <p><i>E. Ruiz Arabi*</i> (Lausanne, Spain), <i>E. Pérez-Nadales, J.A. Marín-Sanz, J.J. Castón, I. Machuca, A. Cano, M. Marín-Sanz, B. Gutiérrez-Gutiérrez, J. Torre-Cisneros</i></p>
			E0369	11:24	<p>Epidemiological patterns of carbapenem resistance in solid organ transplantation: a contemporary multi-centre analysis</p> <p><i>T. Yanik Yalçın*</i> (Ankara, Türkiye), <i>A.Ö. Mete, Ş. Acar, T. Arslan-Gülen, G. Çınar, I. Hasanoğlu, E. Olcucuoglu, E. Günal, T. Turunç, V. Avkan-Oguz, M.C. Ergon, M. Yavuz-Çolak, Ö. Azap, H. Aslan</i></p>

E0370	11:30	<p>Infections in Paediatric Liver Transplantation: Risk Factors and Clinical Outcomes <i>L. Romani*</i> (Rome, Italy), <i>M. De Luca, A.C. Epifani, F. Fini, C. Tripiciano, S. Mercadante, S. Bernardi, G. Spagnoletti, A.M. Fratti, R. Somma, V. Tuccio Guarna Assanti Vanessa, L. Dei Giudici, T. Alterio, D. Liccardo, F. Chiusolo, C.F. Perno, A. Pietrobattista, M. Spada</i></p>	E0376	11:12	<p>Determination of meropenem heteroresistance in a diverse collection of OXA-48-producing <i>Klebsiella pneumoniae</i> clinical isolates <i>M. Alcalde-Rico*</i> (Seville, Spain), <i>A. Angós, F. Docobo-Pérez, M. Delgado-Valverde, J.M. Rodríguez-Martínez, L. López-Cerero, Á. Pascual</i></p>
E0371	11:36	<p>Risk factor analysis for early and late invasive <i>Candida</i> infections in solid organ transplant recipients <i>L. Meyer*</i> (Zurich, Switzerland), <i>J. Frossard, P. Schreiber, O. Manuel, F. Lamoth, N. Khanna, K. Boggian, L. Walti, C. Garzoni, C. Van Delden, N. Mueller, D. Neofytos</i></p>	E0377	11:18	<p>Human serum albumin (HSA) modulates cefiderocol activity in carbapenem-resistant (CR) pathogens <i>M.S. Ramirez*</i> (Fullerton, United States), <i>A. Varnado, S. Moheb, K. Lopez, C. Rodriguez, S.D. Sanchez, G. Traglia, F. Pasteran, M.E. Tolmasky, R.A. Bonomo, L.A. Actis, G. Rao</i></p>
E0372	11:42	<p>Durability of RSV-specific IgG, neutralising activity and T-cell responses after respiratory syncytial virus vaccination in kidney transplant recipients <i>S. Bronder*</i> (Homburg, Germany), <i>H. Gruell, S. Lennartz, R. Urschel, D. Fliser, T. Schmidt, D. Schmit, M. Sester</i></p>	E0378	11:24	<p>Sigma E factor transcriptional regulates the expression of metallo-β-lactamase NDM and mediates heteroresistance <i>Y. Wang*</i> (Hangzhou, China), <i>W. Huang, Q. Shi, J. Zhou, R. Weng, H. Hu, J. Quan, Y. Jiang, Y. Yu</i></p>
E0373	11:48	<p>Systemic absorption and epithelial lining fluid concentration of inhaled vancomycin in lung transplant recipients <i>G. Escudero Arnés*</i> (Barcelona, Spain), <i>I. Los-Arcos, J. Sacanell, A. Pau, Y. Villena, C. Berastegui, J. Rosado, D. Campany, L. Castellote, B. Saez, L. Domenech, M.T. Martin, M. Culebras, C. Laborda, R. Barquín, S. Luque, O. Len, J. Gavaldà</i></p>	E0379	11:30	<p>The role of colistin resistance genes in the formation of colistin-induced tolerant and persister cells in clinical isolates of <i>Klebsiella pneumoniae</i>, <i>Acinetobacter baumannii</i>, and <i>Pseudomonas aeruginosa</i> <i>G. Ozcan Kuyucu*</i> (Ankara, Türkiye), <i>C. Vatansever, J. Boral, A. Akpinar, S. Menekse, M. Gonen, F. Can</i></p>
E0380	11:36	<p>East-west divergence in carbapenem-resistant <i>Klebsiella pneumoniae</i> across Europe (2016–2022): temporal trends, spatial heterogeneity, and relation to antibiotic use <i>A. Sergouni*</i> (Amfissa, Greece), <i>P. Dimitrelou, E. Alonaris, D. Rigas</i></p>	E0381	11:42	<p>Aztreonam/avibactam resistance due to synergistic interplay of ampC-related mutations in carbapenem-resistant <i>Enterobacter</i> spp. <i>Y. Zeng*</i> (Chengdu, China), <i>Y. He, Z. Zong</i></p>
E0382	11:48	<p>Does use of ceftazidime/avibactam increase the risk of in vivo emergence of ceftazidime/avibactam and cefiderocol cross-resistance in KPC-producing <i>Klebsiella pneumoniae</i>: a case-control study <i>Y.T. Lin*</i> (Taipei, Taiwan), <i>C. Chuang, S.Y. Liu, Y.C. Ho, S.H. Chou, Y.R. Huang, W. Chin, N.W. Hsu, L. Chen</i></p>			
EF053	11:00 - 12:00	<p style="text-align: right;">Arena 4</p> <p>TRN ePoster Flash Session</p>			
Carbapenem resistance: surveillance, mechanisms, and clinical implications					
Chair	<p><i>Rafael Canton</i> (Madrid, Spain)</p>				
E0374	11:00	<p>A nationwide survey of carbapenemase-producing Gram-negative bacilli in bloodstream infections in a paediatric population (2015–2024) <i>C. Kiffer*</i> (São Paulo, Brazil), <i>P.Z. Charf, D. Testoni Costa-Nobre, E. Carmo, C.B. Wagner, T.T.F. Rezende, A.S.S. Marinonio, A.P.C. Assef, C.L. Pessoa-Silva, R. Peral, D. Kulek, L. Kraft, M. Pilonetto</i></p>	E0382	11:48	<p>Does use of ceftazidime/avibactam increase the risk of in vivo emergence of ceftazidime/avibactam and cefiderocol cross-resistance in KPC-producing <i>Klebsiella pneumoniae</i>: a case-control study <i>Y.T. Lin*</i> (Taipei, Taiwan), <i>C. Chuang, S.Y. Liu, Y.C. Ho, S.H. Chou, Y.R. Huang, W. Chin, N.W. Hsu, L. Chen</i></p>
E0375	11:06	<p>Diffusion of OXA-23 producing <i>Acinetobacter baumannii</i> in Zagreb post-pandemic <i>B. Bedenic*</i> (Zagreb, Croatia), <i>D. Bandić-Pavlović, M. Nađ, M. Kasalo, D. Varda-Brkić, N. Beder, V. Bratić, M. Dobrić, H. Car, J. Vraneš</i></p>			

Scientific Programme

Sunday, 19 April 2026

FO090 11:00 - 12:00 Arena 1
 IPC Open Forum


IPC nurses corner: building bridges across Europe

- Chair* Ermira Tartari (Msida, Malta)
- F0241 11:00 Training the invisible workforce: what (still) makes sense in cleaning staff education?**
Veronica Weterings (Breda, Netherlands)
- F0242 11:10 From recipient to partner: patient involvement in infection prevention**
Erik Briers (Belgium)
- F0243 11:20 Simulation-based IPC training: the real-life test lab**
Constantinos Tsioutis (Nicosia, Cyprus)
- F0244 11:30 Reinventing the wheel: hand hygiene meets AI innovation**
Silvana Gastaldi (Mazzano, Italy)

Co-organised with: EUCIC Steering Committee

KN082 11:00 - 12:00 Hall ICM 14
 CLN DX Keynote Lecture

Rickettsioses: widespread and neglected

- Chairs* Li Yang Hsu (Singapore, Singapore)
 Xavier Lescure (Paris, France)
- K0226 11:00 Nicholas Day (Bangkok, Thailand)**
- 
- Nicholas Day is Director of the MORU Tropical Health Network, a Wellcome Major International Programme, and a Professor of Tropical Medicine at the University of Oxford. He has over 30 years of experience conducting infectious disease research in low-resource settings. His interest in rickettsioses began after seeing the unexpectedly high incidence of scrub typhus and other rickettsial infections in multiple studies of acute febrile illness across Southeast Asia. Despite their global prevalence, efforts to tackle these neglected but often serious infections are hindered by a limited understanding of their epidemiology and public health burden, low awareness among healthcare workers and affected communities, a lack of available and standardised diagnostics, and a paucity of clinical evidence to guide treatment.

Fireplace Session 19 April, 12:15 - 13:15

LB003 11:00 - 12:00 Hall B0-2
 ANT CLN 1-hour Oral Session

Late-breaking antiviral drug trials

- Chairs* Laurent Kaiser (Geneva, Switzerland)
 Marta Mora-Rillo (Madrid, Spain)
- L0016 11:00 Positive treatment response of pritelivir achieved in refractory HSV infections in immunocompromised patients, including haematopoietic stem cell and solid organ transplant recipients and oncology patients: PRIOH-1 phase III trial**
R. Chemaly (Houston, United States), K. Peggs, D. Neofytos, K. Workowski, R. Avery, Y.J. Lee, R. Maves, O. Cornely, J. Stemler, D. Teschner, M. Yong, J. Sasadeusz, S. Dadwal, J. Dickter, A. Birkmann, C. Wat, D.C. Herath, A. Marini, B. Surujbally, M. Sumner, G.A. Papanicolaou*
- L0017 11:12 Implementing a controlled human infection model (CHIM) with a reverse genetics H3N2 (A/Texas/71/2017, clade 3C.3a) influenza challenge virus in healthy volunteers**
V. Cnossen (Leiden, Netherlands), G. Groeneveld, O. Engelhardt, J. Samolej, G. Piccini, S. Jochems, W. Huisman, T. Muster, M. Roestenberg, I. Kamerling*
- L0018 11:24 UMIT-1, Phase IB Trial: IV favipiravir and ribavirin for the treatment of CCHF**
I. Bozkurt (Samsun, Türkiye), H. Bodur, M. Ertek, F. Altuntaş, N. Elaldi, G. İskender, D. Mert, Y. Cosgun, E. Beren Tanik, E. Challenger, C.R. Thompson, L. Read, L. Else, L. Marsh, S.A. Büyüktuna, H. Can Bilek, H. Karadeniz, H. Oksuzoglu, A. Haykir Solay, E. Türkoğlu, M. Arslan, A. Torun, S. Kulari, J. Read, C. Rawcliffe, M. Yıldız, S. Khoo, T. Fletcher*
- L0019 11:36 Long-term viral suppression, and cardiometabolic benefits of switch to ainovirine coformulated with lamivudine, and tenofovir DF in virologically suppressed people with HIV-1: 144-week, open-label results from the SPRINT post-study**
Z. Jie (Beijing, China)*
- L0020 11:40 Rivaroxaban, colchicine and famotidine/loratadine with integrated clinical care for Long COVID, a multi-site, open-label randomised controlled trial**
E. Wall (London, United Kingdom), M. Heightman, A. Banerjee, G. Prescott, H. Dehbi, C. Watkins*

ME088 11:00 - 12:00 Hall ICM 5
 ANT TRN Meet-the-Expert

To model or not to model? A debate on the role of modelling and simulation in clinical PK trials

MO237 11:00 Markus Zeitlinger (Vienna, Austria)

MO238 11:12 Lena Friberg (Uppsala, Sweden)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

ME089 11:00 - 12:00 Hall BO-1
 CLN DX Meet-the-Expert

Global health on the move: advances and strategies in travel medicine

MO239 11:00 German Henostroza (Lima, Peru)

MO240 11:12 Andreas Neumayr (Basel, Switzerland)

OS044 11:00 - 12:00 Hall A1-1
 TRN VAX 1-hour Oral Session

Mechanisms of pathogenesis across different pathogens

Chairs Maria Kaparakis-Liaskos (Melbourne, Australia)
 Anna Norrby-Teglund (Stockholm, Sweden)

OO321 11:00 **A systems serology approach to identify antibodies to PfEMP1 that correlate with protection from paediatric cerebral malaria in Malawi**
 P. Banda* (Blantyre, Malawi), I. Walker, C. Juwawo, W. Hasang, D. Mathanga, T. Taylor, T. Nyirenda, E. Aitken, S. Rogerson, K. Seydel

OO322 11:12 **Wzi modulates immune evasion of hypervirulent *Klebsiella pneumoniae* in a CPS-dependent and independent manner**
 K. Zhou* (Shenzhen, China), S. Wei, T. Xu

OO323 11:24 **Binding of host glycans and vitronectin drive *Neisseria gonorrhoeae* pathogenesis and reveal potential vaccine targets**
 E. Macdonald* (Bristol, United Kingdom), S. Savino, W. Pansegrau, D. Hill

OO324 11:36 **A 3D-Bioprinted human skin model to study *Candida* colonisation and species-dependent phenotypes**
 M. Cacaci* (Rome, Italy), D. Squitieri, G. Artemi, F. Bugli, R. Torelli, M. Papi, V. Palmieri, A. Augello, C. Perfilli, M. De Spirito, R. Benvenuto, E. Stigliano, E. Benini, P. Fazi, M. Sanguinetti

OO325 11:48 **Host-specific platelet-activating factor acetylhydrolase selectively remodels diacylglycerophospholipids to control schistosome development**
 F.U. Prodjinotho* (Munich, Germany), J. Ertl, Z. Rao, A. Anisuzzaman, J. Schluckebier, Y. Hamway, P. Baar, M. Haslbeck, C.G. Greveling, S. Haeberlein, F.H. Falcone, S. Schulz, A. Koeberle, C. Prazeres Da Costa

OS045 11:00 - 12:00 Hall A1-3
 CLN VAX 1-hour Oral Session

Invasive fungal infections: therapeutic strategies and emerging options

Chairs Oliver A. Cornely (Cologne, Germany)
 Cornelia Lass-Flörl (Innsbruck, Austria)

OO326 11:00 **Invasive Aspergillois in Chronic Lymphocytic Leukemia: Case-Control Study**
 B.S. Bisono Garcia* (Rochester, United States), K.G. Rabe, S.A. Parikh, P. Vergidis

OO327 11:12 **Olorofim for the treatment of invasive *Aspergillus* in haematology patients with limited or no treatment options: sub-analysis of an open-label, single-arm, phase IIb trial (Study32; NCT03583164)**
 J. Maertens* (Leuven, Belgium), S. Hammond, G. Rahav, A. Bruns, O. Uspenskaya, M. Chayakulkeeree, V. Mehra, A. Spec, J.M. Aguado, J. Fortun, C. Heath, M.H. Nguyen, J. Schaanman, S. Schwartz, M. Miceli, M. Moussa, O. Marin Fernandez, D. Zinzi, J. Rex

OO328 11:24 **Fosmanogepix expanded access in patients with invasive mould infections from Germany, Austria, and Switzerland**
 J. Stemler* (Cologne, Germany), J. Prattes, N. Khanna, H. Schlamm

OO329 11:36 **Immunisation against *Aspergillus* is associated to poor outcome and higher mortality in patients with idiopathic pulmonary fibrosis: The Asp-IPF study**
 J.P. Gangneux* (Rennes, France), H. Guegan, F. Reizine, P. Chauvin, F. Robert-Gangneux, M. De Saint Jore, T. Guy, A. Mabo, Y. Bazin, M. Kerjouan, S. Jouneau

OO330 11:48 **Oteseconazole concentrations in plasma and CSF in HIV-related cryptococcal meningitis**
 M. Nicol* (Minneapolis, United States), M. Rutakingirwa, M. Kabahubya, T. Mugabi, J. Gakuru, S. Namombwe, F. Ssekindi, S. Kimuda, C.P. Skipper, M. Abassi, S.R. Brand, D.B. Meya, D.R. Boulware

Scientific Programme

Sunday, 19 April 2026

OS046 11:00 - 12:00 Hall A1-4
 CLN TRN VAX 1-hour Oral Session

Translational science in mycobacterial infections

Chairs Deborah Chong (London, United Kingdom)
 Delia Goletti (Rome, Italy)

O0331 11:00 **Increased cAMP levels compromise cell wall integrity by promoting the production of reactive oxygen species in *Mycobacterium tuberculosis***
 Y. Li* (Guangzhou, China), J. Wan, X. Xia, X. Deng, G. Tian, L. Zhong, S. Feng

O0332 11:12 **Spatial single-cell transcriptomic analysis reveals elevated platelet-neutrophil interaction and platelet-derived MMP-1 secretion in human CNS-TB granulomas**
 Y.H. Wong* (Singapore, Singapore), H. Lee, F.K. Loh, B. Chen, T.H. Hu, H.T. Chong, C.L. Tan, A.F. Vallejo, C.W.M. Ong

O0333 11:24 **Characterisation and genetic engineering of a novel mycobacteriophage for therapeutic use**
 A. Bonacorsi* (Pisa, Italy), A. Fusco, D. Manessi, F. Filippini, G. Delogu, I. Palucci, M. Lai, G. Freer, S. Dominici, F. Pratesi, G. Hatfull, A. Tavanti, L. Rindi, M. Di Luca

O0334 11:36 **BCG vaccination induces partial NK cell tolerance in people with HIV-1 on suppressive ART**
 C. Dollé* (Zurich, Switzerland), T. Tutumlu, D. Russenberger, M. Zeeb, E. West, D. Braun, H. Günthard, J. Nemeth

O0335 11:48 **Persister cells are highly prevalent across *Mycobacterium abscessus* clinical isolates**
 L. Geerts* (Wilrijk, Belgium), L. De Vooght, G.J. Wijnant, E. André, N. Lorent, P. Cos

OS047 11:00 - 12:00 Hall A1-5
 CLN DX 1-hour Oral Session

Diagnosing respiratory infections: from PCR to metagenomics

Chairs Gilbert Greub (Mollie-Margot, Switzerland)
 Qiwen Yang (Beijing, China)

O0336 11:00 **Machine learning-driven daily VAP risk stratification for real-time ICU decision support**
 Y. Fromage* (Limoges, France), A. Hernandez Padilla, J. Vaidie, H. Sayadi, A. Barac, O. Cremer, D. Garot, A. Rouzé, T. Daix, L. Vintcent, H. Jackson, M. De Karker, H. Van Werkhoven, J.B. Woillard, B. François

O0337 11:12 **Novel Thermo-Induced Switching Probes Enable Dual-Target Detection per Fluorescence Channel for Seven Respiratory Viral Targets in a One-Tube Multiplex PCR Assay**

J. Lee* (Jeonju, Korea, Republic of), J. Yoon, H. Kim

O0338 11:24 **The First National EQA for Clinical Metagenomics: Design, Delivery and Results**

A. Alcolea Medina* (London, United Kingdom), L.B. Snell, R. Doyle, V. Patel, R. Chang, M. Gumbanmarasigan, V. Vorslava, B. Leta, D. Ward, J. Brown, A. Kopec, S. Rock, M. Valappil, K. Laws, S. Parmar, S. May, P. Patel, M. Ibrahim, S. Green, K. Saeed, N. Norton, C. Reid, A. Every, A. Hughes, A. Kottara, K. Nelson, B. Browne, P. Grant, G. Nebbia, R. Batra, J. Edgeworth

O0339 11:36 **Whole genome sequencing of *Mycoplasma pneumoniae* directly from clinical samples using a novel target sequence capture probe panel**

C. Dixon* (Cardiff, United Kingdom), N. Couto, M. Ramirez, R. Mamede, H. Milton, M. Maiwald, C. Moore, S. Sidorov, J. Flipse, R. Nir-Paz, A. Michael-Gayego, J. Moran-Gilad, D. Kese, G. Greub, P.M. Meyer Sauter, M.L. Beeton

O0340 11:48 **Diagnostic performance of clinical metagenomics in pneumonia for blood and respiratory specimens: a single centre study**

C. Bode* (Bonn, Germany), A. Sauer, K. Peukert, S. Mazzitelli, M. Parcina, C. Putensen, T. Muders, J. Poth, F. Lehmann, B. Seeliger, S. Grumaz

OS048 11:00 - 12:00 Hall A2-1
 1-hour Oral Session

Field investigations of community-acquired infections

Chairs Aula Abbara (London, United Kingdom)
 Steen Ethelberg (Copenhagen, Denmark)

O0341 11:00 **Rapid deployment of a large epidemiological investigation: lessons learnt from a mains water outbreak of *Cryptosporidium parvum*, South West UK, 2024**

P. Charlotte* (London, United Kingdom), C. Patterson, B. Winer, M. Bardsley, F. Halford, S. Bird, N. Verlander, R. Chalmers, E. Smout, R. Kwiatowska, N. Young

- O0342 11:12 A national iatrogenic botulism outbreak associated with cosmetic procedures in England, 2025**
*V. Wong** (London, United Kingdom),
S. Gokool, D. Rajendram, B. Ahmed, R. Pebody, I. Hayden, G. Godbole
- O0344 11:36 Epidemiological characteristics and outcomes of the 2023–2024 cholera outbreak in South Yemen: a retrospective descriptive study from MSF-supported centres**
*M. Sallam** (Aden, Yemen),
N.O. Abdulgany, A.M. Farhan, M. Shomasi, A. Abdulhaq, U.Z. Khan, D. Dela Cruz-Diaz, H. De Clerck, S. Lim, K. Moussally, P. Garcia-Vello
- O0345 11:48 Echoes of vibrio: seasonal context variables, microbial signatures, and critical illness in cholera infections**
*P. Thummalagunta** (Mangalagiri, India),
M. Kumar A, D. Debabrata, C.N. Chithra, H. G. S.V. Kutty, R. Upparakadiyala, A. Rajeev

OS049 11:00 - 12:00 Hall A2-2
 ANT CLN PHEI 1-hour Oral Session

From silent malaria infections to severe disease in a globalised world

*Chairs Emmanuel Bottieau (Antwerp, Belgium)
 Fitsum Tadesse (Addis Ababa, Ethiopia)*

- O0346 11:00 Late treatment failures of artemisinin-based combination therapies in imported *Plasmodium falciparum* malaria in France (2013–2024): a case-control and genomic investigation**
*S. Boufares** (Paris, France), *R. Coppee, A. Cosson, N. Mathieux, S. Anthony, Z. Rizwana, S. Veronique, T. Nicolas, H. Sandrine*

- O0347 11:12 Prevalence of truly asymptomatic malaria and its determinants in a high burden rural district in India: a community-based study from Uttar Pradesh**
*R.S. Rath** (Gorakhpur, India),
G.R. Dwivedi, H.S. Joshi, A. Singh, P. Kharya, N.M. Agarwal, M. Bisht, D. Upadhyaya, A.R. Koparkar, A.M. Dixit

- O0348 11:24 Outpatient management of imported non-severe malaria in the UK: a multi-site clinical safety evaluation**
*J. Milburn** (London, United Kingdom),
A. Williamson, S. Baljekar, R. Rachman, A. Daunt, N. Richardson, F. Olcott, C. Rodrigues, R. Thangarajah, S. Yeung, M. Arias, C. Jennings, A. Delmonte Sen, J.L. Klein, A. Odedra, N. Jacobs, C. Drapeau, C. Van Halsema, G. O'hara, A. Checkley

- O0349 11:36 Host and parasite biomarkers to trigger intravenous antimalarials and prioritise ICU admission in severe imported *Plasmodium falciparum* malaria patients**
*D. Camprubi-Ferrer** (Barcelona, Spain),
J. Pedreira-Rincon, C. Bertran-Cobo, M. Alguacil, L. Balerdi Sarasola, M.J. Alvarez-Martinez, J. Muñoz, C. Parolo
- O0350 11:48 Whole genome sequencing to inform the epidemiology of *Plasmodium falciparum* malaria in the elimination setting of Malaysia**
*K. Tan** (London, United Kingdom),
N. Billows, P. Divis, C. Daneshvar, J. Edgeworth, J. Cox-Singh, S. Campino, T. Clark

OS050 11:00 - 12:00 Hall A3-1
 CLN 1-hour Oral Session

Personalised approaches to infectious diseases in high-risk haematologic and transplant patients

*Chairs Andreas H. Groll (Münster, Germany)
 Stefan Schwartz (Berlin, Germany)*

- O0351 11:00 The role of rectal swabs in driving empirical antibiotic therapy in febrile neutropenic patients: a quasi-experimental multi-centre study within the REVERSE project**
*R. Scardellato** (Verona, Italy), *M. Morra, M. Tebon, A.M. Azzini, M.C. Negulescu, A.L. Mohorea-Neata, A. Araújo, M.T. Pérez-Rodríguez, G. Nadali, C. Tecchio, A. Sonpar, J. Rodríguez-Baño, P. Retamar-Gentil, N. Zuabi Garcia, A. Hristea, C.M. Niculae, W. Zingg, E. Tacconelli, E. Carrara*

- O0352 11:12 Antibiotic discontinuation in paediatric low-risk febrile neutropenia: a multi-centre randomised trial (eSTOP)**
*N. Mendoza-Palomar** (Barcelona, Spain),
L. Valero-Arrese, B. Espinosa-López, M. Sancosmed-Ron, N. Wörner, S. Melendo-Pérez, M.N. Larrosa-Escartín, M.B. Viñado-Pérez, J. Esperalba-Esquerria, S. Simó-Nebot, P. Mazonza-Roig, A. Faura-Morros, C. Grasa, P. Guerra-García, C. Echeocopar-Parente, E. Cendejas-Bueno, B. Herrero-Velasco, D. Quintero-García, M.T. García-Ascaso, M. González-Amores, P. Soler-Palacin

- O0353 11:24 Efficacy and safety of peri-transplant probiotic supplementation among allogeneic stem cell transplant recipients: a phase IIb randomised controlled trial**
*S. Selvakumar** (Vellore, Tamil Nadu, India), *A. Arumugam, N. Veerasamy, S. Selva Kumar, J.S. John, S. Selvarajan, K. Lakshmi, B. George, P. Rupali*

Scientific Programme

Sunday, 19 April 2026

O0354 11:36 Quantitative assessment of associations between early antibacterial drug exposure and late infective and noninfective complications after allogeneic stem cell transplantation

M. Yakubovsky (Tel-Aviv, Israel), R. Ram, R. Ben-Ami*

O0355 11:48 Infections after invasive biliary procedures in liver transplant recipients: a retrospective single-centre analysis

A. Lombardi (Milan, Italy), A. Tonizzo, L. Alagna, G-E Tontini, M. Michelin, A. Murru, B. Antonelli, G. Viero, A. Celotti, S. Colombo, M. Sagasta, F. Lozio, C. Dibenedetto, V. Scaravilli, P. Lampertico, G. Grasselli, C. Quintini, F. Caprioli, A. Bandera*

SY083 11:00 - 12:00 Hall ICM 1
1-hour Symposium

Can large language models (LLMs) transform clinical diagnostics from start to finish?

Chairs Bram Lestrade (Roermond, Netherlands) Mario Ramirez (Lisbon, Portugal)

S0227 11:00 LLM validation and integration for AST

Christian Giske (Stockholm, Sweden)

S0228 11:30 LLM models in clinical diagnostics: from lab results to patient care

De Vito Andrea (Sassari, Italy)

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), Swiss Society for Microbiology (SSM)

SY084 11:00 - 12:00 Hall ICM 13a
1-hour Symposium

Moving towards patient-centered evidence in infectious diseases

Chairs Colin R. Mackenzie (Neuss, Germany) Luigia Scudeller (Pavia, Italy)

S0229 11:00 Can AI help us to incorporate the patients' perspective into clinical research and guidelines?

Bernardo Sousa-Pinto (Porto, Portugal)

S0230 11:30 Our fight too: empowering patients against AMR

Vanessa Carter (Altrincham, United Kingdom)

Co-organised with: ESCMID Guidelines Subcommittee

SY085 11:00 - 12:00 Hall ICM 13b
1-hour Symposium

Early-life respiratory infections and their association with chronic lung disease

Chairs Susanna Esposito (Parma, Italy) Chrysanthi Skevaki (Marburg, Germany)

S0231 11:00 Long-term impact of early-life exposures including RSV disease on lung function

Shaakira Chaya (Cape Town, South Africa)

S0232 11:30 Rhinovirus infections and asthma in children: mechanisms and at-risk phenotypes

Manuel E. Soto-Martinez (San Jose, Costa Rica)

Co-organised with: International Society of Pediatric Respiratory Diseases (INSPIRED)

SY086 11:00 - 12:00 Hall A1-2
1-hour Symposium

Therapeutic management of carbapenem-resistant Gram-negative infections: where are we globally?

Chairs Yin Mo (Singapore, Singapore) Pranita Tamma (Philadelphia, United States)

S0233 11:00 Treating carbapenem-resistant Enterobacterales in HIC and LMIC

Anupa Thampy (Vellore, Tamil Nadu, India)

S0234 11:30 Beyond Enterobacterales: advances in the management of carbapenem resistant non-fermenters

Michele Bartoletti (Milan, Italy)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Critically Ill Patients (ESGCIPI), European Society of Intensive Care Medicine

SY087 11:00 - 12:00 Hall A3-2
1-hour Symposium

The role of the microbiota in vaccine response

Chairs Zitta Barrella Harboe (Hillerød, Denmark) Ed J. Kuijper (Leiden, The Netherlands)

S0235 11:00 The impact of intestinal microbiota on vaccine response

Petra Zimmermann (Lucerne, Switzerland)

S0236 11:30 Early-life gut microbiome and infant vaccination

Julie Bines (Parkville, Australia)

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), ESCMID Vaccine Study Group (EVASG)

EF058 13:30 - 14:30 Arena 1
 CLN DX TRN ePoster Flash Session

Predicting complications and outcome of sepsis

- Chair* Despoina Koulenti (London, United Kingdom)
- E0403 13:30 The epidemiology of severe clinical manifestations caused by Group A streptococci in Denmark**
 C. Evald-Schelde* (Copenhagen, Denmark), T.B. Johannesen, S. Hoffmann, P.H. Andersen, S. Hermann, Z.B. Harboe, M. Stegger, L.S. Vestergaard, U. Nygaard
- E0404 13:36 Subphenotype and complication-guided adjunctive fosfomycin therapy for *Staphylococcus aureus* bacteraemia: pooled analysis of two randomised trials**
 J. García-Larrauri* (L'hospitalet De Llobregat, Spain), F. Escrhuella-Vidal, J. Carratalà, B. Gutiérrez-Gutiérrez, J. López-Contreras, G. Euba, A. Vázquez, S. Gómez-Zorrilla, L.E. López-Cortés, O. Gasch, E. Aparicio-Minguijón, R. Escudero-Sánchez, M.T. Pérez-Rodríguez, M.D. Rodríguez Pardo, A. Jover-Sáenz, G. García-Pardo, J. Rodríguez-Baño, M. Pujol
- E0405 13:42 *Burkholderia* as a silent antimicrobial resistance driver in lower-middle-income countries: genomic insights from the BALANCE study**
 K.J. Hoog* (Oxford, United Kingdom), R. Farzana, N. Haque, M. Sultana, J.B. Joyee, F. Humayra, M.R. Tasfia, S. Afroj, C. Abdellaoui, R. Zahra, M. Hamza, B. Hassan, K. Shafique, G. Fatima, K. Onjuro, H. Nerima, C.R. Achi, K. Iregbu, P. Nwajiobi-Princewill, I.N. Nwafia, E. Carretto, T.R. Walsh
- E0406 13:48 Development and validation of machine learning models for long-term survival prediction in elderly patients admitted to the intensive care unit for acute respiratory infection: the Genially project**
 J. Herbert* (Tours, France), A. Kassa-Sombo, A. Migeon, L. Platel, C. Salpérier, A. Guillon, L. Grammatico-Guillon
- E0408 14:00 The role of serum cholinesterase levels in monitoring covert immunosuppression in critically ill patients with septic shock: evidence from a monocentric retrospective analysis**
 A. Frattari* (Pescara, Italy), F. Cedrone, E. Polilli, R. Zocaro, P. Fazii, V. Fortunato, G. Parruti

- E0409 14:06 Risk of dementia after bloodstream infection: propensity score matched cohort study**
 J. Underwood* (Cardiff, United Kingdom), D. Farewell, D. Gillespie, A. Akbari, N. Harrison, H. Ahmed
- E0410 14:12 Predicting in-hospital mortality in sepsis patients using machine learning methods in low- and middle-income country (LMIC) settings**
 S. Awan* (Karachi, Pakistan), N. Aziz, Z. Nasim, N. Nasir
- E0411 14:18 Integrated immune and endothelial profiling predicts 90-day mortality in postoperative sepsis and septic shock**
 R.D. Prieto Utrera* (Valladolid, Spain), M. Bardaji-Carrillo, A. García-Concejo, E. Tamayo, D. Bernardo

EF059 13:30 - 14:30 Arena 2
 ePoster Flash Session

Decoding herpesviruses: from bench to bedside

- Chair* Sylviane Defres (Liverpool, United Kingdom)
- E0412 13:30 LY6C+ monocyte derived macrophages contribute to pathological neuroinflammation in herpes simplex encephalitis**
 Q. Xue* (Shanghai, China), Z. Shen
- E0413 13:36 Development of a risk score to predict encephalitis by herpes simplex virus and varicella zoster virus**
 R. Hasbun* (Houston, United States), J. Portugal, A. Heck, P. Bean, R. Habis, J. Probasco, A. Venkatesan
- E0414 13:42 Clinical Determinants of Outcome in Chronic Active Epstein-Barr Virus Infection: Derivation of a Risk Stratification Score**
 Q. Yang* (Shanghai, China), Z. Zhou
- E0415 13:48 CXCL9, CXCL10, and CXCL11: sensitive predictors of acute EBV infection**
 A. Nikcevic* (Zagreb, Croatia), K. Bodulić, S. Židovec Lepej, L. Radmanić Matotek, G. Tešović
- E0416 13:54 Distinguishing clinical significance from latent infection: Establishing mNGS-based EBV diagnostic cut-offs in blood and CSF**
 Y. Cao* (Shanghai, China), X. Li, Y. Qingluan
- E0417 14:00 Using QuantiFERON-EBV to measure EBV-specific T-Cell function in thoracic transplant recipients**
 Y. Zhao* (Groningen, The Netherlands), L. Gard, K. Damman, E. Verschuuren, V.L.B. Coretta

Scientific Programme

Sunday, 19 April 2026

E0418	14:06	Digital PCR enables high-resolution quantification of HCMV UL123 in clinical and experimental samples <i>A.R. Silvain* (Limoges, France), M. Mayeras, E. Guerin, T. Reishig,, O. Bestard, L. Cousi, E. Alezra, A. Koenig, C. Roger, N. Kamar, M. Sester, H. Kaminski, S. Alain</i>	E0424	13:48	Phylogenetic diversity of Mediterranean spotted fever group Rickettsiales: species-level sequencing in a Spanish tertiary hospital (2021–2025) <i>E. Gremaldos Mira* (Valencia, Spain), E. Cortés Giménez, J.M. Sahuquillo Arce, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz</i>
E0419	14:12	Real-world effectiveness of recombinant zoster vaccine in high-risk adult populations in Greece <i>V. Petrakis* (Alexandroupolis, Greece), P. Rafailidis, N. Mpampaka, G. Karagiannis, V. Kyrgiannaki, D. Papapazoglou, P. Panagopoulos</i>	E0425	13:54	Diversity of Rickettsia species identified by Metagenomics in ticks collected from a Brazilian University <i>F. Carvalho* (São Carlos, Brazil), D.S.F. Guedes, G. Montenegro De Campos, A. Sarana Da Silva, C.V.P. Hernandez, B.M. Begalli, L.C. Barci, J.M. Penedo, R.G.D.S. Taliassaqui, T.K.S. Felipe, S.J. Badra, F.D.F. Anibal, S.N. Slavov</i>
E0420	14:18	The recombinant adjuvant zoster vaccine induces similar immune responses in ruxolitinib-treated patients with myelofibrosis and polycythemia vera <i>V. Leguizamon* (Madrid, Spain), B. Astibia-Mahillo, E. Mateos, M. Torres, N. Armenteros, A. Fernández-Chávez, M.C. Luengo-Martínez, N. Daza, M. Coiras, V. García-Gutierrez</i>	E0426	14:00	Epidemiology of toxigenic Corynebacterium ulcerans infections in England <i>K. Harman* (London, United Kingdom), C. Robin, E. Mugwagwa, T. Patel, R. Cordery, D. Litt, S. Neale, A. Mackintosh, D. Chudasama, R. Pudney</i>
<hr/>					
EF060	13:30 - 14:30	Arena 4			
  	ePoster Flash Session				
Zoonotic infections: expect the unexpected					
E0421	13:30	Clinical characteristics and treatment strategies in a cohort of patients with tularemia: a retrospective multi-centre analysis of 65 cases in Germany <i>C. Lübbert* (Leipzig, Germany), B. Arnold, N. Kellner, H. Trawinski, H.M. Orth, D. Tominski, A. Mikolajewska, K. Rothfuss, G. Grupe, D. Ruf, F. Reichert, K. Marx, K. Heuner, D. Jacob</i>	E0427	14:06	First insights into the wild, wild west of Borrelia plasmids <i>S. Hepner* (Oberschleissheim, Germany), R. E. Rollins, E. Mourkas, K. Kuleshov, S. Casjens, W. Qiu, A. Dangel, D. Velázquez, S.Y. Kovalev, A. Wieser, J. Hübner, A. Sing, V. Fingerle, G. Margos</i>
E0422	13:36	Characterisation of tularaemia cases in Southwest Germany and identification of two natural transmission clusters in a clinical high-endemic region Tuniberg/ Kaiserstuhl (TuniKa) <i>D. Hornuss* (Freiburg, Germany), S. Rieg, J. Borde, H. Von Buttlar, V. Goetz, P. Mathé, J. Klein, M. Leibenguth, L. Chitimia-Dobler, A.S. Claus, M. Scherer-Lorenzen, G. Dobler</i>	E0428	14:12	The impact of previous brucellosis treatment on the clinical course of neurobrucellosis: a multi-centre retrospective study <i>O. Evlice* (Van, Türkiye), Y. Ezgi, H. Kır, S. Incecik, D. Ertürk, M. Aydın, A.S. İnal, Y. Çakır, Z. Karazeybek, B.B. Sivrikaya, B. Turaç, E. İnci, S.Y. Kaya, Z. Çelik, A. Şabablı Çetin, I.D. Alırvacı, Ö. Özgen, H. Özüt, M. Çelik, S. Alkan, S. Surme, A. Mert</i>
E0423	13:42	Paediatric tularemia: clinical outcomes and immunological insights from an endemic region in Türkiye <i>K. Aykac* (Ankara, Türkiye), O. Cakici, B. E. Seyrek, İ.C. Yılmaz, O.O. Demir, İ. Evcili, T. Canavar Yıldırım, M. Yıldırım, E.H. Erdeniz, S.Y. Durmus, A. Sahin, S. Ocal Demir, A.B. Cengiz, M. Gürsel, İ. Gürsel, Y. Ozsurekci</i>	E0429	14:18	Early markers of severe leptospirosis in French Amazonia, 2007–2022 <i>L. Epelboin* (Cayenne, French Guiana), P. Le Turnier, M. Zenou, A. Fremery, H. Kallel, N. Higel, A. Kpangon, P. Abboud, F. Djossou, M. Boutrou, M. Nacher</i>

EW095 13:30 - 15:30 Hall ICM 13b
 DX PHEI 2-hour Educational Session

Updates on emerging and re-emerging vector-borne viral infections

- Chairs* Xavier Lescure (Paris, France)
 Alfonso J. Rodriguez-Morales (Pereira, Colombia)
- W0220 13:30 **Global epidemiological situation and diagnostic challenges of vector-borne viral infections**
 Marta Giovanetti (Rome, Italy)
- W0221 13:50 **Translational advances about West Nile virus**
 Anna Papa-Konidari (Thessaloniki, Greece)
- W0222 14:10 **Oropouche virus and its emergence**
 Felipe Naveca (Manaus, Brazil)
- W0223 14:30 **Changing epidemiology of Dengue: a global outlook**
 Gathsaurie Neelika Malavige (Nugegoda, Sri Lanka)

Co-organised with: SBI, Colombian Association of Infectious Diseases, Latin American Society for Travel Medicine, API, Dominican Society of ID, Ecuadorian Society for MM and Pediatric ID, ESCMID EIS, ESCMID SAS

FO096 13:30 - 14:30 Arena 3
 PRO Open Forum

Communicating science today: new media, new platforms

- Chair* Angela Huttner (Geneva, Switzerland)
- F0224 13:30 **Influencing in infectious diseases and clinical microbiology: tweet or fly?**
 Neil Stone (London, United Kingdom)
- F0225 13:40 **Starting and sustaining a podcast**
 Erin McCreary (Pittsburgh, United States)

Co-organised with: CMI Communications Board of Editors

JS002 13:30 - 14:30 Hall ICM 5
 Journal Session

Late-breaking research from CMI & CMI Comms - On invasive infections and antimicrobial resistance

- Chairs* Andre Kalil (Omaha, United States)
 Anne-Grete Mårtson (Leiden, Netherlands)
- J0005 13:30 **Estimating antibiotic resistance following antibiotic treatment in outpatients: a retrospective study**
 Michal Chowers (Kfar-Saba, Israel)

J0006 13:40 **Clinical utility of the DENOVA score for predicting infective endocarditis in *Enterococcus faecalis* bacteraemia: external validation with decision curve analysis**
 Benedetta Varisco (Milan, Italy)

J0007 13:50 **Challenges in nasal and throat microbiota composition during and after mupirocin and chlorhexidine decolonisation treatment in asymptomatic MRSA carriers: a longitudinal observational study**
 Sofie Marie Edslev (Copenhagen, Denmark)

J0008 14:00 **A multicentre evaluation of metagenomic sequencing for pathogen detection in central nervous system infections**
 Rui Zhang (Beijing, China)

J0009 14:10 **Prevalence of submicroscopic malaria parasitemia among migrant pregnant women: a prospective cohort study**
 Léa Docquier (Brussels, Belgium)

J0010 14:20 **Antenatal corticosteroid treatment and infectious diseases in children and adolescents aged 5-16 years**
 Katri Räikkoönen (Helsinki, Finland)

ME093 13:30 - 14:30 Hall ICM 1
 ANT CLN IPC Meet-the-Expert

Novel therapeutics for *C. difficile* infection

- M0216 13:30 *Eugenie Basseres (Houston, United States)*
- M0217 13:42 *Marek Duricek (Prague, Czechia)*

Co-organised with: ESCMID Study Group for Clostridioides difficile (ESGCD)

ME094 13:30 - 14:30 Hall ICM 13a
 CLN PED Meet-the-Expert

Recent evidence on the role of steroids in paediatric bacterial infections: focus on meningitis and pneumonia

- M0218 13:30 *George A. Syrogiannopoulos (Larissa, Greece)*
- M0219 13:42 *Susanna Esposito (Parma, Italy)*

Scientific Programme

Sunday, 19 April 2026

OS054 13:30 - 14:30 Hall B0-2
 AMR DX TRN 1-hour Oral Session

Harnessing artificial intelligence against AMR

Chairs *Fusun Can (Istanbul, Türkiye)*
Lorena Lopez Cerero (Seville, Spain)

00398 13:30 **A machine-learning workflow to investigate cefiderocol uptake defects arising from mutations in the siderophore receptor**

M. Mohammad (Stockholm, Sweden), M. Razavi, C. Tellapragada, C.G. Giske*

00399 13:42 **Prediction of bacterial antimicrobial resistance based on resistance determinants and whole genome annotation neural networks algorithms**

M.R. Pulido (Seville, Spain), F. Sola, D. Ayala, L. Monge-Olivares, R. Ayala, I. Portillo-Calderón, I. Hernández, D. Ruiz, L. López-Cerero*

00400 13:54 **Seven loci, one threat: Decoding and predicting azithromycin resistance in *Neisseria gonorrhoeae* with machine learning**

M. Krishna (Oxford, United Kingdom), F. Rudi, A. Unitt, K. Jolley, O. Harrison*

00401 14:06 **Domain-aware vs machine-learning imputation for sparse antimicrobial susceptibility data**

F. Mutisya (Strasbourg, France), C. Moore, M. Raad, K. Taylor, S. Alavi, T. Yokoyama, S. Boujaafar, P. Berger, C. De Turckheim*

00402 14:18 **Predicting risk of multidrug-resistant tuberculosis using long short-term memory (LSTM) and multimodal programmatic data in the Philippines**

M.I. Saldaña (Metro Manila, Philippines), I.P. Mendoza, G.D. Sison, R. Destura, M. Kato-Maeda, F. Jiang, K.E. Henson, R. Basilio, J-E. Bascuña*

OS055 13:30 - 14:30 Hall A2-1
 AMR PHEI 1-hour Oral Session

Susceptibility testing of phages

Chairs *Annika Yanina Classen (Cologne, Germany)*
Marjolein Hensgens (Utrecht, Netherlands)

00393 13:30 **Mechanisms of phage-driven resensitisation to aztreonam/avibactam in *Escherichia coli***

C. Tellapragada (Stockholm, Sweden), M. Razavi, S. Patpatia, A. García Navarro, A.M. Örmälä-Tiznado, C.G. Giske*

00394 13:42 **Impact of Antimicrobials on Bacteriophage-Host Interactions in *Pseudomonas aeruginosa***
Y. Chikhani (São Paulo, Brazil), C. Siqueira, C. Rubio, R. Farzana, E. Portal, K. Sands, O. Spiller, A. Gales, W. Martins*

00395 13:54 **Two years (2024–2025) of bacteriophage susceptibility testing of bacterial isolates from persistent bacterial infections: results from the Israeli Phage Therapy Centre**

R. Braunstein (Jerusalem, Israel), O. Yerushalmy, L. Khalifa, A. Rimon, S. Copenhagen-Glazer, R. Hazan, R. Nir-Paz*

00396 14:06 **Tigecycline-selected tyrosine kinase mutation in *Klebsiella pneumoniae* triggers metabolic rewiring and increased phage susceptibility without affecting virulence**

N.N. Rakhi (Oxford, United Kingdom), A.K. Lankapalli, W. Martins, T. Lanyon-Hogg, T.R. Walsh*

00397 14:18 **Broth microdilution-based phage/antibiotic synergy in Gram-negative pathogens**

A.M. Örmälä-Tiznado (Stockholm, Sweden), A. Williamson, E. Loo, S. Patpatia, C. Tellapragada, C. Giske*

OS056 13:30 - 14:30 Hall A2-2
 CLN PHEI 1-hour Case Session

Not the consult I expected this morning...

Chairs *Flaminia Olearo (Berlin, Germany)*
Ryan Rego (Ceske Budejovice, Czechia)

00383 13:30 **Hidden pathogen: *Mycoplasma hominis* as the cause of a prosthetic vascular infection**

M. Bettencourt Silva (Lisbon, Portugal), A. Duarte, A.L. Silva, A. Lopes, P. Amorim, L. Mendes Pedro, L. Mendonça, D. Mendes Pedro*

00384 13:41 **Non-typhoidal *Salmonella* Brain Abscesses in a Newly-Diagnosed HIV Patient: A Case Report**

E.K. Barreda (Metro Manila, Philippines), A. Estuart, C. Valdez, M.F. Tayzon, M. Sanieł*

00385 13:52 **A Novel Case of Non-Imported *Rickettsia Akari* Infection in Ireland**

T. Coyne (Dublin, Ireland), A. Brown*

00386 14:03 **When you hear hoofbeats, sometimes it's camels not horses**

J. Anderson (Edinburgh, United Kingdom), E. Vink, S. Woolley, J. Jervis, R. Sutherland*

00387 14:14 Identification of *Pigmentibacter ruber* in the peripheral blood of a drowning patient: a case report and literature review
*H. Jiang** (Changsha, China), *L. Xie, T. Li*

OS057 13:30 - 14:30 Hall A3-2
 ANT CLN
 1-hour Case Session

Mind your Ps - PK/PD

Chairs *Linda Aulin* (Leiden, Netherlands)
Joseph Meletiadis (Athens, Greece)

00388 13:30 PK/PD-optimised eravacycline for vancomycin-resistant *Enterococcus faecium* in a liver transplant recipient
*J. Qu** (Changsha, China)

00389 13:41 Therapeutic drug monitoring-guided antimicrobial optimisation in thoraco-omphalopagus twins with partially shared hepatic circulation undergoing surgical separation
*B. Monti** (Monza, Italy), *A. Mesini, E. Ricci, M. Mariani, G. Mattioli, F. Palo, G. Cangemi, A. Cafaro, C. Saffioti, A. Wolfler, G. Spiga, E. Castagnola, A. Moscatelli*

00390 13:52 First clinical case of aztreonam/avibactam during venovenous ECMO support: is standard dosing adequate?
*A. Pau Parra** (Barcelona, Spain), *S. Luque, L. Doménech Moral, M. Martínez Pla, X. Nuvials, M. Sosa, I. Los-Arcos, A. Conto, F. Lasteros, E. Gallart, O. Castillo, A. Sánchez, S. Garcia, E. Del Barrio, M.Q. Gorgas Torner, R. Ferrer, J. Riera*

00391 14:03 TDM-guided antibiotic therapy in a patient with recurrent *Listeria monocytogenes* meningitis and augmented renal clearance (ARC): from hospitalisation to oral home therapy
*D. Aquilino** (Naples, Italy), *P. Grimaldi, L. Alessio, S. De Pascalis, C. Ricozzi, K. Gjeloshi, S. Imbriani, M. Macera, C. Monari, L. Onorato, M. Pisaturo, N. Coppola*

00392 14:14 Virological failure of long-acting cabotegravir/rilpivirine: a multifactorial case involving low drug exposure, high viral reservoir and rapid weight loss
*A. Andrianaki** (Zurich, Switzerland), *P. Thoueille, C. Marzolini, M. Huber, H.F. Günthard, I.A. Abela*

SEL 13:30 - 15:30 Hall ICM 14
 Special Session

Selective Pressure

Chairs *Niessen Annabel* (Utrecht, Netherlands)
Jacob Moran-Gilad (Beer Sheva / Jerusalem, Israel)
Josh Nosanchuk (Bronx, United States)
José Ramón Paño-Pardo (Zaragoza, Spain)
Jesús Rodríguez-Baño (Seville, Spain)
Anja Šterbenc (Ljubljana, Slovenia)
David Van Duin (Chapel Hill, United States)

SY091 13:30 - 15:30 Hall B0-1
 AMR IPC
 2-hour Symposium

Screening for multidrug-resistant pathogens in various populations: are we doing good?

Chairs *Rita Ng* (Hong Kong, Hong Kong)
Spyros Pournaras (Athens, Greece)

S0210 08:30 Rectal screening and perioperative prophylaxis
Elda Righi (London, United Kingdom)

S0211 09:00 Implications of positive MDR bacterial screen for clinical practice: algorithm for treatment
Marco Falcone (Pisa, Italy)

S0212 09:30 Screening for MDR bacteria and *Candida auris*: lab methods
Yesim Besli (Istanbul, Türkiye)

S0213 10:00 Rectal screen for MDR bacteria in haematological and solid organ transplant patients
Michael Satlin (New York, United States)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Infections in the Elderly (ESGIE)

Scientific Programme

Sunday, 19 April 2026

SY092 13:30 - 14:30 Hall A3-1
PHEI 1-hour Symposium

Fungi in the flow: wastewater as a hidden threat

Chairs *Mihai Mares (Iasi, Romania)*
Esther Segal (Tel Aviv, Israel)

S0214 13:30 **New EU wastewater directive: why fungi must be included**
Joao Brandao (Lisboa, Portugal)

S0215 14:00 **Candida and Aspergillus in the environment: resistance starts here**
Monika Novak Babič (Ljubljana, Slovenia)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), European Confederation of Medical Mycology (ECMM), Israel Society for Medical Mycology (ISMM), Portuguese Society of Infectious Diseases and Clinical Microbiology, Romanian Society for Medical Mycology and Mycotoxicology (SRMMM), Hellenic Society of Medical Mycology, Spanish Study Group for Medical Mycology of SEIMC (GEMICOMED)

EF066 14:45 - 15:45 Arena 1
DX ePoster Flash Session

The escalating problem of antifungal resistance

Chair *Ana Alastruey (Madrid, Spain)*

E0455 14:45 **Azole fungicides promote C. auris resistance to manogepix: a new One Health concern**
A. Bouillier (Poitiers, France), A. Baillod, J. Moreau, S. Marchand, J. Clarhaut, K. Brunet*

E0456 14:51 **Clonal Emergence and Mechanistic Insights into Amphotericin B Resistance in Candida auris from Indian Hospitals**
P. Kagra (Delhi, India), S. Yadav, N. Shukla, K. Jain, S. Srivastava, S.L. Kelly, M.F. Alomair, D.C. Lamb, N. Chauhan, A. Chowdhary*

E0457 14:57 **Clinically relevant gene flow leads to substantial loss of antifungal susceptibility in a rare invasive fungal pathogen**
R. Dai (Beijing, China), Y. Huang, Y. Xu, M. Zhou, M. Xiao*

E0458 15:03 **Epidemiological trends and genomic insights from national surveillance of Candida auris in Singapore**
K.N. Sein Tun (Singapore, Singapore), G. Lee, B. Tan, G. Toh, X.Y. Ong, L. Cui, M. Ang, Z. Said, C. Huang, K. Marimuthu*

E0459 15:09 **Detection of fluconazole resistant C. parapsilosis clinical isolates bearing both Y132F and S862C substitutions at MALDI-TOF analysis**
I. Franconi (Pisa, Italy), B. Tuvo, L. Maltinti, M. Falcone, L. Mancera, A. Lupetti*

E0460 15:15 **Tandem gene duplications driven rising azole resistance in expanding Candida orthopsilosis population**
Y.T. Ning (Beijing, China), R.C. Dai, Y.C. Xu, T.S. Sun, L. Zhang*

E0461 15:21 **Nationwide multi-centre surveillance of species distribution and antifungal resistance in Candida and Candida related-bloodstream isolates in Brazil (2023-2025)**
F. Guinsburg Hamburger (São Paulo, Brazil), F. De Camargo Ribeiro, K. Rosa Fernandes Beraldo, R. Tigulini De Souza Bogo, A.L. De Abreu, A.P. D'Alincourt Carvalho Assef, J. Nóbrega De Almeida Júnior, A.L. Colombo*

E0462 15:27 **Unique genetic clades and frequent zoonotic transmission of Sporothrix brasiliensis with reduced itraconazole susceptibility**
E.F.J. Meijer (Nijmegen, Netherlands), M. Orzechowski Xavier, M. Rodrigues Trápaga, B. Spruijtenburg, J. Estefânia Dávila Hidalgo, B. Jacomel, I. Martins Madrid, D. Isabel Brayer Pereira, A. Souza Mattei, A. Reis Gomes, R. Osório De Faria, F. Silveira, C. Bittencourt Severo, V. Rodrigues Aquino, A. Paula Giolo Franz, S. De Ávila Botton, R. Maria Zancopé-Oliveira, V. Rodrigues Poester, T. De Groot*

E0463 15:33 **High triazole resistance rates of Aspergillus fumigatus in Belgian composting facilities**
L. Cuypers (Leuven, Belgium), L. Vinken, R. Merckx, A. Reséndiz-Sharpé, G. Vande Velde, K. Lagrou*

EF067 14:45 - 15:45 Arena 2
AMR IPC PED ePoster Flash Session

Infection control and antimicrobial stewardship in neonatal and pediatric critical care

Chair *Irja Lutsar (Tartu, Estonia)*

E0464 14:45 **Colonisation pressure is associated with infant acquisition of ESBL genes on the neonatal unit**
A. Cook (London, United Kingdom), M. Berkell, D.R.M. Smith, H. Van Werkhoven, E. Sieswerda, C. Minotti, L. Van Heirstraeten, S. Malhotra-Kumar, J.A. Bielicki*

E0465 14:51 **First report of a neonatal intensive care unit outbreak linked to *Serratia sarumanii* in Latin America: insights from WGS and IR Biotyper**
*P. Orlandi Barth** (Porto Alegre, Brazil), *W. Latosinski Matos*, *L. Lutz*, *L. Rita Konkewicz*, *D. Castro Pereira*, *L. Czekster Antochevis*, *J.V. Barboza Cardoso*, *L. Quadro Stein*, *A.L. Barth*, *A. Francisco Martins*

E0466 14:57 **Infection prevention surveillance across 29 neonatal units: Methods and initial analyses from the NeolPC Surveillance Network**
*G. Karadağ** (Berlin, Germany), *A. Bekker*, *A. Dramowski*, *B. Loureiro*, *J. Pérez López*, *J.I. Pijoan Zubizarreta*, *P.T. Heath*, *B. Piening*

E0467 15:03 **What do surveillance cultures really tell us in neonates?**
*P. Favier** (Valencia, Spain), *P. Suarez-Urquiza*, *A. Valentín-Martín*, *A. Pinilla-González*, *M. Marco-Plá*, *M. Gomis-Sánchez*, *E.M. González-Barberá*, *M. Cernada-Badía*

E0468 15:09 **Rapid Nanopore sequencing and Average Nucleotide Identity (ANI) to guide a *Serratia marcescens* complex outbreak in a neonatal ward**
*R. Sierra** (Geneva, Switzerland), *C. Cave*, *L. Munoz*, *C. Ougier Riccio*, *A. Borghesi*, *R. Pfister*, *N. Buetti*, *D. Andrey*

E0469 15:15 **Searching for the needle in the haystack with the right lens: impact of chromogenic *Serratia* spp. agar to neonatal ICU surveillance**
*P. Favier** (Valencia, Spain), *P. Suárez-Urquiza*, *A. Valentín-Martín*, *A. Pinilla-González*, *M. Marco-Plá*, *M. Gomis-Sánchez*, *M. Cernada-Badía*, *E.M. González-Barberá*

E0470 15:21 **The caveats and (im)possibilities of tracking outbreaks directly from swabs in neonates**
*S. Ayala Montaña** (Freiburg, Germany), *A.O. Afolayan*, *I.J. Akintayo*, *R. Kociurzynski*, *L. Duarte Dos Santos*, *C. Schneider*, *T. Nguyen*, *M. Kuntz*, *H. Fuchs*, *G.A. Häcker*, *S. Reuter*

E0471 15:27 **Impact of BARNARDS II: Introduction of Standard Diagnostic Protocols on Antibiotic Stewardship and Neonatal Outcomes in a NICU**
*S. Fatima** (Islamabad, Pakistan), *S. Riaz*, *M.A. Khan*, *S. Naqvi*, *R. Zahra*, *E. Rashid*, *K. Thomson*, *T. Walsh*, *B. Hassan*

E0472 15:33 **Cefiderocol use in paediatric intensive care and neonatal intensive care units: real-world use, safety, and clinical outcomes in a tertiary hospital**
*A. Estevez Prieto** (Madrid, Spain), *F. Camero*, *J. Serrano-Lobo*, *C. Redondo Galán*, *M. Slöcker-Barrío*, *E. Zamora-Flores*, *M. Sánchez-Luna*, *P. Muñoz*

EF068 14:45 - 15:45 Arena 3
 ePoster Flash Session

Saving lives, preserving antibiotics: stewardship in the ICU

Chair *Bhanu Sinha* (Groningen, Netherlands)

E0473 14:45 **Beyond acceptance rates: What makes antimicrobial stewardship work in intensive care?**
*S. Camilleri** (Melbourne, Australia), *S. Khumra*, *A. Thomas*, *S. Vogrin*, *A. Batrouney*, *M. Devchand*, *S. Motaganahalli*, *S.J. Warrillow*, *J.A. Trubiano*, *G.K. Reynolds*, *S. Narayanasamy*

E0474 14:51 **Antimicrobial Stewardship Implementation Across Intensive Care Units: Insights from a National Survey**
*A. Van Boekel** (Leiden, Netherlands), *B. Bolhuis*, *R. Bentvelsen*, *C. Van Den Berg*, *L. Van Bodegom-Vos*, *N. Deetman*, *D. Dongelmans*, *W. Falkenburg*, *E. Van De Garde*, *J. Haringman*, *E. De Jong*, *M. Lambregts*, *D. De Lange*, *J. Schouten*, *C. Den Uil*, *S. Arbous*, *M. De Boer*, *J. Van Paassen*

E0475 14:57 **Optimising Intravenous to Oral antibiotic switch in Intensive care units: A multi-site audit using UKHSA IVOS criteria across three West Midlands NHSTrusts**
*N. Agravedi** (Birmingham, United Kingdom), *A. Jenkins*, *A. Brush*, *S. Gilani*

E0476 15:03 **Optimising Prospective Audit Feedback (PAF): Hybrid approach combining AI2D (Augmented Intelligence in Infectious Diseases) and Rule-Based algorithm**
*Y. Zhou** (Singapore, Singapore), *J.L. Lim*, *S. Tang*, *J.S. Chung*, *Y.B. Wang*, *A. Kwa*

E0477 15:09 **Beyond the 'antibiotic police': ICU clinicians' perspectives on effective antimicrobial stewardship communication**
*S. Khumra** (Melbourne, Australia), *S. Camilleri*, *A. Thomas*, *A. Batrouney*, *M. Devchand*, *S. Motaganahalli*, *S. Warrillow*, *J. Trubiano*, *G. Reynolds*, *S. Narayanasamy*

Scientific Programme

Sunday, 19 April 2026

E0478	15:15	<p>Long-term impact of a high-intensity multimodal antimicrobial stewardship programme on broad-spectrum antibiotic consumption and resistance in an adult intensive care unit: an interrupted time series analysis (2013–2025)</p> <p><i>G. Roncancio Villamil* (Medellin, Colombia), A.A. Pineda-Florez, D.A. Diaz-Ospina, A.R. Vargas-Garcia, A.M. Montoya-Duque, C.I. Garcia-Rincon, C.G. Garces-Zamudio</i></p>	E0485	15:03	<p>Neural network-based predictions of antimicrobial resistance phenotypes in multidrug-resistant <i>Acinetobacter baumannii</i> from whole genome sequencing and gene expression</p> <p><i>H. Jia* (Hangzhou, China), X. Li, Y. Zhuang, Q. Yang, Z. Ruan</i></p>
E0479	15:21	<p>Overcoming implementation challenges: achieving sustained excellence in antimicrobial prescribing through prospective audit and feedback in intensive care units</p> <p><i>N. Sandoval* (Guatemala, Guatemala), G. Ozaeta, G. Reyes, C. Karla, P. Abdi, C. Alessandra</i></p>	E0486	15:09	<p>Predicting genomics-based antibiotic susceptibilities and treatment-emergent resistance in <i>Acinetobacter baumannii</i></p> <p><i>K. Hall* (San Diego, Ca, United States), E. Solares, L. Bledsoe, L. Williams, R. Shields</i></p>
E0480	15:27	<p>Reassessing risk in critical illness: antibiotic de-escalation remains a safe practice without increasing adverse events or mortality</p> <p><i>M. Inan Hekimoğlu* (Ankara, Türkiye), E. Gülten, E.M. Sarıcaoglu, A.H. Elhan, F. Yörük</i></p>	E0487	15:15	<p>stackPred: AI boosted AMR phenotype prediction for multiple species and antimicrobial agents</p> <p><i>J. Welling* (Essen, Germany), M. Balzer, L. Consten, S. Bletz, J. Buer, V. Chapot, D. Harmsen, E. Heintschel Von Heinegg, A. Mellmann, W. Pölkling, F. Salhöfer, F. Schaumburg, N. Scherff, N. Wiesmann, F. Meyer</i></p>
E0481	15:33	<p>Effect of clinical pharmacist-led antibiotic optimisation in a resource limited tertiary ICU in South India lacking dedicated infectious disease physician support</p> <p><i>A. Mohamed Mohideen* (Chengalpattu, India), D. Ganesh, F. Jose, S. Kurian Mathew, M. George</i></p>	E0488	15:21	<p>Interpretable Machine Learning Predicts Antimicrobial Resistance and Reveals Regulatory Mechanisms in ESKAPEE Pathogens</p> <p><i>A. Skoulakis* (Lamia, Greece), K. Daniilidis, S. Digenis, C.G. Gkoutinoudis, E. Petinaki, A. Hatzigeorgiou</i></p>
E0489	15:27		E0489	15:27	<p>MicroBIS: a novel artificial intelligence and machine learning-based digital platform for rapid bacterial identification and antimicrobial resistance prediction to strengthen diagnostics, clinical decision-making, and surveillance in resource-limited healthcare settings across Africa</p> <p><i>A.M. Martin* (Nairobi, Kenya), D. Otieno, K. Sam</i></p>
E0490	15:33		E0490	15:33	<p>A scalable machine learning-based approach to enhance AMR surveillance in LMICs</p> <p><i>T. Agboeze* (Ibadan, Nigeria), O. Daramola, R. Adedeji, A. Akomolafe</i></p>
<hr/>					
EF069	14:45 - 15:45	Arena 4			
<div style="display: flex; gap: 5px;"> <div style="background-color: #800040; color: white; border-radius: 10px; padding: 2px 5px; font-size: 0.8em;">ANT</div> <div style="background-color: #4B0082; color: white; border-radius: 10px; padding: 2px 5px; font-size: 0.8em;">DX</div> </div>		ePoster Flash Session			
AI-powered pathogen detection and AMR prediction					
<p><i>Chair</i> <i>Belen Rodriguez-Sanchez (Madrid, Spain)</i></p>					
E0482	14:45	<p>Leveraging machine learning for predicting urine culture outcomes: a multi-centre prospective study</p> <p><i>Q. Yi* (Beijing, China), X. Zhou, Y. Guo, Y.C. Xu</i></p>			
E0483	14:51	<p>Pilot study for the differentiation of <i>Clostridium botulinum</i> group I and <i>Clostridium sporogenes</i> using MALDI-TOF MS and unsupervised machine learning</p> <p><i>F. Dematheis* (Munich, Germany), R. Schneider, D. Amort, H. Von Buttler, S. Zange</i></p>			
E0484	14:57	<p>A data-driven framework for <i>Streptococcus pneumoniae</i> serotype prediction from mass spectrometry profiles</p> <p><i>J. Zintgraff* (Barracas, Argentina), N. Sánchez Eluchans, M.A. Moscoloni, C.S. Lara</i></p>			

ME098 14:45 - 15:45 Hall ICM 1
 AMR DX Meet-the-Expert

What's new in Antimicrobial Susceptibility Testing (AST)

M0247 14:45 Erika Matuschek (Växjö, Sweden)

M0248 14:57 Rafael Canton (Madrid, Spain)

Co-organised with: EUCAST Steering Committee

ME099 14:45 - 15:45 Hall B0-2
 PHEI Meet-the-Expert

Pathogens and people: modelling epidemics for preparedness

M0249 14:45 William Hanage (Boston, United States)

M0250 14:57 Vittoria Colizza (Paris, France)

OS061 14:45 - 15:45 Hall ICM 13a
 PRO 1-hour Oral Session

AI applications in CM/ID: speaking the new language (model)

Chairs Riina Richardson (Manchester, United Kingdom)
 Bernardo Sousa-Pinto (Porto, Portugal)

O0450 14:45 **Assessing Large Language Model (LLM) performance in abstract screening for an infection-focused systematic review with >16,000 records**
 D. Ashiru-Oredope* (London, United Kingdom), O. Quinn, G. Shannon, H. Ollie, L. Timothy, F. Felix, H. Joshua, L. Leo, N. Toby

O0451 14:57 **Development of an ESCMID Global AI-based abstract categorisation tool**
 G. De Angelis* (Basel, Switzerland), E. Dexter, J. Moran-Gilad

O0452 15:09 **AI-Assisted Infectious Disease Consultation: Concordance Analysis Between a Custom GPT Model and Specialist Recommendations**
 S. Karunakara Ramesh* (Tamil Nadu, India), K. Sarika, D. Suresh Kumar, M. Indumathi, B. Rithik Dharan

O0453 15:21 **Performance of large language models in management of complex infectious diseases cases**
 A. Pradhan* (Oxford, United Kingdom), B.J. Waxse, W. Matias, K. Bowman, C. Nutt, S. Mercaldo, S. Kanjilal, J. Hillis

O0454 15:33 **Multimodal artificial intelligence using entire electronic health record and complete pathogen genome data to predict clinical outcomes from life-threatening infection: the SuperbugAI platform**
 A. Peleg* (Melbourne, Australia), S. Tyagi, Y. Ramakrishnaiah, J. Hawkey, J. Wisniewski, T. Christian, V. Sikiric, G. Webb, C. Bain, J. Song, A. Stewardson, T. Peel, N. Macesic

OS062 14:45 - 15:45 Hall ICM 5
 CLN PHEI 1-hour Case Session

Puzzling parasites

Chairs Rodrigo Gurgel-Gonçalves (Brasília, Brazil)
 Tin Tin Myaing (Bangkok, Thailand)

O0435 14:45 **Rapidly progressive parasitic meningoencephalitis: diagnostic challenges**
 C. Silva* (Vila Nova De Gaia, Portugal), A. Silva-Pinto, A.S. Santos, C. Gonçalves, R. Baptista, A. Ferreira, S. Xerinda, L. Andrade, J. Ganicho, P. Figueiredo, A. Sarmento, A. Costa, C. Reis, S. Rebelo, S. Guimarães, L. Santos

O0436 14:56 **Double trouble in the liver: amoebic and staphylococcal abscess in a Belgian MSM without travel history**
 M. Moretti* (Jette, Belgium), N. M'rabet, K. Demeyer

O0437 15:07 **Eosinophilic liver abscess caused by invasive Fasciola**
 B. Uadomsataporn* (Bangkok, Thailand), O. Putharoen

O0438 15:18 **Learning from the unusual: three autochthonous paediatric cases of Entamoeba histolytica colitis in Southern Italy suggesting a new challenge for clinical practice and public health**
 R. Astorri* (Casamassima (bari), Italy), M. Bartiromo, R. Melone, A. Di Martino, P. Marzuillo

O0439 15:29 **Reactivation of Trypanosoma cruzi with medullary tropism: an unexpected turn in a patient with HIV**
 J.I. Mateo-Gonzalez* (Valencia, Spain), M. Garcia-Rodriguez, M. Martinez-Serrano, M.D. Ocete-Mochon, V. Abril-Lopez-De-Medrano, E. Ballester-Belda, C. Ricart-Olmos, M. Garcia-Deltoro

Scientific Programme

Sunday, 19 April 2026

OS063 14:45 - 15:45 Hall A2-1
 ANT CLN PHEI 1-hour Case Session

Malicious *Mycobacteria*

Chair Raquel Duarte (Porto, Portugal)
 TBA

O0430 14:45 Donor-derived renal allograft tuberculosis detected by plasma metagenomic sequencing in two kidney transplant recipients

A. Diaz Arumir Vergara*
 (Jackson, United States)

O0431 14:56 Leprosy in an Indonesian patient diagnosed after childbirth in a tertiary hospital in Germany

A. Frenz* (Dresden, Germany),
 R. Kardashi, K. De With, S. Meisterfeld,
 P. Spornraft-Ragaller

O0432 15:07 XDR-Tuberculosis meningitis in patient with advanced HIV infection: therapeutic challenge with limited treatment options

M. Schiuma* (Milan, Italy), F. Fama,
 A. Piubello, F. Saluzzo, D. Bernasconi,
 M. Schiavini, A. Covizzi, B. Caloni, D. Zizzo,
 D. Maddalena, M. Bognetti, A. Rizzo,
 F. Salari, A. Civati, M. Galimberti, A. Riva,
 S. Antinori, D. Cirillo, A. Gori, A. Torre

O0433 15:18 An unexpected case of disseminated MAC infection in a non-HIV immunocompromised thymoma patient

L. Vos* (Utrecht, Netherlands), A. Bruns

O0434 15:29 *Mycobacterium riyadhense*: a rare emerging NTM in a TB endemic country

B. Kumar* (Jodhpur, India), A. Sarangal,
 D. Meena, N. Midha, G. Bohra

OS064 14:45 - 15:45 Hall A2-2
 CLN TRN 1-hour Oral Session

Rattle my bones - bone and joint infections

Chairs Parham Sendi (Bern, Switzerland)

Andrej Trampuz (Brisbane, Australia)

O0440 14:45 Validation of the KLIC score and development of a new predictive model in a multi-centre cohort of prosthetic joint infections treated with debridement and implant retention

G. Zumbo* (Seville, Spain), I. Martínez
 Alemany, J.M. Bravo Ferrer, I. Nieto Diaz
 De Los Bernardos, J. Praena, A. Del Arco,
 N. Enrique, C.D. Juan Enrique,
 B. Francisco, C. Natera, A. Romero
 Palacios, B. Sobrino, J. Rodriguez Baño,
 M.D. Del Toro Lopez

O0441 14:57 Hypoxia-driven *sdhB*-mediated antibiotic tolerance impairs prophylactic antibiotics against MRSA in a mouse prosthetic joint infection model

O. Gordon* (Jerusalem, Israel)

O0442 15:09 The use of [¹⁸F]FDG-PET/CT and magnetic resonance imaging in the diagnosis of pyogenic vertebral osteomyelitis secondary to *Staphylococcus aureus* bacteraemia

I. Johansen* (Odense C, Denmark), S. Olaf
 Lindvig, T. Benfield, I. Pedersen, S. Hess,
 F. Rosenvinge, M. Kehrer

O0443 15:21 Fatty acid profiling of biofilms formed by *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*

E. Torrecilla-Sádaba* (Madrid, Spain),
 D. Carrizo-Gallardo, L. Sánchez-García,
 L. Salar-Vidal, J. Esteban, J.J. Aguilera-
 Correa

O0444 15:33 Investigation of *Staphylococcus aureus* infections in human-derived musculoskeletal *ex vivo* tissue slices

K. Strenger* (Basel, Switzerland),
 M. Morgenstern, M. Clauss, R. Küh,
 A.K. Woischnig, L. Sauteur, D. Bumann,
 N. Khanna

OS065 14:45 - 15:45 Hall A3-1
 AMR CLN IPC 1-hour Oral Session

Engineering the gut microbiome: new therapeutics and clinical practice

Chairs Markus Arnoldini (Zürich, Switzerland)
 Fidelma Fitzpatrick (Dublin, Ireland)

O0445 14:45 Randomised double-blinded clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin vs placebo in the prevention of recurrence of *Clostridioides difficile* infection in patients receiving systemic antibiotic therapy (PREVANTRIAL)

R. San-Juan* (Madrid, Spain), J. Origüen,
 M. Fernández-Ruiz, K. Campion,
 J.T. Silva, F. Lopez-Medrano, J. Villa,
 B. Diaz-Pollan, A. Callejas, G. Candela,
 J. Boan, E. Aparicio-Minguíjon,
 M.A. Perez-Jacoiste, I. Rodriguez-Goncer,
 C. Martin-Arriscado, M. Martinez-Uña,
 J.M. Ferrari, J.M. Aguado

O0446 14:57 Longitudinal tracking of microbial restoration after faecal microbiota transplantation (FMT)

D. Guevara Nuñez* (Barcelona, Spain),
 P. Camps-Massa, L. Saiz-Escobedo,
 A. Carrera-Salinas, S. Antón, J. Orbitg,
 M. Bonilla, A. González-Díaz, C. Arajol,
 J. Guardiola, M.A. Domínguez, S. Martí

- O0447 15:09 VE707, a live biotherapeutic product, reduces intestinal vancomycin resistant enterococci in a murine model of pathogen colonisation**
G. Medlock (Cambridge, United States), C. Russell, C. Felix, W. Alsharif, L. Cornacchione, M. Schinn, A. Watson, S. Bedard-Shurtleff, J. Norman, J. Faith, E. Kuijper, B. Olle, S. Caballero*
- O0448 15:21 Single-donor lyophilised encapsulated faecal microbiota transplant (cFMT) supports home dosing with dose-to-dose heterogeneity driven by inter-donor microbiome differences**
B. Merrick (Harrow, United Kingdom), D. Prossomariti, N.M.M. Zain, B. Forbes, C. Sergaki, S.D. Goldenberg*
- O0449 15:33 Clostridioides difficile infection recurrence and antibiotic utilisation following treatment with Food and Drug Administration-approved faecal microbiota products: a multi-centre analysis using Epic Cosmos**
S. Boettcher (Detroit, United States), R. Kenney, N. Everson, I. Kashat, G. Tengler, A. Soyad, S. Davis, M. Veve*

SY097 14:45 - 15:45 Hall A3-2
 IPC PHEI
 1-hour Symposium

Capacity strengthening in antimicrobial stewardship and infection, prevention and control in LMICs

- Chairs Gloria Cordoba (Copenhagen, Denmark)
 Syed Faisal Mahmood (Karachi, Pakistan)*
- S0245 14:45 What is drive-AMS and what have we learned?**
Jeroen Schouten (Nijmegen, Netherlands)
- S0246 15:15 Drive AMS East Africa, inducing behaviour change in resource-constrained settings**
Igizeneza Acsa (Kigali, Rwanda)

Co-organised with: International Centre for Antimicrobial Resistance Solutions (ICARS), ESCMID Parity Commission, ESCMID Professional Affairs Subcommittee

EF071 16:15 - 17:15 Arena 1
 VAX
 ePoster Flash Session

Risky business: preventing respiratory virus infection in high-risk groups

- Chair Vana Spoulou (Athens, Greece)*
- E0496 16:15 Real-world effectiveness of maternal influenza vaccination in children under six months: a retrospective cohort study in a tropical setting**
N. Goh (Singapore, Singapore), E.W. Liang, R. Ho, C. Chiew, R. Li, D. Lye, K. Tan*
- E0497 16:21 Two-year real-world impact and effectiveness of universal RSVpref vaccination during pregnancy in preventing infant RSV-related hospitalisations in the metropolitan area of Buenos Aires**
M. Caballero (Buenos Aires, Argentina), J. Dvorkin, D. Parada, G. Guinazu*
- E0498 16:27 Two-season impact of nirsevimab against RSV hospitalisation in Galicia: findings from the NIRSE-GAL study**
F. Martín-Torres (Santiago De Compostela, Spain), J.L. Razzini, I. Giné-Vázquez, J. Jin, N. Mallah, M.I. Santiago-Pérez, O. Pérez-Martínez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, Á. Manzanares-Casteleiro, A.I. Dacosta-Urbieta, C. Álvarez-Smith, I. Rivero-Calle, A. Salas, C. Durán-Parrondo*
- E0499 16:33 RSV prefusion F vaccine effectiveness in older adults according to Charlson Comorbidity Index: A prespecified analysis of the DAN-RSV trial**
K. Feldballe Bernholm (Copenhagen, Denmark), M.C.H. Lassen, N. Dyrby Johansen, S. H. Christensen, N. Aliabadi, K.G. Skaarup, D. Modin, K. Hyldekær Janstrup, B. L. Claggett, C. S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. G. Lindholm, A.M. Reimer Jensen, M. Dons, F. Soeskov Davidovski, L. S. Duus, C. I. Ottosen, A. B. Nielsen, J. H. Borchsenius, C. Espersen, G. Köse, F. H. Fussing, L. Køber, S. D. Solomon, J.U. Stæhr Jensen, C. Jean-Marie Martel, M. Goeijenbier, S. Tellerup Nielsen, L. Russell, T. Skovsgaard Itenov, B. D. Gessner, C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, E. Begier, T. Biering-Sørensen*

Scientific Programme

Sunday, 19 April 2026

E0500	16:39	<p>Immune response and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (adjuvanted RSVPreF3) in immunocompromised (IC) adults with lung or kidney transplant compared to non-IC adults up to 12 months post-vaccination</p> <p><i>K. Oluwayi* (London, United Kingdom), C. Small, D. Kumar, A. Abbas, A. Sánchez-Fructuoso, S. Yamanaga, V.L. Pérez-González, H. Karakizlis, M. Nissen, P.G. Choe, V. Paloschi, S. Chadban, H.A. Hailemariam, C. Gerard, M.P. David, D. Descamps, C. Agutu, V. Hulstrøm</i></p>	EF072	16:15 - 17:15	Arena 3
			DX	ePoster Flash Session	
Advances in sepsis diagnostics - improving speed and accuracy					
		<i>Chair</i>		<i>Özlem Kurt Azap (Ankara, Türkiye)</i>	
E0501	16:45	<p>Effectiveness of the adapted XBB.1.5. COVID-19 vaccine received as a 2023 autumn dose among immunocompromised persons in six EU/EEA countries, a VEBIS EHR network study</p> <p><i>A. Blake* (Paris, France), J. Humphreys, N. Nicolay, T. Braeye, I. Van Evercooren, C. Holm Hansen, I. Rask, M. Fabiani, A. Mateo-Urdiales, J. Castilla, I. Martínez Baz, A. Machado, A. Brito, R. Ljung, N. Pihlström, S. Monge, K. Olsson, B. Nunes</i></p>	E0505	16:15	<p>True bacteraemia vs contamination in positive blood cultures: development of a prediction model</p> <p><i>E. Nannini* (Rosario, Argentina), M. Dumas Marucci, J.I. Rodriguez Lia, M. Pallotta, C. Scipione, R. Bonifacio, M. Rinaudo</i></p>
E0502	16:51	<p>Interim Analysis of the Effectiveness of Conventional and Self-amplifying JN.1-adapted mRNA COVID-19 Vaccines Against Symptomatic Infection in Adults Aged ≥60 Years, Japan</p> <p><i>H. Maeda* (Nagasaki, Japan), A. Igarashi, S. Mitsui, K. Suzuki, T. Kutomi, H. Fujino, T. Onoe, T. Kimura, Y. Ichigi, H. Kozai, T. Komazaki, S. Kida, K. Morimoto</i></p>	E0506	16:21	<p>Epidemiology and interpretation of positive blood cultures when polymerase-chain reaction-based blood culture results are "not detected"</p> <p><i>S. Boettcher* (Detroit, United States), R. Kenney, R. Tibbetts, L. Samuel, S. Davis, M. Veve</i></p>
E0503	16:57	<p>A novel approach assessing the impact of SARS-CoV-2 variant drift on effectiveness and durability of an XBB.1.5-adapted COVID-19 vaccine using the id.DRIVE platform</p> <p><i>H.R. Volkman* (New York, United States), J.L. Nguyen, K. Bollaerts, T.M.P. Tran, M.M. Mustapha, L. De Munter, C. Marques, H. Dunford, J.V. Hernandez-Villena, M. Mitratza, A. Antón, I. Casas Garcia, B. Gruner, G. Icardi, G. Luit Ten Kate, C. Martin, A. Mira-Iglesias, A. Orrico-Sanchez, S. Otero-Romero, G. Rohde</i></p>	E0507	16:27	<p>Modeling Point-of-Care QIAstat-Dx® Implementation for Rapid Bloodstream Infection Identification in Remote Settings: A Cost-Effectiveness Analysis</p> <p><i>K. Bagge* (Copenhagen, Denmark), F.H. Jensen, J.G. Lisby</i></p>
E0504	17:03	<p>Safety, tolerability, pharmacokinetics, and immunogenicity in a phase I first-in-human study with VYD2311, a SARS-CoV-2-directed monoclonal antibody</p> <p><i>P. Richmond* (Nedlands, Australia), L. Hu, K. Narayan, K. Tosh, R. Gerlach, I. Yacin, D. Wilfret, M. Wingertzahn</i></p>	E0508	16:33	<p>Patient factors associated with circulating bacterial DNA in critically ill sepsis patients</p> <p><i>C. Lannsjö* (Stockholm, Sweden), B. Stammeler Jaliff, D. Yu, S. Cajander, A. Bäckman, E. Tina, A. Somell, H. Alpkvist, M. Ullberg, C. Jorns, J. Wernerman, V. Özenci, K. Strålin</i></p>
			E0509	16:39	<p>Culture-free detection of bloodstream bacteria in ICU patients within six hours</p> <p><i>A. Wijen* (Maastricht, Netherlands), C. Von Wintersdorff, R. Driessen, S. Van Mens, D. Bergmans, P. Savelkoul</i></p>
			E0510	16:45	<p>From culture to clarity in four hours: accelerating clinical management of bloodstream infections</p> <p><i>R. Ahmad* (Hamar, Norway), J. Ali, A. Basavaraj Bellankimath, S. Therese Opgård, E. Varman Manivannan, G. Skov Simonsen</i></p>
			E0511	16:51	<p>Rapid pathogen and antimicrobial resistance detection in bloodstream infections using short subculture and nanopore sequencing</p> <p><i>M. Pitombeira Liborio* (Brisbane, Australia), P. Harris, C. Ravi, K. Ramsay, T. Da Silva Duarte, A. Irwin</i></p>
			E0512	16:57	<p>Rapid identification of bacteraemia-causing microorganisms using MALDI-TOF MS: a comparative study of three in-house methods with two matrices</p> <p><i>Z.C. Karahan* (Ankara, Türkiye), R. Waheed Osman</i></p>

E0513 17:03 **Four-day vs five-day blood culture incubation: a retrospective study of diagnostic performance using the BACT/ALERT VIRTUO system**
K. Tron (Newcastle, United Kingdom), C. Cullerton, J. Lupton, P. Mpwilu, J. Samuel, D. Weiland*

EF073 16:15 - 17:15 **Arena 4**
ANT CLN PHEI ePoster Flash Session

Surveillance of antimicrobial use around the world

Chair Kalisvar Marimuthu (Singapore, Singapore)

E0514 16:15 **The ECRAID Emerging Resistance Index by European region: assessing the index's applicability in different epidemiological contexts**
J. Garlasco (Verona, Italy), F. Arieti, M. Morra, D-E. Ortiz, E. Addis, M. Tebon, O. Awwad, K. Odoj, M.D. Pezzani, S. Harbarth, E. Presterl, G. Kahlmeter, A. Cassini, A. Savoldi, E. Tacconelli*

E0515 16:21 **Antibiotic use, rapid escalation practices and access in neonatal sepsis across LMIC tertiary care hospitals: findings from the BARNARDS II cohort**
K. Thomson (Oxford, United Kingdom), K. Sands, J. Oduwo, C. Achi, R. Farzana, B. Hassan, E. Owinoh, M. Nziliani, A. Ko, K. Iregbu, N. Medugu, T. Akujobi, A. Mairami, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A.T. Bolajoko, O. Oduyebo, O. Olutekunbi, A. Odedina, I. Nwafia, N. Ukaegbu, C. Nzurumike, T. Amin, S. Arefin, T.N. Shatu, A.T. Promi, T. Haque, R. Tasnim, R. Zahra, E. Rashid, M.I. Shah, S. Riaz, S. Naqvi, S. Naeem, M. Haroon Hamid, S. Shabbir, U. Hussain, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, M. Mahrang, T.R. Walsh*

E0516 16:27 **Global antibiotic use (AMU) patterns in 2023: insights from WHO's global AMU surveillance system (GLASS-AMU)**
M. Escher (Geneva, Switzerland), A. Muller, V. Ivanovska, D. O'doherty, D. Tong, B. Huttner*

E0517 16:33 **Scaling a national antimicrobial prescribing surveillance programme incorporating an appropriateness assessment to drive policy and practice**
R. James (Melbourne, Australia), C. Chen, K. Thursky*

E0518 16:39 **Being more AWARe: assessing appropriateness of antimicrobial prescribing against the World Health Organization AWARe classifications**
C. Chen (Melbourne, Australia), L. Hall, K. Thursky, N. Sivapragasam, N. White, C. Ierano, R. James, L. Marquart-Wilson*

E0519 16:45 **How do we define 'appropriate antimicrobial use' in One Health? A global Delphi survey**
R. Scarborough (Parkville, Australia), C. Ierano, K. Bailey, G. Browning, K. Thursky, R. Biezen, B. Hur, B. Mc Mullan, L. Dowson, A. Schermuly, L. Teoh, L. Hardefeldt*

E0521 16:57 **Real-world use of novel β -lactams in fragile patients with multidrug-resistant Gram-negative infections: insights from an Italian retrospective cohort**
M. Boggetti (Milan, Italy), F. Fama, M. Colaneri, E. Palomba, C. Conflitti, F. Brivio, M. Piscaglia, M. Schiavini, M.V. Cossu, S. Vimercati, E. Rossin, C. Pagani, S.G. Rimoldi, A. Gori*

E0522 17:03 **Strengthening Antimicrobial Stewardship Across Europe: EU-JAMRAI2 on Frameworks, Implementation, and Collaborative Action on Human Health**
M. Nunez-Nunez (Granada, Spain), B. Bradley-Valdenebro, J.L. Trillo-Contreras, A. López-Navas, R. Fernández-Urrusuno*

FO105 16:15 - 17:15 **Arena 2**
CLN PRO Open Forum

Science in action: implementation science for effective CM/ID practice in diverse settings

Chair Marlies Hulscher (Nijmegen, Netherlands)

F0262 16:15 **Implementation science fundamentals: a toolkit for CM/ID practice**
Fabiana Lorenatto (London, United Kingdom)

F0263 16:25 **Measuring success: metrics that matter**
José Molina Gil-Bermejo (Seville, Spain)

F0264 16:35 **Implementing infection control best practices across diverse resource settings**
Raheelah Ahmad (London, United Kingdom)

Co-organised with: ESCMID Education Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee

Scientific Programme

Sunday, 19 April 2026

KN100 16:15 - 17:15 Hall ICM 14
 CLN Keynote Lecture

From post-mortem discoveries to precision care: the evolution of opportunistic fungal infection management in haematological malignancies

Chair *Murat Akova (Ankara, Türkiye)*
Anuradha Chowdhary (Delhi, India)

K0251 16:15 **Dimitrios P. Kontoyiannis**
(Houston, United States)



Dimitrios P. Kontoyiannis is the Robert C Hickey Chair in Clinical Care and Deputy Head for Research in the Division of Internal Medicine at the University of Texas MD Anderson Cancer Center in Houston (MDACC). He received his medical degree from the National and Kapodistrian University of Athens. Kontoyiannis was then trained in Internal Medicine at Baylor College of Medicine, where he served as a Chief Medical Resident and subsequently trained as a clinical fellow in infectious diseases at Massachusetts General Hospital. Kontoyiannis is the leader of the ECMM Diamond Excellence in Mycology Center at MDACC, the only US centre to receive such designation by ECMM. He serves as president of the Mycoses Study Group Education Consortium and is cofounder of the International Society for Fungal Immunotherapy.

Fireplace Session 19 April, 17:30 - 18:30

LB004 16:15 - 17:15 Hall BO-2
 IPC PHEI 1-hour Oral Session

Recent and ongoing high impact outbreaks

Chairs *Daniel Grupel (Jerusalem, Israel)*
Barbara Juliane Holzknacht (Copenhagen, Denmark)

L0021 16:15 **The January 2026 Nipah virus outbreak investigation and successful containment in West Bengal, India: direct report from the field**

S. Banerjee (Kalyani, India), A. Das, R. Basu, S. Maharatna, R. Sahay, M.K. Kundu, P. Yadav*

L0023 16:27 **Uncovering a multi-centre outbreak of *Candida viswanathii* candidaemia caused by contaminated milrinone in Italy**

A. Mesini (Genoa, Italy), V. Di Pilato, D. Contu, M. Castignone, M.L. Ciofi Degli Atti, G. Vrenna, L. Ricotta, C. D'amore, V. Fox, P. Bernaschi, G. Travi, M. Merli, C. Vismara, E. Matarazzo, G. Vento, V. Arena, E. Nardi, A. Marchese, R. Bandettini, G. Spiga, E. Castagnola*

L0022 16:39 **A complete soil-water-air transmission network for urban melioidosis: source identification and successful intervention in Hong Kong**

T.F. Wong (Hung Hom, Hong Kong), K.H.G. Siu, W.N.F. Chow*

L0024 16:51 **Outbreak of NDM-1-producing *Burkholderia contaminans* bloodstream infections linked to contaminated intravenous metoprolol**

M. Fantoni (Rome, Italy), P. Laurenti, B. Fiori, S. Vincenti, M. Di Donato, R. Murri, M. Wachocka, F. De Maio, M. Cioce, N. Mores, R. Campopiano, C. Pais, G. Vetrugno, T. D'inzeo, B. Posteraro, C. Torti, M. Sanguinetti*

L0025 17:03 **Ongoing outbreak of *Burkholderia stabilis* ST480 linked to non-sterile cleansing wipes in the United Kingdom: investigation findings and mitigating patient safety risks**

R. Stretch (London, United Kingdom), A. Carroll, S. Milligan, J. Elston, D. Blackman, A. Popay, D. Kenna, M. Day, C. Willis, K. Staniforth, D. Williams, K. Osman, G. Russell, J. Pappriill, J. Gordon-Brown, G. Fear, M. Mirfenderesky, D. Jeyaratnam, I. Sinha, C. Searle, C. Patterson, R. Peabody, C. Brown, E. Betts*

LB005 16:15 - 17:15 Hall ICM 1
 ANT 1-hour Oral Session

New drugs and anti-infective solutions

Chairs *Shampa Das (Liverpool, United Kingdom)*
Alasdair Peter Macgowan (Bristol, United Kingdom)

L0026 **A chimeric CXCL8(3-72) K11R/G31P-BPI233 protein modulates neutrophil-driven inflammation and protects against carbapenem-resistant Gram-negative bacteria**

D. Pu (Beijing, China), J. Zhao, B. Cao*

L0027 **Breaking bacterial communication signals: Anti-QS antibodies to block pathogenicity**

T. Posvai (Barcelona, Spain), L. Vilaplana, M.P. Marco*

L0028 ***In vivo* efficacy and PK/PD of OSUAB-0284: a preclinical candidate for MRSA**

M. Mitton-Fry (Columbus, United States), P. Srivastava, A. Landgraf, J. West, C. Mann, R. Kebriaei, T. Murphy, D. Andes*

L0029 **Enzybiotic therapy for species-selective eradication of staphylococcal biofilms**

M. Yousefi (Warsaw, Poland), P. Haniewicz, M. Zaród, M. Korzeniowska, J. Kornatowski, E. Jagielska, I. Sabała*

L0030 Investigating the antiviral activity of (±)Bay K8644 against Enterovirus D68
J.A. Lee (Taipei, Taiwan), K.C. Yang, L. Jin-Yi*

ME104 16:15 - 17:15 Hall ICM 13a
 CLN PHEI Meet-the-Expert

Crimean-Congo haemorrhagic fever: best practices and advances in therapeutics and vaccines

M0260 16:15 Önder Ergönül (Istanbul, Türkiye)

M0261 16:27 Ali Mirazimi (Stockholm, Sweden)

Co-organised with: ESCMID Emerging Infections Subcommittee

OS070 16:15 - 17:15 Hall A3-2
 CLN DX TRN 1-hour Oral Session

Turning mechanisms into clinical strategies in chronic viral hepatitis

Chairs Ruxandra Calin (Paris, France)
 Yogesh Kumar Gupta (Jaipur, India)

O0491 16:15 NTCP-based HBV infection model to define ncRNA drivers of post-transplant HCC recurrence
S. Ak-Aksoy (Bursa, Türkiye), İ. Sağlık, F. Aksoy*

O0492 16:27 Distinct hepatitis B virus mutational patterns in hepatocellular carcinoma patients vs chronic hepatitis B patients highlight potential biomarkers for cancer progression
E. Gupta (Delhi, India), S. Maniraj, R. Agarwal, P. Gautam, C. Bihari, M. Sharma*

O0493 16:39 Prophylaxis for hepatitis B virus reactivation in patients undergoing immunosuppressive therapy: is there a continued role for lamivudine?
G. De Simone (Rome, Italy), L. Campogiani, V. Malagnino, E. Teti, T. Mulas, M. Compagno, D. Checchi, A.M. Geretti, L. Sarmati*

O0494 16:51 Hepatitis C virus reactivation in cancer patients receiving Bruton tyrosine kinase inhibitors
T. Harrys (Houston, United States), J. Arvelaez Pasucci, K. Mustafayev, P. Jain, Y. Jiang, E. Yopez Guevara*

O0495 17:03 Bulevirtide treatment of HBV-HDV coinfecting patients: 12 months of real-life experience
G.S. Gherlan (Bucharest, Romania), R.M. Cretu, A. Blidaru, D.S. Lazar, A. Culinescu, A. Condurache, S.M. Ruta, S.A. Florescu, C.P. Popescu*

SY101 16:15 - 18:15 Hall A3-1
 PED VAX 2-hour Symposium

Pertussis resurgence: understanding epidemiological trends, immune and vaccine challenges, and policy responses

Chairs Tom Snelling (Sydney, Australia)
 Julie Toubiana (Paris, France)

S0252 16:15 Pertussis in its most severe forms: risks, realities, and responses
Carla Rodrigues (Paris, France)

S0253 16:45 Tracking pertussis: epidemiological trends and global patterns
Gayatri Amirthalingam (London, United Kingdom)

S0254 17:15 Genomic surveillance and emerging strains
Noémie Lefrancq (Basel, Switzerland)

S0255 17:45 Rethinking pertussis immunity: challenges and innovations in vaccine strategy
Dimitri Diavatopoulos (Nijmegen, Netherlands)

SY102 16:15 - 17:15 Hall B0-1
 AMR ANT TRN 1-hour Symposium

The future of clinical phage susceptibility testing

Chairs Saima Aslam (San Diego, United States)
 Laurent Frederic (Lyon, France)

S0256 16:15 Bacteriophage potency and quality control: guidelines vs. real life
Pieter-Jan Ceysens (Brussels, Belgium)

S0257 16:45 Bacteriophage susceptibility testing: EUCAST perspectives on standardisation
Annika Yanina Classen (Cologne, Germany)

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), EUCAST Steering Committee

Scientific Programme

Sunday, 19 April 2026

SY103 16:15 - 17:15 Hall A2-1
 DX PHEI 1-hour Symposium

Implementation of WHO Fungal Priority Pathogens List: landscape and challenges

Chairs Katrien Lagrou (Leuven, Belgium)
 Rita Oladele (Lagos, Nigeria)

S0258 16:15 **Pilot implementation of WHO's global surveillance system for monitoring antimicrobial resistance (GLASS-AMR) in fungal diseases**
 Silvia Bertagnolio (Geneva, Switzerland)

S0259 16:45 **WHO global blueprint for the implementation of the Fungal Priority Pathogens List**
 Nelesh Govender (Johannesburg, South Africa)

EF077 17:30 - 18:30 Arena 1
 CLN DX PHEI ePoster Flash Session

Diagnosing mycobacterial infections across the globe

Chair Jakko Van Ingen (Nijmegen, Netherlands)

E0538 17:30 **Clinical and microbiological correlation of NTM PCR**
 N. Shah* (Svs Road, Mahim West, India),
 K. Ajbani, A. Sunavala, S. Shirole,
 B. Jadeja, S. Gore, S. Ganta, S. Naik,
 C. Rodrigues, S. Basu, A. Bijwe, U. Agrawal

E0539 17:36 **Improving tuberculosis diagnosis through AI (CAD4TB) and Stool-Xpert MTB/RIF: a prospective study from Oromia, Ethiopia**
 G. Guido* (Bari, Italy), B. Gulo, S. Cotugno,
 W. Nigussa, K. Bobosha, F.V. Segala,
 B. Zauli, B. Kenate Sori, G. Putoto,
 F. Cavallin, G. Madeddu, F.A. Bobbio,
 N. Veronese, A. Biset Asmare, A. Reta,
 R. Iatta, S. Abata, M. Miressa, F. Gobbi,
 L. Guglielmetti, M. Tilahun, A. Saracino,
 A. Alemseged, F. Manenti, F. Di Gennaro

E0540 17:42 **A \$26 gold standard *Mycobacterium tuberculosis* complete genome using long read sequencing**
 A. Osmaston* (London, United Kingdom),
 C. Leon, O. Romero, D. Taquiri,
 P. Avellaneda, J.B. Raez Pereyra,
 J.L. Perez, S. Huaman, J. Coronel,
 W. Solano, R. Gilman, A. Torres-Ortiz,
 G. Tan, B. Sobkowiak, P. Sheen, M. Zimic,
 L. Grandjean

E0541 17:48 **Whole genome sequencing-based clonality assessment of *Mycobacterium simiae* isolates from Lebanon**
 M. Antar* (Beirut, Lebanon), Z. Awad,
 S. Aqsous, L. Tabet, C. Allam, M. Abifadel,
 F. Mougari, J. Najjar-Pellet, E. Cambau

E0542 17:54 **Machine learning-assisted differentiation of *Mycobacterium tuberculosis* complex species from MALDI-TOF mass spectra**
 M. Gutiérrez-Pareja* (Madrid, Spain),
 F. Alcaide, L. Herrera, D. Domingo,
 V. González-Galán, J. Viñuelas-Bayon,
 M. Simón-Sacristán, C. Castelló-Abietar,
 B. Fernández-Pérez, M. Oviaño,
 L. Fernández-Delgado, A. Candela,
 E. Abascal, M.J. Ruiz-Serrano,
 B. Rodríguez-Sánchez, D. Rodríguez-Temporal

E0544 18:06 **Consensus-based diagnostic evaluation of a novel tuberculosis IGRA in a low-endemic population**
 K. Callebaut* (Bruges, Belgium), T. Chin,
 V. Verbeke, A. Muyldermans, M. Verhulst,
 M. Reynders

E0545 18:12 **Evaluation of *Mycobacterium tuberculosis* derived cell-free DNA (CF-DNA) based multi-targeted real-time PCR (MRT-PCR) from extrapulmonary (EPTB) samples for diagnosis of extrapulmonary tuberculosis (EPTB)**
 K. Sharma* (Chandigarh, India), M. Modi

E0546 18:18 **Targeted next-generation sequencing-a promising approach in the diagnosis of *Mycobacterium tuberculosis* and drug resistance**
 X. Wu* (Shanghai, China)

EF078 17:30 - 18:30 Arena 2
 CLN IPC ePoster Flash Session

Prevention and management of implant-associated infections: biofilm control and beyond

Chair Biljana Carevic (Oslo, Norway)

E0547 17:30 **Preventing bacterial colonisation of synthetic bone grafts using nanostructured hydroxyapatite and cold atmospheric plasma-treated liquids**
 A. Ruiz Sorribas* (Barcelona, Spain),
 F. Tampieri, C. Canal, M.P. Ginebra

E0548 17:36 **Supercritical CO₂ as an innovative method to inactivate biofilms on orthopedic implants**
 R. Hafjan Al-Homsi* (Madrid, Spain),
 A. Cabañas, L. Calvo, R. Hafjan, P. Sanz

E0549 17:42 **Bilayer sol-gel coating prevents *Staphylococcus aureus* prosthetic joint infection and improves bone integration in mice**
 J. Aguilera Correa* (Madrid, Spain),
 B. Toirac, Á. Solís-Garrido, A. Mediero,
 F. Mulero, O. Velyt-Vepryk, J. Esteban,
 A. Jiménez-Morales

- E0550 17:48 Risk factors for early infection after spinal instrumentation surgery: a multi-centre case-control study**
M. Muelas-Fernandez (Barcelona, Spain), J.A. Iribarren, E. Benavent, A. Marron, J.M. Bravo-Ferrer, H. Vilchez, D. Rodriguez-Montserrat, N. Sopena, M. Riera, O. Gasch, A. Lersundi, M.D. Del Toro, O. Murillo*
- E0551 17:54 Risk stratification and clinical impact of Gram-negative fracture-related infections**
F. Petrucci (Rome, Italy), D. De Meo, P. Martini, M. Rivano Capparuccia, G. Iaiani, S. Gumina, C.M. Mastroianni, A. Oliva*
- E0552 18:00 Keeping It Clean When Things Inflate: Evidence Gaps in Antimicrobial Strategies for Penile Prosthesis Surgery**
R. Ghani (London, United Kingdom), P. Sangster, W.G. Lee, S. Dewan, P. Panesar, G. Satta*
- E0553 18:06 Rifampicin Combination Therapy Fails to Enhance Clearance and Induces Growth Delay in a Rat Model of *Staphylococcus aureus* Vascular Graft Infection**
E. Faddy (Aarhus N, Denmark), J. Bär, M.I. Johansen, C. Gadeberg, L.B. Carstens, L. Østergaard, L.T. Erikstrup, S. Mairpady Shambat, A. Zinkernagel, R.L. Meyer, N.P. Jørgensen*
- E0554 18:12 Characteristics, management and outcomes of vascular graft and endograft infections in Eastern Denmark: a retrospective cohort study**
A.J. Christensen (Hilleroed, Denmark), S. Bjerrum, K. Sörelus, I.H.M. Mathiesen, C. Moser, J. Helweg-Larsen, B.V. Sandholt, D. Faurholt-Jepsen, C. Kraef*
- E0555 18:18 Antibiotic and surgical treatment in staphylococcal ventriculoperitoneal shunt infections in adults**
I. Pelegrín Senent (Barcelona, Spain), M. Sanz De Mena, J. Gómez-Junyent, C. Iglesias, M.M. Moreno, A. Siverio, S. Gómez-Zorrilla, L. Sorli, M.M. Montero, J.P. Horcajada*

EF079 17:30 - 18:30 Arena 3
 AMR IPC PHEI ePoster Flash Session

Molecular epidemiology and genomic evolution of high-priority MDROs

- Chair Helena Zemlickova (Prague, Czechia)*
- E0556 17:30 Antimicrobial susceptibility and molecular characterisation of carbapenem-resistant Enterobacterales (CRE) from European medical centres stratified by country (2020-2024)**
H.S. Sader (North Liberty, United States), J.H. Kimbrough, G. Stone, K. Perez, R. Mendes, M. Castanheira*
- E0557 17:36 Emergence of new variants of OXA-48 in France**
L. Bientz (Le Kremlin-Bicêtre, France), R. Nermont, C. Emeraud, T. Naas, R.A. Bonnin, L. Dortet*
- E0558 17:42 Spread of carbapenemase-producing *Serratia* spp. in France from 2016 to 2024: a comparative genomic study**
L. Dortet (Le Kremlin-Bicêtre, France), I. Rezzoug, S. Bernabeau, K. Oucel, A. Birer, A. Jousset, L.M. Gerald, E. Cécile, D. Laurent*
- E0559 17:48 Molecular epidemiology and resistome of carbapenem-resistant *Klebsiella pneumoniae* isolates from five referral centres in South Africa**
G. Marais (Cape Town, South Africa), S. Africa, F. Patel, E. Geza, E. Du Toit, F. Franceschi, R.M.A. Da Costa, A. Brink*
- E0561 18:00 Increase in OXA-48-like carbapenemase-producing Enterobacterales driven by clonal expansion and plasmid dissemination in the Netherlands, 2019-2024**
A. Hendrickx (Bilthoven, Netherlands), S. Lansu, A. De Haan, S. Witteveen, J. Bos, F. Landman, C.C.H. Wielders, S.C. De Greeff, D.W. Notermans*
- E0562 18:06 Plasmid population analysis of *Klebsiella pneumoniae* spanning two decades**
E. Nguyen (Silver Spring, United States), A. Sapre, T. Luo, B. Jones, V. Rollins, R. Maybank, A. Ong, Y. Kwak, J. Bennett, P. Mc Gann, M. Martin, F. Lebreton*
- E0563 18:12 High prevalence of ESBL Enterobacterales colonisation in elderly people with high care needs in Liverpool, UK**
J.M. Lewis (Liverpool, United Kingdom), S. Galllchan, E. Picton-Barlow, C. Mckeown, S. Forrest, M. Moore, S. Todd, M. Taegtmeyer, F·E· Graf, N.A. Feasey*

Scientific Programme

Sunday, 19 April 2026

E0564 18:18 Emergence of vancomycin-variable *Enterococcus faecium* following the expansion of Vancomycin-resistant *E. faecium* in Taiwan
W.C. Hung* (Kaohsiung, Taiwan)

EF080 17:30 - 18:30 Arena 4
ANT TRN ePoster Flash Session

Beyond the cocktail: advances in phage therapy

Chair Maria Vehreschild
(Frankfurt Am Main, Germany)

E0565 17:30 Capsule-independent entry route for *Acinetobacter baumannii* phage infection
H. Oliveira* (Braga, Portugal), S. Lorenz, D. Turner

E0566 17:36 Mechanistic insights and clinical implications of cross-reactive anti-phage antibodies on phage therapeutic failure
A. Peleg* (Melbourne, Australia), F. Gordillo Altamirano, D. Subedi, B. Gardiner, J. Hawkey, J. Barr

E0567 17:42 Exploiting the natural power of phage lysins as novel enzyme-based antibiotics to treat polymicrobial Gram-negative infections
G. Vandermarliere* (Ghent, Belgium), G. Hermans, D. Grimon, Y. Briers, R. Vázquez, V. Stove, J. De Waele

E0568 17:48 Hidden lytic potential of human gut phages: discovery of thousands of endolysins and holins
M.K. Mirzaei* (Neuherberg, Germany), A.H.A. Elbeheri, S. Abdullah, B. Neumann, L. Deng

E0569 17:54 Engineered phage therapy using parenteral and intravesical delivery of CRISPR-Cas armed phages (SNIPR001) in mice increase survival and reduces infection?
A. Gram* (Copenhagen, Denmark), A. Østergaard Petersen, J. Krause Haaber, E. Van Der Helm, A. Troy, J. Hink, C. Grøndahl

E0570 18:00 Rational selection of a synergistic phage combination enabled clearance of mouse gut colonisation by carbapenemase-producing *Escherichia coli* ST131
F. Laumay* (Lyon, France), R. Bonnin, R. Bonnet, F. Laurent, G. Dalmaso, R. Beyrouthy, C. Baeza, B. Lapras, M. Bonhomme, P. Martins-Simoes, E. Helluin, L. Blazere, V. Bonnin, L. Guillouard, R. Froissart, M. Medina, C. Kolenda, F. Pirot, L. Dortet

E0571 18:06 Exploring phage-amikacin combination against metallo- β -lactamase Gram-negative bacteria in a murine thigh infection model
P. Paranos* (Athens, Greece), P.C. Georgiou, S. Pournaras, J. Meletiadis

E0572 18:12 A phage cocktail promotes intestinal decolonisation of multidrug-resistant *Klebsiella pneumoniae*: insights from a 3D *in vitro* microbiota model
M. Calvigioni* (Pisa, Italy), E. Fausti, C. Ferretti, G. Vozzi, E. Ghelardi, M. Di Luca

E0573 18:18 Regional therapeutic phages and genomic correlates of susceptibility in refractory/resistant *Pseudomonas* infections: findings from a multi-centre Asian cohort
A. Kwa* (Singapore, Singapore), Y. Liu, S. Thong, Z.S. Chong, S.H. Tan, Y. Zhong, A. Chan, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, Y.H. Lau, P. Chetchotisakd, D. Limmathurotsakul, P.A. Tambyah, B.S. Cooper, Y. Mo

ME112 17:30 - 18:30 Hall A2-2
VAX Meet-the-Expert

Immunisation strategies for vaccine-preventable arboviral diseases: recent advances and future directions

M0277 17:30 Alfonso J. Rodriguez-Morales
(Pereira, Colombia)

M0278 17:42 Antonio Carlos De Albuquerque Bandeira
(Lauro De Freitas, Brazil)

Co-organised with: ESCMID Vaccine Study Group (EVASG)

OS074 17:30 - 18:30 Hall ICM 13a
 CLN PHEI TRN 1-hour Oral Session

Innovations in vector-borne and zoonotic viral infections

Chairs *Cassandra Bulescu (Bucharest, Romania)*
Ines Ushiro-Lumb (Marlow, United Kingdom)

O0528 17:30 The role of the host genetic background in tick-borne encephalitis
S. Grygorczuk (Bialystok, Poland), M. Parczewski, J. Dunaj, P. Czupryna, J. Adamczuk, W. Pawlak-Zalewska, A. Moniuszko-Malinowska*

O0529 17:42 Phenotypic characterisation of emerging neurotropic viruses using embryonic stem cell-derived neural cells and brain organoids
S. Vogiatzis (Padua, Italy), E. Dal Molin, G. Gori Savellini, R. Pia Falco, M. Severa, C. Lucca, A. Sinigaglia, A. Gianella, G. Ceolotto, M. Bogacheva, I. Weinstein, O. Vapalahti, M. Pacenti, M. Trevisan, E. Coccia, M.G. Cusi, L. Barzon*

O0530 17:54 Exploring haematocrit, platelet and leukocyte count trajectories associated with dengue: pooled analysis from Vietnam
N.L. Vuong (Ho Chi Minh City, Vietnam), D.T. Trung, T.V. Ngoc, N.M. Nguyet, D.T.H. Tam, N.T. Truong, H.T.L. Duyen, N.T.H. Quyen, N.T.T. Kieu, N.V.V. Chau, L.T.H. Tai, N.T.H. Lan, P.K. Lam, C.P. Simmons, S. Yacoub, R.B. Geskus, B.A. Wills*

O0531 18:06 A novel ARPE-19 cell-based assay for assessing interferon-mediated protection and autoantibody neutralisation in ZIKV infection
A. Ferrari (Pavia, Italy), I. Cassaniti, F. Roviada, D. Lilleri, S. Croce, F. Trespidi, A. Gervais, S.Y. Zhang, J.L. Casanova, A. Borghesi, F. Baldanti*

O0532 18:18 One health investigation of Tahyna and Batai orthobunyaviruses and Sindbis alphavirus in Northern Italy, 2021-2024
E. Dal Molin (Padua, Italy), M. Pacenti, D. Murova, A. Sinigaglia, A. Giaretta, A. Lavazza, D. Lelli, F. Gobbo, F. Montarsi, L. Barzon*

OS075 17:30 - 18:30 Hall ICM 13b
 ANT CLN 1-hour Oral Session

Primary care and long-term care facilities: what's going on in stewardship?

Chairs *Gaetan Gavazzi (Grenoble, France)*
Bradley Langford (Etobicoke, Canada)

O0533 17:30 Evaluation of a national training roll out implementing a stewardship toolkit in primary care in England: a quasi-experimental analysis using hybrid time series modelling
M.X. Lee (Gloucester, United Kingdom), N.J. Zhu, J. Meadows, R. Ahamad, D.M. Lecky*

O0534 17:42 Between-practice differences, rather than patient case-mix, drive variation in antibiotic prescribing in UK primary care: evidence from a three-way variance decomposition
N. Nguyen (Oxford, United Kingdom), J.V. Robotham, A.S. Walker, D. Eyre, R. Hope, C. Butler, G. Hayward, M. Sharland, K.B. Pouwels*

O0535 17:54 Antimicrobial use and stewardship activities in Swiss long-term care facilities: data from a national point-prevalence survey
S. Toppino (St. Gallen, Switzerland), P. Kohler, D. Flury, F. Grässli, S. Kuster, E. Glampedakis, C. Gardiol, T. Kudrnovsky, V. Piezzi, M. Schlegel*

O0536 18:06 Assessment of antibiotic prescribing and AWaRe classification compliance in Dutch nursing homes using national surveillance data
A. Zondag (Bilthoven, Netherlands), M. Biesheuvel, J. Polman, K. Halonen, A.P.J. Haenen, S.C. De Greeff*

O0537 18:18 Impact of an antimicrobial stewardship intervention in residential aged care: a multi-centre, stepped-wedge cluster randomised trial (START Trial)
N. Jokanovic (Melbourne, Australia), S.J. Lee, T. Haines, S. Hilmer, Y.H. Jeon, D. Ayton, R.L. Stuart, A. Cheng, A.J. Stewardson, T.N. Peel, A.Y. Peleg*

Scientific Programme

Sunday, 19 April 2026

OS076 17:30 - 18:30 Hall A3-2
CLN 1-hour Case Session

A zoonotic carnival: masquerade syndromes and unusual presentations

Chairs Loïc Epelboin (Cayenne, French Guiana)
Joseph Papaparaskevas (Athens, Greece)

O0523 17:30 Buffalopox beyond borders: first imported human case in Europe
L. Soldevila* (Badalona, Spain), L. Valerio, A. Plana, X. Vallès, E. Fernández-Pedregal, S. Roure

O0524 17:41 Fulminant multisystem anthrax with delayed haemorrhagic gastrointestinal involvement: a clinically unique case from an endemic region
M. Javakhadze* (Tbilisi, Georgia), M. Kobakhidze, L. Goliadze, E. Choladze, M. Kanashvili

O0525 17:52 Imported round cavitory pneumonia: an unusual presentation of Murine Typhus
J.R. Le Henaff* (Toulouse, France), G. Grouteau, G. Martin-Blondel, D. Pierre, A. Merckx, G. Moulis, L. Cavalié, P. Floch, R. Gueneau

O0526 18:03 A spectacular differential diagnosis of lung cancer and the elucidation of its origin
S. Zange* (Munich, Germany), K. Kösters, F. Löhr, E. Mantel, M. Hohls, C. Hinz, F. Dematheis, T. Hoffmann, K. Silberreis, M. Seidel, M. Walter, H. Scholz, W. Roman, D. Lang

O0527 18:14 Seeing the unexpected: intraretinal dirofilariasis
H. Aldhaheri* (Abu Dhabi, United Arab Emirates), G. Rashwan, Z.O.E. Babiker, A.P. Srinivasulu, R.S. Ganeshan

SY106 17:30 - 18:30 Hall ICM 14
DX 1-hour Symposium

Year in clinical microbiology

Chairs Brigitte Lamy (Bobigny, France)
Holger Rohde (Hamburg, Germany)

S0265 17:30 -
Belen Rodriguez-Sanchez (Madrid, Spain)

S0266 18:00 -
Surbhi Malhotra-Kumar (Antwerp, Belgium)

SY107 17:30 - 18:30 Hall ICM 1
CLN DX 1-hour Symposium

Machine learning to fight against MDR *Acinetobacter baumannii*

Chairs Hege Vangstein Aamot (Lørenskog, Norway)
Abhilasha Karkey (Kathmandu, Nepal)

S0267 17:30 AI approaches to improve diagnosis and treatment of MDR-AB
Anton Peleg (Melbourne, Australia)

S0268 18:00 ML algorithms for distinguishing colonisation from infection by MDR-AB
Gert Marais (Cape Town, South Africa)

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID)

SY108 17:30 - 18:30 Hall ICM 5
TRN VAX 1-hour Symposium

Immunological determinants of host-pathogen interactions in inflammation and immune compromise

Chairs Silvio Daniel Brugger (Zurich, Switzerland)
Anna Norrby-Teglund (Stockholm, Sweden)

S0269 17:30 Human genetics as a compass to understand the host-microbe interactions
András N. Spaan (Utrecht, Netherlands)

S0270 18:00 Modulation of granulocyte effector response in patients with inflammatory and immunodeficiency disorders
Srikanth Mairpady Shambat (Zurich, Germany)

SY109 **17:30 - 18:30** **Hall B0-1**
CLN DX **1-hour Symposium**

New evidence challenging the UTI paradigm

Chairs *Merel Lambregts (Leiden, Netherlands)*
Arjana Tambic Andrasevic (Zagreb, Croatia)

S0271 17:30 **Urobiomics: detection and utility in the UTI universe**
Nicole De Nisco (Richardson, United States)

S0272 18:00 **Complicated UTI: diagnosis and treatment strategies**
Florian Wagenlehner (Giessen, Germany)

Co-organised with: ESCMID Scientific Affairs Subcommittee, ESCMID Study Group for Urinary Tract Infections (ESGUTI)

SY110 **17:30 - 18:30** **Hall B0-2**
CLN DX **1-hour Symposium**

Dosing by breakpoints vs guidelines: are S/I/R results based on the focus of infection best practice or source of confusion?

Chairs *Iva Butic (Zagreb, Croatia)*
Sören Gatermann (Bochum, Germany)

S0273 17:30 **Pro: make AST reports as informative as possible, add different S/I/R results per indication**
Mandy Wootton (Cardiff, United Kingdom)

S0274 18:00 **Con: don't confuse clinical colleagues, keep S/I/R fixed and add dosages in the guidelines**
Miquel Ekkelenkamp (Utrecht, Netherlands)

Co-organised with: Dutch Committee on Antimicrobial Policy

SY111 **17:30 - 18:30** **Hall A2-1**
PED VAX **1-hour Symposium**

How to tackle congenital viral infections

Chairs *Susanne Gjeruldsen Dudman (Oslo, Norway)*
Boris Kramer (Poznan, Poland)

S0275 17:30 **Congenital CMV screening: lessons and implications for prevention**
Dana Wolf (Jerusalem, Israel)

S0276 18:00 **Opportunities and challenges of vaccination in pregnancy**
Chrissie Jones (Southampton, United Kingdom)

Scientific Programme

Monday, 20 April 2026

EF082 08:30 - 09:30 Arena 2
 AMR ePoster Flash Session

Chasing resistance to anti(retro)virals

Chair *Snjezana Zidovec Lepej (Zagreb, Croatia)*

- E0584 08:30 Emergence and persistence of RSV-B resistant variants under monoclonal antibody pressure: Evidence in a 3D human airway model**
A. Caillault (Créteil, France), A. Ly, P. Cappy, A. Soulier, J.M. Pawlotsky, L. Softic, S. Fourati*
- E0585 08:36 Resistance mutations on M2 gene of A(H5N1) viruses: are adamantanes still useful against avian influenza?**
I. Sanz-Muñoz (Valladolid, Spain), A. Martín-Toribio, M. Toquero-Asensio, S. Galindo-Carretero, L. Sanchez-De Prada, J. Sánchez-Martínez, C. Rodríguez-Crespo, R. Iglesia-Aparicio, C. López-Gonzalo, S. Rojo-Rello, M. Domínguez-Gil, M. Hernández-Pérez, J.M. Eiros*
- E0586 08:42 Emergence of the novel PA-D27G mutation conferring reduced baloxavir susceptibility in influenza A viruses circulating in China, 2018–2025**
B. Sun (Shanghai, China), H. Wang, X. Zhao, J. Ai, W. Zhang*
- E0587 08:48 Tracking RSV fusion protein variability across seven decades: risks of resistance to prophylactic antibodies**
F. Serrano Cano (Antwerp, Belgium), K. Stobbelaar, S. Van Looy, K. Van Hoorenbeeck, R. Sanjuán, P. Delputte*
- E0588 08:54 Integrated viral resistance analysis in participants with COVID-19 treated with remdesivir across six phase III clinical studies**
C. Hedskog (Foster City, United States), L. Rodríguez, J. Moshiri, D. Han, N. Peinovich, T. Aeschbacher, J. Li, R. Martin, J.K. Perry, R.H. Hyland*
- E0589 09:00 Ensitrelvir treatment of COVID-19 across multiple global phase III trials resulted in reduced culture positivity and RNA copy number with minimal viral rebound**
A. Hurt (England, United Kingdom), H. Nobori, H. Sakaguchi, A. Luetkemeyer, D. Verdj, F. Draica, S. Portsmouth, T. Uehara*
- E0590 09:06 Identification of epitope mutation in HBV mono-infection and HBV-HDV coinfection**
M.S. Mehmood (Karachi City, Pakistan), S.H. Abidi*

E0591 09:12 APOBEC-context mutations vs true HIV resistance: evidence from a hospital population in Quito, Ecuador
G. Sevilano (Quito, Ecuador), C. Moreno-Izquierdo, M. Granja, J. Zurita, C. Zurita-Salinas*

E0592 09:18 Limited emergence of dolutegravir-associated resistance mutations in HIV-1 across Africa
P. Appiah (Accra, Ghana), M. Adusei-Poku, B.M. Obeng, R. Osei-Yeboah, E.T. Norgbe, P. Omoniyi, M. Akuka, L. Mac-Ankrah, I. Jamfaru, S. Ankamah, K.O. Duedu, K.W.C. Sagoe*

EW118 08:30 - 10:30 Hall ICM 13a
 IPC 2-hour Educational Session

Integrating IPC into hospital design: a collaborative approach to safer hospitals

- Chairs *Sabiha Essack (Durban, South Africa), Constantin Tsioutis (Nicosia, Cyprus)*
- W0382 08:30 Building safer hospitals: what is the role of the IPC practitioner?**
Margreet C. Vos (Rotterdam, Netherlands)
- W0383 08:50 Consult your architect: optimising infection control through hospital layout and design**
Marco Gola (Italy)
- W0384 09:10 Collaborating with operations: HVAC systems in healthcare, balancing airflow and infection control**
Jeffrey Siegel (Toronto, Canada)
- W0385 09:30 Consult your water hygienist: engineering and planning aspects of water systems for safe patient care**
Evdokia Katsemi (Frankfurt Am Main, Germany)

EW119 08:30 - 10:30 Hall ICM 13b
 CLN DX 2-hour Educational Session

Your attention, please! Parasitic infections in immunocompromised patients

- Chairs *Miriam José Alvarez Martínez (Barcelona, Spain), Hanne Brekke (Oslo, Norway)*
- W0386 08:30 A deadly duo: immunosuppression and alveolar echinococcosis**
Ansgar Deibel (Zurich, Switzerland)
- W0387 08:50 Please, do not forget: *Strongyloides* and immunosuppression**
Dora Buonfrate (Negrar, Italy)

W0388 09:10 Management of visceral leishmaniasis in the immunocompromised
Jaya Tapadar Née Chakravarty
 (Varanasi, India)

W0389 09:30 Double challenge: Chagas diseases and immunosuppression
Marisa Liliana Fernandez
 (Buenos Aires, Argentina)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP), Latin American Society for Travel Medicine, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica

EW120 08:30 - 10:30 Hall A2-2
 2-hour Educational Session

Future of fungi: biomarkers, big data and mycobiome

Chairs
Methee Chayakulkeeree
 (Bangkok, Thailand)
Oliver A. Cornely (Cologne, Germany)

W0390 08:30 Next-gen biomarkers for invasive fungal disease
Laura Alcazar Fuoli (Madrid, Spain)

W0391 08:50 AI in action: big data and models in fungal infections
Daniele Roberto Giacobbe (Genoa, Italy)

W0392 09:10 Pulmonary mycobiome: a missing link in lung health?
Cecile Angebault (Creteil, France)

W0393 09:30 Steroids and risk: quantifying IFI susceptibility
Andrés Henao (Aurora, United States)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), European Confederation of Medical Mycology (ECMM), Portuguese Society of Infectious Diseases and Clinical Microbiology, Romanian Society for Medical Mycology and Mycotoxicology (SRMMM), Austrian Society for Medical Mycology (ÖGMM), Belgian Society of Human and Animal Mycology, Spanish Study Group for Medical Mycology of SEIMC (GEMICOMED), Asia Fungal Working Group (AFWG), Taiwan Society of Microbiology

OS081 08:30 - 10:30 Hall B0-2
 2-hour Oral Session

Hot topics in tuberculosis

Chairs
Emmanuelle Cambau (Paris, France)
Christian Wejse (Aarhus, Denmark)

O0574 08:30 A 3D-Bioprinted Granuloma Platform with Controlled Syringe-Based Infection for Studying Mtb Drug Response and Host-Pathogen Interactions
*R. Sorrentino** (Milan, Italy), *C. Scielzo*, *D.M. Cirillo*, *R. Pinos*, *P. Miotto*, *A. Ghodousi*, *F. Saluzzo*, *A. Muscetti*

O0575 08:42 Airway microbiome signatures accurately discriminate *Mycobacterium tuberculosis* infection status
*G. Olweny** (Kampala, Uganda), *A. Kayongo*, *M.L. Ntai*

O0576 08:54 A platelet activation signature defines the CSF compartment in early tuberculous meningitis
*K. Skolimowska** (London, United Kingdom), *A.G. Davis*, *T. Reid*, *N. Bangani*, *C. Stek*, *P. Renner*, *M. Panchoo*, *R.J. Wilkinson*, *J.S. Friedland*

O0577 09:06 A randomised comparison of management strategies for drug-induced liver injury associated with tuberculous meningitis treatment
*J. Donovan** (Ho Chi Minh City, Vietnam), *N.T.T. Hiep*, *T.T. Hung*, *H.D.T. Nghia*, *L.H.B. Ngoc*, *N.D. Bang*, *K. Maharani*, *P.K.N. Oanh*, *E. Riwanti*, *N.T.T. Thuong*, *E. Kestelyn*, *D. Imran*, *R.L. Hamers*, *R.B. Geskus*, *N.H. Phu*, *G.E. Thwaites*

O0578 09:18 Genomic epidemiology as a high-resolution tool to investigate local tuberculosis outbreaks
*M.G. López** (Valencia, Spain), *A. Blasco-Molla*, *P. Cano-Jiménez*, *J.C. Gascó-Laborda*, *I. Gómez-Navarro*, *V. Furió*, *M. Torres-Puente*, *F.J. Roig-Sena*, *J. Bellido-Blasco*, *I. Comas*

O0579 09:30 Assessing the Diagnostic Accuracy of TB Transcriptomic Signatures in Children: Insights from the RaPaed-TB Study
*A. Razid** (Munich, Germany), *O. Baranov*, *M. Mcclean*, *Z. Franckling-Smith*, *H. Zar*, *C. Khosa*, *D. Banze*, *I. Sabi*, *N. Ntinginya*, *M. Niiwasa*, *E. Corbett*, *R. Semphere*, *V. Verghese*, *J. Michael*, *M. Ninan*, *E. Saathoff*, *T. Mchugh*, *S. Graham*, *R. Song*, *P. Nabeta*, *A. Trollip*, *M. Nicol*, *M. Ahmed*, *M. Hoelscher*, *N. Heinrich*, *L. Olbrich*, *C. Geldmacher*, *K. Held*

O0580 09:42 Tuberculosis infections among rifampicin-resistant tuberculosis household contact persons: a multi-central prospective cohort study (TCCT study)
*F. Zhou** (Shanghai, China), *Y. Lan*, *Q. Yang*, *W. Zhang*, *Q. Ruan*

O0581 09:54 Phenotypic drug susceptibility testing of *Mycobacterium tuberculosis* in less than a day
*B.M. Tran** (Uppsala, Sweden), *J. Larsson*, *E. Amselem*, *P. Knagge*, *J. Elf*

O0582 10:06 Are WHO recommended rapid diagnostic tests a panacea for the diagnosis of multidrug-resistant tuberculosis?
*N. Mvelase** (Durban, South Africa), *G. Vadivelu*, *R. Singh*, *Y. Mahabeer*

Scientific Programme

Monday, 20 April 2026

O0583 10:18 Inadequate Access to TB and MDR-TB Therapies in the EU and the European Economic Area: The Role of Regulatory Pathways
M. Van Der Heijden (London, United Kingdom), R. Otto-Knapp, C. Årdal*

PM001 08:30 - 10:30 Hall A2-1
Pipeline Symposium

AI in infectious diseases: the future is now

Chairs *Giorgia Carra (Lausanne, Switzerland)*
Ursula Theuretzbacher (Vienna, Austria)

D0001 08:30 AI - risks and opportunities
Bram Lestrade (Roermond, Netherlands)

D0002 09:00 AI - experiences in drug discovery
Stephan Sieber (Munich, Germany)

D0003 09:30 AI - modelling epidemics and analysing disease outbreaks
Moritz U. G. Kraemer (United Kingdom)

D0004 10:00 AI in the regulatory field
Radu Botgros (Amsterdam, Netherlands)

SY113 08:30 - 10:30 Hall ICM 1
2-hour Symposium

Sepsis 2026: practice-changing insights you can't ignore

Chairs *Thierry Calandra (Lausanne, Switzerland)*
Robin Patel (Rochester, United States)

S0361 08:30 ISF-ESCMID Sepsis Award

S0362 08:45 Reversing sepsis mortality in Uganda's refugee settlements: a solar-powered diagnostic revolution
U. Muhumuza (Kampala, Uganda), Z. Nahumuza, B.B. Nanyange*

S0363 09:00 The new surviving sepsis campaign 2026 guidelines
Willem Joost Wiersinga (Amsterdam, Netherlands)

S0364 09:30 Immunotherapy for sepsis: finally there!
Eleni Karakike (Athens, Greece)

S0365 10:00 Sepsis: year in review
Annelies Zinkernagel (Zurich, Switzerland)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)

SY114 08:30 - 10:30 Hall ICM 5
2-hour Symposium

Barriers to infectious disease control and treatment in resource-limited settings

Chairs *Nitin Gupta (Manipal, India)*
Priscilla Rupali (Vellore, India)

S0366 08:30 Scrub typhus: a neglected tropical disease
Winsley Rose (Vellore, India)

S0367 09:00 The impact of recent severe flooding events and global funding shifts on HIV in Malawi
Sam Phiri (Lilongwe, Malawi)

S0368 09:30 Polio eradication in Pakistan: health services, violence, and the 'Long Goodbye'
Svea Closser (Baltimore, United States)

S0369 10:00 Barriers to cholera control in Malawi amidst climate disasters
Anat Rosenthal (Beer Sheva, Israel)

SY115 08:30 - 10:30 Hall BO-1
2-hour Symposium

Interconnected microbiomes and resistomes across One Health

Chairs *Debby Bogaert (Edinburgh, United Kingdom)*
John W. A. Rossen (Groningen, Netherlands)

S0370 08:30 Hospital microbiomes as hotspots for emerging resistance: surveillance-to-intervention
Amy Mathers (Charlottesville, United States)

S0371 09:00 Silent transmission: the genetic bridges between worlds
Bruno Gonzalez-Zorn (Madrid, Spain)

S0372 09:30 Into the wild: connectivity of wildlife resistomes and antimicrobial resistance across sectors
Jacob Moran-Gilad (Beer Sheva / Jerusalem, Israel)

S0373 10:00 From barn to city: environmental transmission of livestock-associated microbiota and antimicrobial resistance
Myrna Maria Theresia De Rooij (Utrecht, Netherlands)

SY116 08:30 - 10:30 Hall A3-1
 AMR DX 2-hour Symposium

Mobile elements and plasmids in Gram-positive pathogens: new frontiers in structure, function and clinical impact

- Chairs* Kristin Hegstad (Tromsø, Norway)
 Marc Stegger (Copenhagen, Denmark)
- S0374 08:30** **Conjugation and host-range in Gram-positive plasmids: barriers and bridges**
 Elisabeth Grohmann (Berlin, Germany)
- S0375 09:00** ***Enterococcus faecium*: mobile elements and AMR spread**
 Jia Qi Beh (Melbourne, Australia)
- S0376 09:30** **The adaptation of *Staphylococci* for clonal success**
 Maria Miragaia (Oeiras, Portugal)
- S0377 10:00** **Resolving mobile elements and plasmids in Gram-positive pathogens: what new genomics reveals**
 Jukka Corander (Oslo, Norway)

Co-organised with: ESCMID Study Group for Mobile Elements and Plasmids (ESGMAP), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

SY117 08:30 - 10:30 Hall A3-2
 DX PHEI 2-hour Symposium

How to maintain the microbial safety of transfusion and transplantation?

- Chairs* Oscar Len (Barcelona, Spain)
 Anna Papa-Konidari (Thessaloniki, Greece)
- S0378 08:30** **Emerging infections and blood safety: urgent matter**
 Heli Harvala (Turku, Finland)
- S0379 09:00** **Are syphilis and other sexually transmitted infections a problem for blood safety?**
 Thijs Van De Laar (Amsterdam, Netherlands)
- S0380 09:30** **Tools to prevent transmission of HHV-8 via organ transplantation**
 Ines Ushiro-Lumb (Marlow, United Kingdom)
- S0381 10:00** **Amyloid beta as a novel transmissible agent**
 John Collinge (London, United Kingdom)

Co-organised with: European Society for Clinical Virology (ESCV)

EF083 09:30 - 10:30 Arena 1
 DX TRN ePoster Flash Session

Expanding the role of genomics and proteomics against AMR

- Chair* Lorena Lopez Cerero (Seville, Spain)
- E0593 09:30** **Genomic characterisation of carbapenem-resistant Enterobacterales (CRE) reveals high-risk clones and patient-environment transmission in a Nigerian tertiary hospital**
 B.A. Olanipekun* (Ilorin, Nigeria), A. Afolayan, A. Keller, S. Becker, L.A. Molano, J. Rehner, P. Jung, R. Raheem, A. Fadeyi, A. Shittu, C. Nwabuisi
- E0594 09:36** **Molecular characterisation of the first CTX-M-15 and OXA-9 β -lactamase-producing *Haemophilus influenzae* isolates in the Iberian Peninsula**
 A. González-Díaz* (Barcelona, Spain), M. Pinto, I. Cadenas-Jiménez, S. Duarte, C. Ardanuy, M.M. Ribeiro, S. Marti, P. Bajanca-Lavado
- E0595 09:42** **Genomic surveillance uncovers polyphyletic, high-risk *Escherichia coli* lineages in apparently healthy children and household livestock**
 N. Okumu* (Nairobi, Kenya), J. Juma, D. Mulo, E. Cook, O. Cumming, A. Moodley, S. Oyola, J. Ngeranwa
- E0596 09:48** ***In vitro* activity of cefiderocol against carbapenemase-producing *E. coli*: phenomics vs genomics for antimicrobial susceptibility prediction**
 C. Tellapragada* (Stockholm, Sweden), M. Razavi, P. Jonsson, C. Giske
- E0597 09:54** **Quantifying the association of resistance with antimicrobial resistance genes in *Escherichia coli* for new β -lactam/ β -lactamase-inhibitor/enhancer combinations**
 J. Takata* (Oxford, United Kingdom), D. Nagy, V. Pennetta, K. Hopkins, A. Roohi, D. Karageorgopoulos, M.B. Avison, A. Mathers, R. Hope, D. Williams, A. Ledda, J. Robotham, C.S. Brown, P. Bejon, G. Mcvean, A.S. Walker, K.L. Hopkins, S. Lipworth, N. Stoesser
- E0598 10:00** **K-MARVEL: K-Mer-based antimicrobial resistance virtual exploration lab**
 R. Ahmad* (Hamar, Norway), N.S. Mahar, S. Branders, M.G. Grabherr, I. Gupta
- E0599 10:06** **Early antimicrobial resistance prediction using urinary proteomics and machine learning**
 E. Lemann* (Gothenburg, Sweden), A. Marchi, R. Karlsson, A. Polster

Scientific Programme

Monday, 20 April 2026

E0600 10:12 **Benchmarking antimicrobial resistance gene prediction tools from metagenomic sequencing data of positive blood cultures**
*K. To** (Hong Kong, Hong Kong), *A. Li, D. Buhl, A. Chu, W.M. Chan*

E0601 10:18 **A Next-Generation platform for culture-free AMR gene identification in human infections**
*T. Mehrotra** (Faridabad, India), *B. Das*

EF084 09:30 - 10:30 **Arena 3**
 ePoster Flash Session

From virus to host and back again: exploring retroviruses

E0602 09:30 **Defining the contribution of T lymphocyte activation and proliferation to the HIV reservoir**
*L. Santinelli** (Rome, Italy), *L. Bortolani, L. Maddaloni, M. Andreotti, Z. Michelini, C. Falvino, G. Ceccarelli, C.M. Mastroianni, G. D' Ettore*

E0603 09:36 **Unexpected high prevalence of HTLV-1 in HIV-1 positive patients: A looming crisis?**
*G. Zahra** (Tehran, Iran, Islamic Republic of), *A. Letafati, L. Abbasian, S. Sadeghipour Marvi, S.H. Mozhgani, B. Sarshari*

E0604 09:42 **Immune Checkpoint LAG3 overexpression Reflects T Cell Dysfunction in PLWH with Low CD4/CD8 Ratio**
*S. Spampinato** (Catania, Italy), *G. Scuderi, M. Pinzone, N.L. Parrinello, M. Di Rosa, F. Condorelli, E. Venanzi Rul, A. Marino, R. Bruno, B. Cacopardo, B.M. Celesia, F. Di Raimondo, P. Fagone, G. Nunnari*

E0606 09:54 **Altered gene expression in migration and angiogenesis pathways of HTLV-1 infected individuals: implications for disease progression in asymptomatic carriers**
*A. Letafati** (Tehran, Iran, Islamic Republic of), *S.H. Mozhgani*

E0607 10:00 **Exploring immune correlates of low viral reservoir burden in people living with HIV following early ART initiation: a retrospective longitudinal study from the DZIF TOP-HIV cohort**
*M. Figueroa Orozco** (Munich, Germany), *E. Grüner, M. Münchhoff, R. Cohen, T. Trenkner, M. Beiersdorfer, A. Hölzemer, J. Röider*

E0608 10:06 **HIV-1 Subtype definition in the era of whole genome sequencing**
*F. Stefanelli** (Genova, Italy), *N. Randazzo, N. Nigro, S. Varesano, M. Ferraris, E. Massaro, V. Paolozzi, M. Ogliastro, L. Taramasso, V. Ricucci*

E0609 10:12 **Comparison of HIV Clusters in Metropolitan France and Overseas Territories**
*B. Visseaux** (Frepillon, France), *N. Rybak, G. Wartel, L. Nguyen, M. Niang, E. Hedbaut, S. Teixeira, V. Kailainathan, K. Diallo, S. Lastere*

E0610 10:18 **Near full genome sequencing of HIV-2**
*Ö. Yildirim** (Berlin, Germany), *M. Prentice, R. Ehret, M. Obermeier*

SY121 09:30 - 10:30 **Hall ICM 14**
 1-hour Symposium

Year in public health

Chairs *Alexandra Mailles* (Saint-Maurice, France)
Rita Oladele (Lagos, Nigeria)

S0394 09:30 -
David Fisman (Toronto, Canada)

S0395 10:00 -
Kurt Hanevik (Bergen, Norway)

EF092 11:00 - 12:00 **Arena 2**
 ePoster Flash Session

Antimicrobial stewardship in low resource countries: challenges and solutions

Chair *Igizeneza Acsa* (Kigali, Rwanda)

E0646 11:00 **Antimicrobial prescribing in five primary healthcare centres in northern Syria: a Global PPS based period prevalence survey**
*F. Abdo** (Amman, Jordan), *K. Parikh, Z. Ejjelat, A. Boven, A. Versporten, I. Pauwels, E. Vlieghe, A. Luczynska, R. Esguerra, C. Roman*

E0647 11:06 **Observed vs expected antibiotic use in MSF-supported primary outpatient MSF settings in North-West Syria**
*C. Naim** (Beirut, Lebanon), *A. Comelli, A. Farra, K. Moussally, P. Garcia-Vello, M. Khalife, C. Arias Vicente, A. Almohamad, Z. Ejjelat, A. Wetli, B. Alonso, A. Ali, C. Roman, M. Yaacoub, M. Gazal*

E0648 11:12 **A practical observational tool to measure antimicrobial stewardship and infection prevention behaviours in a low-resource hospital setting**
*C. Bonaconsa** (Cape Town, South Africa), *T. Makamu, A. Kona, M. Samkele, E. Charani*

E0649	11:18	<p>Assessing implementation fidelity of Malawi's antimicrobial resistance policy: key findings from a cross-sectional qualitative study on policy practice and perceived impact</p> <p>A. Lubanga* (Lilongwe, Malawi), K. Kunmin, T. Daniel, Z. Peter, N. Thomas</p>	EF093	11:00 - 12:00	Arena 3
ePoster Flash Session					
MDR pathogens around the globe: mechanisms, risk, and treatment optimisation					
			Chair	Merica Carev (Split, Croatia)	
E0650	11:24	<p>Tailoring empirical antibiotics to local resistance in severely malnourished hospitalised children in Niger: secondary analysis of a prospective cohort</p> <p>A. Delafon-Pariset* (Paris, France), B. Mollo, C. Langendorf, N. Peiffer-Smadja, R. Kanapathipillai, C.T. Andersen, S. Garba, N. Sayinzonga-Makombe, E.I. Tassiou, R. Daré, S. Isanaka, C. Amaris Hobson, M. Thy, C. Jimenez</p>	E0655	11:00	<p>Clinical Outcomes and Risk Factors for Mortality in Serious Infections due to Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Asia</p> <p>Y. Chang* (Kaohsiung City, Taiwan), A. Manesh, L. Mezzadri, X. Hao, Y. Ding, C. Yang, C. Yiyang, S. Kitsaran, H.H. Chua, B. Sotharith, S.S.L.S. Ponnampalavanar, S. Anunnatsiri, M.Z. Mazlan, A.K. Dhiloo, R. Plongla, A.L.H. Kwa, S.F. Mahmood, A.D. Roman, L. Thwaites, K.A. Nguyen, V.T. Phan, S. Wu, D. Chotiprasitsakul, K.J. Wong, H. Wijaya, C.L. Abad, M.O.R. Khalid, G.M.S. Mamun, G.S. Rajahram, H. Guterres, N.H. Huynh, V.G. Tran, N.T. Pham, A. Karkey, S. Gunasekara, R.L. Hamers, R. Sinto, I.N.D. Lubis, M. Wang, M. Moni, P.Y. Liu, Y. Xiao, B. Khanal, L. Priya, Y. Doi, H. Hitoshi, B. Baljin, R. Asli, U. Gurjav, L. Ling, A. Dhungana, L.Y. Hsu, Y. Mo, D.L. Paterson</p>
E0651	11:30	<p>Factors influencing antibiotic use in patients without bacterial infections during the COVID-19 pandemic in a tertiary care centre in a low-middle-income country</p> <p>N. Nasir* (Karachi, Pakistan), W. Fazal, Z. Nasim, N.S. Khan</p>	E0656	11:06	<p>Activity of cefiderocol against <i>Stenotrophomonas maltophilia</i> clinical isolates collected in multi-national antimicrobial surveillance studies SIDERO-WT (2014 - 2019) and SENTRY (2020 - 2024)</p> <p>Y. Yamano* (Osaka, Japan), C. Longshaw, S.T. Nguen, J.M. Maher, R.E. Mendes, M. Hackel, H. Yamashiro, B.L.M. De Jonge</p>
E0652	11:36	<p>Antimicrobial and corticosteroid prescribing for adults with suspected CNS infection in Botswana and Zimbabwe</p> <p>C. Coughlan* (London, United Kingdom), T. Mwarumba, R. Suresh, K. Ngoni, G. Manenji, R. Doyle, K. Boyd, C. Northcott, J. Penney, M. Kinsella, I. Mechie, S. Ensor, C. Williams, K. Lechiile, K. Siamisang, L. Owen, E. Gwakuba, T. Milton, T. Machiya, H.E. Barton, P. Ponatshego, K. Seatla, G. Boitshepo, I. Rulaganyang, L. Gwaunza, K. Kranzer, D. Grint, M.W. Tenforde, D.M. Goldfarb, M. Mokomane, M. Mine, G. Ngwende, C. Ndhlovu, J.N. Jarvis, J. Milburn</p>	E0657	11:12	<p>Emergence and characterisation of multi-carbapenemase-producing <i>Klebsiella pneumoniae</i> in Italy: genomic features and <i>in vitro</i> therapeutic options</p> <p>A. Cornacchia* (Teramo, Italy), S. Comini, F. Pomilio, C. Costa, M. Boattini, G. Bianco</p>
E0653	11:42	<p>Hospital Pharmacists in Antimicrobial Stewardship in Latin America: Roles and Challenges</p> <p>E. Zavaleta* (San Jose, Costa Rica), J.P. Diaz, R. Mosmann, P. Lichtenberger, R. Quiros</p>	E0658	11:18	<p>Epidemiology of Penicillin-Binding Protein 3 Variants in carbapenem-resistant <i>Escherichia coli</i> isolates from France</p> <p>I. Mehidi* (Le Kremlin-Bicêtre, France), A. Birer, A. Jacquemin, A.B. Jousset, P. Glaser, R.A. Bonnin, L. Dortet, S. Oueslati, T. Naas</p>
E0654	11:48	<p>Effects of participatory learning and action with primary care doctors on antibiotic prescribing for acute respiratory infections in Vietnam: a pilot cluster randomised study</p> <p>M.D. Vu* (Hanoi, Vietnam), N.Y. Nguyen, N.T.H. Nguyen, P.B. Bui, V.T. Khuong, H.T.T. Duong, L.V. Le, G. Coact Investigators, H.R. Van Doorn, N.T.T. Do, S. Nagraj, S. Lewycka</p>	E0659	11:24	<p>Integrating the ECRAID Emerging Resistance Index (ERI) into Antibiotic Policy for New Antibiotics Targeting Multidrug-Resistant Gram-Negative Bacteria: A Proof-of-Concept Analysis</p> <p>M.D. Pezzani* (Verona, Italy), J. Garlasco, D. Ortiz, K. Odoj, F. Arieti, A. Savoldi, M. Morra, E. Addis, M. Tebon, O. Awwad, A. Cassini, S. Harbarth, E. Presterl, G. Kahlmeter, E. Tacconelli</p>

Scientific Programme

Monday, 20 April 2026

- E0660 11:30** **Tracking *Clostridioides difficile* in Ireland: genomic landscape and antimicrobial resistance profiles of clinical isolates, 2022–present**
*D. Espadinha** (Dublin, Ireland),
N. O' Mara, A. Carroll, T.K. Teoh
- E0661 11:36** **Molecular antimicrobial resistance gene profiles in community-acquired, healthcare-associated, and hospital-onset *E. coli* and *K. pneumoniae* bacteraemia**
*G. Korürek** (Istanbul, Türkiye), *H. Tutan, U. Özgür, D.Y. Sevgi, B. Bayraktar*
- E0662 11:42** **Molecular epidemiology and antimicrobial resistance of *Mycoplasma genitalium* in Tokyo, 2023–2025**
*R. Omachi** (Saitama, Japan), *K. Imai, T. Maeda, A. Sato, M. Tanaka, N. Mori*
- E0663 11:48** **Profiling of dalbavancin resistance in clinical MRSA through a nationwide genomic survey in China: insights into resistance mechanisms**
*Y. Hong** (Hangzhou, China), *Y. Chen*

FO129 11:00 - 12:00 **Arena 1**
PRO **Open Forum**

Panic vs calm: the pivotal roles of trainees in infectious disease responses

- Chair* *Cassandra Bulescu* (Bucharest, Romania)
- F0333 11:00** **Being in the frontline: shaping public messaging during outbreaks**
Ferenc Balázs Farkas (Budapest, Hungary)
- F0334 11:10** **From crisis to resilience: the role of early career researchers in outbreak response**
Jules Villa (Paris, France)
- F0335 11:20** **COVID-19 pandemic memories: what can we learn for future crises?**
Laetitia Atlani-Duault (Paris, France)

Co-organised with: ESCMID Emerging Infections Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee

KN122 11:00 - 12:00 **Hall ICM 14**
PHEI **TRN** **Keynote Lecture**

On virus origin, evolution, and the next pandemic threat

Chairs *Giulia De Angelis* (Rome, Italy)
Jacob Moran-Gilad (Beer Sheva / Jerusalem, Israel)

K0320 11:00 **Edward Holmes** (Sydney, Australia)



Edward Holmes is an NHMRC Leadership Fellow and Professor of Virology in the School of Medical Sciences, University of Sydney, Australia, which he joined in 2012. Holmes received his undergraduate degree from the University of London (1986) and his PhD from the University of Cambridge (1990). Between 1993-2004 he held various positions at the University of Oxford, including University Lecturer in Evolutionary Biology and Fellow of New College. He was elected a Fellow of the Australian Academy of Science (FAA) in 2015 and of the Royal Society (FRS) in 2017. In 2021, he received the Australian Prime Minister's Prize for Science, and in 2023 he was awarded the 2024 Croonian Medal and Lecture by The Royal Society.

Fireplace Session 20 April, 12:15 - 13:15

LB006 11:00 - 12:00 **Hall A1-1**
PHEI **1-hour Oral Session**

Late-breaking disease surveillance approaches

Chairs *Megan Carey* (Amsterdam, Netherlands)
Carla Rodrigues (Paris, France)

L0031 11:00 **Inferring the global risk of dengue outbreaks**

*V. Cabrini** (Singapore, Singapore),
M.K.B. Mohamad Rosle, E.L.W. Choo, Y. Chen, J.T. Lim

L0032 11:12 **A climate-responsive emerging disease risk projection platform: version 1 release and early adoption opportunities**

*J. Abbate** (Montpellier, France),
V. Heurteaux

L0033 11:24 **Evaluation of a host-based, pathogen-agnostic viral biomarker for early outbreak detection**

*R. Mehta** (London, United Kingdom),
H. Hopkins, D. Mabey, E. Fitchett, P. Randell, A. Mohamed, M. Mayxay, Q. Bassat, J. Chipanga, C. Christopher, L. Papargyris, H. Wagstaff, S. Ascough, S. Hamilton, M. Levine, J. Herberg, O. Ioana-Diana, L. Maslen, M. Valdivia-Garcia, C. Anthony, E. Chekmeneva, S. Sriskandan

L0034 11:36 Metagenomics surveillance collaboration and analysis programme (mSCAPE): preliminary results from a national metagenomics surveillance pilot
S. Rokadiya (London, United Kingdom), N.J. Loman, M. Chand, N. Groves, R. Graham, A. Aryee, C. Rodrigues, R. Cohring, C. Houlihan, R. Puleston, S.A.J. Wilkinson, T. Brier, J. James, A. Banyard, D. Ward, R. Batra, J. Edgeworth*

L0035 11:48 Sustained mpox clade I human-to-human spread in DRC calls for continuous variant monitoring
E. Kinganda-Lusamaki (Kinshasa, Congo, the Democratic Republic of the), A. Amuri-Aziza, J.C. Makangara Cigolo, R. Lumembe-Numbi, G. Kabamba-Lungenyi, G. Luakanda-Ndelemo, P. Akil-Bandali, T. Wawina-Bokalanga, S. Ahuka Mundeke, J.J. Muyembe-Tamfum, A. Ayouba, E. Delaporte, M. Peeters, P. Mbala-Kingebeni*

ME126 11:00 - 12:00 Hall ICM 1
 AMR DX Meet-the-Expert

Applications of machine learning for predicting virulence and resistance by MALDI-TOF MS: opportunities and challenges

M0327 11:00 *Adrian Egli (Zurich, Switzerland)*

M0328 11:12 *Jaroslav Hrabak (Plzen, Czechia)*

ME127 11:00 - 12:00 Hall B0-1
 DX TRN Meet-the-Expert

Microbiome-based diagnostic tools, are we ready for prime-time?

M0329 11:00 *Debby Bogaert (Edinburgh, United Kingdom)*

M0330 11:12 *Gianluca Ianiro (Rome, Italy)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

ME128 11:00 - 12:00 Hall B0-2
 CLN DX Meet-the-Expert

The returned traveler with eosinophilia: clinical, diagnostic and therapeutic approaches

M0331 11:00 *Martin Montes (Lima, Peru)*

M0332 11:12 *Diana Ayoola Mabayoje (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

OS085 11:00 - 12:00 Hall ICM 13a
 CLN 1-hour Oral Session

Artificial intelligence: emerging applications for medical mycology

Chairs Ronen Ben-Ami (Tel Aviv, Israel) Toni Gabaldón (Barcelona, Spain)

O0636 11:00 Machine learning-based predictive model for invasive mould infections in haematology patients: development and validation

E. Gras (Barcelona, Spain), C. Teijón-Lumbreras, P. Monzo-Gallo, B. Glemain, T.F. Aiello, A. Gallardo-Pizarro, A. Martínez-Urrea, C. Terrones, A. Castiella, A. Vergara, C. Martínez, M. Suarez-Lledó, J. Esteve, A. Soriano, C. Garcia-Vidal*

O0637 11:12 Geo-seasonal AI modelling of airborne filamentous fungi reveals divergent climatic niches relevant to invasive mould infections

A. Sergounioti (Amfissa, Greece), P. Dimitrelou, E. Alonaris, D. Rigas*

O0639 11:36 Evaluation of the performance of large language models in mycological diagnosis

M. Aras (Istanbul, Türkiye), M.I. Tosun, N. Samancı, I. Caklovica Kucukkaya, S.A. Ozyar Kurtcu, E. Kirbas, B. Sayar, B. Sancak, D.Y. Metin*

O0640 11:48 Machine learning-based gene screening unravels key determinants of caspofungin resistance

Y. Su (Beijing, China), Y. Xu*

Scientific Programme

Monday, 20 April 2026

OS086 11:00 - 12:00 Hall ICM 13b
 PHEI VAX 1-hour Oral Session

Vaccines: landmark trials and preventive immunisation

Chairs *Joel Mossong (Luxembourg, Luxembourg)*
Oana Sandulescu (Bucharest, Romania)

- O0641 11:00 Randomised phase III trial of a 9-valent vaccine (ExPEC9V) for prevention of invasive *Escherichia coli* disease (IED) in older adults (E.mbrace)**
K.A. Cohen (Titusville, United States), C. Mclean, T. Day, M. Peeters, I. Scheys, M.G. Pau, J. Poolman, M. Bonten*
- O0642 11:12 Avian influenza A (H5N1) clade 2.3.4.4b haemagglutinin–Matrix-M nanoparticle vaccine (H5-MNP) induces neutralising responses and protection against H5N1 challenge in mice**
R. Draghia-Akli (Gaithersburg, United States), J.F. Trost, B. Zhou, K. Pyles, T.L. Darling, A.C.M. Boon, G.E. Smith*
- O0643 11:24 Final results from a phase IIb randomised controlled trial assessing the efficacy and impact of full- and fractional-dose regimens of the RTS,S/AS01E malaria vaccine in Ashanti Region, Ghana and Siaya County, Kenya, September 2019 - November 2024**
D. Otieno (Kisumu, Kenya), K. Sam*
- O0644 11:36 High-dose vs standard-dose influenza vaccine effectiveness according to frailty risk: a prespecified analysis of the DANFLU-2 trial**
C. Espersen (Hellerup, Denmark), N.D. Johansen, D. Modin, K.H. Janstrup, M.M. Loiacono, R.C. Harris, Y. Huang, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B.L. Claggett, K.V. Bartholdy, K.F. Bernholm, J.I.M.H. Borchsenius, F.S. Davidovski, L.W. Davodian, M. Dons, L.S. Duus, F.H. Fussing, A.M.R. Jensen, N.E. Landler, A.C.F. Langhoff, M.C.H. Lassen, A.B. Nielsen, C.I. Ottosen, M. Sengeløv, K.G. Skaarup, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, C.J.M. Martel, J.U.S. Jensen, G. Gavazzi, T. Biering-Sørensen*
- O0645 11:48 Effectiveness of PCV10 and PCV13 against invasive pneumococcal disease in Vietnamese children: a multi-centre matched case–control study**
C. Truong (Ho Chi Minh, Vietnam), T. Nguyen, N. Speybroeck*

OS087 11:00 - 12:00 Hall A1-2
 AMR IPC 1-hour Oral Session

Hospital- and ventilator-associated pneumonia: new insights on prevention, diagnosis and treatment

Chairs *Elisabeth Presterl (Vienna, Austria)*
Jeroen Schouten (Nijmegen, Netherlands)

- O0611 11:00 The hospital acquired pneumonia prevention (HAPPEN) study: a multi-centre randomised controlled trial**
B. Mitchell (Gosford, Australia), N. White, P. Russo, A. Cheng, M. Kiernan*
- O0612 11:12 Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): Secondary analysis using Desirable Outcome Ranking with Response Adjusted for Duration Antibiotic Risk and Generalised Pairwise Comparison**
A. Blanco Arévalo (Barcelona, Spain), N.A. Binte Mohamed, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, Y.H. Lau, P. Chetchotisakd, D. Limmathurotsakul, P.A. Tambyah, B.S. Cooper, Y. Mo*
- O0613 11:24 Antibiotic duration-response curve for ventilator-associated pneumonia using a target trial emulation**
W.C. Tan (Singapore, Singapore), J. Quah, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, L. Yie Hui, P. Chetchotisakd, D. Limmathurotsakul, P.A. Tambyah, J. Chaisurote, P. Poomthong, A. Kawiwangsanon, K. Semram, S. Kitsaran, P. Wongsrikaew, N. Wetchagama, S. Patamatham, A. Rujisirasankul, A. Narmwong, C. Sodapak, S. Nuntalohit, S. Boonsong, J. Nilsakul, J. Moolasart, A. Phunmanee, A. Panitchote, P. Duangthongphon, P. Pisuttimarn, N. Srisurat, Y. Hwee Seng, G. Maclaren, T.W. Lim, K.L. Chew, S.L. Lim, B.W. Teo, T.J. Lim, L.J. Sun, S. Peng, N. Graves, Y.T. Chew, L.M. Ling, P.Y. Chia, Y.W. Chia, W. Huang, Y.K. Chan, P. Roshan, S. Anil, K. Abhilasha, D. Sabina, F.F. Tuon, B.S. Cooper, Y. Mo*
- O0614 11:36 Trimethoprim/sulfamethoxazole vs vancomycin for MRSA ventilator-associated pneumonia: a retrospective study**
F.F. Tuon (Curitiba, Brazil), A. Salomão, V. Sabbaga Amato, J.P. Telles*
- O0615 11:48 Impact of antimicrobial stewardship programmes on hospital-acquired and ventilator-associated pneumonia among adults: a systematic review and meta-analysis**
S. Rachina (Moscow, Russian Federation), N. Ablakimova, D. Strelkova, A. Suvorov, G. Smagulova*

OS088 11:00 - 12:00 Hall A1-3
 CLN DX TRN 1-hour Oral Session

Focus on infective endocarditis: from pathogens to prognosis

Chairs Tatjana Lejko Zupanc (Videm–Dobrepolje, Slovenia)
 Parham Sendi (Bern, Switzerland)

O0616 11:00 BlaZ-associated mortality in patients with *Staphylococcus aureus* endocarditis
*P. Mathé** (Freiburg, Germany),
M.T. Leibenguth, M. Hanke, S. Schuster, J. Camp, D. Hornuss, G. Peyerl-Hoffmann, A.J. Kaasch, I. Joost, H. Seifert, W. Kern, S. Rieg

O0617 11:12 Evaluation of different scores for the prediction of infective endocarditis among patients with *Staphylococcus aureus* bacteraemia
*Z. Dennebouy** (Lausanne, Switzerland),
M. Padrutt, P. Monney, G. Tzimas, M. Frank, L. Senn, L. Niclauss, M. Kirsch, M. Van Hemelrijck, O. Dzemali, B. Guery, B. Hasse, M. Papadimitriou-Olivgeris

O0618 11:24 Removal of cardiac implanted electronic devices in patients with *Staphylococcus aureus* bacteraemia without endocarditis is not associated with improved survival
*D. Macfadden** (Ottawa, Canada),
N. Daneman, L. Lau, S. Almoosawy, E. Athan, D. Birnie, J. Davis, W. Gold, M. Golian, J. Johnstone, T. Lee, E. Mcdonald, D. Messika-Zeitoun, S. Ong, M. Cheng, S. Tong, H. Wijeyesundera, C. Yu

O0619 11:36 Characteristics of infective endocarditis caused by *Enterococcus faecium*: a study from the GAMES cohort
*E. Aparicio-Minguijón** (Madrid, Spain),
P. Muñoz, M. Machado-Vilchez, M. Valerio-Minero, A. Josune Goikoetxea-Agirre, M.J. Blanco-Vidal, M.Á. Rodríguez-Esteban, C. Hidalgo-Tenorio, G. Ojeda-Burgos, J.M. Miró, R. Parra-Fariñas, V.A. Hortigüela Martín, I. Diego Yagüe, F. López-Medrano

O0620 11:48 Should we extend the use of oral antibiotics in infective endocarditis? the ENDO-ORAL study
*R. Pouy** (Reims, France), *B. Rallet, C. Coutureau, M. Blot, F. Bani-Sadr, T. Sixt, M. Moutel, L. Piroth, M. Hentzien*

OS089 11:00 - 12:00 Hall A1-4
 AMR DX VAX 1-hour Oral Session

Mechanistic insights into antimicrobial activity and resistance of Gram-negative bacteria

Chairs Kwame Ohene Buabeng (Ho, Ghana)
 Thomas Tängdén (Uppsala, Switzerland)

O0621 11:00 Activity of ciprofloxacin vs delafloxacin in acidic environments: impact of SOS response inactivation in *Escherichia coli*
*M. Murillo-Torres** (Seville, Spain),
K. Alexandre, Á. Pascual, F. Docobo-Pérez, J.M. Rodríguez-Martínez

O0622 11:12 Characterising penicillin-binding protein 2 (PBP2) mutations causing zidebactam resistance in *Pseudomonas aeruginosa*
*M.Á. Sastre-Femenia** (Palma, Spain),
M.A. Gomis-Font, B. Moya, A. Oliver

O0623 11:24 Spontaneous resistance to siderophore-conjugated β -lactams in *Klebsiella pneumoniae*: diverse mechanisms and fitness effects
*G. Zaborskyte** (Oxford, United Kingdom),
G. Zaborskytė, A. Lankapalli, A.J.M. Farley, C.J. Schofield, T.R. Walsh

O0624 11:36 Pre-existing β -lactamase gene diversity reduces ESBL-producing Enterobacterales colonisation risk in patients exposed to ceftriaxone
*Q. Le Bastard** (Nantes, France),
M. Emmanuel, R. Etienne, R. Gschwind, J. Lao, M.A. Vibet, B. Eric, C. Stéphane

O0625 11:48 Optimising the treatment regimen with phage cocktails and ceftolozane/tazobactam against carbapenem-resistant *Pseudomonas aeruginosa* endotracheal tube biofilms
*V. Oliveira** (Barcelona, Spain), *A. Rocha, A. Soler-Comas, G. Macip, E. Watanabe, M. Ferrer, A. Torres, L. Fernandez-Barat*

Scientific Programme

Monday, 20 April 2026

OS090 11:00 - 12:00 Hall A1-5
 DX PHEI 1-hour Oral Session

Overcoming diagnostic challenges in low resource settings

- Chairs* Nitin Gupta (Manipal, India)
 Juliette Severin (Rotterdam, Netherlands)
- O0626 11:00** **BADLOCK: A rapid, portable, inexpensive diagnostic for bacterial pathogen and resistance detection in resource-limited settings**
 D. Roach* (Somerville, United States),
 P. Sangruji, S. Bhat, R. Bhattacharyya
- O0627 11:12** **Accelerating bacteraemia management with molecular-AI vs molecular-phenotypic AI antimicrobial recommendations: a prospective study in a resource-limited setting**
 M. Hueda-Zavaleta* (Tacna, Peru),
 J.C. Gómez De La Torre, A. Frenkel,
 C. Chavez-Lencinas, A. Rendon, Y. Higuchi,
 L. Alvarado, J.A. Cáceres-Delaguila,
 D. Minchon-Vizconde
- O0628 11:24** **Microbiology lab implementation in low-resource settings: Does it help clinicians reducing antibiotic prescriptions for hospitalised patients?**
 H. Nguyen Thi* (Ha Noi, Vietnam),
 T. Hoang Van, H. Tran Thi, C. Dang Quang,
 H. Tran Thi Bich, H. Phan Quoc, M. Nguyen
 Duy, H. Nguyen Ba, H. Phan Van,
 T. Pham Le, G. Bui Thi Huong, T. Pham Thi
 Thanh, H. Nguyen Thi Thu, D. Pham Minh,
 H. Dinh Xuan, K. Bui Xuan, H. Nguyen
 Thi Bich, L. To Duc, H. Nguyen Ngoc, T. Van
 Dinh, H. Nguyen Thanh, Y. Nguyen Hai,
 P. Bui Bich, H. Vu Thi Lan, R. Van Doorn,
 T. Kesteman
- O0629 11:36** **Addressing diagnostic limitations in enteric fever in resource-limited settings**
 S. Dongol* (Lalitpur, Nepal), N. Maharjan,
 A. Karkey, C. Parry, B. Basnyat
- O0630 11:48** **Evaluation of immunochromatographic assays for carbapenemase detection: a multi-centre study within the strengthening a Brazilian system for surveillance and prevention of antimicrobial resistance network (VigiRAM)**
 M. Pillonetto* (São José Dos Pinhais,
 Brazil), L. Kraft, G.A. Gonçalves,
 H.R.S. D'espindula, D. Kulek,
 A.P.S. Chacon, J.M. Cieslinski, R.T. Souza,
 A.L. Abreu, A.P. Assef

OS091 11:00 - 12:00 Hall A3-2
 TRN VAX 1-hour Oral Session

Intracellular persistence of Gram-negative pathogens: immune evasion and implications for treatment

- Chairs* Christian Stephan Lentz (Tromsø, Norway)
 Nina Van Sorge (Amsterdam, Netherlands)
- O0631 11:00** **OmpA controls intracellular survival of *Acinetobacter baumannii* through TFEB activation and lysosomal remodeling**
 Á. Rey Hidalgo* (Seville, Spain), M. Pérez-
 Pérez, G. Olgiati, C. Atalaya-Rey, I. Molina-
 Panadero, Y. Smani
- O0633 11:24** **T5SS-Mediated contact-dependent inhibition drives intracellular UPEC persists contributing to recurrent UTI**
 M. Obrebski* (Warsaw, Poland), M. Kirzyc,
 M. Równicki, J. Piwowarski
- O0634 11:36** **The intracellular state: a fortress of persistence for uropathogenic *Escherichia coli***
 J. Atrissi* (Brussels, Belgium),
 J.F. Ouédraogo, F. Van Bambeke
- O0635 11:48** **The human bladder microenvironment and urinary fluid dynamics modulate antibiotic and bacteriophage treatment against uropathogenic *Escherichia coli***
 J. Rohn* (London, United Kingdom),
 R. Garcia Maset, A. Crowther, V. Chu, D. Di
 Grande, R.O.A. Jariah, J. Yoon,
 D. Blumgart, M.A.E. Hodek, N. Yuen,
 B.O. Murray, L. Pasquina-Lemonche,
 S.N.H. Alghamdi, A.D. Millard, G. Lutheryn,
 M.E.K. Haines, M.R.J. Clokie, E. Stride,
 D. Carugo

PM002 11:00 - 12:00 Hall A2-1
 AMR PHEI Pipeline Symposium

Accelerating access: rethinking HTA to unlock AMR solutions

- Chairs* Maarten Postma (Groningen, Netherlands)
 Charlotte Vernhes (Brussels, Belgium)
- D0005 11:00** **Data: what's available today and where are the key gaps?**
 Marlieke De Kraker (Geneva, Switzerland)
- D0006 11:15** **Full economic value of AMR solutions in HTA**
 Michele Cecchini (Paris, France)
- D0007 11:30** **EU HTA regulation and AMR solutions: lessons from vaccines**
 Eliana Biundo (Wavre, Belgium)

SY123 11:00 - 12:00 Hall ICM 5
ANT TRN 1-hour Symposium

Going super small: nano-technology in infectious diseases

Chairs Gregor Fuhrmann (Erlangen, Germany)
Kimberly Kline (Geneva, Switzerland)

S0321 11:00 Repurposing antimicrobials with ultrasound-triggered nanoscale systems for targeted biofilm drug delivery
Eleanor Stride (Oxford, United Kingdom)

S0322 11:30 Nanotechnologies for precision immunotherapy and infection treatment
Willem Mulder (Eindhoven, Netherlands)

SY124 11:00 - 12:00 Hall A2-2
ANT CLN DX 1-hour Symposium

Innovations in the management of tuberculosis and non-tuberculous mycobacteria

Chairs Catherine Ong (Singapore, Singapore)
Onya Opota (Lausanne, Switzerland)

S0323 11:00 New diagnostics for mycobacterial infection
Daniela Maria Cirillo (Milan, Italy)

S0324 11:30 Applying pharmacokinetics for the optimisation of mycobacterial treatments
Elin Svensson (Uppsala, Sweden)

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

SY125 11:00 - 12:00 Hall A3-1
CLN IPC 1-hour Symposium

Surgical site infections after solid organ transplantation: an underestimated driver of transplant outcome

Chairs Wanessa Clemente (Belo Horizonte, Brazil)
Elda Righi (London, United Kingdom)

S0325 11:00 SSIs after visceral transplantation
Nicolas Mueller (Zurich, Switzerland)

S0326 11:30 SSIs after thoracic transplantation
Manuela Carugati (Durham, United States)

EF097 13:30 - 14:30 Arena 1
AMR ANT CLN ePoster Flash Session

Fosfomycin for difficult-to-treat resistant pathogens: is it really a useful weapon?

Chair Andre Kalil (Omaha, United States)

E0679 13:30 Can the fosfomycin MIC value be used in the evaluation of response to treatment of carbapenemase-producing Enterobacterales infections with fosfomycin-containing regimens?
M. Törüyenler Coskunpınar (Ankara, Türkiye), D. Ocal, G. Cinar, L. E. Dogangul Doygun, Z. Tekbas*

E0680 13:36 Effectiveness of antibiotic regimens for the treatment of bloodstream infections caused by carbapenem-resistant *Acinetobacter baumannii*: a national, multi-centre study
F. Serapide (Catanzaro, Italy), A. Russo, S.P. Gulli, A. Vena, L. Spadafora, M. Bernardi, S. Corcione, G. Ceccarelli, F. Alessandri, C.M. Mastroianni, A. Oliva, E. Venanzi-Rullo, G. Caviglia, A. Cortegiani, M.C. Ippolito, G. Nunnari, F. Di Gennaro, A. Saracino, A. Marino, B. Cacopardo, G. Tiseo, M. Falcone, V. Galfo, C. Iaria, G. Pipitone, A. Cascio, S. Carbonara, L. Montemurro, F.S. Serino, N. Boffa, M. Libanore, F.G. De Rosa, A. Mattei, A. Calabresi, M. Tumbarello, L. Fontanelli Sulekova, C. Pallotto, P. Brugnaro, R. Mascianà, B. Tiri, N. Coppola, G. Calabria, A. Bandera, A. Lombardi, P. Vassalini, N. Carannante, V. Scaglione, M. Meschiari, O. Simonetti, A. Mularoni, F. Bar, C. Mussini, M. Bassetti, G. Biondi-Zoccai*

E0681 13:42 Evaluation of fosfomycin including regimens in culture-confirmed carbapenem-resistant Gram-negative pneumonia: analysis of 53 cases
M.B. Özkara (Izmir, Türkiye), D. Kaya, M. Mert Vahabi, D. Akyol Seyhan, O. Acet, A. Kaya, A.M. Parmaksızoğlu Aydın, M. Ceylan, F.B. Arıkan, S. İstek, D. Yaman, B. Süllü, D. Verendağ, H.A. Erdem, H. Sipahi, T. Yamazhan, B. Arda, Ş. Aydemir, O.R. Sipahi*

E0682 13:48 How and why clinicians use intravenous (IV) fosfomycin in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) Registry
G. Zhanel (Winnipeg, Canada), M. Baxter, M. Wong, Y. Mirzanejad, A. Lee, R. Dhani, J. Kosar, D. Werry, N. Irfan, J.F. Tessier, G. Girouard, C. Tascini, T. Von Den Baumen, M. Savoie, A. Serebryansky, J. Chan, M. Kucey, A. Walkty, J. Karlowsky*

Scientific Programme

Monday, 20 April 2026

E0683	13:54	Fosfomycin resistance in Enterobacterales: a comprehensive national surveillance in the Czech Republic <i>K. Chudejova* (Plzen, Czechia), V. Mattioni Marchetti, S. Kanova, V. Zaccaria, I. Bitar, J. Hrabak</i>	E0689	13:36	Direct penicillin allergy de-labelling at a pre-anaesthesia consultation: picking the low-hanging fruit? <i>S. Deryckere* (Ghent, Belgium), P. De Nocker, H. Lapeere, L. De Baerdemaeker, D. Huis In 't Veld</i>
E0684	14:00	Synergistic activity of fosfomycin and temocillin against GES carbapenemase-producing Enterobacteriaceae <i>J.L. Rodriguez Ochoa* (Santander, Spain), N. Fraile-Valcárcel, S. García-García, M. Siller-Ruiz, D. Pablo-Marcos, S. García-Fernández, M.P. Roiz-Mesones, A. Ocampo-Sosa</i>	E0690	13:42	Implementation of a penicillin allergy delabelling service in a UK centre: measuring indicators of success <i>B. Morris* (Cambridge, United Kingdom), U. Ahmed, R. Santos, C. Aherne, I. Lowings, X. Yi, S. Nasser, P. Gurugama, T. Gouliouris</i>
E0685	14:06	Evolution of the <i>in vitro</i> activity of fosfomycin against carbapenemase-producing microorganisms in Colombia <i>G.A. Muñeton Lopez* (Bogota, Colombia), M.F. Rueda, N.C. Mendoza, J.C. Torres, D. Celis-Giraldo, H. Vergara</i>	E0691	13:48	Penicillin allergy de-labelling by non-specialists in NHS acute care: A UK-wide survey and review of current practice by the PADL-UK survey <i>A. Blanshard* (Manchester, United Kingdom), H. Lewis, N. Fleming, P. Howard, T. Locke, R. Payne</i>
E0686	14:12	Discovery and characterisation of gfa, a novel fosfomycin resistance gene family already spread in environmental and clinical bacteria <i>N. Kieffer* (Madrid, Spain), L. Ortiz-Miravalles, A. Hipolito, A. Prieto, A. Carvalho, E. Vergara, J.A. Escudro</i>	E0692	13:54	Patients' experiences of penicillin allergy evaluation and delabeling process in primary care <i>T. Langeveld* (Bilthoven, Netherlands), T. Schoffelen, A. Timen, M. Hulscher, N. Milevska-Kostova</i>
E0687	14:18	In vitro activity of fosfomycin against <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Enterococcus faecalis</i> isolated from urine specimens in Canada: CANWARD surveillance study 2007–2022 <i>J. Karlowsky* (Winnipeg, Canada), G. Zhanel, H. Adam, M. Baxter, A. Walkty, P. Lagacé-Wiens</i>	E0693	14:00	Can vancomycin therapeutic drug monitoring detect acute kidney injury before serum creatinine? <i>M. Scheetz* (Downers Grove, United States), S. Leech, A. Sathyanarayanan, S. Roy, P. Sabourenkov</i>
E0698	13:30 - 14:30	Arena 2 ePoster Flash Session	E0694	14:06	Vancomycin-induced kidney injury in adult oncology: adjudicated incidence and a pragmatic dosing framework derived from AUC-guided care <i>J.P. Telles* (São Paulo, Brazil), D. Coelho Jr, K. Migotto, D. Feriani Da Silva, R. Reghini, G.T. Daiane, F. Lima De Oliveira, P. Caruso, I. França E Silva</i>
First, do no harm: allergy, kidney safety and length of stay in antimicrobial stewardship			E0695	14:12	Development and validation of a prediction model for acute kidney injury risk in patients receiving concomitant vancomycin and piperacillin/tazobactam <i>D. Chen* (Macau Sar, Macao), H. Zhang, X. Luo, M. Yu, J. Kan, A. Zhao, W. Ge</i>
Chair	<i>Pilar Retamar Gentil (Seville, Spain)</i>				
E0688	13:30	ESCMID Clinical Guidelines on the Evaluation and Management of a Reported Antibiotic Allergy <i>O. Joean* (Jena, Germany), K. Sermet, L. Ashkenazi-Hoffnung, Y. Cakir Kiyamaz, K. Blumenthal, C.M. Bonazzetti, A.M. Chiriac, S. Gomez-Zorrilla, E. Karakike, E. Khatamzas, N. Powell, J.A. Trubiano, R. Wijnakker, J. Sandoe, B. Nagavci, M.G.J. De Boer</i>	E0696	14:18	Saving beds and budgets: real-world efficacy, safety, and pharmacoeconomics of Long-Acting Lipoglycopeptides in a day hospital setting <i>A. Marino* (Catania, Italy), E. Venanzi Rullo, G. Pipitone, A. Albanese, A. Franzò, A. De Vito, N. Geremia, C. Iaria, G. Madeddu, B. Cacopardo, G. Nunnari</i>

EF099 13:30 - 14:30 Arena 3
ANT CLN ePoster Flash Session

Ask AI how to manage antibiotics!

Chair Carolina Garcia Vidal (Barcelona, Spain)

E0697 13:30 Evaluating a machine learning-based decision support tool for early antibiotic discontinuation in Lower Respiratory Tract Infections (LRTI): a randomised controlled trial

S. Tang* (Singapore, Singapore), D. Yii, R. Lim, M.P. Chlebicki, J. Chung, A. Kwa

E0698 13:36 Cost-effectiveness of a machine-learning (ML) approach for reducing unnecessary antibiotic use in patients with suspected lower respiratory tract infections (LRTI): An economic analysis of a randomised clinical trial

Y. Cai* (Singapore, Singapore), N. Nazeha, S. Tang, D. Yii, A.L. Kwa, N. Graves

E0699 13:42 Who's the smartest in the room? Benchmarking large language models for antimicrobial stewardship support

G. Pellejero* (Zaragoza, Spain), Á. Abejez-Arrizabalaga, J. Schouten, T. Schoffelen, E. Morte-Romea, E. Ruizendaal, J. Origüen, M.T. Pérez-Rodríguez, P. Retamar-Gentil, N. Sisamón-Dolader, B. Franco-García, R. Del Hoyo, S. Letona-Giménez, J.R. Paño-Pardo

E0700 13:48 An antibiotic chatbot for providing guideline-based antimicrobial advice

D. Eyre* (Oxford, United Kingdom), R. Corrigan, L. Hookham, S. Lumley, D. Clarke, K. Jeffery, L. Dunsmure, N. Jones

E0701 13:54 Antimicrobial stewardship programme: a data-driven approach to continuously optimised, locally adapted empirical antibiotic guidelines

M. Raad* (Sarrebouurg, France), T. Yokoyama, S. Boujaafar, F. Mutisya, C. De Turckheim, P. Berger, L. Vezard, M. Valette, C. Moore

E0702 14:00 Investigating UK online antibiotic provision: A covert simulated patient ethnographic study

S. Boyd* (London, United Kingdom), N. Zhu, R. Jain, A. Parmar, A. Matthews, A. Holmes, R. Ahmad

E0703 14:06 UK Outpatient parenteral antimicrobial therapy/Complex outpatient antimicrobial therapy (OPAT/COpAT) point prevalence dashboard

S. Khan* (London, United Kingdom), J. Grayson, M. Gilchrist, A. Seaton

E0704 14:12 Performance of a clinical decision support tool on targeted antibiotic treatment in the emergency department: A retrospective study

S.N. Sogaard* (Aabenraa, Denmark), L. Ward, M.L. Mogensen, C.B. Mogensen, M.B. Cartuliales, H. Skjøt-Arkil

E0705 14:18 Bayesian neural network (BNN) with uncertainty-thresholding for personalised empirical antibiotic guidance, compared to clinician prescribing

A. Luk* (Oxford, United Kingdom), K. Yuan, J. Wei, S.A. Walker, D. Eyre

JS003 13:30 - 14:30 Hall A3-1
Journal Session

Late-breaking research from The Lancet - new interventions for more established pathogens

Chairs Syeda Saleha Hassan (London, United Kingdom)
Onisillos Sekkides (London, United Kingdom)

J0010 13:30 Clinical effectiveness and bacteriological eradication of three different short-course antibiotic regimens and single dose fosfomycin for uncomplicated lower urinary tract infections in adult women (SCOUT study): a pragmatic, multicentre, multi-arm, open-label, randomised clinical trial

Carl Llor (Barcelona, Spain)

J0011 13:42 Maribavir for clinically significant cytomegalovirus infection in hematopoietic cell transplantation: a real-world retrospective international study of the Infectious Disease Working Party of EBMT

Annalisa Paviglianiti (Barcelona, Spain)

J0012 13:54 Characterisation of immune responses targeting highly pathogenic avian influenza A(H5) viruses in health-care workers in the Netherlands: an observational, cross-sectional analysis

Rory De Vries (Rotterdam, Netherlands)

J0013 14:06 Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin resistant tuberculosis (SMARTT): a pragmatic, randomized, single-blinded phase IV medical device trial

Annelies Van Rie (Wilrijk, Belgium)

J0014 14:18 Adjunctive Betamethasone Treatment of Hypoxemic Adults Hospitalised with Mycoplasma pneumoniae Community-acquired Pneumonia: An Open-Label, Multicentre, Randomised, Controlled Trial

Karl Hagman (Göteborg, Sweden)

Scientific Programme

Monday, 20 April 2026

LB007 13:30 - 15:30 Hall ICM 1
 AMR CLN 1-hour Oral Session

The trial run

Chairs Angela Huttner (Geneva, Switzerland)
 David L. Paterson (Singapore, Singapore)
 Steven Tong (Melbourne, Australia)

L0036 13:30 **PipEracillin Tazobactam vs mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacterales (PeterPen)**
 M. Paul* (Haifa, Israel), Y. Dishon, D. Yahav, T.C. Lee, L. Leibovici, M. Kristen, K. Afra, C. Condin, T. Bai, J. Strahilevitz, V. Daitch, R. Ben-Ami, M. Chowders, L. Nesher, M. Hershman, A. Carignan, P. Daley, P. Leighanne, J. Eastmond, T. Finn

L0037 13:50 **Ertapenem vs meropenem for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales: an ASTARTE post hoc analysis**
 J. Rodríguez-Baño* (Seville, Spain), F. Cogliati Dezza, L. Barrera Pulido, I. Borreguero Borreguero, F. Docobo Pérez, V. Palomo Jiménez, S. De La Rosa Riestra, J.M. Bravo-Ferrer, Z.R. Palacios-Baena, M.Á. López Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. Horcajada, E. Merino, M. Parra, J. López-Contreras, A. Rivera, D. Sousa Regueiro, M. Pampín García, S. López Cardenas, M.C. Gómez Sánchez, I. Pérez Camacho, S.M. Martín Ramos, E. León Jiménez, A.I. Aller García, M.T. Pérez-Rodríguez, A. Sousa, M. Siller Ruiz, F. Arnaiz De Las Revillas Almajano, L. Gisbert Pérez, J. Goikoetxea Agirre, Á. Cano, F.J. Martínez-Marcos, M.J. García País, R. Escudero-Sánchez, S. De La Villa, J.R. Yuste Ara, M.Á. Esteban-Moreno, A. Ruiz-Sancho, M. Pedrosa Aragón, J.A. Fernández, A.M. Barrios Blandino, H.H. Vilchez-Rueda, R. Álvarez-Marín, A. Romero Palacios, E. García Vázquez, E. Nuño Álvarez, C. Rosso-Fernández, B. Gutiérrez-Gutiérrez, Á. Pascual, L. López-Cerero

L0038 14:10 **A decade after the MERINO trial: refusing to grow up?**
 David L. Paterson (Singapore, Singapore)

L0039 14:20 **When the fairy dust settles: critical appraisal of presented trials**
 Angela Huttner (Geneva, Switzerland)

L0040 14:30 **Tick Tock, AMR clock: How should I treat my next ESBL bacteraemia patient?**
 Steven Tong (Melbourne, Australia)

ME133 13:30 - 14:30 Hall ICM 5
 ANT TRN Meet-the-Expert

Membrane vesicles: pathogenic factor and emerging targets for antimicrobial therapies

M0318 13:30 *Maria Kaparakis-Liaskos (Melbourne, Australia)*
 M0319 13:42 *Gregor Fuhrmann (Erlangen, Germany)*

OS094 13:30 - 14:30 Hall ICM 13a
 CLN PHEI 1-hour Case Session

Challenging and complicated viral infections

Chairs Niessen Annabel (Utrecht, Netherlands)
 Alexandra Mailles (Saint-Maurice, France)

O0669 13:30 **Chronic herpes simplex virus type 2 necrotising granulomatous pachymeningitis after glofitamab: an unusual CNS infection in an immunocompromised patient**
 N. Jain* (Auckland, New Zealand), B.S. Chen, L. Berkahn, M. Strauss, R. Lane

O0670 13:41 **First documented case of a fatal autochthonous Usutu virus infection in an immunocompromised patient in Hungary**
 B. Szabo* (Budapest, Hungary), A. Nagy, O. Nagy, A. Koroknai, N. Csonka, D. Korózs, K. Jeszenszky, A. Hardi, N. Deézi-Magyar, J. Sztikler, Z. Bódi, D. Cadar, G-E Tóth, L. Veres, E. Barcsay, M. Takács, J. Sinkó

O0671 13:52 **But its got to be PML, right? chronic myeloencephalitis 14 year after heart transplant**
 L. Lippert* (Berlin, Germany), S. Albus, D. Grund, M. Witzernath, L. Sander

O0672 14:03 **Long-term survivor of BoDV-1 encephalitis: complex immunotherapy, neuroimaging signatures and late viral reactivation: a case report**
 I. Masouris* (Munich, Germany), I. Wilkens, D. Grabova, F. Schöberl, M. Chen, H. Klauß, L. Keidel, D. Hauptstein, C. Eckert, V. Ruf, M. Schmutzer-Sondergeld, M. Brendel, R. Forbrig, G. Höglinger, A. Straube, F. Sörgel, M. Bauswein, D. Tappe

O0673 14:14 **Changing landscape of paediatric influenza-associated neurological complications: a single-centre case series from Northern Italy (2024-2025)**
 L. Franzetti* (Milan, Italy), C. Porro, S.M. Bova, C. Giovannini, A. Gadda, A. Rizzo, A. Lombardi, F. Salari, G. Zuccotti, E. Fusco, L. Folgori

OS095 13:30 - 14:30 Hall ICM 13b
 PRO 1-hour Oral Session

Precision pedagogy: AI-driven and data-driven education

Chairs

Sarah Delliere (Paris, France)
 Mary Horgan (Dublin, Ireland)

- O0674 13:30 Large Language Model-assisted OSCE stations in infectious diseases: faster, high-quality, and well-received by faculty**
 S. Villard* (Paris, France), C.A. Hobson, Y. Guedj, L. Khider, A. Mageau, J. Mesnier, M. Sanchez, S. Voicu, S. Peiffer-Smadja, N. Burnichon, A. Faye, T. Mirault, Y. Nguyen, B. Oules, A. Pellat, D. Bouzid, M. Thy, N. Peiffer-Smadja
- O0675 13:42 Intelligent Multi-Agent Systems for Antimicrobial Stewardship Training: A New Paradigm in Medical Education**
 Y. Chen* (Hangzhou, China), L. Sun, X. Du, F. Chiu, Y. Yu
- O0676 13:54 Large-Scale Artificial Intelligence or Medical Residency: Who Achieves Greater Concordance with ID Specialists in Antibiogram-Guided Antibiotic Selection?**
 M. Lanna* (Sao Paulo, Brazil), N. Adiwardana, V. Marchetti, J. Verissimo
- O0677 14:06 InfectoCast: A Digital Ecosystem for Infectious Diseases Education and Science Communication in Brazil**
 K. Faico-Filho* (Sao Paulo, Brazil), W. Dunke, J. Prats, J. Pinheiro, C. Santos, E. Santos-Junior
- O0678 14:18 List of Recommended Names (LoRN) for Bacteria of Medical Importance**
 E. Moore* (Gothenburg, Sweden), H. Christensen, V. Fingerle, M. Göker, M. Kostovski, G. Margos, A. Oren, S. Patrick, U. Reischl, J. Vazquez-Boland

OS096 13:30 - 14:30 Hall A2-2
 CLN PHEI 1-hour Case Session

Protozoa and microsporidia - rare and emerging

Chairs

Aleksandra Barac (Belgrade, Serbia)
 Emmanuel Bottieau (Antwerp, Belgium)

- O0664 13:30 A Plasmodium vivax case identified only by use of next-generation sequencing**
 C.R. Stensvold* (Copenhagen, Denmark), H.V. Nielsen, J.K. White, J. Szeps, K. Wyss, S. Botero-Kleiven
- O0665 13:41 Leishmania (Mundinia) procaviensis as an emerging pathogen: first confirmed human infection identified by target-gene sequencing**
 A. Andrianaki* (Zürich, Switzerland), D. Weller, F. Grimm, M. Concu, B. Nickel, A. Neumayr, M.B. Kälin

O0666 13:52 Disseminated Toxoplasma gondii infection with haemophagocytic lymphohistiocytosis
 D. Walzer* (Freiburg, Germany), C. Kaech, S. Rieg

O0667 14:03 Insights from a fatal case of disseminated albendazole refractory Annacalilia algerae myositis
 T. Fernando* (St Leonards, Australia), S. Mcginn, S. Ahmer, H.C. Soh, L. Tan, G. Kotsiou

O0668 14:14 Non-resolving cerebral toxoplasmosis in an immunodeficient patient
 J. Olchowski* (Haifa, Israel), M. Paul

PM004 13:30 - 14:30 Hall A2-1
 PHEI PRO Pipeline Symposium

Science under pressure: is it business as usual?

Chairs

Till T. Bachmann (Edinburgh, United Kingdom)
 Robert Leo Skov (Copenhagen, Denmark)

D0010 13:30 A funder's perspective
 Ghada Zoubiane (London, United Kingdom)

D0011 14:00 Industry perspective
 Marc Gitzinger (Basel, Switzerland)

SY130 13:30 - 14:30 Hall BO-1
 CLN PED 1-hour Symposium

Special issues of IFI in paediatrics

Chairs

Andreas H. Groll (Münster, Germany)
 Aspasia Katragkou (Morristown, United States)

S0312 13:30 Antifungal prophylaxis in neonates in the era of increased resistance to fluconazole
 Paolo Manzoni (Torino, Italy)

S0313 14:00 Implementation of guidelines in different settings: challenges and solutions
 Laura Ferreras-Antolin (London, United Kingdom)

Co-organised with: German Society for Pediatric Infectious Diseases (DGPI), German-Speaking Mycological Society, Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG)

Disclaimer

Scientific programme as of 16 of March

Scientific Programme

Monday, 20 April 2026

SY131 13:30 - 14:30 Hall B0-2
 CLN TRN 1-hour Symposium

Top papers in infections in immunosuppressed patients

- Chairs* Carlota Gudiol (Barcelona, Spain)
 Stefan Schwartz (Berlin, Germany)
- S0314 13:30 Infections in immunocompromised patients: what you need to know**
 Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)
- S0315 14:00 Shifting evidence in transplant infectious diseases: key studies that change practice**
 Oriol Manuel (Lausanne, Switzerland)

SY132 13:30 - 14:30 Hall A3-2
 ANT TRN 1-hour Symposium

Innovative methodologies for advancing PK/PD studies

- Chairs* Birgit Koch (Rotterdam, Netherlands)
 Sebastian Wicha (Hamburg, Germany)
- S0316 13:30 Development and application of organs on chip to study infectious diseases**
 Girija Goyal (Boston, United States)
- S0317 14:00 Multi-Omics approaches to personalise and improve antibiotic efficacy**
 Gauri Rao (Rancho Palos Verdes, United States)

EF106 14:45 - 15:45 Arena 1
 PHEI VAX ePoster Flash Session

Latest trends in vaccinology: from current strategies to next-generation vaccines

- E0736 14:45 Long-term impact of a single-dose inactivated hepatitis A vaccine in Korean military recruits: a nationwide cohort analysis (2011-2024)**
 J.H. Im* (Incheon, Korea, Republic of),
 J.S. Lee, S. Cho, D.Y. Kang, D.Y. Lee

- E0737 14:51 Effectiveness of high-dose vs standard-dose influenza vaccine against recurrent hospitalisations and through extended follow-up: a prespecified analysis of the DANFLU-2 trial**
 N.D. Johansen* (Hellerup, Denmark),
 D. Modin, M.M. Loiacono, R.C. Harris,
 M. Dufournet, C.S. Larsen, L. Larsen,
 L. Wiese, M. Dalager-Pedersen,
 B.L. Claggett, K.H. Janstrup,
 K.V. Bartholdy, K.F. Bernholm, J.I.M.H.
 Borchsenius, F.S. Davidovski,
 L.W. Davodian, M.F. Dons, L.S. Duus,
 C. Espersen, F.H. Fussing, A.M.R. Jensen,
 N.E. Landler, A.C.F. Langhoff, M.C.H.
 Lassen, A.B. Nielsen, C.I. Ottosen,
 M. Sengeløv, K.G. Skaarup, S.D. Solomon,
 M.J. Landray, G.H. Gislason, L. Køber,
 P. Sivapalan, C.J.M. Martel, J.U.S. Jensen,
 T. Biering-Sørensen

- E0738 14:57 Effectiveness of high-dose vs standard-dose influenza vaccine in older adults according to age: a prespecified analysis of the FLUNITY-HD study**
 K. Hosseini* (Copenhagen, Denmark),
 N. Dyrby Johansen, D. Modin, J. Pardo-Seco,
 C. Rodriguez-Tenreiro-Sánchez,
 M. M. Loiacono, R. C. Harris, R. Van Aalst,
 A. Chit, C. Schade Larsen, L. Larsen,
 M. Pareek, L. Wiese, M. Dalager-Pedersen,
 B. L. Claggett, K. Hyldekær Janstrup,
 C. Duran-Parrondo, M. Piñeiro-Sotelo,
 M. Dufournet, M. Cribeiro-González,
 M. Conde-Pájaro, S. Mirás-Carballal,
 J.M. González-Pérez, S. D. Solomon,
 P. Sivapalan, C. Jean-Marie Martel, J. Ulrik
 Stæhr Jensen, F. Martínón-Torres,
 T. Biering-Sørensen

- E0739 15:03 Impact of nirsevimab and maternal Abrysvo immunisation on socio-economic disparities in RSV SARI incidence in Lyon, France, 2018-2025**
 K. Jaakkola* (Lyon, France), A.A. Dehove,
 L. Rojas, B. Lina, J.S. Casalegno

- E0740 15:09 Predicting COVID-19 vaccination decision-making profiles among Dutch adults: from survey to national administrative data**
 T. Abreu* (Utrecht, Netherlands),
 J. Bernardo-Garcia, I. De Wolf,
 M. Matthijssen, D. Timmermans,
 V. Buskens

- E0741 15:15 Intramuscular SARS-CoV-2 vaccination fails to induce de novo local antibodies in older adults: a Com-COV randomised substudy**
 R. Shaw* (Oxford, United Kingdom),
 T. Dinesh, J. Alderson, S. Belij-Rammerstorfer,
 S. Bibi, E. Clutterbuck,
 M.R.N.U. Ramasamy, M. Snape, X. Liu,
 T. Lambe

E0742	15:21	Vaccines insight, beliefs, and experiences in school-aged children and parents: a questionnaire and structured interview in UK families (VIBES) <i>W. Carroll* (Uttoxeter, United Kingdom), A. Jagadish, F. Gilchrist, R. Horne</i>	E0748	15:03	CRE colonisation as a marker for CRE ventilator-associated pneumonia (VAP): insights from a 15-month ICU cohort in Rome <i>L. Campogiani* (Rome, Italy), A.M.A. Crea, L. Alborghetti, P. Vitale, I. Spalliera, M. Zordan, A.M. Geretti, V. Malagnino, M. Iannetta, L. Sarmati</i>
E0743	15:27	Next-generation vaccines for hepatitis E virus <i>J. Situ* (Hongkong, China), X. Ma, Y. Liang, S. Wu, S. Sridhar</i>	E0749	15:09	Behavioral insights and motivational challenges within infection control committees: mixed-methods study using COM-B and TDF frameworks <i>T. Yanık Yalçın* (Ankara, Türkiye), A. Pehlivanlı, B. Gönülal, F. Callak Oku, B. Madran, E. Sargin Altunok, Ş. Keske, M. Aydın, Ö. Kurt Azap, Ö. Ergönül, H. Akalın</i>
EF107	14:45 - 15:45	Arena 2			
	AMR	IPC			
Infection control and prevention around the world: risks, behaviours, and solutions					
Chair		<i>Maria João Lopes (Amadora, Portugal)</i>			
E0745	14:45	Perception vs practice in hospital cleaning: assessing task-prioritisation between hospital cleaning staff and IPC practitioners, an interim analysis <i>A. Kearney* (Dublin, Ireland), M. Fallon, J. Doyle, B. Fletcher, A.F. Talento, R. Cunney, C. Cahir, D. Fitzgerald Hughes, B. Mitchell, M. Kiernan</i>	E0750	15:15	Candidozyma auris colonisation: point-prevalence and long-term outcomes in a tertiary university hospital <i>D. Basoulis* (Athens, Greece), A. Karapanou, E. Apostolidi, S. Zerva, A.R. Andritsou, K. Panteli, C. Psarakis, K. Reppas, A. Rigatou, D. Stefani, A. Strikou, D. Mpora, D. Petraki, M. Sampanis, S. Zagkavierou, K. Theodoridou, T. Koliou, S. Kritikou, A. Millioni, E. Giannitsioti, E. Mastrogianni, F. Ntziora, A. Anastasopoulou, M. Samarkos, M. Psychogiou, N.V. Sipsas, G. Vrioni, M.N. Gamaletsou</i>
E0746	14:51	Environmental reservoirs of carbapenemase-producing organisms (CPO) in intensive care unit (ICU) hand hygiene (HH) sinks and haemodialysis (HD) wall boxes: investigation and control measures <i>J. Guerrero* (Scarborough, Canada), S. Paramalingam, J. Lerma, M. Pekelny, S. Arefin, A. Garga, M. O'connor, R. Lovinsky</i>	E0751	15:21	A 20-year single-centre retrospective study on the impact of hospital environmental factors on the incidence of candidaemia <i>A. Bedini* (Modena, Italy), G. Franceschi, S. Esperti, S. Generoso, L. Benassi, U. Calvi, M. Meschiari, E. Franceschini, C. Venturelli, C. Mussini</i>
E0747	14:57	Hospital surfaces as reservoirs of carbapenemase- and ESBL-producing bacteria in hospitals across Bangladesh, Nigeria and Pakistan <i>A. Cooke* (Oxford, United Kingdom), J. Rzaska, R. Farzana, B. Hassan, C. Achi, M. Nieto-Rosado, L. Wilson, S. Langhorne, A. Sindhu, J. Oduwo, E. Owinoh, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, H. Naz, A. Muhammad, S. Ali, W. Sombul, M. Khan, S.U. Nisa, A. Khan, S. Riaz, S. Naqvi, J. Zafar, H. Hamid, A. Sajid, R. Razzaq, K. Iregbu, N. Medugu, T. Akujobi, F.Z.Z. Abdu, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A. Panti, O. Oduyebo, O. Olutekunbi, F. Okenla, I. Nwafia, P. Nwachukwu, S. Chukwuma, T. Sultana, S. Arefin, P.I. Disha, N. Tasnim, T. Hossain, T. Haque, T.R. Walsh, K. Sands, K.M. Thomson</i>	E0752	15:27	Swiss minimum requirements for infection prevention and control: results of a national survey <i>A. Sonpar* (Zurich, Switzerland), C. Balmelli, M. Eder, A. Metsini, Z. Zhang, W. Zingg</i>
			E0753	15:33	A Multi-Modal Intervention with Patient Engagement to Reduce Multidrug-Resistant Organisms (MDROs) in Post-Acute Care <i>L. Mody* (Ann Arbor, United States), M. Cassone, K. Gibson, G. Vijayasiri, E. Snitkin, S. Saint, S. Krein, M. Janevic, J. Thiel, A. Nguyen, T. Bej, O. Hicks, N. El Chakhtoura, L. Min, A. Galecki, T. Greene, M.C. Roghmann, L. Chigurupati, F. Perez, R. Jump</i>

Scientific Programme

Monday, 20 April 2026

EF108 14:45 - 15:45 Arena 3
 CLN PED ePoster Flash Session

Little patients, big challenges: tackling bacterial infections in children

Chair Christina Obiero (Kilifi, Kenya)

E0754 14:45 Klebsiella pneumoniae: a leading cause of neonatal sepsis from 13 hospitals in Nigeria, Pakistan and Bangladesh
 K. Sands* (Oxford, United Kingdom), K. Thomsom, C. Achi, R. Farzana, B. Hassan, A. Cooke, J. Rzaska, A.K. Lankapalli, J. Oduwo, E. Owinoh, N. Haque, R. Farzana, T.A. Sumi, P.I. Disha, S.K. Sara, T. Haque, K. Iregbu, N. Medugu, T. Akujobi, K. Abdulraheem, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A. Adamu, O. Oduyebo, O. Olutekunbi, O. Ogunsanya, I. Nwafia, S. Chukwuma, P. Nwachukwu, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, S. Ali, S. Amin, M. Khan, S. Arif, S.U. Nisa, S. Riaz, S. Naqvi, I. Zeb, M. Haroon Hamid, U. Hussain, S. Shabbir, T.R. Walsh

E0755 14:51 Antibiotic dosing practices in neonates in low- and middle-income countries: model-based comparison with guidelines and implications for target attainment and toxicity
 W. Van Os* (Leiden, Netherlands), K.M. Thomson, K. Sands, T.R. Walsh, C.R. Achi, B. Hassan, R. Farzana, E. Owinoh, J. Oduwo, K. Iregbu, N. Medugu, T. Akujobi, A. Mairami, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, S.M. Zainu, O. Oduyebo, O. Olutekunbi, A. Odedina, I. Nwafia, J. Unigwe, C. Onyejekwe, T.A. Sumi, B. Majumder, S.B. Prama, T. Haque, R. Khatun, T. Hossain, E. Rashid, R. Zahra, M.I. Shah, A. Mehboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, M. Mahrang, S. Riaz, S. Naqvi, R. Hamza, M.H. Hamid, M. Malik, R. Temur, R. Sajjad, J.G.C. Van Hasselt

E0756 14:57 Antibiotic resistance genes in meconium of newborns very early after admission to neonatal intensive care unit
 A. Ftergjioti* (Thessaloniki, Greece), M. Simitsopoulou, A. Kontou, K. Sarafidis, E. Roilides, E. Iosifidis

E0757 15:03 Stool-based Truenat as a non-invasive frontline diagnostic tool for paediatric pulmonary tuberculosis: a cross-sectional study from a tertiary care paediatric centre
 A. Soni* (Noida, India), S. Nandwani, S.B. Mathur, B. Kumar

E0758 15:09 Predictors of Outcomes of Paediatric Diphtheria in Sub-Saharan Africa: a Systematic Review and Meta-Analysis
 I.A. Rufai* (Sokoto, Nigeria), S. Abubakar, F. Shagari

E0759 15:15 Post-pandemic resurgence and epidemiology of group A Streptococcus infection in children
 C.H.N. Tan* (Singapore, Singapore), W.J.W.H. Goh, C.Y. Chong, J. Li, C.F. Yung, K.C. Thoon, K.Q. Kam, K.D. Nadua, C.W.X. Seow, Y. Yelen, M. Maiwald, S.B. Yusof, K.P.L. Wong, C.Y. Woo, N.W.S. Tee, L. Cui, M. Ang

E0760 15:21 IPSCC 2005 and Phoenix Sepsis Score in children under 60 days: strengths and diagnostic pitfalls
 L. Di Meglio* (Rome, Italy), G. Lorenzetti, M. Roversi, C. Tripiciano, S. Mercadante, M. Di Giuseppe, S. Chiurchiù, M. De Luca

E0761 15:27 An early mortality prediction tool for children with haematologic malignancy and Gram-negative bloodstream infection
 A. Ayad* (Cairo, Egypt), Y. Taher, M. Jamal, M. Mohammed, O. Ahmed, A. Alameldein, G. Ziad, Y. Madeny

E0762 15:33 Epidemiology and antibiotic use for pertussis and pertussis-like cough in Italian children: a population study (2010–2024, PEDIANET)
 E. Gres* (Padua, Italy), G. Sturniolo, S. Masenello, D. Dona, G. Brigadoi, A. Cantarutti, C. Giaquinto, V. Baldo, E. Barbieri

MOVIE 14:45 - 18:30 Hall ICM 13a
 PHEI PRO Special Session

Behind the scenes: Don't Look Up

Chairs Diane Ashiru-Oredope (London, United Kingdom)
 Ana Raquel Freitas (Porto, Portugal)
 William Hanage (Boston, United States)
 Holger Rohde (Hamburg, Germany)
 Luigia Scudeller (Pavia, Italy)
 Sotirios Tsiodras (Athens, Greece)

OS100 14:45 - 15:45 Hall ICM 5
TRN 1-hour Oral Session

Microbiome-host interplay in intestinal disease and under selection pressure

Chairs Silvia Corcione (Turin, Italy)
Ed J. Kuijper (Leiden, Netherlands)

O0731 14:45 A hit with a scar: amoxicillin alters the infant gut microbiome long-term but without fungal expansion

J. Hurych* (Helsinki, Finland), R. Ventin-Holmberg, J. Honkanen, V. Castrén, A. Nikkonen, J. Koskimäki, V. Peltola, K. Korpela, P. Saavalainen, K.L. Kolho

O0732 14:57 Protease-induced activation of colonic afferent neurons by gut bacterium *Phocaeicola vulgatus*, previously associated with inflammatory bowel disease

R. Nakhle* (Kingston, Canada), H.M. Wood, K. Blazkova, F.F. Faucher, M. Farquhar, P.M. Sheth, B.L. Schmidt, S.J. Vanner, N.W. Bunnett, M. Bogyo, D.E. Reed, A-E Lomax

O0733 15:09 Recapturing individual inflammatory responses in IBD microbiomes using an *in vitro* colonic model (MiGut)

I. Moura* (Leeds, United Kingdom), W. Davis Birch, N. Beauchemin, K. Bentley, M. Vulic, M. Henn, A. Buckley, C. Ford, N. Kapur, E. Halvorsen, I. B. Moura

O0734 15:21 Development of antibiotic-associated diarrhea in sepsis patients is associated with dysbiosis at baseline

E. Kyriazopoulou* (Athens, Greece), E. Stylianakis, G. Damoraki, A. Spyrou, S. Symbardi, G. Chrysos, G. Adamis, E. Giamarellos-Bourboulis

O0735 15:33 Ecological instability of the gut microbiome during haematopoietic stem cell transplantation

C. Hajjar* (Beirut, Lebanon), A. Ibrahim, A. Bazarbachi, M. Abifadel

OS101 14:45 - 15:45 Hall B0-1
AMR ANT CLN 1-hour Case Session

Phage therapy for complex infections

Chairs Zuzanna Drulis-Kawa (Wroclaw, Poland)
Spyros Pournaras (Athens, Greece)

O0711 14:45 Personalised phage therapy for multidrug-resistant infections in thoracic organ transplant recipients

C. Kuehn* (Hannover, Germany), E. Rubalskii, L. Sedlacek, S. Ruemke, N. Schwerk, J. Gottlieb, A. Haverich, D. Schlüter, G. Hansen, A. Ruhparwar

O0712 14:56 Breaking the cycle of relapse: personalised phage therapy in MDR *Pseudomonas aeruginosa* LVAD infection

S. Ferin* (Udine, Italy), S. Flammini, P. Della Siega, M. Merelli, D. Pecori, S. Giuliano, C. Tascini

O0713 15:07 Novel antibiotic-phage therapy duo rapidly resolves XDR-AB pneumonia after liver transplant

W. Wang* (Xian, China)

O0714 15:18 Precision-matched bacteriophage therapy for prosthetic aortic graft infections: a single-centre observational case series

E. Rubalskii* (Hannover, Germany), S. Ruemke, L. Sedlacek, A. Haverich, D. Schlüter, A. Ruhparwar, C. Kuehn

O0715 15:29 Phage therapy for refractory, native joint *Staphylococcus aureus* arthritis with infected bone necrosis

M. Dekel* (Tel Aviv, Israel), R. Nir Paz, R. Ben Ami, N. Bishouty, A. Houry, N. Snir, T. Ben Tov

OS102 14:45 - 15:45 Hall B0-2
CLN 1-hour Oral Session

Pitfalls in modern HIV therapy

Chairs Justyna Kowalska (Warsaw, Poland)
Milena Stevanovikj (Skopje, North Macedonia)

O0726 14:45 A Plasma Proteomic Aging Clock Reflects Reversal of Accelerated Aging in People with HIV Under Antiretroviral Therapy

B. Ryan* (Lausanne, Switzerland), M. Ait Oumelloul, S. Rouached, A. Juillerat, J. Fellay, P. Tarr, J. Nemeth, L. Giacchetto, I. Schoepf, L. Bartl, C. Dollé, D. Russenberger, P. Nanni, T. Kockmann, M. Stöckle, G. Wandeler, A. Calmy, M. Cavassini, L. Elzi, P. Schmid

O0727 14:57 Effect of 1HP on dolutegravir concentrations

M. Nicol* (Minneapolis, United States), A. Buzibye, A. Fieberg, B. Dai, P. Nerima, E. Ajilong, C. Waitt, D. Boulware, E. Nalintya, R. Rajasingham

O0728 15:09 Renal function, HIV reservoir and immune marker changes after one year of long-acting ART

L. Maddaloni* (Rome, Italy), L. De Martino, L. Santinelli, C. Falvino, G. Bugani, A. Lazzaro, R. Donà, L. Bortolani, M. Andreotti, Z. Michelini, G. Antonelli, C.M. Mastroianni, C. Scagnolari, G. D' Ettore

Disclaimer

Scientific programme as of 16 of March

Scientific Programme

Monday, 20 April 2026

O0729 15:21 **Doravirine: two vs three-drugs based regimens, a multi-centre observational study**
F. Casari (Modena, Italy), A. Cervo, A. Giacomelli, R. Rossotti, M. Menozzi, M. Albertini, G. Menegotto, E. Martini, M.V. Cossu, C. Mussini, G. Guaraldi, C. Gervasoni, B. Fontana*

O0730 15:33 **No biomarker evidence of CNS injury after switching to dual therapy with Dolutegravir/Lamivudine in HIV**
L. Renborg (Gothenburg, Sweden), A.L. Benedet, A. Yilmaz, S. Nilsson, K. Nyström, K. Blennow, H. Zetterberg, M. Gisslén*

OS103 14:45 - 15:45 **Hall A2-2**
 CLN IPC
 1-hour Case Session

What did you get in the hospital?

Chairs
Christina König (Hamburg, Germany)
Sara Tomczyk (Berlin, Germany)

O0706 14:45 **Hospital acquired tularemia: a case report of nosocomial transmission of Francisella tularensis**
M. Simon Sacristan (Madrid, Spain), A. Collazos Blanco, M.F. Ramos Ferriol, M. Rozas Bellido, I. Darid Y Ceron, S. Sanchez Sanchez, G. Arán Toha, S. Medrano Pardo, M.T. Llorente Rodriguez, O. Arce, G. Ramirez Olivencia*

O0707 14:56 **Gemella haemolysans endocarditis in a southern Spain Hospital**
P. Monroy (Malaga, Spain), L. Balderas Fernández, L. Mora Navas, M.V. García López*

O0708 15:07 **Nosocomial myiasis: Report of Two Cases and Review of the Literature**
D. Verendag (Izmir, Türkiye), D. Kaya, H.A. Erdem, N. Bilgili Korkmaz, B. Arda, O.R. Sipahi*

O0709 15:18 **Difficult-to-treat Gram-positive health-care associated ventriculitis treated with combination antibiotic therapy including fosfomycin: a series of three cases**
A. Frattari (Pescara, Italy), F. Spagnuolo, C. Di Iorio, E. Polilli, P. Fazii, G. Parruti*

O0710 15:29 **The unusual outbreak of sepsis in a cancer hospital caused by intrinsically contaminated heparin injection vials**
V. Bajpai Batra (Varanasi, India), A. Kapoor*

OS104 14:45 - 15:45 **Hall A3-1**

AMR ANT CLN 1-hour Oral Session

Emerging and repurposed therapeutic options in resistant Gram-negatives

Chairs
Jaroslav Hrabak (Plzen, Czechia)
Giusy Tiseo (Pisa, Italy)

O0716 14:45 **Treatment strategies for CRKP central nervous system infections after neurosurgery: a prospective observational study comparing intravenous ceftazidime/avibactam and intraventricular/intrathecal polymyxin B sulphate injections**
M. Wang (Shanghai, China), W. Mei-Hua, L. Yang, L. Nan-Yang, C. Wei, F. Ya-Xin, W. Gang, H. Jin, Z. Jing*

O0717 14:57 **Clinical and genomic insights into emerging resistance to novel β -lactam/ β -lactamase inhibitor combinations in KPC-producing *Klebsiella pneumoniae* (Italy, 2021–2024)**
M. Boattini (Turin, Italy), S. Comini, G. Ricciardelli, R. Casale, L. Guarrasi, R. Cavallo, C. Costa, P. Gaibani, G. Bianco*

O0718 15:09 **Clinical outcomes and treatment-emergent resistance of bloodstream infections due to AmpC β -lactamase-producing Enterobacterales**
S. Shah (Pittsburgh, United States), J. Jawanda, M. O'donnell, R. Shields, L. Clarke, H. Creager, R. Marini, B. Falcione*

O0719 15:21 **A multi-centre cohort study of tigecycline effectiveness and safety in patients with carbapenem-resistant *Klebsiella pneumoniae* and carbapenem-resistant *Acinetobacter baumannii* co-infection**
D. Chen (Nanjing, China), S. Wang, N. Hu, P. Liang, J. Liu, H. Xie, H. Zhang, J. He*

O0720 15:33 **Efficacy of minocycline-based combination therapy in *Stenotrophomonas maltophilia* infections from a randomised controlled trial, and the activity of antimicrobial combinations against isolates as determined by the checkerboard method**
A. Boonyasiri (Bangkok, Thailand), T. Pongdumbun, S. Tiengrim, Y. Rongrungruang*

OS105 14:45 - 15:45 Hall A3-2
 DX TRN 1-hour Oral Session

Decoding inflammation and innovating diagnostics of parasitic diseases

Chairs *Pikka Jokelainen (Copenhagen, Denmark)*
Martin Montes (Lima, Peru)

O0721 14:45 Monocyte-dependent antigen specific inflammation in Neurocysticercosis is regulated by mitogen activated protein kinases

L.M. Toribio (London, United Kingdom),
 D.L. Chong, H.H. Garcia, J.S. Friedland*

O0722 14:57 First cases of male genital schistosomiasis reported in Zambia: a pilot study integrating semen-based parasitology, molecular diagnosis and portable ultrasonography

S. España Cueto (Badalona, Spain),
 E.C. Sergio, N. Bronwyn, M. Isaac,
 N. Rhoda, C. Lucas, A. Fiona, V.L. Lisette,
 W. Bonnie L., C. Maina, M. Tegwen,
 H. Shinjiro, R. Silvia, P. Roger,
 K. Sekeleghe, S. J. Russell, S. Kwame,
 B. Amaya L.*

O0723 15:09 Evaluating the diagnostic performance of a recombinase polymerase amplification assay compared to polymerase chain reaction for the diagnosis of female genital schistosomiasis using cervicovaginal self-sample swabs

N. Hrouda (London, United Kingdom),
 S. Nanyinza, L. Smith, M. Cheeba,
 R. Ndubani, B. Neufeld, K. Shanaube,
 B. Webster, A. Bustinduy*

O0724 15:21 Diagnostic Evaluation of Parasite-Derived microRNAs as Serum Biomarkers for Cystic Echinococcosis

Y. Akyön Yilmaz (Ankara, Türkiye),
 S. Orsten, İ. Baysal, M. Sarıkaya,
 E. Yagmur, O. Bozkurt, E. Ünal,
 S. Yabanoğlu Çiftçi, H.A. Dinçer, D. Dirim,
 D. Akıncı, A.B. Doğrul, E. Karaağaoğlu,
 M. Korkmaz, T. Çiftçi, O. Akhan*

O0725 15:33 Hookworm infection drives inflammation and tissue destruction in tuberculosis

M. Loader (London, United Kingdom),
 S.E. Vásquez Alves, M.R. Verástegui,
 R.H. Gilman, J.S. Friedland*

PM005 14:45 - 15:45 Hall A2-1
 PHEI PRO Pipeline Symposium

From AI for evidence synthesis to decision making

Chairs *David Eyre (Oxford, United Kingdom)*
Holger Rohde (Hamburg, Germany)

D0012 14:45 AI decision support in antibiotic prescribing - novel aspects and direction
Daniele Roberto Giacobbe (Genoa, Italy)

D0013 15:15 AI for ESCMID guideline development - a perspective on feasibility and safety
José Molina Gil-Bermejo (Seville, Spain)

SY134 14:45 - 15:45 Hall ICM 14
 CLN 1-hour Symposium

Year in infectious diseases

Chairs *Murat Akova (Ankara, Türkiye)*
Yoav Keynan (Winnipeg, Manitoba, Canada)

S0336 14:45 -
Dafna Yahav (Ramat-Gan, Israel)

S0337 15:15 -
Margaret Ip (Hong Kong, Hong Kong)

SY135 14:45 - 15:45 Hall ICM 13b
 AMR DX 1-hour Symposium

Resistance redefined: how to analyse biofilms and anaerobes

Chairs *Tom Coenye (Ghent, Belgium)*
Efthymia Giannitsioti (Athens, Greece)

S0338 14:45 Resistance in slow growing anaerobic communities
Catalina Suzana Stingu (Leipzig, Germany)

S0339 15:15 What *in vitro* susceptibility testing does (not) tell you about *in vivo* anti-biofilm activity in the respiratory tract
Valerie Waters (Toronto, Canada)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Anaerobic Infections (ESGAI)

Scientific Programme

Monday, 20 April 2026

EF112 16:15 - 17:15 Arena 1
ANT CLN ePoster Flash Session

Respiratory bacterial infections: challenges and advances

Chair Margaret Ip (Hong Kong, Hong Kong)

E0778 16:15 Invasive pneumococcal disease in a Portuguese hospital: 19-year retrospective study
C. Batista* (Oporto, Portugal), S. Araújo, C. Azeredo, C. Bacelar, J. Oliveira, F. Reis, L. Neto, T. Dos Santos, E. Pena, M.J. Gonçalves, F. Duarte, S. Rocha, S. Jordão, M. Guimarães, A. Read, R. Correia De Abreu, C. Soeiro

E0779 16:21 Re-emergence of *Chlamydia pneumoniae* after the COVID-19 pandemic: a retrospective PCR-based study in a Spanish tertiary hospital (2019–2025)
P. Suárez Urquiza* (Valencia, Spain), E. Cortés Giménez, E. Gremaldos Mira, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz

E0780 16:27 Procalcitonin and lung ultrasonography-guided antibiotherapy in patients with lower respiratory tract infection in Swiss emergency departments: a pragmatic stepped-wedge cluster-randomised trial: The PLUS-IS-LESS study
N. Boillat-Blanco* (Lausanne, Switzerland), C. Bessat, O. Hugli, E. Garcia, R. Bingisser, M. Schwendinger, T. Bulaty, Y. Fournier, V. Della Santa, M. Pfeil, D. Schwab, J. D. Leuppi, N. Geigy, S. Steuer, F. Roos, M. Christ, A. Sirova, A. Atzl, F. Napieralski, O. Manuel, I. Locatelli, W. Albrich

E0781 16:33 Effect of clarithromycin on inflammatory proteomic expression in community-acquired pneumonia: secondary analysis of the ACCESS trial
E. Stylianakis* (Athens, Greece), K. Tsiakos, V. Tzavara, L. Skorda, K. Iliopoulou, G. Adamis, G. Niotis, K. Akinosoglou, N. Kakavoulis, G. Chrysos, S. Gerakari, T. Kontopoulou, G.N. Dalekos, I.C. Papanikolaou, M.G. Netea, V. Kumar, E.J. Giamarellos-Bourboulis

E0782 16:39 Antimicrobial-associated acute kidney injury in patients hospitalised with community-acquired pneumonia
R.S. Knudsen* (Hvidovre, Denmark), C. Leding, H. Løvendahl Jørgensen, M. Fally, P. Ravn, L. Kolte, S. Bastrup Israelsen, T. Benfield

E0783 16:45 Efficacy of β -lactam monotherapy vs clindamycin or addition of metronidazole in peritonsillar abscess: an observational study with a focus on *Fusobacterium necrophorum*

D. Nygren* (Lund, Sweden), M. Loggarfve, E. Lindberg, K. Holm, M. Gisselson-Solén

E0784 16:51 A randomised, double-blind, placebo-controlled trial of the safety and microbiological activity of bacteriophage therapy in cystic fibrosis participants chronically colonised with *Pseudomonas aeruginosa*

P. Tamma* (Philadelphia, United States), T. Hamasaki, M. Souli, D. Van Tyne, D. Pride, S. Nayak, K. Moon, E. Raterman, K. Greenwood-Quaintance, D. Ellison, A. Filippov, M. Nikolich, T. Lodise, D. Conrad, A. Jaunara, Z. Wintrob, D. Albon, P. Allyn, T. Barto, J. Billings, L. Caverly, A. Graham, W. Hunt, R. Jain, J. Koff, K. Mcbennett, D. Miller, P. Mohabir, B. Morrissey, K. Patel, J. Wang, N. West, M. Bates, J. Leonard, G. Sah, M. Chiu, B. Evans, H. Geres, C. Koscianski, U. Rappo, J. Fackler, H. Chambers, S. Evans, R. Patel, V. Fowler, R. Schooley

E0785 16:57 Evolution of the respiratory microbiological profile in people with cystic fibrosis undergoing treatment with elexacaftor/tezacaftor/ivacaftor
B.S. Orena* (Milan, Italy), F. Girardi, E. Tomassini, D. Girelli, M. D'accico, F. Blasi, V. Daccò, A. Callegaro, L. Cariani

E0786 17:03 Nosocomial pneumonia in Georgia: a rising threat of multidrug-resistant pathogens
S. Khetsuriani* (Tbilisi, Georgia), G. Mgeladze, L. Gabunia, G. Janigashvili, L. Ratiani |

EF113 16:15 - 17:15 Arena 2
CLN PHEI ePoster Flash Session

Parasitic diseases in a changing world: climate, mobility, and clinical impact

Chair Camilla Rothe (Munich, Germany)

E0788 16:21 Estimating unreported malaria cases in England: a capture-recapture study
P. Charlotte* (London, United Kingdom), C. Patterson, A. Simbo, D. Turner, S. Leinster, P. Katwa, P. Veal, A. Checkley, C. Redman, C.A. Gibb, C. Williams, P. Chiodini

- E0789 16:27 Paediatric imported malaria infections with a non-falciparum species: a 2011-2023 retrospective study in France**
C. Melenotte* (Paris, France), P. Buffet, S. Houzé, V. Joste, M. Thellier, F. Gay, F. Sorge, J. Toubiana, O. Lortholary, F. Lanternier, P.H. Consigny, L. Musset, B. Pradines
- E0790 16:33 Effectiveness of intermittent preventive treatment for malaria in pregnancy in an area of high sulfadoxine/pyrimethamine resistance in Northern Uganda: a directed acyclic graph-guided analysis**
F.V. Segala* (Bari, Italy), J. Ictho, R. Novara, N. Olung, G. Patti, R. Papagni, G. Atim, V. Totaro, L. Olal, E. De Vita, J. Adongo, M. L'episcopio, S. Okori, G. Dall'oglio, L. Pisani, A. Dondorp, G. Putoto, P. Lochoro, A. Saracino, F. Di Gennaro
- E0791 16:39 The PK6 project: a test-and-treat operational strategy for *Plasmodium vivax* elimination among hard-to-reach illegal gold miners in French Guiana**
D. Patarot* (Cayenne, French Guiana), M. Oberlis, T. Levarato, M. Rozé, P. Feller, L. Houssais, A. Carfantan, M. Boutrou, Y. Lazrek, L. Musset, F. Mubenga, C. Michaud, L. Epelboin
- E0792 16:45 Leishmaniasis as an opportunistic infection in HIV patients in Europe: lack of guidelines harmonisation and limited diagnostic arsenal**
G. Zaremba* (Warsaw, Poland), A. Papadopoulou, K. Protopapas, M. Stevanovikj, N. Yancheva, S. Dragaš, A.Ç. İnkaya, C. Oprea, J. Begovac, Z. Bartovská, M. Zlámál, O. Beran, D. Jilich, A. Schembri, R. Matulionyte, I. Gmizic, D. Maric, J. Tomažič, E. Golovco, H. Tiberiu, B. Lakatos, T. Balayan, A. Vassilenko, A. Verhaz, N. Bolokadze, V. Krasniqi, J. Kowalska, A. Harxhi
- E0793 16:51 Leishmaniasis in a Spanish tertiary hospital (2018-2025): epidemiological trends, clinical and diagnostic characteristics of a re-emerging disease**
E. Gremaldos Mira* (Valencia, Spain), E. Cortés Giménez, A. Ruiz Gaitán, P. Suárez Urquiza, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz
- E0794 16:57 Serum circulating anodic antigen as test-of-cure for schistosomiasis in migrants: what is the impact?**
L.C. Vaccari* (London, United Kingdom), I. Chaudhry, J. Martin, C. Sen, N. Longley, G. Godbole, S. Eisen, L. Nabarro
- E0795 17:03 Three decades of echinococcosis in Southern Madrid: insights into an endemic zoonosis**
V. Anton Berenguer* (Leganes, Spain), A.N. Ruiz Benito, K.M. Pinto Tapia, M.D. Martín Rodrigo, S.M. Quevedo Soriano, S. Gómez De Frutos, F.J. Merino Fernández, J.M. Rubio Muñoz, M.D. Flores Chávez
-
- EF114 16:15 - 17:15 Arena 3**
DX IPC ePoster Flash Session
- Controlling *Clostridioides difficile* infections and hospital related challenges**
- Chair Kerrie Davies (Leeds, United Kingdom)
- E0796 16:15 Most recurrent *Clostridioides difficile* infections reflect persistent infection or repeat exposure: findings from whole genome sequencing in Wales, UK**
R. Polani Chandrasekar* (Cardiff, United Kingdom), L. Campbell, T. Connor, N. Craine, V. Daniel, H. Hughes, V. McClure, T. Morris, M. Perry, R. Phillips, D. Williams, M. Morgan
- E0797 16:21 Evaluation and Comparison of Three Methods for the Detection of *Clostridioides difficile* Toxin in Faecal Samples**
R. Asif* (Cardiff, United Kingdom), P. Talagtag, F. Ismail, S. Mitchell, M. Perry, S. Jones
- E0798 16:27 Gut microbiome characterisation in inflammatory bowel disease and *Clostridioides difficile* infection**
S. Vázquez-Cuesta* (Madrid, Spain), I. Marín, M. Díaz-Navarro, G. Álvarez-Calatayu, C. Sánchez, M. Guembe, A. Visedo, E. Bouza, P. Muñoz, L. Menchén, R. Samaniego, R. Bañares, E. Reigadas
- E0799 16:33 Screening for asymptomatic carriage of *Clostridium difficile*: results from a two year intervention**
M. Gilboa* (Ramat Gan, Israel), N. Barde, E. Meltzer, Y. Peretz, I. Levy, S. Amit, G. Rahav, N. Pinas-Zade, B. Mechnik, G. Regev-Yochay
- E0800 16:39 *Clostridioides difficile* infection in Europe: Are We Meeting Best Practices?**
M. Krutova* (Prague, Czechia), J. Prehn, W.K. Smits, O. Burduniuc, M. Wilcox, E. Kuijper

Scientific Programme

Monday, 20 April 2026

- E0801 16:45** **Epidemiological trends in *Clostridioides difficile* infections in France, 2019-2024: TRACE national population-based study**
*M. Decalonne** (Tours, France),
M.H. Pham-Hi, C. Gaborit, C. Salpérier,
N. Khanafer, C. Daniau, F. Barbut,
L. Grammatico-Guillon
- E0802 16:51** **Exploring patient experiences of infection prevention and control across a range of healthcare associated infections: the stories behind the numbers**
*M. Skally** (Dublin, Ireland), *J. Strawbrige,*
C. Cox, J. Heritage, S. Rajesh, A. Walsh,
C. Finn, P. Conran, K. Bennett,
H. Humphreys, F. Fitzpatrick
- E0803 16:57** **From insight to impact: leveraging opportunity mapping to drive system-wide reductions in CLABSI, CAUTI, *C. difficile*, and MRSA over a three-year period**
*G. Rosello** (Miami, United States),
J. Somani, C. Ghaemmaghani,
D. Zambrana, H. Clark, C. Biggs, L. Abbo
- E0804 17:03** **Wipe-based solutions for hand hygiene: Do they really work?**
*A. Barry** (Salisbury, United Kingdom),
G. Moore

- KN136 16:15 - 17:15** **Hall ICM 14**
 CLN DX **Keynote Lecture**

Viral infection in the immunocompromised: from discovery to emerging therapies

Chairs *Maddalena Giannella (Bologna, Italy)*
Monica Slavin (Melbourne, Australia)

- K0340 16:15** *Hans H. Hirsch (Tromsø, Norway)*



Hans H. Hirsch is Professor of Medicine at The University of Tromsø – The Arctic University of Norway and of the University of Basel, Switzerland. Throughout his career, he has contributed to our understanding of BK virus pathogenesis, latency and reactivation, and continues his research on virus complications in immunocompromised patients. Hirsch has (co-)authored more than 200 peer-reviewed papers and contributed to guidelines in virology, infectious diseases, and transplantation. Hirsch remains an integral force across many medical societies, that have also recognised him for his achievements; he is Fellow of ESCMID, Fellow of the American Society of Transplantation (AST), past president of the International Immunocompromised Host Society (ICHS), and long-time member of the European Society of Clinical Virology (ESCV), wherein he was awarded the ESCV Gardner Lecture Award in 2024.

Fireplace Session 20 April, 17:30 - 18:30

- ME140 16:15 - 17:15** **Hall ICM 1**
 AMR IPC **Meet-the-Expert**

Artificial Intelligence in antimicrobial stewardship and infection control: from prediction to precision

- M0349 16:15** *Damien Ming*
 (London, United Kingdom)

- M0350 16:27** *José Ramón Paño-Pardo*
 (Zaragoza, Spain)

- ME141 16:15 - 17:15** **Hall ICM 5**
 CLN DX PED **Meet-the-Expert**

Children are not small adults: interactive paediatric cases

- M0351 16:15** *Julie Toubiana*
 (Paris, France)

- M0352 16:27** *Sanjay Patel*
 (Southampton, United Kingdom)

- OS109 16:15 - 17:15** **Hall ICM 13b**
 CLN PHEI **1-hour Case Session**

Melioidosis finds new destinations

Chairs *Yogesh Kumar Gupta (Jaipur, India)*
Maria João Lopes (Amadora, Portugal)

- O0768 16:15** **First documented blood culture-confirmed melioidosis case in Mozambique: implications for awareness, surveillance, and diagnosis**
*S. Cruz** (Beira, Mozambique),
C. Raimundo, L. Andela, N. Joao,
J. Marcos, C. Joyce, Z. Seni, M. Barrios,
A. Dicko, C. Monjane, A. Comelli,
F. Gordillo, P. Garcia-Vello

- O0769 16:26** **Saving the spleen: importance of timely diagnosis in relapsing melioidosis**
*W. Khot** (Navimumbai, India)

- O0770 16:37** **Rhino-Orbital Melioidosis Masquerading as Invasive Fungal Sinusitis: A Case Report**
*N. Kaur** (Jodhpur, India), *T. Kanagiri, D. Kumar,*
V. Tak, G.K. Bohra

- O0771 16:48** **Ruptured aneurysm unmasking disseminated melioidosis: a case report**
*M.L. Panes** (Manila, Philippines),
J. Poblete, C. Ramos

- O0772 16:59** **A rare case of melioidosis reactivation in Germany twelve years after travel to Thailand**
*T. Cronen** (Berlin, Germany), *S. Schaber,*
F. Bremer, H. Müller-Redetzky, A. Uhrig

OS110 16:15 - 17:15 Hall A2-2
 ANT CLN TRN 1-hour Case Session

New and novel approaches to complex infections

- Chairs* *Rekha Pai Mangalore (Melbourne, Australia)*
Jacques Simkins (Miami, United States)
- O0763 16:15** **Allogeneic cytomegalovirus-specific T cell therapy in a small-bowel transplant recipient with multidrug-resistant CMV infection**
L. Van Den Bogaart (Lyon, France), E. Frobert, T. Antonini, J.H. Dalle, J.Y. Mabrut, T. Perpoint, L. Reppel, D. Bensoussan, F. Ader*
- O0764 16:26** **Faecal microbiota transplantation (FMT) as a novel therapy for refractory chronic norovirus infection in immunocompromised hosts: clinical response and metagenomic analysis**
K. Chaw (Qld, Australia), K. Garnham, M. Buller, S. Schlebusch, T. Badrick, V. Grey, M. Sullivan, A. Sai, B. Koh, I. Gosbell*
- O0765 16:37** **Cycloheptasin: A novel antimicrobial peptide From *Periplaneta americana* for combating Carbapenem-resistant *Klebsiella pneumoniae* (CRKP)**
I. Iheukwumere (Uli, Nigeria)*
- O0766 16:48** **Daratumumab and belimumab for patients with neutralising anti-interferon- γ autoantibodies mediated adult-onset immunodeficiency: a case series**
Y.T. Weng (Taipei, Taiwan), M.T. Tsai, H.Y. Sun, K.Y. Lin, Y.S. Huang, W.T. Tsai, C.Y. Yao, B.C. Guo, J.T. Wang, S.C. Chang, A. Cheng*
- O0767 16:59** **Refractory resistant *Salmonella* empyema successfully treated with compassionate adjunctive bacteriophage therapy**
J. Chung (Singapore, Singapore), Y.Y. Chua, E.C.Y. Sng, J.M.F. Chien, A. Taha, W.M. Chew, K.J. Goh, S. Thong, N.G.S. Chua, A.L.H. Kwa*

OS111 16:15 - 17:15 Hall A3-2
 AMR ANT DX 1-hour Oral Session

Novel aspects of susceptibility testing methods

- Chairs* *Arjana Tambic Andrasevic (Zagreb, Croatia)*
Andreas Voss (Groningen, Netherlands)
- O0773 16:15** **Prospective assessment of heteroresistance to first-line β -lactams in Gram-negative bloodstream infections**
D. Squitieri (Rome, Italy), G. Menchinelli, B. Berinson, N. Degel-Brossmann, B. Posteraro, M. Sanguinetti, H. Rohde*
- O0774 16:27** **Comparative evaluation of agar dilution and Etest against broth microdilution for ceftobiprole susceptibility testing in methicillin-resistant *Staphylococcus aureus*: a multi-centre study in China**
F. Zhu (Hangzhou, China), Y. Chen*
- O0775 16:39** **Implementation of Cost-Effective Antimicrobial Susceptibility Testing in Resource-Constrained Settings: Lessons from the BALANCE Study**
R. Farzana (Oxford, United Kingdom), E. Carretto, N. Haque, M. Rahman, A. Monir, R.A. Ansary, S. Shahid, S.T. Reza, N. Haque, E. Kibaru, G. Ganda, D. Adera, K. Onjuro, C. Achi, K. Iregbu, P. Nwajiobi-Princewill, K. Abdulraheem, F. Kilani, J. Udeh, A. Aminu, A.M. Idris, J.D. Joshua, I.N. Nwafia, A. Nkiruka, C.I. Chiedu, R. Zahra, M. Hamza, B. Hassan, A. Naqvi, G. Guljanan, K. Shafique, G. Fatima, R. Siddiqi, M. Idrees, A. Khattak, N. Rehman, K. Hoog, C. Abdellaoui, S. Langhorne, A. Sindhu, M. Christodoulou, E. Owinoh, F. Demetrio, T.R. Walsh*
- O0776 16:51** **An innovative fluorogenic assay for reliable detection of staphylococcal penicillinase**
C. Dupieux (Lyon, France), P. Martins-Simoes, B. Youenou, G. Antoniotti, F. Vandenesch, A. Tristan, F. Laurent*
- O0777 17:03** **Comparison of piperacillin/tazobactam susceptibility testing with a Microscan system and the novel rapid system QuickMIC**
L. Lopez Cerero (Seville, Spain), M. Sánchez-Ruiz De La Muela, M. Oliva-Sánchez, L. Monge-Olivares, I. Portillo-Calderón, M. Pulido, A. Pascual*

Scientific Programme

Monday, 20 April 2026

PM006 16:15 - 18:15 Hall A2-1
 DX PHEI Pipeline Symposium

The value of diagnostics and enhancing utilisation

- Chairs* Till T. Bachmann (Edinburgh, United Kingdom)
 Betsy Wonderly Trainor (Boston, United States)
- D0014 16:15 Adoption and implementation in infection diagnostics – the long and winding road**
 Jane Freeman (Leeds, United Kingdom)
- D0015 16:45 Beyond the test: social and organizational realities of implementing RTI diagnostics in primary care**
 Sibyl Anthierens (Wilrijk, Belgium)
- D0016 17:15 What are diagnostics actually worth? Rethinking value beyond accuracy**
 Brooke Nichols (Boston, United States)
- D0017 17:45 From great science to routine clinical use**
 Matthew Mckillip (Chicago, United States)

SY137 16:15 - 18:15 Hall B0-2
 AMR ANT 2-hour Symposium

Stronger together: rational design and use of antibiotic combination therapies

- Chairs* Sandrine Marchand (Poitiers, France)
 Anouk Edwina Muller (The Hague, Netherlands)
- S0341 16:15 Combination therapies in tuberculosis: how to design and evaluate new regimen**
 Elin Svensson (Uppsala, Sweden)
- S0342 16:45 Towards rational breakpoints for antibiotic combination therapies**
 Sebastian Wicha (Hamburg, Germany)
- S0343 17:15 Antibiotic combination therapies: can we suppress resistance?**
 Linda Aulin (Leiden, The Netherlands)
- S0344 17:45 Optimal off-patent antimicrobial combinations regimens for Gram-negative infections**
 Joe Standing (London, United Kingdom)

SY138 16:15 - 17:15 Hall B0-1
 AMR ANT CLN 1-hour Symposium

Bacteriophages in implant-related infections: translating a century-old concept into a modern solution for AMR

- Chairs* Gina Suh (Scottsdale, United States)
 Andrej Trampuz (Brisbane, Australia)
- S0345 16:15 Bacteriophage therapy in cardiac and orthopaedic device-related infection**
 Tristan Ferry (Lyon, France)
- S0346 16:45 Challenges and future directions of phagotherapy in multidrug-resistant implant infections**
 Thomas Fintan Moriarty (Davos, Switzerland)

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

SY139 16:15 - 17:15 Hall A3-1
 PHEI 1-hour Symposium

Setbacks to strength: re-imagining global health partnerships at times of geopolitical uncertainty

- Chairs* Tetiana Melnyk (Paris, France)
 Marc Jean Struelens (Rochefort, Belgium)
- S0347 16:15 Effects on the global HIV pandemic**
 Mosa Moshabela (Cape Town, South Africa)
- S0348 16:45 Come back stronger: WHO's strategic plans for fighting infections in a globalised world**
 Maria Van Kerkhove (Geneva, Switzerland)

Co-organised with: Dutch Society for Medical Microbiology (NVMM), ESGPHM, ESGVM, Médecins Sans Frontières (MSF), European AIDS Clinical Society (EACS)

EF118 17:30 - 18:30 Arena 1
 DX PHEI ePoster Flash Session

Beyond culture: spectroscopy for pathogen identification and typing

- Chair* Angela Novais (Porto, Portugal)
- E0820 17:30 FTIR Spectral Fingerprinting for Rapid Identification of High-Risk Shiga Toxin-Producing *Escherichia coli* Serotypes**
 L. Díaz-Formoso* (A Coruna, Spain),
 S. Sánchez, G. Bou, M. Oviaño

- E0821 17:36 Automated discrimination of *E. coli* from *Shigella* spp. using FT-IR spectroscopy and machine learning**
M. Cordovana* (Bremen, Germany), N. Mauder, A.B. Pranada, C. Hess, W. Geissdoerfer, F. Pankok, U. Loderstaedt, S. Scheithauer, D. Dekker, A. E. Zautner, J. Overhoff, M. Werner, A. Wille, P. Warnke, T. Koeller, P. Morales, M. Suleiman, A. Perez-Lopez, J. Jiménez-Rodríguez, P. Garcia, G. Da Silva Collar, N. Kehl Moreira, A.L. Barth, J. Caierao, O. Join-Lambert, A.A. Muntean, C. Ghitulescu, C. Daniela, M.I. Popa, R.M. Hagen, U. Schotte, H. Frickmann
- E0822 17:42 Accelerated identification of high-risk *E. coli* ST131 isolates via fourier-transform infrared (FTIR) spectroscopy and neural network analysis**
N. Rakovitsky* (Tel Aviv, Israel), M. Bechor, A. Keren-Paz, Y. Carmeli
- E0823 17:48 Development of surface-enhanced Raman spectra coupled with machine learning analysis for differentiation of closely related species within *Enterobacter cloacae* complex**
Y. Li* (Beijing, China), M. Zhou, X. Xu, Y. Xu, B. Gu, J. Gu
- E0824 17:54 Discriminating old from new: application of Fourier-transform infrared spectroscopy (FTIR) to the reappearance of *Pseudomonas aeruginosa* in cystic fibrosis and primary ciliary dyskinesia**
M. Rossitto* (Rome, Italy), S. Raimondi, M. Cristiano, G. Vrenna, V. Fox, V. Tuccio Guarna Assanti, N. Essa, M.S. Lepanto, G. Foglietta, E. Montemitro, F. Alghisi, F. Majo, L. Cristiani, A. Boni, N. Ullmann, R. Cutrera, C.F. Perno, P. Bernaschi
- E0825 18:00 Performance of a machine learning algorithm for FTIR-based typing of NDM-producing *Klebsiella pneumoniae* in a hospital outbreak**
C. Garrido* (Santiago, Chile), J. Jimenez, M. Lecerasi, A. Wozniak, G. Arratia, P. Garcia
- E0826 18:06 Serotyping of *Haemophilus influenzae* strains and *Yersinia enterocolitica* by Fourier-transform infrared (FTIR) spectroscopy**
S. Zimmermann* (Heidelberg, Germany), C. Janssen, J. Rau, M. Cordovana, N. Mauder, T.T. Lam
- E0827 18:12 Fourier-transform infrared spectroscopy as a tool for *Streptococcus pneumoniae* serotyping: optimisation of the PCV15-classifier (Version 2.0)**
J. Caierão* (Porto Alegre, Brazil), G. Rosa Da Cunha, C. Tondolo Romero, N. Kehl Moreira, A.L. De Oliveira Gonçalves, J. Cover Salvador, A. Luis Barth, C.A. Gomes Dias
- E0828 18:18 Comparative evaluation of FTIR spectroscopy and whole genome sequencing for typing *Salmonella enteritidis***
S. Suto* (Zagreb, Croatia), N. Pražić, T. De Zan, M. Kvaternik Celjak, J. Knežević, J. Vraneš
-
- EF119 17:30 - 18:30 Arena 2
CLN DX ePoster Flash Session
- When fungi break the rules: rare pathogens in unusual sites**
- Chair Johan Maertens (Leuven, Belgium)
- E0829 17:30 *Candida* prosthetic joint infections, including multidrug-resistant *Candida auris*, at Hospital La Fe: a 15-patient 15-year experience (2010–2025)**
L. Brusca Vidao* (Valencia, Spain), S. Giner Almaraz, J. Frasquet, P. Suárez Urquiza, P. Muñoz Brell, E. Gremaldos, C. Castillo Martínez, J.L. López Hontangas, A. Ruiz-Gaitán
- E0830 17:36 Epidemiology of fungal joint infections**
J. Vazquez* (Augusta, United States), K. Omeir, C. Phillips, R. Martin, T. Craig
- E0831 17:42 Beyond hepatosplenic candidiasis: the changing face of paediatric chronic disseminated yeast infection**
M. Husain* (Paris, France), F. Alby Laurent, J. Guitard, M. Gits-Muselli, B. Brethon, F. Lanternier
- E0832 17:48 Rezafungin for *Candida* osteoarticular infections: the REZ-GEIO project**
S. De La villa Martinez* (Madrid, Spain), J. Guinea, J. Gómez Junyent, L. Ramos Merino, R. Escudero Sánchez, B. Sobrino, M.J. Moya, A. Muñoz, E. Múñez, M. Sánchez Somolinos, P. Sanz Ruiz, P. Muñoz
- E0834 18:00 Prospective evaluation of itraconazole for the treatment of Jorge Lobo's disease (lobomycosis)**
A. Nishikaku* (São Paulo, Brazil), J. Nobrega De Almeida Jr, F. Gonçalves, R.R. Durlacher, M.R. De Sousa Trindade, A. Panizza Jalkh, M. De Melo Teixeira, M. Dalla Valle, A. Satie Nishikaku

Scientific Programme

Monday, 20 April 2026

- E0835 18:06 Severe histoplasmosis in intensive care units: a multi-centre retrospective study in France**
L. Chantelot (Paris, France), H. Kallel, L. Camous, E. Dufranc, L. Zafrani, T. Urbina, A. Curtiaud, F. Boissier, P. Szychowiak, D. Roux, A. Rouze, A. Robert, N. Heming, F. Pene, R. Sonnevile, S. Hraiech, G. Voiriot, G. Martin Blondel, J. Hayon, G. Jolly, N. Issa, E. Blanchard, F. Ader, M. Decavele, B. Peiffer, F. Botterel, A. Adenis, F. Lanternier, K. Razazi*
- E0836 18:12 Multi-centre outbreak of both *Magnusiomyces capitatus* and *Magnusiomyces clavata* in Italy**
B. Spruijtenburg (Nijmegen, Netherlands), E. De Carolis, C. Magri, M. Sanguinetti, T. De Groot, V. Di Pilato, M. Mikulska, J.B. Buil, E.F.J. Meijer*
- E0837 18:18 From detection to decision-making: clinical utility of plasma microbial cell-free DNA sequencing for invasive mould infections**
M. Al Mohajer (Houston, United States), R. Berger, N. Howard, S. Grant*

- E0843 18:00 Comparative evaluation of a real-time PCR assay vs conventional culture for detecting carbapenemase-producing Gram-negative bacteria in rectal swabs**
A. Tychala (Thessaloniki, Greece), P. Trikoupis, Z. Sereni, Z. Tsinaris, G. Kagkalou, O. Vasilaki, K. Kouirouxis, P. Mantzana, E. Protonotariou, L. Skoura*
- E0844 18:06 MIC creep in the shadows: an interactive dashboard for forecasting MIC trends in newer antimicrobials against MDR pathogens across WHO regions**
N. Nityadarshini (New Delhi, India), J. Biswas, T. Bordoloi*
- E0845 18:12 Explaining phenotypic carbapenem resistance in GeneXpert-negative Gram-negative bacteria and evaluating concordance with whole genome sequencing**
S. Alotaibi (Riyadh, Saudi Arabia), A. Alomani, S. Alharbi, M. Alghoribi, L. Faqih, T. Abdulrahman, F. Alasmari*
- E0846 18:18 Genomic surveillance in an LMIC: convergent colistin resistance in epidemic *Klebsiella pneumoniae* (ST11, ST147) in Peshawar, Pakistan**
M. Khan (Peshawar, Pakistan)*

EF120 17:30 - 18:30 Arena 3
 AMR DX ePoster Flash Session

Advances in AMR diagnostics

- Chair Tomislav Kostyanev (Esbjerg, Denmark)*
- E0838 17:30 Evaluation of a new CRISPR-Cas-based assay for the detection of *bla*KPC in bacterial isolates**
A. Valêncio Siqueira (Massachusetts, United States), A.C. Gales, P.J.M. Bispo*
- E0840 17:42 PathCrisp: a next-generation CRISPR diagnostic platform for rapid detection of antimicrobial resistance**
M. Naik (English, India), K. Bs, R. Arora, S. Annes, D. Hafiz, D. Bhagchandani, V. Hegde, V. Chandru, V. Gupta*
- E0841 17:48 Rapid Aptamer-Based Biosensor for Identifying *K. pneumoniae* strains and Testing Meropenem–Colistin Susceptibility**
K.N. Yilmaz (Kars, Türkiye), N. Ciftci, Z.O. Uygun*
- E0842 17:54 Digital AST Annotator: standardising Kirby–Bauer reading with an open-source app**
A. Guerrero-López (Zurich, Switzerland), A. Diversi, E. Sosa, A.G. Monsalve, A. Egli*

LB008 17:30 - 18:30 Hall A1-4
 CLN IPC 1-hour Oral Session

Late-breaking trials in surgical infection prevention

- Chair Ili Margalit (Ramat Gan, Israel) TBA*
- L0041 17:30 Improvement in staff behavior during surgical procedures to prevent postoperative complications (ARIBO²): a cluster randomised trial.**
G. Birgand (Nantes, France), J.C. Lucet, B. Giraudeau, N. Jacquet, E. Tavernier, C. Gaborit, T. Haudebourg, N. Mauduit, C. Leux, D. Lepelletier, L. Grammatico-Guillon*
- L0042 17:42 Polyhexanide vs mupirocin and chlorhexidine for pre-operative *Staphylococcus aureus* decolonisation in elective spine surgery (SPADE): a pilot randomised controlled trial**
R. Sommerstein (Lucerne, Switzerland), J. Krebs, M. Grigorov, T. Poetzel, F. Michael, D. Bratelj, C. Capone, X. Zhou, J. Stoyanov*

- L0043 17:54** **One day of antibiotic treatment is non-inferior to four to seven days in patients with acute cholangitis after adequate biliary drainage: a multi-centre randomised controlled trial (COBRA)**
A. Overdevest (Amsterdam, Netherlands), E. Sieswerda, S. Haal, J.A. Bogaards, K.S. Boparai, F. Ter Borg, M.A. Brink, F. Van Delft, V.K. Dik, L.P.L. Gilissen, M. Hadithi, W.L. Hazen, F. Van Der Heide, W.J. Den Hollander, A. Inderson, P.J.F. De Jonge, S.D. Kuiken, J.M. Munneke, B. Opsteeg, L-E. Perk, A.C. Poen, J.W. Poley, R. Quispel, R.C.H. Scheffer, D.W. Schölvinck, E.J. Van Soest, A.C.I.T.L. Tan, W.J. Thijs, N.G. Venneman, R.C. Verdonk, F.P. Vleggaar, W. Van De Vrie, J.M. Vrolijk, R.L.J. Van Wanrooij, P.W. Weijenborg, M.G.W. Dijkgraaf, J.M. Prins, R.P. Voermans*
- L0045 18:06** **Effectiveness of an AI-based augmented reality tool for hand hygiene: preliminary findings of a cluster randomised controlled trial**
L. Yang (Hong Kong, Hong Kong), Y. Lai, J. Meng, Y. Li, J. Lu, S. Lu, J. Chen, C.F. Ho, E. Tartari, G. Birgand*
- L0044 18:18** **Epidemiology, medical-surgical approach, and clinical and functional outcomes in fracture-related infection: an international multi-centre study from ESGIAI**
B. Dahiri (Sevilla, Spain), R. García, M. Papadimitriou-Olivgeris, H. Ernandes, F. Almeida, J. Gomez-Junyent, O. Lesens, T. Martínez-Pascual, I. Contadini, D. Vaznaisiene, J.A. Iribarren-Loyarte, G. Euba, R. Escudero, J. Courjon, M.H. Ezzelarab, B. Sobrino-Díaz, A. Muñoz-Gómez, J. Rodríguez-Baño, M.D. Del Toro*

ME145 17:30 - 18:30 **Hall ICM 5**
 CLN DX VAX **Meet-the-Expert**

Implementing WHO Hepatitis guidelines in LMICs: challenges and perspectives

- M0359 17:30** *Olufunmilayo Lesi (Geneva, Switzerland)*
- M0360 17:42** *Zeinab Said (Cairo, Egypt)*

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Society for the Study of liver Diseases in Africa (SOLDA), Slovenian Society for Infectious Diseases, British Infection Association (BIA)

OS115 17:30 - 18:30 **Hall ICM 1**
 CLN DX TRN **1-hour Oral Session**

Functional and translational advances in microbiome analysis

- Chairs** *Lena Biehl (Cologne, Germany), Maurizio Sanguinetti (Rome, Italy)*
- O0815 17:30** **Validation of microbiome-guided fluorescence *in situ* hybridisation (MG-FISH) in clinical microbiology: integrating next-generation sequencing with molecular microbiome imaging**
J. Kikhney (Leipzig, Germany), Z. Xiong, K. Sarbandi, M. Muchova, D. Von Schöning, A. Moter*
- O0816 17:42** **Machine learning-based optimisation of long-read 16S rRNA sequencing parameters enhances species-level microbiome classification**
A.K. Bari (Groningen, Netherlands), B. Sinha, J.W.A. Rossen, B.B. Xavier, B.J. Olij, J.H-E. De Lange, T.T. Severs*
- O0817 17:54** **Salivary host-microbe interactions reveal pathogenic signatures in early colorectal cancer**
S. Rezasoltani (Aachen, Germany), H. Asadzadeh Aghdaei, G. Conrads*
- O0818 18:06** **Culturomics-Guided Bacterial Extracellular Vesicle Profiling Reveals the Gut Microbiota's Role in Patients with CTLA4 Deficiency**
R. Magdy Wasfy (Montreal, Canada), C. Morin, M. Naegele Aranguren, C. Masse, J. Poudrier, E.L. Falcone*
- O0819 18:18** **Site-stratified multi-omics profiling reveals body site specific microbiome immune signatures for clinical state classification**
D. Sebukpor (Chandigarh, India), I. Odezuligbo, M. Nagey, M. Chukwuka, O. Akinsuyi*

Scientific Programme

Monday, 20 April 2026

OS116 17:30 - 18:30 Hall A2-2
 AMR CLN TRN 1-hour Oral Session

Challenging the *status quo* in herpesvirus therapy

- Chairs* Sylviane Defres (Liverpool, United Kingdom)
 Dionysios Neofytos (Geneva, Switzerland)
- O0805 17:30 ABI-5366-101: a phase Ib study of a novel, oral, long-acting, investigational HSV helicase-primase inhibitor in recurrent genital herpes**
 M. Bloch* (Sydney, New South Wales, Australia), E. Gane, C. Sellwood, A. Edwards, W. Hayter, T. Tonkin, K. Kaluhin, D. Smith, G. Wang, J. Liu, S. Knox, K. Zomorodi, K. Kitrinios, A. Gaggar, J. Sasadeusz
- O0806 17:42 Helicase-primase inhibitor adibelivir (IM-250) shows potent antiviral activity against HSV clinical and acyclovir-resistant isolates and achieves therapeutic exposure in phase I/Ib studies**
 G. Kleymann* (Munich, Germany), A. Blank, M. Bergamino, J. Burhenne, D. Czock, C. Gege, Z. Haiying, A.C. Pérez-Osorio, B. Madarampalli, K.R. Jerome, N. Pretzsch, D. Huzly, V. Falcone, T. Hoffmann
- O0807 17:54 Updated use of CHARMD, a comprehensive herpesviruses antiviral resistance mutation database and HSA tool for easy cytomegalovirus genotyping interpretation**
 S. Alain* (Limoges, France), V. Tilloy, D. Diaz-Gonzalez, S. Chou, G. Andrei, F. Baldanti, G. Boivin, H. Hirsch, T. Lazzarotto, M. Marcos-Angeles, D. Michel, W.D. Rawlinson, S. Hantz
- O0808 18:06 Clinical experience of maribavir use for the treatment of refractory or resistant cytomegalovirus infection in solid-organ transplant recipients**
 M. Jayne* (London, United Kingdom), A. Stafford, K. Fung, G. Jones, R. Evans, M. Harber, R. Westbrook, J. Ryan, J. Potts, A. Marshall, M. Lanzman, N. Kanani Alviri, D. Cunningham, T. Haque, J. Hart, B. Patterson
- O0809 18:18 Delayed treatment alters pharmacodynamics of anti-CMV drugs**
 L. Sudarsono* (Leiden, Netherlands), K. Puspitasari, X. Liu, C. Van Hasselt, A.G. Märtson

OS117 17:30 - 18:30 Hall A3-2
 ANT CLN TRN 1-hour Oral Session

PK/PD-based antimicrobial dosing optimisation in children

- Chairs* William Couet (Poitiers, France)
 Ursula Theuretzbacher (Vienna, Austria)
- O0810 17:30 Population Pharmacokinetics of Cefotaxime for Optimising Dosing in Paediatric Meningitis and Bacteraemia**
 Z.X. Mun* (Melbourne, Australia), C. Landersdorfer, A. Gwee, A. Boast, A. Lei, A. Di Carlo, R. Chiletta, A. Daley, D. Fuhs, G. Gonis, B. Mcwhinney, A. Moody, R. Nation, J. Ungerer
- O0811 17:42 Ceftazidime/avibactam in neonates and infants < three months old: population pharmacokinetic (PopPK) analysis and PopPK model application**
 E. Soto* (Sandwich, United Kingdom), J.L. Yan, P. Irani, R. England
- O0812 17:54 Population pharmacokinetic/ pharmacodynamic analyses of cefiderocol for paediatric patients**
 D. Yamaguchi* (Osaka, Japan), T. Katsube
- O0813 18:06 Optimising posaconazole dosing in children through population PK modelling and simulation**
 M.L. Vuong* (Leuven, Belgium), O. Elkayal, J. Standing, S. Boonsathorn, Z. Kane, S. Bentley, A. Tragiannidis, A. Groll, J. Nickless, A. Brothers, A. Uyttebroeck, R. Valenzuela, J. Morales, I. Spriet, E. Dreesen
- O0814 18:18 Evaluation of optimal empirical antibiotic combinations for neonatal sepsis in low- and middle-income countries: a pharmacokinetic/pharmacodynamic approach**
 W. Van Os* (Leiden, Netherlands), K.M. Thomson, K. Sands, T.R. Walsh, R. Zahra, G. Chan, D. Bekele, S. Solomon, A. Rucogoza, J.B. Mazarati, K. Iregbu, S.N.C. Uwaezuoke, A.B. Mairami, F.Z. Modibbo, L.I. Audu, S. Gambo, A. Aliyu, J.G.C. Van Hasselt

PM007 17:30 - 18:30 Arena 4
 AMR PHEI Policy Forum

From global research priorities to national and local impact: implementing AMR priority research agendas

Chair *Benedikt Huttner (Geneva, Switzerland)*

- D0018 17:30 Challenges and opportunities on the implementation of the OHPRA**
Sabiha Essack (Durban, South Africa)
- D0019 17:45 Implementing global research agendas on AMR: tracking research projects and activities**
Lesley Ann Ogilvie (Berlin, Germany)
- D0020 18:00 National research projects based on Global research agendas**
Gloria Cordoba (Copenhagen, Denmark)
- D0021 18:15 Promoting global research agendas for policy makers**
Geneviève Boily-Larouche (Toronto, Canada)

SY142 17:30 - 18:30 Hall ICM 13b
 PHEI 1-hour Symposium

Redefining One Health

Chairs *Pikka Jokelainen (Copenhagen, Denmark)*
Sonja Lofmark Behrendtz (Solna, Sweden)

- S0353 17:30 New theoretical frameworks for One Health**
Julianne Meisner (Seattle, United States)
- S0354 18:00 New operational frameworks for One Health**
Jakob Zinsstag (Basel, Switzerland)

SY143 17:30 - 18:30 Hall B0-1
 DX PHEI 1-hour Symposium

The future of pathogen surveillance: molecular data without borders

Chairs *Adrian Egli (Zurich, Switzerland)*
Paula Mölling (Örebro, Sweden)

- S0355 17:30 The Swiss Pathogen Surveillance Platform: a model for international collaboration and data sharing**
Tim-Christoph Roloff (Zürich, Switzerland)
- S0356 18:00 Lessons learned from the Trakka Data Sharing Ecosystem in Australia and beyond**
Benjamin Peter Howden (Melbourne, Australia)

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)

SY144 17:30 - 18:30 Hall A3-1
 AMR CLN 1-hour Symposium

Update on STIs: epidemiology, drug resistance and role of DoxyPEP

Chairs *Arjan Harxhi (Tirana, Albania)*
Jean-Michel Molina (Paris, France)

- S0357 17:30 The impact of travel on the global epidemiology of STIs**
Zofia Bartovska (Prague, Czechia)
- S0358 18:00 Impact of DoxyPEP on the human microbiome and resistome**
Victoria Chu (San Francisco, United States)

Co-organised with: ESCMID Education Subcommittee, ESCMID Fungal Infection Study Group (EFISG), ESCMID Study Group for Sexually Transmitted Infections (ESTISG), ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)

Scientific Programme

Tuesday, 21 April 2026

CGR 08:30 - 10:30 Hall ICM 14
 CLN Special Session

Clinical Grand Rounds

Chairs Yoav Keynan (Winnipeg, Canada)
 Nina Khanna (Basel, Switzerland)
 Dimitrios P. Kontoyiannis (Houston, United States)
 David L. Paterson (Singapore, Singapore)
 Priscilla Rupali (Vellore, India)
 Monica Slavin (Melbourne, Australia)

CGR01 Case 1

Tom Cartau (Caen, France)

CGR02 Case 2

Paul M. I. Chabert (Dumbéa, New Caledonia)

CGR03 Case 3

Johanna Erber (München, Germany)

CGR04 Case 4

Rotem Gorfinkel (Kibbutz Beeri, Israel)

CGR05 Case 5

Rohan Patel (London, United Kingdom)

CGR06 Case 6

Lauren Saint (Chapel Hill, United States)

CGR07 Case 7

Samuel Showalter (Aurora, United States)

Co-organised with: Infectious Disease Society of America (IDSA)

EF123 08:30 - 09:30 Arena 2
 CLN ePoster Flash Session

Novel aspects on epidemiology and therapeutics of urinary tract infections

Chair Suzanne Geerlings
 (Amsterdam, Netherlands)

E0862 08:30 Incidence of urinary tract infections among diabetic and non-diabetic patients following treatment with SGLT-2 inhibitors compared with GLP-1 receptor agonists
*O. Biham** (Lehavim, Israel), *L. Hassan*, *N. Burrack*, *L. Neshor*

E0863 08:36 Characterising complicated urinary tract infections (POS-cUTI): preliminary results of a multinational prospective cohort (POST-cUTI / ECRAID)

*J.M. Bravo-Ferrer** (Seville, Spain), *E. Rubio Martin*, *N. Maldonado*, *B. Gallego*, *E. Moreno*, *F. Cogliati Dezza*, *R. Compagnone*, *I. Portillo*, *A. Barac*, *F. Arieti*, *O. Awwad*, *P. De Nardo*, *A. Cano*, *P. Clevenbergh*, *N. Merchante*, *A. Hernandez-Torres*, *E. Frangou*, *E. Merino*, *T. Lafon*, *T. Ten Doesschate*, *O. Sandulescu*, *B. Koprivica*, *P. Andrade*, *A. Ternhag*, *M. Samarkos*, *M. Bokhari*, *A. Bandera*, *L. Jacquin*, *E. Iosifidis*, *E. Durante-Mangoni*, *D. Chadwick*, *J. Rupp*, *P. Muñoz-García*, *A. Røder*, *D. Vighino*, *J. Van Laethem*, *B. Kjurchikj*, *G. Marchetti*, *S. Tsiodras*, *M. David*, *A.R. Veiga-Ferraz*, *J.R. Paño-Pardo*, *C. Kirakli*, *N. Catorze*, *M. Tumbarello*, *M. Akova*, *I. Gentile*, *A. Bartoloni*, *L. Radulovic*, *C. Constantinou*, *M. Bonten*, *L.P.G. Derde*, *E. Cappelli*, *E. Tacconelli*, *J. Rodríguez-Baño*

E0864 08:42 Clinical effectiveness of four different short-course antibiotic regimens in adult women with bacteriological confirmation of urinary tract infection

*R. Monfa** (Barcelona, Spain), *A. García-Sangenis*, *R. Morros*, *C. Llor*, *D. Ouchi*, *S. Fernández-García*, *C. Miranda-Jiménez*, *A. Moragas*, *M. Aguilar-Sánchez*, *A. Leiva*, *A. Troncoso-Mariño*, *J. Marín-Cañada*, *R. Rodríguez*, *J.M. Molero*, *M.A. Sánchez-Calavera*

E0865 08:48 Proteomic endotypes in patients with *Escherichia coli* pyelonephritis

*L. Bolinder** (Stockholm, Sweden), *T. Sutantiwanichkul*, *A. Reepalu*, *A. Linder*, *L. Mellhammar*, *M. Sundqvist*, *D. Nestor*, *C. Unge*, *A. Färnert*, *H. Janols*, *M. Lipcsey*, *J. Sundén-Cullberg*, *S. Cajander*, *M. Uhlén*, *F. Edfors*, *K. Strålin*

E0866 08:54 Predicting antibiotic resistance risk in urinary tract infections using machine learning to support safer empirical prescribing in hospitalised children and adults

*L. Aerts** (Basel, Switzerland), *D. Malpetti*, *S. Bouizaguen*, *C. Berchtold*, *P. Neuschwander*, *G. Greub*, *L. Azzimont*, *J.A. Bielicki*

E0867 09:00 Nitrofurantoin for *Neisseria gonorrhoeae* urethritis? an *in vitro* and *in vivo* study in *Galleria mellonella*

*C. Kenyon** (Antwerp, Belgium), *S. Manoharan-Basil*, *I. Kanesaka*, *I. De Baetselier*, *S. Abdellati*, *T. De Block*, *T. Vanbaelen*, *R. Naesens*, *B. Britto Xavier*

- E0868 09:06** **The effectiveness of a weekly antimicrobial stewardship intervention on antibiotic prescriptions in Dutch nursing homes: a randomised controlled trial**
L. Van Buul (Amsterdam, Netherlands), K. Paap, M. Schim Van Der Loeff, S. Kuil*
- E0869 09:12** **In private facilities, expensive medications are sometimes used as a first choice: attitudes and practice of health care workers in the management of UTIs in Kampala, Uganda**
D. Ekusai Sebatta (Kampala, Uganda), N. Miriam, P. Kirabo, J. Enomut, M. Iwami, H. Kajumbula, F. Kitutu, J. Kapsi, C. E. Moore*
- E0870 09:18** **Clinical symptom improvement and resolution following uUTI treatment with gepotidacin: a post-hoc subgroup analysis**
J. Diaz-Regañon (Madrid, Spain), K. Gupta, D. Powell, R. Banerjee, J. Bablani, S. Janmohamed, M. Ramirez*

EW151 08:30 - 10:30 Hall ICM 13a
 2-hour Educational Session
 DX PHEI

Bird flu is no longer just for birds: from strategic planning to public health readiness

- Chairs* *Edoardo Colzani (Solna, Sweden) Barbara Rath (New Orleans, United States)*
- W0475 08:30** **What drives pandemic risk? Virus, population and policy factors influencing Influenza H5N1 spread**
Benjamin Cowling (Pokfulam, Hong Kong)
- W0476 08:50** **Surveillance in action: diagnostic tools for early detection of zoonotic influenza human infections**
Kanta Subbarao (Quebec City, Canada)
- W0477 09:10** **Zoonotic influenza: from signals to public health response actions**
Angeliki Melidou (Stockholm, Sweden)
- W0478 09:30** **Antivirals and vaccines: readiness for a future influenza pandemic**
Marco Cavaleri (Amsterdam, Belgium)

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV), European Centre for Disease Prevention and Control (ECDC)

EW152 08:30 - 10:30 Hall A3-1
 2-hour Educational Session
 PED VAX

Vaccination during pregnancy: for the mother, and for the child

- Chairs* *Olivier Epaulard (Grenoble, France) Ulrich Heininger (Basel, Switzerland)*
- W0479 08:30** **Burden of vaccine-preventable infections in pregnant women**
Shamez Ladhani (London, United Kingdom)
- W0480 08:50** **Mother-to-child transmission of antibodies: how and when**
Marta Nunes (Lyon, France)
- W0481 09:10** **Vaccination of pregnant women to protect the child: successes and hurdles**
Pawel Stefanoff (Stockholm, Sweden)
- W0482 09:30** **Vaccination during pregnancy: from doctors to mother-to-be, who is hesitant?**
Emilie Karafillakis (London, United Kingdom)

Co-organised with: ESCMID Vaccine Study Group (EVASG)

LB009 08:30 - 09:30 Hall A1-3
 1-hour Oral Session
 CLN

Late-breaking clinical trials in sepsis management

- Chairs* *Jean-Francois Timsit (Paris, France) Steven Tong (Melbourne, Australia)*
- L0046 08:30** **Imipenem/cilastatin-funobactam for hospital-acquired/ventilator-associated bacterial pneumonia: a multinational phase III trial (REITAB-2)**
K. Chang (Beijing, China), Y. Wang, C. Wang, Z. Tang, J. Yin, J. Zhao, Y. Wang, B. Cao, T. Mei, A. Li, H. Li, Q. Jiang, P. Wang, F. Ye, L. Ding, Z. Liu, F. Yin, X. Mo, H. Qu, Y. Xia, J. Wang, J. Wu, S. Yang, R. Lin, G. Lv, H. Luo, B. Liu, J. Gu, F. Wei, J. Zhu, H. Liang, S. Qiu, H. Mai, X. Zhu, R. Yu, G. Han, T. Lou, H. Wang, J. Zhang, Y. Li, H. Wang, H. Lu, T. Xin, C. Li, X. Wang, X. Zhang, H. Gao, H. Wang, A. Pan, Q. Wang, J. Cao, Y. Zhu, Z. Xiao, L. Pan, S. Peng, X. Ding, Q. Chi, H. Xu, F. Liu, A. Guo, J. Zhan, Q. Zhang, R. Guo, J. Li, D. Zhu, H. Zhao, A. Cano Yuste, T. Huynh, I. Biney, K. Remy*
- L0047 08:42** **Low-dose CT cOmPared to Lung UltraSonography vs standard of care-based strategies for the diagnosis of pneumonia in the elderly: a multi-centre randomised controlled trial (OCTOPLUS)**
V. Prendki (Geneva, Switzerland), J. Stirnemann, W. Hautz, N. Garin, A. Platon, E. Bernasconi, T. Ruder, A. Poncet*

Scientific Programme

Tuesday, 21 April 2026

L0048	08:54	A multi-centre, randomised controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in severely ill neonates and children: BENEFICIAL trial <i>P. De Cock*</i> (Ghent, Belgium), <i>R. Colman, A. Smits, F. Piersigilli, M. Renard, A. Van Damme, A. Clarysse, E. Dhont, S. Vanhaesebrouck, V. Bordon, L. Boland, B. De Wilde, A. Amza, L. Vanlanduyt, T.V.A. Nguyen, F. Cools, J. Van Der Werff Ten Bosch, D. Vens, F. Derriks, L. Houtekie, M. Reiner, D. Van Der Linden, P. Schelstraete</i>	
L0049	09:06	Use of procalcitonin point-of-care test to guide de-escalation of empiric antibiotic therapy in adult patients with sepsis in a tertiary hospital in Bangladesh (PROCALBAN): a randomised, controlled, open-label trial <i>F.U.H. Chowdhury*</i> (Oxford, United Kingdom), <i>R.A.M-E. Uddin, M. Ali, P.K. Dutta, D. Das, A.H. Hanif, M. Kar, F.B. Jahangir, S.I. Khan, M.M. Huq, A.A. Sayeed, M.H.O. Roshid, N.U. Chy, M.A. Hossain, M.A. Sattar, M. Schilstra, E. De Jong, C. Schultsz, M. Nijsten, M.J. Uddin, A. Ghose, K. Plewes, L. Pisani, P. Guerin, M. Mukaka, A.M. Dondorp</i>	
L0050	09:18	Adjunctive clindamycin for treatment of <i>Staphylococcus aureus</i> bacteraemia: a randomised controlled trial within the S. aureus Network Adaptive Platform (SNAP) <i>A. Bowen*</i> (Wembley, Australia)	
OS121	08:30 - 10:30		Hall BO-1
AMR	2-hour Oral Session		
Genomic epidemiology and emerging bacterial resistance			
Chairs		<i>Valeria Bortolaia</i> (Copenhagen, Denmark) <i>João Pires</i> (Oslo, Norway)	
O0852	08:30	Long-term persistence and cross-reservoir transmission of antimicrobial resistant <i>Serratia marcescens</i>: a genomic epidemiology study <i>J. Lay*</i> (Melbourne, Australia), <i>B. Vezina, N. Macesic, J. Lacey, R. Patwa, A.Y. Peleg</i>	
O0853	08:42	High prevalence of NDM-5-producing <i>Escherichia coli</i> with Penicillin-Binding Protein 3 Mutations in Germany: An emerging threat? <i>J.B. Hans*</i> (Berlin, Germany), <i>L.M. Höfken, S. Haller, S. Gatermann, S. Möller, N. Pfennigwerth, F. Reichert, M. Sandfort, M.A. Fischer, T. Semmler, T. Eckmanns, G. Werner</i>	
O0854	08:54	A decade of evolving <i>Pseudomonas aeruginosa</i> resistance: Epidemiology and antimicrobial trends (2014–2024) <i>D. Mendes Pedro*</i> (Lisbon, Portugal), <i>M. Meneses, C. Mimoso Santos, A. Bruschy Fonseca, Á. Ayres Pereira, E. Valadas, J. Melo Cristino, C. Caneiras</i>	
O0855	09:06	Associations between antidepressant prescribing and antibiotic resistance in <i>Escherichia coli</i> urinary tract infections in Scotland <i>L. Ciaccio*</i> (Dundee, United Kingdom), <i>K.N. Barnett, C.A. Marwick, B.J. Parcell, H. Wang, J. Daniai, F. Kerr, J. McEwen, A. Morrison, D. O'driscoll, A. Seaton</i>	
O0856	09:18	Integrated Genomic Surveillance of carbapenemase-producing <i>Klebsiella pneumoniae</i> in Germany in 2023-2024 revealed frequent case imports from abroad and local outbreaks <i>M. Sandfort*</i> (Berlin, Germany), <i>L.M. Höfken, F. Reichert, M.A. Fischer, S. Möller, J.B. Hans, H. Öhler, D. Said, N. Pfennigwerth, T. Eckmanns, G. Werner, S.G. Gatermann, S. Haller</i>	
O0857	09:30	The emergence and spread of NDM-type carbapenemase-producing <i>Acinetobacter baumannii</i> clones in Hungary <i>A. Hanczvikkel*</i> (Budapest, Hungary), <i>D. Göbhardt, E. Ungvári, N. Derzsy, A. Darab, L. Jánvári, L. Holub, L. Majoros, K. Kamotsay, M. Farkas, A. Kark, K. Mályi, B. Roskó, M.A. Peti, Á. Tóth</i>	
O0858	09:42	Clonal complex 398 emerging as community- and healthcare-associated methicillin-resistant <i>Staphylococcus aureus</i> in the Czech Republic 2017-2024 <i>J. Tkadlec*</i> (Prague, Czechia), <i>A. Rozsypalkova, S. Polivkova, P. Drevinek, J. Gooskens, M. Krutova</i>	
O0859	09:54	Epidemiological and Molecular Insights of Community- and Hospital-Acquired MRSA in Antwerp, Belgium <i>D. De Smet*</i> (Antwerp, Belgium), <i>B.B. Xavier, S. Van Goethem, P. Van Lint, W. Verstrepen, R. Naesens</i>	
O0860	10:06	Antimicrobial resistance in the zoonotic pathogen <i>Capnocytophaga canimorsus</i>: Global distribution of resistance genes and their phenotypic impact <i>Z. Germuskova*</i> (Zurich, Switzerland), <i>E. Pronzini, T. Roloff, H. Seth-Smith, K.K. Søgaard, E.M. Broens, F. Renzi, A. Egli</i>	
O0861	10:18	Comprehensive Genomic Surveillance of Invasive <i>Salmonella</i> in India Reveals Plasmid Evolution and Expanding Antimicrobial Resistance <i>V. Shamanna*</i> (Bengaluru, India), <i>P.R. Sowmya, S. Varun, C. Natacha, N. Geetha, K.L. Ravikumar</i>	

OS122 08:30 - 09:30 Hall A1-2
 CLN DX 1-hour Oral Session

Moving from culture to molecular diagnostics in implant-associated infections

Chairs Thomas Fintan Moriarty (Davos, Switzerland)
 Marjan Wouthuyzen-Bakker (Groningen, Netherlands)

00847 08:30 **Rapid novel molecular method for enhanced detection of periprosthetic joint infection**

E. Morreel* (Maastricht, Netherlands), P. Savelkoul, I. Van Loo

00848 08:42 **Enhancing diagnostics in orthopaedic infections: clinical impact of syndromic multiplex pcr compared to traditional culture**

F. De Winter* (Turnhout, Belgium), N. Van Beek, J. Frans, T. Goegebuer, W. Schuermans, E. Van Even, P. Verbeeck, D. Van Der Beek, H. Nailis

00849 08:54 **Optimising culture strategies in chronic orthopedic device-related infections: do blood culture bottles deliver?**

J. Van Heuverswyn* (Ghent, Belgium), H. Hamerlinck, D. Huis In 't Veld, S. Vandendriessche, B. Verhasselt, J. Boelens

00850 09:06 **Pathogen spectrum of aortic graft infections uncovered by combined microbiologic testing and *in situ* metagenomic sequencing**

Q. Miao* (Shanghai, China), J. Yue, Y. Chen, Y. Luo, H. Liu, Y. Kan, B. Hu

00851 09:18 **Utility of metagenomic sequencing of microbial cell-free DNA as a diagnostic tool in vascular graft and endograft infections: a cross-sectional study**

M. Eneberg* (Aalborg, Denmark), R.A. Nielsen, A.M.F. Eskildsen, M. Albertsen, N.P. Jørgensen, J. Budtz-Lilly, H.L. Nielsen, L.J. Østergaard, N.B. Stærke

SY146 08:30 - 10:30 Hall ICM 5
 CLN DX TRN 2-hour Symposium

Fungal OMICS: from bench to bedside

Chairs Lottie Brown (London, United Kingdom)
 Josh Nosanchuk (Bronx, United States)

S0455 08:30 **Evolutionary genomics of emerging fungal pathogens**

Toni Gabaldón (Barcelona, Spain)

S0456 09:00 **Host transcriptome response to *Candida auris* extracellular vesicles**

Lysangela Ronalte Alves (Curitiba, Brazil)

S0457 09:30 **How *Candida* drives oral cancers: host and pathogen omics**
 Attila Gacser (Szeged, Hungary)

S0458 10:00 **Functional consequences of mycobiota on host immunity**
 Tobias Hohl (New York, United States)

SY147 08:30 - 10:30 Hall BO-1
 ANT CLN 2-hour Symposium

The what and how of using AI in Antimicrobial Stewardship

Chairs Mark G. J. De Boer (Leiden, Netherlands)
 Mark Gilchrist (London, United Kingdom)

S0459 08:30 **An introduction and overview of the evolving use of AI in Antimicrobial Stewardship**
 Bradley Langford (Etobicoke, Canada)

S0460 09:00 **Responsible use of AI in prediction modeling for real-life clinical practice tools**
 Pontus Naucler (Stockholm, Sweden)

S0461 09:30 **The role of ChatGPT and AI chatbots in optimising antibiotic therapy: believe or disbelieve?**
 Alexis Maillard (Paris, France)

S0462 10:00 **Is AI the key to acceleration of Antimicrobial Stewardship in LMICs?**
 Mike Nsubuga (Bristol, United Kingdom)

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Society of Infectious Diseases Pharmacists (SIDP)

SY148 08:30 - 10:30 Hall A1-1
 CLN DX 2-hour Symposium

Advancing diagnostic strategies for detecting bacteremia across the globe

Chairs Christina Obiero (Kilifi, Kenya)
 Agnes Maria Sonnevend (Pécs, Hungary)

S0463 08:30 **Rethinking bacteraemia: how diagnostic innovation is improving outcomes**
 Kai Sohn (Stuttgart, Germany)

S0464 09:00 **From PCR to whole genome: the molecular revolution in bacteraemia diagnosis**
 Kwan Ki Karrie Ko (Singapore, Singapore)

S0465 09:30 **Low-tech blood culture techniques and protocols: what is truly necessary?**
 Liselotte Hardy (Antwerp, Belgium)

S0466 10:00 **Needs and barriers for performing blood cultures in resource limited settings**
 Makeda Semret (Montreal, Canada)

Co-organised with: ESCMID Parity Commission, ESCMID Professional Affairs Subcommittee

Disclaimer

Scientific programme as of 16 of March

Scientific Programme

Tuesday, 21 April 2026

SY149 08:30 - 10:30 Hall A2-1
 CLN TRN 2-hour Symposium

The role of the microbiome in shaping clinical outcomes in immunocompromised patients

- Chairs* *Nicolas Benech (Lyon, France)*
Silvia Corcione (Turin, Italy)
- S0467 08:30 The role of the microbiome in immune reconstitution after cancer therapy**
Kate Markey (Seattle, United States)
- S0468 09:00 Targeting the gut microbiome: an emerging trend in haematopoietic stem cell transplantation**
Jonathan Peled (New York, United States)
- S0469 09:30 Optimising cancer treatment through gut microbiome modulation**
Maria Rescigno (Milan, Italy)
- S0470 10:00 Role of microbiome in GVHD**
Mette Hazenberg (Amsterdam, Netherlands)

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

SY150 08:30 - 10:30 Hall A2-2
 DX 2-hour Symposium

The real-world impact of IVDR on patient care: threat or opportunity?

- Chairs* *Antti Hakanen (Turku, Finland)*
David Ong (Rotterdam, Netherlands)
- S0471 08:30 Implications of IVDR on clinical decision making and patient care**
Erlangga Yusuf (Rotterdam, Netherlands)
- S0472 09:00 IVDR impact on molecular diagnostic workflows**
Maurizio Sanguinetti (Rome, Italy)
- S0473 09:30 How metrology can support IVDR and outbreak response**
Esmeralda Valiente (Berlin, Germany)
- S0474 10:00 IVDR from a European policy perspective**
Gülşen Özkaya Şahin (Lund, Sweden)

Co-organised with: Clinical Microbiologists of Finland, Dutch Society for Medical Microbiology (NVMM), ESCMID Ethics Advisory Committee, ESCMID Professional Affairs Subcommittee, Nordic Society of Clinical Microbiology and Infectious Diseases (NSCMID), UEMS, Biomed Alliance

EF126 09:30 - 10:30 Arena 1
 CLN DX TRN ePoster Flash Session

Clinical and diagnostic insights into invasive fungal diseases

- Chair* *Cecile Angebault (Creteil, France)*
- E0881 09:30 Detection of Mucorales antigen in serum samples using a newly developed lateral-flow device**
J. Rousselot (Besançon, France), L. Millon, E. Scherer, A.P. Bellanger, C.R. Thornton*
- E0882 09:36 High rates of *Candida* colonisation in European neonates: a sub-analysis of the NeoVanc randomised controlled trial**
L.F. Hill (London, United Kingdom), L. Ferreras-Antolin, M.N. Clements, F. Shahed, J. Fermin Luque, I. Monahan, T. Planche, M.A. Turner, I. Lutsar, E. Roilides, M. Sharland, J.A. Lindsay, P.T. Heath*
- E0883 09:42 Epidemiology, resistance patterns, and outcomes of candidaemia acquired in Italian intensive care units: insights from the GIVITI Network (2020-2024)**
G. Scaglione (Milan, Italy), M. Colaneri, M. Offer, G. Montrucchio, C.G.I. Genovese, B. Viaggi, F. Dore, G. Tricella, L. Dalfino, G. Monti, A. Gori, E.P.I. Palomba, S. Finazzi*
- E0884 09:48 CandEYE: serial non-mydratric fundoscopy in patients with candidaemia**
I. Reinhold (Cologne, Germany), J. Müller, L. Altay, A. Lentzsch, K. Löw, E. Mackevic, J. Salmanton-García, C. Cursiefen, O.A. Cornely, R. Sprute*
- E0885 09:54 Clinical, laboratory and financial evaluation of diagnostic testing for invasive *Aspergillus* infections in haemato-oncology patients with neutropenic fever in a large U.K. teaching hospital**
J. Moore (Cambridge, United Kingdom), W. Hamilton, P. Patel, A. King, J. Mason, D. Enoch*
- E0886 09:54 Diagnostic value of galactomannan in tracheobronchial aspirate for *Aspergillus* infection in lung transplant recipients (the GALACTBAS study)**
A. Monforte (Barcelona, Spain), M.T. Martín-Gómez, C. Berastegui, E. Márquez-Algaba, J. Sacanell, J. Rosado, A. Falcó-Roget, G. Escudero, J. Casanovas, C. Kirkegaard-Biosca, B. Sáez-Giménez, J. Gavalda, O. Len, I. Los-Arcos*
- E0887 10:00 Fungal diagnostic approach among hospitalised patients receiving polyene vs azole in US, 2021-2024**
T. Sandison (Baltimore, United States), E. Harvey, M. Zilberberg, A. Knee, Q. Andan, B. Nathanson, K. Marr, A. Shorr*

E0888 10:12 ***Pneumocystis jirovecii* pneumonia in solid organ transplant recipients: a cross-sectional study in France**
*A. Alanio** (Paris, France), *K. Sitbon*, *T. Obadia*, *M. Desnos-Ollivier*, *D. Garcia-Hermoso*, *V. Bru*, *G. Desoubieux*, *E. Guemas*, *M.F. Durieux*, *F. Morio*, *F. Robert-Gangneux*, *J. Bonhomme*, *F. Lanternier*, *O. Lortholary*

E0889 10:18 **A qPCR identification scheme to detect the most common mycetoma causative agents in Africa**
*W. Van De sanDe** (Rotterdam, Netherlands), *A. Watson*, *S. Bakhiet*, *E. Siddig*, *C. Pab Minlekib*, *R. Mohammed*, *W. Zandijk*, *M. Konings*, *A. Fahal*, *M. Faye*, *F. Mazraati Tajabadi*, *J. Errington*, *D. Sow*

EF127 09:30 - 10:30 Arena 3

AMR DX IPC ePoster Flash Session

Genomic surveillance for infection prevention and outbreak investigation

Chair *Richard V. Goering* (Omaha, United States)

E0890 09:30 **From potential to practice: an internationally transferable roadmap for implementing whole genome sequencing in infection prevention and control**
*J. Price** (Brighton, United Kingdom), *J. Otter*, *E. Jauneikaite*

E0891 09:36 **Full-chain genomic surveillance reveals ecological and genetic determinants of *Staphylococcus aureus* transmission**
*S. Liu** (Beijing, China), *K. Wang*, *M. Wang*, *C. Yao*, *Q. Wang*, *H. Wang*

E0892 09:42 **Exploring Filth Flies as Sentinels of Hospital Environments in 16 Countries and Regions: High Prevalence of Clinically Relevant Antimicrobial-Resistant Bacteria observed in resource-limited settings**
*K. Sands** (Oxford, United Kingdom), *E.A. Portal*, *T. Iannetelli*, *S. Premchand-Branker*, *T. Beard*, *M. Li*, *K. Cook*, *A.K. Lankapalli*, *V. Dougnon*, *A. Gaye*, *A. Opazo-Capurro*, *A.M. Soliman*, *M.H. Legese*, *J. Acolatse*, *E. Carretto*, *E.G. Kibaru*, *O. Sy*, *K. Iregbu*, *A. Zukowska*, *M.C. Seck*, *A.R. Mansaray*, *H. Kuo*, *C. Graham*, *P. Nel*, *C. Achi*, *T.R. Walsh*

E0893 09:48 **Genomic insights into carbapenem-resistant *Klebsiella pneumoniae* from bloodstream infections in Crete, Greece**
*K. Tryfinopoulou** (Heraklion, Greece), *G.C. Karfaki*, *D. Marinopoulou*, *T. Iatridi*, *M. Malliarou*, *E. Skliva*, *D. Stafylaki*, *E. Chatzidospyridaki*, *S. Karakonstantis*, *P. Ioannou*, *D. Kofteridis*, *A. Psaroulaki*, *D. Chochlakis*

E0894 09:54 **ST11 on the move: recurrent capsule switching and the rise of KL62**
*Y. Feng** (Chengdu, China), *Z. Zong*

E0895 10:00 **Outbreak of carbapenemase-carrying plasmids in Urology: implications of bladder irrigation pipe systems**
*A. Freijo Cancio** (Sevilla, Spain), *M. Delgado-Valverde*, *J. Rodriguez-Baño*, *R. López-Marquez*, *A. Pascual*, *L. López-Cerero*

E0896 10:06 **Genomic epidemiology of multidrug-resistant *Enterobacteriaceae* in intensive care units: a one year prospective study in adult intensive care units of three French university hospitals**
*F. Gravey** (Caen, France), *C. Bernachot*, *K. Le Neindre*, *D. Ducheyron*, *J.B. Decros*, *F. Tamion*, *S. Boyer*, *T. Clavier*, *J. Maizel*, *H. Dupont*, *N. Lemaître*, *J. Brochart*, *H. Marini*, *S. Galopin*, *M. Godet*, *S. Le Hello*, *C. Jeanne-Leroyer*, *O. Join-Lambert*

E0897 10:12 **Evaluation of the applicability of nanopore-only whole genome sequencing for *Pseudomonas aeruginosa* outbreak investigation in the ICU setting: a multi-centre study**
*J. Dingemans** (Hasselt, Belgium), *S. Vandersanden*, *P. Hilken*, *F. Crombé*, *D. De Geyter*, *A.M. Van Den Abeele*, *P. Bruynseels*, *J. Frans*, *P. Vandecandelaere*, *A. Boel*, *R. Cartuyvels*, *K. Magerman*

E0898 10:18 ***Pseudomonas aeruginosa* genome adaptations in bleached sink traps**
*D. Hocquet** (Besançon, France), *T. Chautrand*, *L. Masson*, *C. Couchoud*, *B. Valot*

Scientific Programme

Tuesday, 21 April 2026

EF128 09:30 - 10:30 Arena 4
 CLN PED TRN ePoster Flash Session

CNS infections at a crossroad: rising lineages, host susceptibility and novel mechanisms

Chair Emmanuelle Varon (Creteil, France)

E0899 09:30 **Epidemiology, clinical characteristics and outcomes of invasive meningococcal disease caused by two hypervirulent serogroup W strains belonging to the ST11 clonal complex in England (2010-2019)**
I. Isitt (Stockholm, Sweden), H. Campbell, J. Lucidarme, S. Clark, P.T. Heath, R. Borrow, S.N. Ladhani*

E0900 09:36 **Antimicrobial exposure but not vaccination predicts oropharyngeal *Neisseria meningitidis* clearance among men who have sex with men**
M.F. Lucente (Milan, Italy), F. Ranaldi, A.R. Raccagni, N. Capra, R. Lolatto, C. Candela, M. Ripa, G. Catalano, A. Castagna, S. Nozza*

E0901 09:42 **Global expansion of a CTX-M-15-chromosomally integrated *Escherichia coli* ST1193 sublineage (ST1193-B1-Rx) identified in neonatal meningitis in France, 2000-2023**
Y. Benhadid-Brahmi (Paris, France), K. La, G. Geslain, J. De Larminat, P. Bidet, A. Cointe, L. Armand, C. Courroux, S. Bonacorsi, A. Birgy*

E0902 09:48 **A decade of invasive Group B *Streptococcus* infection in South African neonates and infants: Findings from a retrospective laboratory-based study**
M. Said (Pretoria, South Africa), I. Majira, R. Peters, S. Vally Omar, K. Govender*

E0903 09:54 **Asplenia and functional hyposplenia in community-acquired bacterial meningitis in adults**
E. Schepers (Amsterdam, Netherlands), V. Boon, E. Drost, M. Brouwer, D. Van De Beek*

E0904 10:00 **Neurological manifestations attributable to *Mycoplasma pneumoniae* in adults during the 2023-2024 epidemic: clinical features, management, and outcomes**
M. Holub (Paris, France), R. Palich, A. Gavaud, C. Louapre, A. Bleibtreu, C. Cazanave, V. Pourcher, M. Le Marechal, G. Martin Blondel*

E0905 10:06 **Increasing importance of *Streptococcus anginosus* group as a cause of invasive streptococcal infection in the UK: a retrospective longitudinal observational study**
E. Gil (London, United Kingdom), J. Hatcher, S. De Saram, T. Patel, T. Lamagni, R. Guy, M. Marks, J. Brown*

E0906 10:12 **In experimental neurolisteriosis, the matrix metalloproteinases inhibitor cipemastat protects the brain from apoptotic neuronal injury**
D. Grandgirard (Bern, Switzerland), E. Stahovic, M. Erhardt, S.L. Leib*

E0907 10:18 **RhbdI2 modulates inflammation, coagulation and vascular responses in experimental pneumococcal meningitis**
D. Bakker (Amsterdam, Netherlands), R. Koning, M. Van Roon, V. Jaspers, M. Brouwer, D. Beek*

OS124 09:30 - 10:30 Hall ICM 13b
 ANT CLN 1-hour Oral Session

Facing severe bacterial infections in neonates and children

Chairs Dana Danino (Beer Sheva, Israel)
 Johannes Hübner (Munich, Germany)

O0876 09:30 **Appropriateness of Empirical Antibiotic Therapy and Mortality in Neonatal Sepsis Across LMIC Hospitals**
K. Thomson (Oxford, United Kingdom), C. Achi, B. Hassan, R. Farzana, K. Sands, O.B. Spiller, L.C. Jones, J. Rzaska, A. Cooke, J. Aziz, C. Farley, C. Philips, J. Spencer, J. Oduwo, E. Owinoh, K. Ireghu, N. Medugu, C. Chieze, K. Abdulraheem, F.Z. Zango Abdi, A. Aminu, R.Y. Khalid, M. Bello, Y. Mohammed, J. Abubakar, A.T. Bolajoko, O. Oduyebo, O. Olutekunbi, A. Odedina, I. Nwafia, S. Ihezuruoha, U. Ibekwe, N. Haque, S.B. Proma, S. Arefin, S. Khatun Sara, R. Khatun, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, S. Arif, S. Riaz, S.S. Gul, S. Naqvi, H. Hamid, R. Sajjad, A. Sajid, T.R. Walsh*

O0878 09:54 **Epidemiology and vaccine coverage of group B streptococcal disease in infants zero-three months old in the Netherlands, 1987-2023**
M. Groenveld (Amsterdam, Netherlands), D. Jamrozy, M.C. Brouwer, D.H. Visser, D. Van De Beek, M.W. Bijlsma, N.M. Van Sorge*

O0879 10:06 **Population validation of Phoenix criteria for identifying paediatric sepsis**
S.H. He (Hong Kong, China), J.Z. Zhang, L.C.N. Chan, A. Lin, K.Y. Yeung, M.C.I. Kuok, J.W.C.H. Cheng, D.C.Y. Au, C.Y. Chow, T.W. Wong, W.K. Wong, E. Chan, H.M. Young, E.M. Wong, K.M. Ho, A. Lee, C. Rhee, H.S. Lam, L. Ling*

O0880 10:18 Oral step-down antibiotic therapy in children with infective endocarditis: the EndoChild retrospective study
M. Husain (Paris, France), M. Potie, P. Labe, P. Parize, J. Cohen, E. Bille, D. Khraiche, J. Toubiana*

OS125 09:30 - 10:30 Hall A1-4
 TRN 1-hour Oral Session

Regulatory, metabolic, and evolutionary mechanisms shaping *Staphylococcus aureus* pathogenesis

Chairs Laurent Frederic (Lyon, France)
 Marc Stegger (Copenhagen, Denmark)

O0871 09:30 ClpX deficiency promotes small-colony variants formation and stabilises Rot, leading to reduced virulence in MRSA
H. Chen (Beijing, China), J. Wang, H. Wang*

O0872 09:42 Whole genome CRISPRi-seq reveals a cation-proton antiporter as a critical determinant of *Staphylococcus aureus* survival in monocytes like cells
A. Iizuka (Basel, Switzerland), M.V. Mazzuoli, E. Demirbilek, A.K. Woischnig, D. Bumann, J.W. Veening, A. Zinkernagel, N. Khanna*

O0873 09:54 Integrating phylodynamics and GWAS to uncover drivers of meticillin-sensitive *Staphylococcus aureus* bacteraemia and colonisation
D. Aggarwal (London, United Kingdom), A.J. Van Tonder, L. Du Plessis, W. Figueroa, B. Blane, K.L. Bellis, C. Raisen, X. Ba, E. Lay, E. Nickerson, L. Bedford, R. Saunderson, W. Smith, B. Warne, T. Gouliouris, M.E. Torok, M.A. Holmes, J. Parkhill, F. Coll, S.J. Peacock, E.M. Harrison*

O0874 10:06 *Streptococcus pneumoniae* weaponises its own electrical signature to launch ROS attack against *Staphylococcus aureus*
X. Wu (Hangzhou, China), L. Liu, Y. Wang, Y. Jiang, Y. Yu*

O0875 10:18 Simple sequence repeats power *Staphylococcus aureus* adaptation
R. Guérillot (Melbourne, Australia), A.S. Hayes, A. Hachani, S.G. Giulieri, L. Donovan, L.M. Judd, L.K. Sharkey, A. Gonçalves Da Silva, T. Seemann, T.P. Stinear, B.P. Howden*

SY153 09:30 - 10:30 Hall A3-2
 AMR PHEI 1-hour Symposium

Pro/Con debate: is One Health essential or a distraction in AMR related policies?

Chairs Elena Carrara (Verona, Italy)
 Timothy R. Walsh (Oxford, United Kingdom)

S0483 09:30 AMR is the quintessential One Health issue
Sabiha Essack (Durban, South Africa)

S0484 10:00 One Health is distracting us from addressing policy gaps
Heiman Wertheim (Nijmegen, Netherlands)

EF136 11:00 - 12:00 Arena 2
 AMR DX ePoster Flash Session

Novel aspects in antimicrobial susceptibility testing and resistance detection

Chair Alberto Antonelli (Florence, Italy)

E0943 11:00 Rapid MALDI-TOF MS synergy testing to guide combination therapy in critical infections
M. Bexkens (Rotterdam, Netherlands), S. Van Den Berg, C. De Vogel, W. De Jong, A. Muller*

E0944 11:06 NANOMUR: innovative nanomotion technology for antibiotic susceptibility testing: a game-changer for urinary tract infections?
A. Delfino (Lausanne, Switzerland), D.C. Cãn, O.Y. Chén, A. Sturm, D. Cichocka, G. Greub*

E0945 11:12 Not All MIC Plates Are Equal: Method-Driven Shifts in Cefiderocol Susceptibility for NDM-Producing Enterobacterales
M. Bouillon (Caen, France), C. Isnard, S. Le Hello, F. Gravey*

E0946 11:18 A multi-centre evaluation of routine susceptibility testing methods for linezolid using a clinical *Enterococcus* strain collection
S. De Koster (Edegem, Belgium), S. Van Kleef-Van Koeveringe, J. Boelens, N. Botteldoorn, P.J. Ceyssens, M. Chemais, C. Deckers, S. Desmet, S. Gils, T.D. Huang, B. Lissoir, K. Magerman, C. Meex, K. Floré, A.M. Van Den Abeele, E. Van Honacker, K. Vernelen, I. Verstreken, V. Matheussen, S. Vandamme*

Scientific Programme

Tuesday, 21 April 2026

E0947	11:24	Challenges of phenotypic antimicrobial susceptibility testing of <i>Enterococcus faecium</i> for vancomycin using semi-automated systems and their causes <i>T. Ruegamer*</i> (Cologne, Germany), <i>C. Arz, A. Hiergeist, R. Arazo Del Pino, U. Reischl, P.G. Higgins, A. Gessner, A. Dudakova, M. Simon, J. Jantsch</i>	E0954	11:12	Kp-OMV4: a broadly active OMV vaccine against <i>Klebsiella pneumoniae</i> <i>B. Cano Castaño*</i> (Madrid, Spain), <i>A. Pérez, M.J. Mcconnell, S. Prieto Martín-Gil, A. Tajuelo Moreno-Palancas, E. Gato, P. Miguela-Villoldo, D. Fousteris, A. Peláez García, F. Docando, D. Megias, A.J. Martín-Galiano</i>
E0948	11:30	Waiting for the answer: validation of newly implemented VITEK 2 automated susceptibility testing cards can cause treatment delays in an intensive care unit population <i>A. Abed*</i> (Detroit, United States), <i>S. Boettcher, N. Everson, R. Kenney, R. Tibbetts, L. Samuel, M. Veve</i>	E0955	11:18	Wide strain coverage and protection predicted for K-Vax, a vaccine for prevention of disease by <i>K. pneumoniae</i> presenting OmpA and OmpK36 assembled into chimeric LPS-null whole-cells of <i>A. baumannii</i> <i>J. Infante Viñolo*</i> (Dos Hermanas, Spain), <i>A.I. Rodríguez-Rosado, A. Alonso-Del Valle, J. Sa Pessoa, R. Calderon-Gonzalez, M. Garcia-Lopez, L. Del Pozo-Acebo, M. Cordero-Alba, M.J. Mcconnell, J.A. Bengoechea</i>
E0949	11:36	Utility of tetracycline susceptibility as a predictor of doxycycline activity in non-diphtheriae <i>Corynebacterium</i>: a retrospective analysis <i>K. Barrett*</i> (Rochester, United States), <i>O. Abu Saleh, M. Fida</i>	E0956	11:24	Broad computational and experimental screening of antigenic loops in the <i>Klebsiella pneumoniae</i> porinome <i>A. Pérez Gómez*</i> (Madrid, Spain), <i>S. Prieto Martín-Gil, A. Tajuelo, B. Cano, D. Fousteris, L. Vaughan, P. Miguela-Villoldo, E. Gato, A.J. Martín Galiano, M.J. Mcconnel</i>
E0950	11:42	<i>In vitro</i> evaluation of cefiderocol against <i>Achromobacter xylosoxidans</i> isolates from people with cystic fibrosis <i>F. Tolio*</i> (Verona, Italy), <i>G. Toccaceli, A. Bertoncelli, A. Mazzariol</i>	E0957	11:30	Assessment of KpiD as a promising antigen for vaccine development against <i>Klebsiella pneumoniae</i> <i>A. Tajuelo Moreno-Palancas*</i> (Madrid, Spain), <i>S. Prieto Martín-Gil, L. Vaughan, B. Cano-Castaño, P. Miguela-Villoldo, D. Fousteris, V. Mas, A.J. Martín-Galiano, M.J. Mcconnell, A. Pérez, E. Gato</i>
E0951	11:48	Rethinking ESBL Detection in Enterobacterales: Comparison of EUCAST and CLSI Guidelines and Development of a Clavulanate-Free Algorithm <i>L.K. Muhsal*</i> (Osnabrueck, Germany), <i>A. Hamprecht</i>	E0958	11:36	Developing an outer membrane vesicle-based vaccine against <i>Klebsiella pneumoniae</i> <i>K. Winter*</i> (Vancouver, Canada), <i>K. Chu, N. Wilks, S. Cai, A. Tejani, W.L. Kuan, I. Hadad, L. Presley, T. Harn, M. Lo, M. Sadarangani</i>
EF137	11:00 - 12:00	Arena 3	E0959	11:42	Cost-effectiveness analysis of PCV21, an adult specific 21-valent pneumococcal conjugate vaccine, vs PCV20 in adults in Germany <i>P. Mueller*</i> (Boston, United States), <i>M. Simuzingili, L. Lang, M. De Lepper, K. Owusu-Edusei</i>
VAX	ePoster Flash Session		E0960	11:48	Development of a non-invasion intranasal vaccine for <i>Klebsiella pneumoniae</i> urinary tract infection <i>L.K. Siu*</i> (Zhunan, Taiwan), <i>M.H. Huang</i>
Bacterial vaccine pipeline: focus on <i>Staphylococcus</i> and <i>Klebsiella</i>					
Chair	<i>Guido Werner</i> (Wernigerode, Germany)				
E0952	11:00	AntiPan: a genome-informed in silico pipeline for advancing subunit vaccine discovery against <i>Staphylococcus aureus</i> <i>M.S. Ibrahim*</i> (6th Of October, Egypt), <i>J.A. Fahmy, M.A. Helal, F.T. Hakim, L.R. Sidarous, N-E Attallah, S. Abouelhadid, M. Elhadidy, E. Badr</i>			
E0953	11:06	Rational selection of vaccine candidates based on proteomic analysis of thermal stress-induced <i>S. aureus</i> dispersion <i>B. Vieira*</i> (Bragança Paulista, Brazil), <i>G.C. Mantini Cangussu, T. Rojas Converso, A. Hakansson</i>			

EF138 11:00 - 12:00 Arena 4
 VAX ePoster Flash Session

Pneumococcal vaccines: impact and serotype dynamics

Chair Ron Dagan (Beer-Sheva, Israel)

E0961 11:00 The first comprehensive whole genome sequencing of *Streptococcus pneumoniae* from the Arabian Gulf region: Implications for vaccine strategies
 A. Senok* (Dubai, United Arab Emirates), S. Verma, L. Mohamed, E. Kaambo, S. Boucherabine, M. Senghore, A. Nabi, M. Habou, F. Jabeen, A. Alatoon, N. Abdulrazzaq, W. Jamal, R. Nassar, E. Mokaddas, D. Everett

E0962 11:06 Dominance of PCV13-nonPCV10 serotypes in paediatric invasive pneumococcal infections in Serbia after sequential PCV programs
 N. Vuckovic Opavski* (Belgrade, Serbia), M. Jovicevic, J. Kabic, D. Kekic, Z. Vasiljevic, O. Hadzic Simovic, S. Laban Nestorovic, T. Djordjevic, D. Medic, L. Ranin, I. Gajic

E0963 11:12 Serotype evolution and sequence types of *Streptococcus pneumoniae* meningitis isolates before and after PCV13 introduction in Algeria
 S. Bouheraoua* (Algiers, Algeria), A. E. Deghmane, K. Hebbachi, R. Laliem, F. Djedjig, C. Bentchouala, R. Abi Ayad, S. Mahrane, M.K. Taha, H. Tali Maamar

E0964 11:18 Assessing the impact of different pneumococcal conjugate vaccine (PCV) programs on invasive pneumococcal disease (IPD) using population based surveillance in Ontario
 A. Mcgeer* (Toronto, Canada), A. Shigayeva, Z. Zhong, C. Amirov, A. Belhaj, S. Chakrabarti, D. Chen, W. Gold, A. Golden, L. Goneau, C. Kandel, S. Krajden, R. Lovinsky, I. Martin, L. Matukas, T. Mazzulli, M. Muller, J. Nadarajah, K. Ostrowska, N. Rau, D. Ricciuto, D. Richardson, D. Rose, M. Saffie, V. Sales, A. Simor, C. Vermeiren

E0965 11:24 Would implementing a risk-based or an age-based PCV20 vaccination program in adults 60+ years in Brazil be cost effective and budget saving?
 L. Huang* (Collegeville Pa, United States), R.F. Alexandre, A. Claro, R. Ferreira, D. Pachito

E0966 11:30 Estimated impact of pneumococcal conjugate vaccine implementation on disease burden and mortality: strategies to guide PCV program introduction in low-resource settings
 T. Ngamprasertchai* (Bangkok, Thailand), V. Mahd-Adam, W. Pan-Ngum

E0967 11:36 Long-term persistence of pneumococcal antibodies five years after sequential PCV13 and PPSV23 vaccination in kidney transplant recipients: indications for revaccination
 L. Van De Sand* (Essen, Germany), B. Wilde, K. Völk, O. Witzke, M. Lindemann, N. Mülling

E0968 11:42 Effect of introducing pneumococcal conjugate vaccines into national immunisation programmes on antimicrobial-resistant *Streptococcus pneumoniae* disease burden across 188 countries: a synthetic-control study
 Z. Chen* (Shanghai, China), C. Zhihui, L. Zhonghua, W. Jing, Y. Xiangru, J. Jialin, Z. Wenhong

E0969 11:48 Immunogenicity and safety of a 21-valent pneumococcal conjugate vaccine (V116) compared with the 23-valent polysaccharide vaccine (PPSV23) in older adults: a systematic review and meta-analysis of randomised controlled trials
 H. Mewafy* (Giza, Egypt), M. Abdrabou

FO162 11:00 - 12:00 Arena 1
 PRO Open Forum

Integrating Sustainable Development Goals (SDGs) 3 and 5 in policy and practice

Chair Sabine Bèlard (Tübingen, Germany)

F0447 11:00 From policy to practice: gender equality in the SDG framework
 Irit Nachtigall (Berlin, Germany)

F0448 11:10 Gender and access to infectious disease diagnostics and treatment
 Daniela Fusco (Hamburg, Germany)

F0449 11:20 Integrating gender and community realities into AMR for SDGs 3 & 5 in Sub-Saharan Africa
 Judith Asin (Nairobi, Kenya)

Co-organised with: Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

Scientific Programme

Tuesday, 21 April 2026

KN154 11:00 - 12:00 Hall ICM 14
 TRN VAX Keynote Lecture

Genetics underlying susceptibility and immunity to infection

Chairs

Jan A.J.W. Kluytmans
 (Utrecht, Netherlands)
 Gülşen Özkaya Şahin
 (Lund, Sweden)

K0432 11:00 **Filomeen Haerynck (Ghent, Belgium)**



Filomeen Haerynck is associate professor in the Faculty of Medicine at Ghent University and clinical head of Paediatric Pulmonology, Infectiology and Immunology at Ghent University Hospital. Following training in paediatric pulmonology and immunology, she established and now coordinates the Centre for Primary Immunodeficiency in Ghent, an internationally recognised facility treating over 2,000 patients. She leads the PID Research Laboratory at Ghent University investigating novel genes in immune disorders, with groundbreaking discoveries including GT-F3A mutations in viral susceptibility and RC3H1 mutations in hyperinflammatory syndrome reflected in over 135 publications and more than 12,000 citations. Haerynck bridges cutting-edge research with improved clinical outcomes for rare immune disorders.

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

Fireplace Session 21 April, 12:15 - 13:15

ME161 11:00 - 12:00 Hall A1-2
 CLN Meet-the-Expert

Clinical challenges and management strategies for slowly progressing cutaneous infections

M0445 11:00 **Maria Luisa Aznar (Barcelona, Spain)**

M0446 11:12 **Richard Odame Phillips (Kumasi, Ghana)**

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC)

OS129 11:00 - 12:00 Hall ICM 13a
 ANT TRN 1-hour Oral Session

Making phages GMP-ready: the manufacturing challenge

Chairs

Ran Nir-Paz (Jerusalem, Israel)
 Jean-Paul Pirnay (Brussels, Belgium)

O0933 11:00 **Consensus-based guideline on personalised bacteriophage therapy**
 S. Würstle* (Frankfurt, Germany),
 S. Lieberknecht-Jouy, M. Vehreschild,
 A. Classen

O0934 11:12 **Optimising bacteriophage manufacturing for human therapeutics: a scalable approach**
 R. Ng* (Perth, Australia), K.M. Ling,
 D. Laucirica, M. Hedges, Z. Velickovic,
 A. Kicic

O0935 11:24 **Virulent phage infection triggers prophage induction and lysogenic conversion in *Staphylococcus aureus*: Implications for therapeutic phage production safety and virulence dynamic**
 P.A. Pastouriaux* (Lyon, France),
 M. Bonhomme, P. Martins-Simoes,
 L. Blazere, E. Helluin, K. Royet, M. Medina,
 C. Kolenda, F. Laurent, F. Laumay

O0936 11:36 **Tailoring the next generation bacteriophage therapy with a cell-free system**
 S.C. Nang* (Melbourne, Australia),
 H.H.Y. Yu, H. Wickremasinghe, X. Li,
 J. Zhao, J. Li

O0937 11:48 **Implementation of the first French public platform for the production of GMP-grade therapeutic phages at reasonable cost**
 L. Frederic* (Lyon, France), M. Medina,
 B. Lapras, C. Kolenda, C. Marchand,
 F. Laumay, C. Merienne, M. Bonhomme,
 F. Pirot

OS130 11:00 - 12:00 Hall ICM 13b
 CLN PHEI 1-hour Oral Session

Navigating clinical realities in travelers and migrant populations

Chairs *Andreas Neumayr (Basel, Switzerland)*
Elaine Maria Seles Dorneles (Lavras, Minas Gerais, Brazil)

00938 11:00 **Safety of the dengue vaccine TAK-003 and risk factors for developing adverse events in travellers from non-endemic areas: a real-world prospective multi-centre pharmacovigilance study in Spain**
D. Camprubí-Ferrer (Barcelona, Spain), M. Saloni, L. Valerio, J. Villar, V. Lopez-Lopez, C. Bertran-Cobo, D. Garcia, E. Jurado, M.L. Machado, C. Masuet, S. Cuevas Marin, I. Gonzalez Nieto, D. Herena Garcia, R. Morales, A. Gomila-Grange, I. Vera, F. Vila, N. Martin, T. De Alba, N. Morales Llorente, E. Gorriz Hidalgo, J. Muñoz*

00939 11:12 **Cluster of rash dominant dengue fever in newly arrived Chinese expatriates at Bangalore (India): a sentinel event in travel health**
A. Mb (Bangalore Rural, India), S. Banti, D. Shobha, R. Surendran*

00940 11:24 **AdMiRE study: development and validation of a WHO-aligned tool to assess healthcare access and antibiotic use among migrant populations in Europe: a multicountry Delphi and psychometric study on behalf of ESGITM group**
G. Guido (Bari, Italy), A. Abbara, M. Asaduzzaman, F.B. Farkas, K. Diabate, A. Duvignaud, V. Holmberg, S. Ibrahim, S. Jordao, R. Papagni, L. Jung, B. Lakatos, M. Orcutt, A. Saracino, A. Requena-Méndez, E. Romancenco, M. Schiavone, C. Shortall, C. Napoli, D. Mosca, P. Luga, J. Llenas Garcia, E. Nicastrì, A. Corpolongo, P. Bodenman, E. Florence, F. Eick, L. Závorszky, S. Severoni, C.M. Wejse, F. Di Gennaro*

00941 11:36 **Imported leishmaniasis in Europe (2000–2024): a systematic review of travel-related case reports**
J.D. Acosta-España (Quito, Ecuador), S.M. Alcocer-Veintimilla, V.A. Pillajo-Gangotena, A. Abbara, M. González-Sanz, A. Rodríguez-Morales*

00942 11:48 **Seroprevalence of *Burkholderia pseudomallei* among international travelers: A preliminary result**
Q.M. Ali (Bangkok, Thailand), G. Zschebek, C.M.S. Cagape, N. Saiprom, S. Tandhavanant, R. Phunpang, M.N. Burtnick, P.J. Brett, T. Siripoon, H.A. Imad, C. Chewapreecha, W. Cheirakul, N. Chantratita, W. Matsee*

OS131 11:00 - 12:00 Hall A1-1
 TRN 1-hour Oral Session

Bacterial adaptation: from colonization to pathogenesis

Chairs *Michael Bachman (Ann Arbor, Michigan, United States)*
Elisabeth Grohmann (Berlin, Germany)

00908 11:00 ***Listeria monocytogenes* clonality within the brain revealed by sequence tag-based analysis of microbial populations (STAMP)**
K. Toms (Paris, France), P. Gastineau, J. Gaillard, P. Thouvenot, S. Levallois, M. Lecuit*

00909 11:12 **Integrated multi-omics reveals coordinated *Staphylococcus aureus* metabolic, iron transport, and stress responses to human serum**
A. Hachani (Melbourne, Australia), W. Mujcharyakul, C. Walsh, S. Giulieri, C. Cramond, K.A. Lcao, T. Stinear, B. Howden, R. Guerrillot*

00910 11:24 **IgaA Mutation Enhances Extracellular Polysaccharides Production and Virulence via Rcs Phosphorelay in *Enterobacter cloacae* Complex**
Y. Li (Beijing, China), M. Zhou, Y. Xu*

00911 11:36 **Transcriptional reprogramming driving enterococcal persistence unveiled by RNA-sequencing**
J. Guerreiro (Lisboa, Portugal), C. Galdes, C. Silva, F. Vale, E. Cunha, L. Tavares, J. Fernandes Guerreiro, M. Oliveira*

00912 11:48 **Polymicrobial biofilm communities potentiate host damage in a 3D human bladder microtissue model**
R. Garcia Maset (Oxford, United Kingdom), A. Crowther, V. Chu, I. White, L. Pasquina-Lemonche, M. Hadjifrangiskou, E. Stride, D. Carugo, J. Rohn*

Scientific Programme

Tuesday, 21 April 2026

OS132 11:00 - 12:00 Hall A1-3
 IPC 1-hour Oral Session

Modernising surgical site infection surveillance: AI, automation and patient-centered monitoring

- Chair* Gabriel Birgand (Nantes, France)
TBA
- O0913 11:00** **Impact of a computerised decision support system on the adequacy of surgical antibiotic prophylaxis (SAP) and surgical site infections (SSI)**
A. Agostinho (Geneva, Switzerland), L. Hermant, E. Chalot, J. Sobel, W. Rey, D. Teixeira, J. Goncerut, A. Freitas, J. Achcar, F. Bellissimo-Rodrigues, S. Harbarth*
- O0914 11:12** **Transforming free text into usable data: large language models to support automated surgical site infection surveillance**
E. Chalot (Geneva, Switzerland), A. Agostinho, J. Sobel, D. Teixeira, S. Harbarth, M. Abbas*
- O0915 11:24** **Explainable artificial intelligence models for predicting surgical site infections: a scoping review of predictive features and model transparency**
S. Lu (Hongkong, China), R. Sun, Y. Liu, E. Tartari Bonnici, L. Yang, L. Zhou*
- O0916 11:36** **National Surveillance of Surgical Site Infections in Belgium: Results and Evolution of the Sciensano NSIH-SSI Program**
T. Tamminga (Brussels, Belgium), K. Mertens, L. Van Imshoot*
- O0917 11:48** **Patient-reported, Prospective, and Digital Surveillance of Post-Caesarean Surgical Site Infections in the outpatient setting: the SECURE Sectio study**
K. Last (Bonn, Germany), M.N. Kröncke, M. Jaskolski, E. Früchtl, F. Droop, N. Scholten, N.T. Mutters, B. Strizek*

OS133 11:00 - 12:00 Hall A1-5
 ANT CLN PHEI 1-hour Oral Session

Community-acquired pneumonia: know your enemies, treat them well

- Chairs* Niessen Annabel (Utrecht, Netherlands)
Aurélien Dinh (Garches, France)
- O0918 11:00** **Pneumococcal pneumonia in adults, re-emergence of vaccine serotypes: a prospective multi-centre cohort study in Germany, 2020-2023**
C. Bahrs (Vienna, Austria), N. Rose, G. Barten-Neiner, C. Fleischmann-Struzek, M.P.G. Van Der Linden, G. Rohde, J. Rupp, M. Witzernath, J. Rademacher, M.W. Pletz*
- O0919 11:12** **Incidence and burden of medically and non-medically-attended *Mycoplasma pneumoniae*, 2024-2025**
H. Nguyen (Marshfield, United States), J. King, J. Petrie, B. Kieke, O. Alonge, W. Meng, Z. Zheng, I. Leony Lasso, Y. Park, E.C. Newbern, C. Canan, J. Meece, E. Viscidi, E.J. Anderson*
- O0920 11:24** **Genomic surveillance reveals global spread of macrolide-resistant *Bordetella pertussis* linked to vaccine changes**
C. Min (Shanghai, China), J. Feng*
- O0921 11:36** **Real-world applicability of a three-day antibiotic regimen for community-acquired pneumonia: a ten-year retrospective study across four Swiss university centres**
T. Brahier (Lausanne, Switzerland), J. Regina, G. Carra, M. Méan, N. Boillat Blanco*
- O0922 11:48** **Cardiovascular risk of clarithromycin use in patients hospitalised with community-acquired pneumonia**
S. Bastrup Israelsen (Hvidovre, Denmark), M. Fally, P. Ravn, L. Kolte, M. Schmidt, T. Benfield, A. Matthews*

OS134 11:00 - 12:00 Hall A2-2
 CLN DX 1-hour Oral Session

Changing landscape of opportunistic infections in the immunocompromised host

- Chairs* Malgorzata Mikulska (Genoa, Italy)
 Lior Neshet (Beersheba, Israel)
- 00923 11:00 MUCOPS interventional trial: blood Mucorales PCR screening in high-risk haematology patients**
 Y. Vanbiervliet* (Leuven, Belgium),
 R. Aerts, E. Boon, T. Mercier,
 A. Schauwvlieghe, K. Beuselinck,
 K. Lagrou, J. Maertens
- 00924 11:12 Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)**
 T. Morris* (Saint-Etienne, France),
 L. Fouillet, J. Cornillon, A. Fayard,
 V. Dupont, E. Daguene, C. Thieblemont,
 E. Bachy, G. Manson, C. Herbaux,
 I. Yakoub-Agha, T. Gastinne, D. Blaise,
 L. Roulin, F.X. Gros, P. Bories, R. Houot,
 S. Le Gouill, E. Botelho-Nevers
- 00925 11:24 Strategies for management of human cytomegalovirus (HCMV) reactivation in haematopoietic stem cell transplant recipients (HSCTRs) in the era of letermovir**
 I. Cassaniti* (Pavia, Italy), D. Mele,
 M. Michele, F. Zavaglio, G. Grassia,
 N. Polverelli, D. Russo, A. Algarotti,
 T. Lazzarotto, F. Bonifazi, P. Chiusolo,
 F. Baldanti, D. Lilleri
- 00926 11:36 Transplantation and geographic medicine: analysis of data from the Spanish National Transplant Organisation (ONT), 2015-2024**
 F. Norman* (Madrid, Spain), B. Mahillo,
 M.D. Corbacho-Loarte, M. Gonzalez-Sanz,
 S. Chamorro-Tojeiro, F. Gioia,
 D. Gayoso-Cantero, B. Dominguez-Gil,
 J. Fortun, P. Martin-Davila
- 00927 11:48 Risk factors for invasive mold infections in heart transplant recipients: a nationwide matched case-control study**
 B. Hoellinger* (Strasbourg, France),
 E. Epailly, F. Vuotto, V. Letscher-Bru,
 S. Loidant, C. Goeminne, R. Coelho,
 G. Laurent, S. Guendouz, G. Melica,
 F. Botterel, D. Maubon, A. Boignard,
 S. Pattier, F. Morio, C. Chabanne,
 J.P. Gangneux, K. Blanchart,
 J. Bonhomme, S. Grosjean, F. Dalle,
 C. Nafeh-Bizet, L. Favennec, B. Pilmis,
 J. Guilhaire, A. Gigandon, G. Pasquier,
 V. Dupasquier, C. Vignals, M. Lefranc,
 P. Tirard-Collet, L. Sebbag, L. Van Den Bogaart,
 F. Lanternier, M. Saito, F. Danion

OS135 11:00 - 12:00 Hall A3-2
 AMR PHEI 1-hour Oral Session

Harnessing wastewater for surveillance of AMR

- Chairs* Henry-Michel Cauchie (Belvau, Luxembourg)
 Amy Mathers (Charlottesville, United States)
- 00928 11:00 Longitudinal wastewater metagenomics allows genomic and clinical surveillance of human-associated viruses**
 M. Karatas* (Leuven, Belgium),
 M. Bloemen, J. Swinnen, L. Close,
 M. Van Ranst, E. Wollants, J. Matthijnsens
- 00929 11:12 From influent to effluent: antibiotic resistance gene dynamics in WWTPs**
 C. Stoffers* (Groningen, Netherlands),
 M. Lokate, L. Gard, A. Voss, J.W.A. Rossen
- 00930 11:24 Associations between antimicrobials and antimicrobial resistance genes in urban wastewater**
 M. Penney* (Calgary, Canada), D. Kuzma,
 K. Aleshia, M. Kayla, O. Christine,
 D. Kristine, A. Emily, A. Nicole, W. Barbara,
 L. Jangwoo, W. Benson, C. Rhonda,
 M. Janine, V. Laura, P. Chloe, R.M. Elissa,
 D. Bruce, N. Diego, B. Herman, C. John,
 K.H. Susana, H. Casey, P. Michael
- 00931 11:36 Hospital use of ciprofloxacin and sulfamethoxazole correlates with their concentrations in hospital wastewater in Norway, 2019-2025**
 H.J. Espvik* (Oslo, Norway), M. Grung,
 C. Vogelsang, K.M. Gravningen
- 00932 11:48 Cross-compartment genomic epidemiology of cephalosporin- and carbapenem-resistant Enterobacterales: an international multi-centre study in patients, hospital aquatic environments and wastewater**
 N. Macesic* (Melbourne, Australia),
 M. De Kraker, A. Peleg, N. Hassoun-Kheir,
 M. Andre, D. Andrey, M. Beiers,
 X. Bertrand, B. Burri, D. Haber, S. Harbarth,
 J. Hawkey, M. Karram, L. Opatowski,
 M. Paul, R. Patwa, R. Sierra, K. Van Hoorde

Scientific Programme

Tuesday, 21 April 2026

SY155 11:00 - 12:00 Hall ICM 1
 CLN PED VAX 1-hour Symposium

Year in paediatric ID

- Chairs* Julia Anna Bielicki (London, United Kingdom)
 Hervé Haas (Nice, France)
- S0433 11:00** **Epidemiology, diagnosis, treatment**
 Ulrich Von Both (Munich, Germany)
- S0434 11:30** **Infection prevention and vaccines**
 Dana Danino (Beer Sheva, Israel)

SY156 11:00 - 12:00 Hall ICM 5
 AMR IPC 1-hour Symposium

Decoding resistance: the new ESCMID guidelines to halt transmission of multidrug-resistant Gram-negatives

- Chairs* Ana Budimir (Zagreb, Croatia)
 Andreas Voss (Groningen, Netherlands)
- S0435 11:00** **The ESCMID blueprint for prevention: a deep dive into the new guidelines**
 Evelina Tacconelli (Verona, Italy)
- S0436 11:30** **Making the guidelines stick: innovative implementation strategies for effective uptake**
 Bianca Albers (Zurich, Switzerland)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

SY157 11:00 - 12:00 Hall B0-1
 AMR ANT 1-hour Symposium

Personalised antimicrobial stewardship for resistant pathogens: beyond clinical trials

- Chairs* Lorenzo Guglielmetti (Verona, Italy)
 Tomislav Kostyanev (Esbjerg, Denmark)
- S0437 11:00** **blaNDM-producing Enterobacterales: optimal selection of adjuvant β -lactamase inhibitors**
 Jacob Strahilevitz (Jerusalem, Israel)
- S0438 11:30** ***Mycobacterium tuberculosis* mutations associated with drug resistance: the way forward**
 Iñaki Comas (Valencia, Spain)

SY158 11:00 - 12:00 Hall A1-4
 DX TRN 1-hour Symposium

Detecting parasites using metagenomics and proteomics

- Chairs* Hanne Brekke (Oslo, Norway)
 Dora Buonfrate (Negrar, Italy)
- S0439 11:00** **Unmasking hidden worlds: the power of metagenomics in parasitology**
 Francesco Asnicar (Trento, Italy)
- S0440 11:30** **From proteomics to the bench**
 Momar Ndao (Montreal, Canada)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

SY159 11:00 - 12:00 Hall A2-1
 DX PHEI 1-hour Symposium

To AI or not to AI: latest trends in digital innovation for respiratory virus detection and management

- Chairs* Benjamin Cowling (Pokfulam, Hong Kong)
 Esmeralda Valiente (Berlin, Germany)
- S0441 11:00** **Using AI-enabled diagnostics to strengthen biosecurity and address gaps in servicing remote populations**
 Holly Seale (Sydney, Australia)
- S0442 11:30** **Latest trends in AI-supported respiratory virus surveillance and monitoring**
 Jude Kong (Toronto, Canada)

Co-organised with: Australasian Society for Infectious Diseases (ASID), ESCMID Study Group for Respiratory Viruses (ESGREV), International Pediatric Association (IPA)

SY160 11:00 - 12:00 Hall A3-1
 AMR ANT 1-hour Symposium

Emerging resistance to new antibiotics: are we already losing the newest tools?

- Chairs* Ana Gales (Sao Paulo, Brazil)
 Balaji Veeraraghavan (Vellore, India)
- S0443 11:00** **Current prevalence and clinical impact of resistance to new drugs**
 Timothy R. Walsh (Oxford, United Kingdom)
- S0444 11:30** **How to minimise resistance to new drugs**
 Elena Carrara (Verona, Italy)

EF141 13:30 - 14:30 Arena 2
 IPC ePoster Flash Session

New threats to occupational health

- Chair *Biljana Carevic (Oslo, Norway)*
- E0985 13:30 SIREN RespOME study: *Staphylococcus aureus* nasal and throat colonisation in a UK healthcare worker cohort**
J. Islam (London, United Kingdom), S. Foulkes, K. Bellis, A. Atti, V. Hall, E.M. Harrison*
- E0986 13:36 Healthcare worker KAP tools regarding flu and COVID-19 vaccination: reliability and structural stability pre- and post-campaign**
M. Latorre-Millán (Saragossa, Spain), A. Milagro, I. Ezpeleta, J.M. Álvarez-Zarate, L. Clusa*
- E0987 13:42 Healthcare workers' infection prevention strategies in primary healthcare facilities of rohingya refugee camps in Bangladesh**
S.M.M. Hasan (Dhaka, Bangladesh), S.A. Prema*
- E0988 13:48 Occupational blood exposure among Sri Lankan healthcare workers: a six-year review**
T. Pattiyakumbura (Kandy, Sri Lanka), R. Muthugala, L. Rajamanthrie, S. Paththamperuma*
- E0989 13:54 Late Diagnosis of Infectious Diseases and Disease Transmission Among Health Care Workers in A Tertiary Care Hospital**
R. Tafveez (Karachi, Pakistan), A. Ali, S. Farhan, N. Virani, R. Roshan, S.F. Mahmood*
- E0990 14:00 Prioritising healthcare workers for Lassa fever vaccination in Nigeria**
D. Smith (Paris, France), K.B. Pouwels, S. Okogbenin, T.D. Hollingsworth, K. Holohan, O.O. Ayodeji*
- E0991 14:06 Do we spread bacteria when 'shooting' disposable gloves after use?**
F. Schaumburg (Münster, Germany), J. Skorning, T. Grebe, P. Neuhaus*
- E0992 14:12 Bridging the Know-Do Gap: Evaluation of a multimodal intervention to increase infection prevention competency of healthcare workers in Bangladeshi hospitals**
S.A. Sumon (Dhaka, Bangladesh), M.G.D. Harun*
- E0993 14:18 Evaluating mask performance through total inward leakage: a human volunteer study**
K. Lassing (Nijmegen, Netherlands), H. Wertheim, P. Scheepers*

EF142 13:30 - 14:30 Arena 3
 DX ePoster Flash Session

Next-generation diagnostics for reproductive health

- E0994 13:30 Vaginal microbiome dysbiosis and post-treatment shifts in Indian women with Bacterial vaginosis: Insights from shotgun metagenomic and resistome profiling**
G. Gurmeet (Chandigarh, India), R. Yadav, R. Bagga, A. Arora, S. Sethi*
- E0995 13:36 Hologic Panther system in the diagnosis of bacterial vaginosis, vulvovaginal candidiasis, and *Trichomonas vaginalis* vaginitis**
N. Aparisi Valero (Valencia, Spain), M. Palomeque Matos, A. Orts Fullana, L. Andrés Eslava, J.L. Ramos Martí, V. Marqués Nova, L. Suarez Lopez, M.G. Ferrando Cerda, M.J. Lahiguera Abalos, N. Talón Costa, L. Sempere Mira, C. Gimeno Cardona, D. Ocete Mochón*
- E0996 13:42 Comparative Evaluation of Diagnostic Strategies for Bacterial Vaginosis: Nugent score, Hay-Ison Score, culture with chromogenic plate, and two molecular Tests**
O. Dauwalder (Lyon, France), M. Andrea, H. Salord, T. Roussel-Gaillard*
- E0997 13:48 High-throughput Multiplex PCR for detection of infertility-associated STIs in gynecologist-referred patients**
B. Cullhaj (Tirana, Albania), I. Marku, D. Sino*
- E0998 13:54 Diagnostic accuracy of Xpert CT/NG assay at the point-of-care for the detection of neonatal *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infection: cohort study in Papua New Guinea**
L. Braunack-Mayer (Bern, Switzerland), M.A. Riddell, A. Mengi, L.M. Vally, P.H. Cunningham, M. Starr, H. Wand, B.D. Spycher, R. Guy, M. Laman, W.S. Pomat, A.J. Vally, N. Low*
- E0999 14:00 Detection of *Treponema pallidum* in saliva and its application to molecular epidemiology**
K. Imai (Saitama, Japan), Y. Ohama, A. Sato, M. Tanaka, R. Omachi, S.I. Nakayama, M. Tokano, N. Tarumoto, T. Maeda, Y. Akeda*
- E1000 14:06 Expanding diagnostic options for STIs: qPCR screening using routine Liquid Cytology samples**
H. Alonso (San Mateo De Gallego, Spain), E. Teresa, E. Villarreal, M. Lopez, S. Aznar, S. Lucea, M. Barco*

Scientific Programme

Tuesday, 21 April 2026

- E1001 14:12** **A pragmatic approach to scaling STI screening in low-resource settings: pooled '3-in-1' Xpert® CT/NG testing achieves high predictive performance at reduced costs among Indonesian MSM**
*S. Suwanti** (Jakarta, Indonesia),
R.L. Hamers, Y.W. Anggraini, N. Kawi, H. Luis, J. Jeny, D.P. Rahmawati, E.P. Sihotang, M. Oktaviani, P.P. Januraga, E. Sukmaningrum, E. Yuniastuti, E.J. Sanders, S. Wignall, K. Gedela
- E1002 14:18** **Large-scale molecular surveillance of bacterial STIs in Brazil: a four-year multi-state analysis of over 335,000 RT-PCR tests for *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Mycoplasma genitalium***
*V. Passarelli** (São Paulo, Brazil),
P. Cappellano, C. Dos Santos Lazar, F. Goldemberg, M. Chiarastelli Salomão, A. Martins Fontes, F. Marques Rodrigues, J. De Sá, F.H. Da Silva, C. Granato, G. Hughes, S. Figueiredo Costa

EW167 13:30 - 15:30 Hall ICM 13a
 2-hour Educational Session

Inside the black box: leading and developing clinical guidelines

- Chairs* *Blin Nagavci* (Gjakova, Kosovo)
Luigia Scudeller (Pavia, Italy)
- W0408 13:30** **How to chair a guideline panel and survive**
Mark G. J. De Boer (Leiden, Netherlands)
- W0409 13:50** **Deconstructing guidelines: how to ensure and assess their trustworthiness**
Mical Paul (Haifa, Israel)
- W0410 14:10** **Pitfalls in developing guidelines: conflicts of interest, panel composition, and updating**
José Ramón Paño-Pardo (Zaragoza, Spain)
- W0411 14:30** **More than a logo: the strategic role of societies in guideline development**
Marcus Zervos (Detroit, United States)

Co-organised with: ESCMID Guidelines Subcommittee, CMI Board of Editors

EW168 13:30 - 15:30 Hall ICM 13b
 2-hour Educational Session

A diagnostic Odyssey: how to enhance diagnostic stewardship

- Chairs* *Polona Maver Vodicar* (Ljubljana, Slovenia)
Neven Papic (Zagreb, Croatia)
- W0412 13:30** **Should I order an IGRA test? Could this be a mycobacterial infection?**
Christoph Lange (Borstel, Germany)
- W0413 13:50** **Do I have antibodies or just anxiety? Gen Z gets real about serology**
Jean-Luc Murk (Blaricum, Netherlands)
- W0414 14:10** **PCR Tests: The Superheroes of Infection Detection... Or Just Really Good Sidekicks?**
Snjezana Zidovec Lepej (Zagreb, Croatia)
- W0415 14:30** **Serum, Culture, PCR—But Wait, Fungi Still Have a Few Tricks Up Their Sleeve!**
Katrien Lagrou (Leuven, Belgium)

EW169 13:30 - 15:30 Hall A2-1
 2-hour Educational Session

UTIs off the beaten path: complex patients, complex choices

- Chairs* *Suzanne Geerlings* (Amsterdam, Netherlands)
Angela Huttner (Geneva, Switzerland)
- W0416 13:30** **UTI in kidney-transplant patients: what's new and what's safe?**
Dionysios Neofytos (Geneva, Switzerland)
- W0417 13:50** **UTI and bacteriuria in pregnancy: two and the same?**
Barbara Trautner (St. Louis, United States)
- W0418 14:10** **UTI in patients with stones and stents: rocks and hard places**
Lorenz Leitner (Zürich, Switzerland)
- W0419 14:30** **UTI in neurogenic bladder/spinal cord injury patients**
Ruxandra Calin (Paris, France)

Co-organised with: ESCMID Study Group for Urinary Tract Infections (ESGUTI)

EW170 13:30 - 15:30 Hall A2-2
 CLN DX 2-hour Educational Session

Take the right path: tips on HIV resistance management in the era of new antiretrovirals

Chair *Botond Lakatos (Budapest, Hungary)*
TBA

W0420 13:30 **State-of-the art approach to HIV resistance analysis**
Ivailo Alexiev (Sofia, Bulgaria)

W0421 13:50 **Epidemiology of HIV resistance in Europe and beyond**
Dimitrios Paraskevis (Athens, Greece)

W0422 14:10 **HIV resistance management in the era of long-acting antivirals**
Dan Otelea (Bucharest, Romania)

W0423 14:30 **Drug resistance testing for optimising HIV management**
Anna Maria Geretti (London, United Kingdom)

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Dat'AIDS Working Group

EW171 13:30 - 15:30 Hall A3-1
 ANT CLN 2-hour Educational Session

Managing bloodstream infections and endocarditis in the context of drug injection or homelessness

Chairs *Brigitte Lamy (Bobigny, France)*
Aneta Nyčová (Praha, Czechia)

W0424 13:30 **Epidemiology and features of bloodstream infections among PWID**
Asko Jarvinen (Helsinki, Finland)

W0425 13:50 **Alternative antibiotic regimens and delivery strategies for infective endocarditis in PWID**
Burcu Isler (Gold Coast, Australia)

W0426 14:10 **Is combination treatment necessary for *Staphylococcus aureus* infections?**
Sara Grillo (Barcelona, Spain)

W0427 14:30 **Oral antibiotics for bacteraemia in people who use drugs**
Pierre Tattevin (Rennes, France)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

EW172 13:30 - 15:30 Hall A3-2
 CLN DX 2-hour Educational Session

Transplant infectious diseases: real-world challenges through the eyes of the next generation

Chairs *Roy Chemaly (Houston, United States)*
Nathan Peiffer-Smadja (Paris, France)

W0428 13:30 **Understanding and applying cell-mediated immunity in transplant infectious diseases**
Carla Walti (Basel, Switzerland)

W0429 13:50 **CNS complications in patients treated with CAR-T cells**
Marjorie Batista (São Paulo, Brazil)

W0430 14:10 **How much is enough? Rational empiric therapy in febrile immunocompromised patients**
Yuri Vanbiervliet (Leuven, Belgium)

W0431 14:30 **Challenges for diagnostic stewardship in transplant recipients**
Ankit Mittal (Hyderabad, India)

Co-organised with: ESGAP, ESGICH, ESGIB, ESCMID Scientific Affairs Subcommittee, ESGREV, International Immunocompromised Host Society (ICHS)

OS139 13:30 - 15:30 Hall ICM 5
 CLN DX TRN 2-hour Oral Session

Clinical metagenomics: from sample processing to actionable results

Chairs *Hege Vangstein Aamot (Lørenskog, Norway)*
Gilbert Greub (Mollie-Margot, Switzerland)

O0975 13:30 **From sample to treatment in four hours: bringing metagenomics precision to complicated UTI diagnostics and management**
R. Ahmad (Hamar, Norway), A.B. Bellankimath, S. Branders, K. Isabell, A. Jawad, A. Fatemeh, T.E.B. Johansen, C. Imirzalioglu, T. Hain, F. Wagenlehner*

O0976 13:42 **Multi-centre evaluation of the EasySeq Full-Length 16S Sequencing kit for bacterial identification in clinical samples**
T.T. Severs (Zwolle, Netherlands), S.D. Pas, S.A. Boers, L. Gard, J.W.A. Rossen, L.B. Van Alphen, R.M. Koeck, P.W. Smit, R.Y. Yahiaoui, S.P.F. Matamoros, B. Van Den Bosch, P. Koopman, R. Cartuyvels, J. Dingemans, M.J.R. Ivens*

O0977 13:54 **Rapid species identification in community-acquired bacteraemia using a short pre-culturing step followed by 16S nanopore sequencing**
D. Nestor (Orebro, Sweden), M. Ekström, S. Cajander, P. Mölling, M. Sundqvist*

Scientific Programme

Tuesday, 21 April 2026

00978 14:06 **Insights from over 11,000 clinical samples in over five years of routine metagenomics in Germany**
*S. Grumaz** (Duisburg, Germany),
J. Becher, C. Disqué, K. Rensing,
J. Bottlang, D. Borda-Molina, P. Stevens

00979 14:18 **MetaGENomic Sequencing to detect Infections in SOTR (Solid Organ Transplant Recipients): Interim Analysis of the mGENISIS Registry**
*S. Khalil** (Houston, United States),
A. Chandorkar, D.W. Charles, L. Fontana,
T. Taylor, I. Kaur, D.R. Kaul, Z. Raglow,
J. Schaenman, K. Obeid, S. Nair,
C.E. Harris, R.O. Adekunle, A. Mills,
S. Yang, J.R. Shah, L. Ogawa, H. Hassouna,
J. Polega, J. Morillas, P. Vijayvargiya,
S. Imam, N. Vissichelli, M. Morales,
R. Shrestha, J. Hand, Z. Esquer,
J. Goldman, E. Eichenberger, M.R. Sohail

00980 14:30 **Implementation of respiratory metagenomics during the 2024/25 autumn/winter season in a large UK specialist referral hospital**
*M. Ibrahim** (Southampton, United Kingdom),
S. Green, N. Norton, E. Pelosi,
J. Swabe, C. Mckenzie, A. Alcolea-Medina,
L.B. Snell, D. Ward,
A. Dushianthan, M. Grocott, J. Edgeworth,
K. Saeed

00981 14:42 **Rapid hybridisation capture workflow for targeted metagenomics of respiratory infections**
*O. E. Torres Montaguth** (London, United Kingdom),
A. Busam, L.M. Martin Bernal,
T. Brooks, I. Ringue, G. Kuczmar, A. Kopec,
S. Buddle, L. Ahmed, R. Williams, J. Brown,
S. Morfopoulou, J. Breuer

00982 14:54 **Ultra-rapid µCaler hybrid-capture tNGS with a fully automated workstation for comprehensive detection of respiratory pathogens**
*W. Feili** (Beijing, China),
Y. Liping,
G. Shan, X. Bangxiang, Z. Jiaying, Z. Lili,
Z. Yulin

00983 15:06 **The world's first direct from raw sample to report NGS platform: delivering rapid BSI pathogen ID and AMR from whole blood clinical samples**
*S. Reed** (London, United Kingdom),
E. Brown, R. Samuel, D. Seth, D. Dylan,
E. Oscar, S. Yazmine, P. Hannah, P. Maria,
S. Laura, E. Liz, M.B. Joanna, M. Raegan,
L. William, P. Marie, G. Flavia, S. Shagun,
D. Jennifer, S. Peter, G. Hailey, C. Giselle,
K. Daniel, W. Jason, C. Brandon,
N. Cristian, R. Jonathan, M. Christian,
P. Shane, V. Steven, D. Miroslav, J. Isaac,
M.C. Fraser, M. Daniel, W. David,
W. Graham, W. Michele

00984 15:18 **An Open-Source, On-Site Nanopore Sequencing Workflow for Rapid Microbial Cell-Free DNA (mcfDNA) Detection in Bloodstream Infections**
*M. Banz** (Jena, Germany),
S. Hagel,
M. Pletz, C. Brandt

OS140 13:30 - 14:30 Hall A1-1
 CLN DX 1-hour Oral Session

Transforming diagnostic microbiology with AI

Chairs
Benjamin Peter Howden (Melbourne, Australia)
Mariska Leeflang (Amsterdam, Netherlands)

00970 13:30 **Democratising MALDI-TOF AMR prediction: from Transformers to simple Neural Networks without accuracy loss, reducing energy costs via knowledge distillation**
*A. Guerrero-López** (Zurich, Switzerland),
L. De Ancos Villa

00971 13:42 **A novel auditable diagnostic support system using constrained retrieval-augmented generation improves accuracy and efficiency in parasitology morphology identification**
*C.C. Hung** (New Taipei, Taiwan)

00972 13:54 **ParaScout: Microscopic Helminth Detection Using AI**
*S. Slavenburg** (Haarlem, Netherlands),
C. Tieken, R. Koelewijn, L. Van Lieshout,
R. Zonneveld, I. Feoktistov,
J. Van Hellemond

00973 14:06 **AI-powered live blood cell imaging for rapid infection and sepsis detection in the emergency department**
*A. Cohen** (Tel Aviv, Israel),
Y. Avior, A. Koenig, N. Bachar, A. Haruvi, Y. Wiener-Well,
O. Wolfovitz-Barchad, Y. Schwartz,
A. Dreifuss, A. Hiba, B. Leshem

00974 14:18 **Accuracy of Gram stain interpretation by smartphone-based computer-aided diagnosis app in blood culture samples**
*K. Ebisawa Furui** (Kobe, Japan),
G. Ohji, K. Yamamoto, I. Miyatsuka, A. Moriya,
K. Akamatsu, H. Nomoto, M. Kurokawa,
K. Ohnuma, M. Kusuki, Y. Uemura,
N. Ohmagari

SY163 13:30 - 15:30 Hall ICM 1
 AMR 2-hour Symposium

Global landscape of AMR surveillance in Gram-negative bacteria

- Chairs* Patrick Mcgann (Silver Spring, United States)
 Paul A. Tambyah (Singapore, Singapore)
- S0396 13:30 **Insights from the genomic surveillance of CRE in Europe: ongoing challenges**
 LEMONIA SKOURA (Thessaloniki, Greece)
- S0397 14:00 **Current epidemiology of CRAB in Europe: diagnostic advances**
 Paul G. Higgins (Cologne, Germany)
- S0398 14:30 **Revolutionising informal AMR data sources vs traditional interfaces**
 Tin Tin MYAING (Bangkok, Thailand)
- S0399 15:00 **Genomic insights into AMR surveillance: lessons from South and South-East Asia**
 Balaji VEERARAGHAVAN (Vellore, India)

Co-organised with: AMR Action Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Public Health Microbiology (ESGPHM), ECDC, ISID

SY164 13:30 - 15:30 Hall A1-2
 PED VAX 2-hour Symposium

From childhood to adulthood: overcoming barriers in vaccine prevention

- Chairs* Hervé Haas (Nice, France)
 Tina Tan (Chicago, United States)
- S0400 13:30 **Meningococcal disease: how and why do vaccination schedules differ across Europe ?**
 Adam Finn (Bristol, United Kingdom)
- S0401 14:00 **Measles: lessons learned from a recent epidemic in the era of vaccine hesitancy**
 Adriana Pistol (Bucharest, Romania)
- S0402 14:30 **RSV prevention and social inequalities**
 Marie Joelle Jabagi (Ivry-Sur-Seine, France)
- S0403 15:00 **Pneumococcal disease prevention: a lifespan approach**
 Emmanuelle Varon (Creteil, France)

Co-organised with: Société de Pathologie Infectieuse de Langue Française, French Pediatric Infectious Diseases Group (GPIP), Infectious Diseases Society of America (IDSA)

SY165 13:30 - 14:30 Hall B0-1
 AMR TRN 1-hour Symposium

Beneath the caspule of *Klebsiella pneumoniae*: hypervirulence, fitness and adaptive evolution

- Chairs* Christian Stephan Lentz (Tromsø, Norway)
 Shiri Navon-Venezia (Ariel, Israel)
- S0404 13:30 **What constitutes hypervirulence during *Klebsiella pneumoniae* infection?**
 Yunn-Hwen Gan (Singapore, Singapore)
- S0405 14:00 **Adaptive evolution and in-host dissemination of *Klebsiella pneumoniae***
 Michael Bachman (Ann Arbor, United States)

SY166 13:30 - 14:30 Hall A1-4
 IPC PHEI 1-hour Symposium

One Health beyond AMR: the challenge of *Clostridioides difficile* infection control outside the hospital

- Chairs* Marcela Krutova (Prague, Czechia)
 Ana Vale (Dublin, Ireland)
- S0406 13:30 ***Clostridioides difficile* in extra-human sources**
 Mónica Oleastro (Lisbon, Portugal)
- S0407 14:00 **Dynamics of transmission of *Clostridioides difficile* within and outside the hospital**
 Semeh Bejaoui (Bologna, Italy)

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD), ESCMID Study Group for Veterinary Microbiology (ESGVM)

EF143 14:30 - 15:30 Arena 1
 AMR ANT PHEI ePoster Flash Session

Shaping policy for antimicrobial use and AMR

- Chair* Babette Rump (Bilthoven, Netherlands)
- E1004 14:36 **The environmental impact of antibiotic treatment: a life-cycle analysis of intravenous-inpatient, -outpatient and oral treatment options**
 P. Elders* (Amsterdam, Netherlands),
 J. Hovius, K. Sigaloff, B. Joosten,
 T. De Vries, L. Kouwenberg, E. Cohen,
 E. Van Bree, F. De Haes, S. Geerlings
- E1005 14:42 **Carbon impact of blood-culture utilisation changes during a global supply constraint**
 E. Chan* (Melbourne, Australia),
 P. Kinsella, C. O'shea, K. Cronin, K. Bond,
 S. Mcalister, F. MCGAIN

Scientific Programme

Tuesday, 21 April 2026

E1006	14:48	An intersectionality-based policy analysis of antimicrobial resistance in national action plans in WHO European Region <i>E. Magrini* (Rome, Italy), C. Shortall, C. Naim, E. Short, A. Abbara</i>	E1014	14:42	Epidemiological and molecular study of relapse cases of infection with the microsporidia <i>Enterocytozoon bieneyi</i> <i>C. Nourrisson* (Clermont-Ferrand, France), M. Moniot, P. Combes, F. Dalle, D. Costa, P. Poirier</i>
E1007	14:54	Towards a global health equity framework for antimicrobial resistance: mapping indicators across disciplines, domains, and levels of aggregation <i>T. Makamu* (Cape Town, South Africa), C. Bonaconsa, S. Mkhumbuzi, A. Kona, M. Mendelson, E. Charani</i>	E1015	14:48	Intestinal Microsporidiosis in Immunocompetent Individuals: Data from the French NRC CMAP (2018–2024) <i>P. Poirier* (Clermont-Ferrand, France), C. Nourrisson, P. Combes, M. Moniot, L. Favennec, F. Dalle, D. Costa</i>
E1008	15:00	Strengthening public health policies for antimicrobial resistance: insights from the EU-JAMRAI 2 sustainability guidance tool <i>B. Davido* (Paris, France), D. Merillon, M. Fuentes-Braesch</i>	E1016	14:54	The skin to heart connection: Linking scabies and skin infections to rheumatic heart disease in a New Zealand national cohort study <i>S. Gupta* (Auckland, New Zealand), S. Thornley</i>
E1009	15:06	Valuing sustainable access to antibiotics: Stakeholder reasoning on trade-offs, preparedness, and ethical priorities in Sweden, Italy, and Bulgaria <i>M. Ancillotti* (Uppsala, Sweden), D. Mascalzoni, R. Biasiotto, A. Diukendjieva, G. Kyosovska, C. Munthe, E. Baraldi, S. Wagrell</i>	E1017	15:00	Scabies prevalence in children under five years old in Ecuadorean remote indigenous communities after the cessation of ivermectin administration <i>A. Garcia Mingo* (London, United Kingdom), M. González Sanz, M. Castro Aliaga, M. Caicedo Orobio, E. Salazar, R. Basu Roy, V. Velasco Tirado, M. Cáceres Alonso</i>
E1010	15:12	How visual representations of AMR and One Health limit possible futures of One Health <i>M.L. Wöhrle* (Edinburgh, United Kingdom)</i>	E1018	15:06	Epidemiological shifts in visceral leishmaniasis incidence, relapse, and mortality in Brazil: Analysis using National Notifiable Diseases Information System <i>D.G. Assefa* (Dilla, Ethiopia), G. Cota, J.P. Wilson, J.A. Mendes, C. Naylor, R. Peplow, S. Singh-Phulgenda, M.S. Saito, P.J. Guerin, P. Dahal</i>
E1011	15:18	Impact of World Health Organization's AWaRe antibiotics on the gut microbiome: a systematic review and meta-analysis <i>A. Di Gallo* (Milan, Italy), E. Crivellaro, A. Banfi, L. Barcellini, S. Panelli, C. Giaroni, E. Fusco, G. Zuccotti, M. Sharland, L. Folgori</i>	E1019	15:12	Epidemiological and clinical features of leishmaniasis in a tertiary hospital in Brazil <i>O.H. Pradi Guenther* (Curitiba, Brazil), E. Dyminski Parente Ribeiro, F. Tomiotto-Pellissier</i>
EF144	14:30 - 15:30	Arena 4	E1020	15:18	A ten-year follow-up of <i>Leishmania donovani</i> transmission dynamics during the visceral leishmaniasis elimination campaign in India <i>A.K. Singh* (Varanasi, India), S. Sundar, E. Hasker</i>
CLN	PHEI	ePoster Flash Session			
Clinical and epidemiological perspectives on neglected parasitic and fungal diseases					
E1012	14:30	Effectiveness of PAIR and aspiration for hepatic hydatid cysts: Ten years of experience from a UK referral centre <i>C. Morgan* (Swansea, United Kingdom), S.V. Blundell, M. Bojorquez-Segura, M. James, D. Lawrence, T. Pissanou, G. Godbole, Z. Amin, L. Nabarro</i>			
E1013	14:36	Structured treatment interruption in alveolar echinococcosis: patient selection and predictors of successful outcome <i>A.L. Allgaeuer* (Ulm, Germany), L. Heinzmann, L. Peters, W. Jiang, B. Gruener</i>			

ME174 14:30 - 15:30 Hall A1-3
 CLN DX Meet-the-Expert

How to use serological tests for Lyme borreliosis

M0453 14:30 *Mariska Leeflang*
 (Amsterdam, Netherlands)

M0454 14:42 *Ram B. Dessau* (Slagelse, Denmark)

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)

SY173 14:30 - 15:30 Hall A1-5
 IPC 1-hour Symposium

Future-proofing IPC: smarter strategies for tomorrow's challenges

Chairs *S. K. Jayatilleke* (Nugegoda, Sri Lanka)
Elisabeth Presterl (Vienna, Austria)

S0451 14:30 **Innovative bundles and strategies for reducing central line and urinary catheter infections**

S0452 15:00 **From firefighting to foresight: shifting IPC from reactive to proactive**
Nico Tom Mutters (Bonn, Germany)